PD-1 ANTIBODIES, POLYPEPTIDES AND USES THEREOF

Abstract
Polypeptides for binding to PD-1 and compositions comprising the same, such as targeting to a cell expressing MAdCAM, which can be used, for example as methods and compounds for conferring site-specific or local immune privilege.
Description
SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 10, 2022, is named 145256_001802_SL.txt and is 896,475 bytes in size.


FIELD

The embodiments provided herein relate to, for example, methods and compositions for local or targeted immune-privilege.


BACKGROUND

Instances of unwanted immune responses, e.g., as in the rejection of transplanted tissue or in autoimmune disorders, constitute a major health problem for millions of people across the world. Long-term outcomes for organ transplantation are frequently characterized by chronic rejection, and eventual failure of the transplanted organ. More than twenty autoimmune disorders are known, affecting essentially every organ of the body, and affecting over fifty million people in North America alone. The broadly active immunosuppressive medications used to combat the pathogenic immune response in both scenarios have serious side effects. Programmed cell death protein 1 (PD-1) is an inhibitory immune checkpoint molecule present on the surface of T cells, and others. PD-1 binds to two ligands, PD-L1 and PD-L2, minimizing or preventing activation and function of said T cells. PD-1 targeted therapies have emerged as ways of providing local or targeted immune privilege. The present disclosure provides for methods and compounds that provide local or targeted immune privilege.


SUMMARY

The present disclosure related to anti-PD-1 antibodies, polypeptides, and uses thereof. In some embodiments, antibodies, or antigen binding fragments thereof, comprising a heavy chain variable region and a light chain variable region, are provided. In some embodiments, the antibody, or antigen binding fragment thereof, comprises the heavy chain variable region comprises a variable heavy CDR1 (HCDR1) having at least one amino acid substitution relative to SEQ ID NO: 1709, or 1719; a variable heavy CDR2 (HCDR2) having at least one amino acid substitution relative to SEQ ID NO: 1712, or 1744; and variable heavy CDR3 (HCDR3) having at least one amino acid substitution relative to SEQ ID NO: 1715, or 1724; and the light chain variable region comprises a variable light CDR1 (LCDR1) having at least one amino acid substitution relative to SEQ ID NO: 1716, or 1726; a variable light CDR2 (LCDR2) having at least one amino acid substitution relative to SEQ ID NO: 1717, or 1728; and a variable light CDR3 (LCDR3) having at least one amino acid substitution relative to SEQ ID NO: 1718, or 1729.


In some embodiments, the antibody, or antigen binding fragment thereof, comprises the heavy chain variable region comprises a variable heavy CDR1 (HCDR1) having an amino acid sequence of SEQ ID NO: 1719; a variable heavy CDR2 (HCDR2) having an amino acid sequence of SEQ ID NO: 1744; and variable heavy CDR3 (HCDR3) having an amino acid sequence of SEQ ID NO: 1724; and the light chain variable region comprises a variable light CDR1 (LCDR1) having an amino acid sequence of SEQ ID NO: 1726; a variable light CDR2 (LCDR2) having an amino acid sequence of SEQ ID NO: 1728; and a variable light CDR3 (LCDR3) having an amino acid sequence of SEQ ID NO: 1729.


In some embodiments, the antibody, or antigen binding fragment thereof, comprises a light chain variable region comprising an amino acid sequence having at least 90% identity to an amino acid sequence selected from SEQ ID NOs: 1359, 1680, 1681, 1682, 1683, 1684, 1479, 1449, 1687, 1688, 1689, 1690, 1691, 1692, 1693, 1694, 1695, 1696, 1697, 1698, 1699, 1700, 1701, 1702, 1703, 1704, 1705, or 1706; and a heavy chain variable region comprising an amino acid sequence having at least 90% identity to an amino acid sequence selected from SEQ ID NOs: 1476, 1679, 1685, 1584, 1478, 1707, or 1708.


In some embodiments, the antibody, or antigen binding fragment thereof, comprises a light chain comprising an amino acid sequence having at least 90% identity to an amino acid sequence of SEQ ID NO: 1751; and a heavy chain comprising an amino acid sequence having at least 90% identity to an amino acid sequence selected of SEQ ID NO: 1752.


In some embodiments, the antibody, or antigen binding fragment thereof, comprises a light chain comprising an amino acid sequence of SEQ ID NO: 1751; and a heavy chain comprising an amino acid sequence of SEQ ID NO: 1752.


In some embodiments, a PD-1 agonist comprising four polypeptide chains is provided. In

    • some embodiments, the PD-1 agonist comprising four polypeptide chains, comprises:
    • Chain 1: N terminus (nt)-VH1-CH1-CH2-CH3-Linker A-scFv[VL2-Linker B-VH2]-C terminus (ct);
    • Chain 2: nt-VH1-CH1-CH2-CH3-Linker A-scFv[VL2-Linker B-VH2]-ct;
    • Chain 3: nt-VL1-CK-ct; and
    • Chain 4: nt-VL1-CK-ct;
    • wherein:
      • VH1 comprises the sequence of SEQ ID NO: 1476;
      • CH1-CH2-CH3 comprises the sequence of SEQ ID NO: 44;
      • Linker A comprises the sequence of SEQ ID NO: 30;
      • VL2 comprises the sequence of SEQ ID NO: 1445;
      • Linker B comprises the sequence of SEQ ID NO: 22;
      • VH2 comprises the sequence of SEQ ID NO: 1367;
    • VL1 comprises the sequence of SEQ ID NO: 1359; and
    • CK comprises the sequence of SEQ ID NO: 45.


In some embodiments, pharmaceutical compositions comprising antibodies provided herein, are provided.


In some embodiments, methods of treating inflammatory bowel disease are provided. In some embodiments, methods of treating auto-immune hepatitis, primary sclerosing cholangitis, Type 1 diabetes, graft-versus-host disease (GVHD), or an autoimmune disorder, are provided.


In some embodiments, methods of producing antibodies provided herein, are provided.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 depicts a bi-specific therapeutic compund in a tandem scFv-Fc format containing a targeting scFv domain and an effector domain consisting of either an scFv or a sequence corresponding to the endogenous ligand. The depiction is an example of a non-limiting embodiment of the therapeutic compounds provided herein.



FIG. 2 depicts a T cell bound to therapeutic componds disclosed herein. In state 1 the effector domain of a bi-specific binds inhibitory receptors of T cells while in systemic circulation, with neither agonism or antagonism of the receptor occurring. In state 2, the targeting domain of bi-specific binds to target organ leading to bi-specific multimerization on the target organ surface. During T cell recognition of target organ, multimerized effector domains bind, cluster and signal through T cell inhibitory molecules. The depiction is an example of a non-limiting illustration of how a therapeutic compound provided herein could function.



FIG. 3A depicts a non-limiting illustration of the therapeutic compounds provided herein.



FIG. 3B depicts a non-limiting illustration of the therapeutic compounds provided herein.



FIG. 4 depicts a non-limiting illustration of the therapeutic compounds provided herein.



FIG. 5 depicts a non-limiting illustration of the therapeutic compounds provided herein.



FIG. 6 depicts a non-limiting illustration of the therapeutic compounds provided herein.



FIG. 7 depicts a non-limiting illustration of the therapeutic compounds provided herein.



FIG. 8 depicts a non-limiting illustration of the therapeutic compounds provided herein.



FIG. 9 depicts a non-limiting illustration of the therapeutic compounds provided herein.



FIG. 10 depicts a non-limiting illustration of the therapeutic compounds provided herein.



FIG. 11 depicts a non-limiting illustration of the therapeutic compounds provided herein.



FIG. 12 depicts a non-limiting illustration of the therapeutic compounds provided herein.



FIG. 13 depicts a non-limiting illustration of the therapeutic compounds provided herein.



FIG. 14 depicts a non-limiting illustration of the therapeutic compounds provided herein.



FIG. 15 depicts a non-limiting illustration of the therapeutic compounds provided herein.



FIG. 16 depicts a non-limiting illustration of the therapeutic compounds provided herein.



FIG. 17 depicts a non-limiting illustration of the therapeutic compounds provided herein.



FIG. 18 depicts a non-limiting illustration of the therapeutic compounds provided herein.



FIG. 19 depicts a non-limiting illustration of the therapeutic compounds provided herein.





DETAILED DESCRIPTION

This application incorporates by reference each of the following in its entirety: U.S. Provisional Application No. 63/117,914, filed Nov. 24, 2020, U.S. Provisional Application No. 63/117,918 filed Nov. 24, 2020, U.S. Provisional Application No. 63/115,243 filed Nov. 18, 2020, U.S. Provisional Application No. 63/115,235 filed Nov. 18, 2020, PCT Application No. PCT/US2020/046920 filed Aug. 19, 2020, U.S. Non-Provisional application Ser. No. 16/997,238 filed Aug. 19, 2020, PCT Application No. PCT/US2020/033707 filed May 20, 2020, and U.S. Provisional Application No. 62/850,172, filed May 20, 2019, U.S. application Ser. No. 15/922,592 filed Mar. 15, 2018 and PCT Application No. PCT/US2018/022675, filed Mar. 15, 2018. This application also incorporate by reference, each of the following in their entirety: U.S. Provisional Application No. 62/721,644, filed Aug. 23, 2018, U.S. provisional Application No. 62/675,972 filed May 24, 2018, U.S. provisional Application No. 62/595,357 filed Dec. 6, 2017, U.S. Provisional Application No. 62/595,348, filed Dec. 6, 2017, U.S. Non-Provisional application Ser. No. 16/109,875, filed Aug. 23, 2018, U.S. Non-Provisional application Ser. No. 16/109,897, filed Aug. 23, 2018, U.S. Non-Provisional application Ser. No. 15/988,311, filed May 24, 2018, PCT Application No. PCT/US2018/034334, filed May 24, 2018, and, PCT/US2018/062780, filed Nov. 28, 2018, each of which is hereby incorporated by reference in their entirety.


As used herein and in the appended claims, the singular forms “a”, “an” and “the” include plural reference unless the context clearly dictates otherwise.


As used herein, the term “about” means that the numerical value is approximate and small variations would not significantly affect the practice of the disclosed embodiments. Where a numerical limitation is used, unless indicated otherwise by the context, “about” means the numerical value can vary by +5% and remain within the scope of the disclosed embodiments. Thus, about 100 means 95 to 105.


As used herein, the term “animal” includes, but is not limited to, humans and non-human vertebrates such as wild, domestic, and farm animals. As used herein, the term “mammal” means a rodent (i.e., a mouse, a rat, or a guinea pig), a monkey, a cat, a dog, a cow, a horse, a pig, or a human. In some embodiments, the mammal is a human.


As used herein, the term “contacting” means bringing together of two elements in an in vitro system or an in vivo system. For example, “contacting” a therapeutic compound with an individual or patient or cell includes the administration of the compound to an individual or patient, such as a human, as well as, for example, introducing a compound into a sample containing a cellular or purified preparation containing target.


As used herein, the terms “comprising” (and any form of comprising, such as “comprise”, “comprises”, and “comprised”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”), or “containing” (and any form of containing, such as “contains” and “contain”), are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. Any composition or method that recites the term “comprising” should also be understood to also describe such compositions as consisting, consisting of, or consisting essentially of the recited components or elements.


As used herein, the term “fused” or “linked” when used in reference to a protein having different domains or heterologous sequences means that the protein domains are part of the same peptide chain that are connected to one another with either peptide bonds or other covalent bonding. The domains or section can be linked or fused directly to one another or another domain or peptide sequence can be between the two domains or sequences and such sequences would still be considered to be fused or linked to one another. In some embodiments, the various domains or proteins provided for herein are linked or fused directly to one another or a linker sequence, such as the glycine/serine sequences described herein to link the two domains together. Two peptide sequences are linked directly if they are directly connected to one another or indirectly if there is a linker or other structure that links the two regions. A linker can be directly linked to two different peptide sequences or domains.


As used herein, the term “individual,” “subject,” or “patient,” used interchangeably, means any animal, including mammals, such as mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, such as humans.


As used herein, the term “inhibit” refers to a result, symptom, or activity being reduced as compared to the activity or result in the absence of the compound that is inhibiting the result, symptom, or activity. In some embodiments, the result, symptom, or activity, is inhibited by about, or, at least, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99%. An result, symptom, or activity can also be inhibited if it is completely elimination or extinguished.


As used herein, the phrase “in need thereof” means that the subject has been identified as having a need for the particular method or treatment. In some embodiments, the identification can be by any means of diagnosis. In any of the methods and treatments described herein, the subject can be in need thereof. In some embodiments, the subject is in an environment or will be traveling to an environment in which a particular disease, disorder, or condition is prevalent. In some embodiments, the subject is at risk of developing a particular disease or disorder that a treatment is intended to treat and/or prevent. Those “in need of treatment” include those patients that may benefit form treatment with the methods of the inventions, e.g. a patient suffering from or at risk of developing an autoimmune disorder or diabetes.


As used herein, the phrase “integer from X to Y” means any integer that includes the endpoints. For example, the phrase “integer from 1 to 5” means 1, 2, 3, 4, or 5.


In some embodiments, therapeutic compounds are provided herein. In some embodiments, the therapeutic compound is a protein or a polypeptide, that has multiple peptide chains that interact with one another. The polypeptides can interact with one another through non-covalent interactions or covalent interactions, such as through disulfide bonds or other covalent bonds. Therefore, if an embodiment refers to a therapeutic compound it can also be said to refer to a protein or polypeptide as provided for herein and vice versa as the context dictates.


As used herein, the phrase “ophthalmically acceptable” means having no persistent detrimental effect on the treated eye or the functioning thereof, or on the general health of the subject being treated. However, it will be recognized that transient effects such as minor irritation or a “stinging” sensation are common with topical ophthalmic administration of drugs and the existence of such transient effects is not inconsistent with the composition, formulation, or ingredient (e.g., excipient) in question being “ophthalmically acceptable” as herein defined. In some embodiments, the pharmaceutical compositions can be ophthalmically acceptable or suitable for ophthalmic administration.


“Specific binding” or “specifically binds to” or is “specific for” a particular antigen, target, or an epitope means binding that is measurably different from a non-specific interaction. Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule, which generally is a molecule of similar structure that does not have binding activity. For example, specific binding can be determined by competition with a control molecule that is similar to the target.


Specific binding for a particular antigen, target, or an epitope can be exhibited, for example, by an antibody having a KD for an antigen or epitope of at least about 10−4M, at least about 10−5M, at least about 10−6M, at least about 10−7M, at least about 10−8M, at least about 10−9M, alternatively at least about 10−10 M, at least about 10−11M, at least about 10−12M, or greater, where KD refers to a dissociation rate of a particular antibody-target interaction. Typically, an antibody that specifically binds an antigen or target will have a KD that is, or at least, 2-, 4-, 5-, 10-, 20-, 50-, 100-, 500-, 1000-, 5,000-, 10,000-, or more times greater for a control molecule relative to the antigen or epitope.


In some embodiments, specific binding for a particular antigen, target, or an epitope can be exhibited, for example, by an antibody having a KA or Ka for a target, antigen, or epitope of at least 2-, 4-, 5-, 20-, 50-, 100-, 500-, 1000-, 5,000-, 10,000- or more times greater for the target, antigen, or epitope relative to a control, where KA or Ka refers to an association rate of a particular antibody-antigen interaction.


As provided herein, the therapeutic compounds and compositions can be used in methods of treatment as provided herein. As used herein, the terms “treat.” “treated,” or “treating” mean both therapeutic treatment and prophylactic measures wherein the object is to slow down (lessen) an undesired physiological condition, disorder or disease, or obtain beneficial or desired clinical results. For purposes of these embodiments, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; diminishment of extent of condition, disorder or disease; stabilized (i.e., not worsening) state of condition, disorder or disease; delay in onset or slowing of condition, disorder or disease progression; amelioration of the condition, disorder or disease state or remission (whether partial or total), whether detectable or undetectable; an amelioration of at least one measurable physical parameter, not necessarily discernible by the patient; or enhancement or improvement of condition, disorder or disease. Treatment includes eliciting a clinically significant response without excessive levels of side effects. Treatment also includes prolonging survival as compared to expected survival if not receiving treatment. Thus, “treatment of an auto-immune disease/disorder” means an activity that alleviates or ameliorates any of the primary phenomena or secondary symptoms associated with the auto-immune disease/disorder or other condition described herein. Methods of the treatment of various diseases or conditions are provided herein. The therapeutic treatment can also be administered prophylactically to preventing or reduce the disease or condition before the onset.


PD-1 Agonists

Provided herein are therapeutic compounds, e.g., therapeutic protein molecules, e.g., fusion proteins, including a targeting moiety and an effector binding/modulating moiety, typically as separate domains. Also provided are methods of using and making the therapeutic compounds. The targeting moiety serves to localize the therapeutic compound, and thus the effector binding/modulating moiety, to a site at which immune-privilege is desired. As used herein, “immune privilege” means lack of, or suppression of an inflammatory response. As a non-limiting example, immune privilege includes situations where a tissue or site in the body is able to tolerate the introduction of antigens without eliciting an inflammatory immune response (Forester J. V., Lambe H. Xu, Comall R. Immune Privilege or privileged immunity? Mucosal Immunology, 1, 372-381 (2008)).


The effector binding/modulating moiety comprises one or more of: (a) an immune cell inhibitory molecule binding/modulating moiety (an ICIM binding/modulating moiety): (b) an immunosuppressive immune cell binding/modulating moiety (an IIC binding/modulating moiety); (c) a soluble molecule binding/modulating moiety (a SM binding/modulating moiety) or (d) a molecule that blocks or inhibits immune cell stimulatory molecule binding/modulating moiety (referred to herein as an ICSM binding/modulating moiety). In some embodiments, the ICSM inhibits immune activation by, for example, blocking the interaction between a costimulatory molecule and its counter structure. In some embodiments, a therapeutic compound comprises: (a) and (b); (a) and (c); (a) and (d); (b) and (c); (b) and (d); (c) and (d); or (a), (b), (c), and (d).


The present disclosure provides, for example, molecules that can act as PD-1 agonists. Without being bound to any particular theory, agonism of PD-1 inhibits T cell activation/signaling and can be accomplished by different mechanisms. For example cross-linking of bead-bound functional PD-1 agonists can lead to agonism. Functional PD-1 agonists have been described (Akkaya. Ph.D. Thesis: Modulation of the PD-1 pathway by inhibitory antibody super agonists. Christ Church College, Oxford, U K, 2012), which is hereby incorporated by reference. Crosslinking of PD-1 with two mAbs that bind non-overlapping epitopes induces PD-1 signaling (Davis, US 2011/0171220), which is hereby incorporated by reference. Another example is illustrated through the use of a goat anti-PD-1 antiserum (e.g. AF1086, R&D Systems), which acts as an agonist when soluble (Said et al., 2010, Nat Med. 2010 April; 16(4):452-9) which is hereby incorporated by reference. Non-limiting examples of PD-1 agonists that can be used in the present embodiments include, but are not limited to, UCB clone 19 or clone 10, PD1AB-1, PD1AB-2, PD1AB-3, PD1AB-4 and PD1AB-5, PD1AB-6 (Anaptys/Celgene), PD1-17, PD1-28, PD1-33 and PD1-35 (Collins et al, US 2008/0311117 A1 Antibodies against PD-1 and uses therefor, which is incorporated by reference), or can be a bi-specific, monovalent anti-PD-1/anti-CD3 (Ono), and the like. In some embodiments, the PD-1 agonist antibodies can be antibodies that block binding of PD-L1 to PD-1. In some embodiments, the PD-1 agonist antibodies can be antibodies that do not block binding of PD-L1 to PD-1.


PD-1 agonism can be measured by any method, such as the methods described in the examples. For example, cells can be constructed that express, including stably express, constructs that include a human PD-1 polypeptide fused to a P-galactosidase “Enzyme donor” and 2) a SHP-2 polypeptide fused to a P-galactosidase “Enzyme acceptor.” Without being bound by any theory, when PD-1 is engaged, SHP-2 is recruited to PD-1. The enzyme acceptor and enzyme donor form a fully active b-galactosidase enzyme that can be assayed. Although, the assay does not directly show PD-1 agonism, but shows activation of PD-1 signaling. PD-1 agonism can also be measured by measuring inhibition of T cell activation because, without being bound to any theory, PD-1 agonism inhibits anti-CD3-induced T cell activation. For example, PD-1 agonism can be measured by preactivating T cells with PHA (for human T cells) or ConA (for mouse T cells) so that they express PD-1. The cells can then be reactivated with anti-CD3 in the presence of anti-PD-1 (or PD-L1) for the PD-1 agonism assay. T cells that receive a PD-1 agonist signal in the presence of anti-CD3 will show decreased activation, relative to anti-CD3 stimulation alone. Activation can be readout by proliferation or cytokine production (IL-2, IFNg, IL-17) or other markers, such as CD69 activation marker. Thus, PD-1 agonism can be measured by either cytokine production or cell proliferation. Other methods can also be used to measure PD-1 agonism.


PD-1 is an Ig superfamily member expressed on activated T cells and other immune cells. The natural ligands for PD-1 appear to be PD-L1 and PD-L2. Without being bound to any particular theory, when PD-L1 or PD-L2 bind to PD-1 on an activated T cell, an inhibitory signaling cascade is initiated, resulting in attenuation of the activated T effector cell function. Thus, blocking the interaction between PD-1 on a T cell, and PD-L1/2 on another cell (for example, a tumor cell) with a PD-1 antagonist is known as checkpoint inhibition, and releases the T cells from inhibition. In contrast, PD-1 agonist antibodies can bind to PD-1 and send an inhibitory signal and attenuate the function of a T cell. Thus, PD-1 agonist antibodies can be incorporated into various embodiments described herein as an effector molecule binding/modulating moiety (sometimes also referred to herein as an effector molecule), which can accomplish localized tissue-specific immunomodulation when paired with a targeting moiety.


The effector molecule binding/modulating moiety can provide an immunosuppressive signal or environment in a variety of ways. In some embodiments, the effector binding/modulating moiety comprises an ICIM binding/modulating moiety that directly binds and (under the appropriate conditions as described herein) activates an inhibitory receptor expressed by immune cells responsible for driving disease pathology. In another embodiment the effector binding/modulating moiety comprises and IIC binding/modulating moiety and binds and accumulates immunosuppressive immune cells. In some embodiments, the accumulated immune suppressive cells promote immune privilege. In another embodiment the effector binding/modulating moiety comprises an SM binding/modulating moiety which manipulates the surrounding microenvironment to make it less permissible for the function of immune cells, e.g., immune cells driving disease pathology. In some embodiments, the SM binding/modulating moiety depletes an entity that promotes immune attack or activation. In some embodiments the effector binding/modulating moiety comprises an ICSM binding/modulating moiety that binds a member of a pair of stimulatory molecules, e.g., costimulatory molecules, and inhibits the interaction between the costimulatory molecule and the costimulatory molecule counter structure, such as, but not limited to, OX40 or CD30 or CD40 and OX40L, or CD30L or CD40L and inhibits the immune stimulation of a cell, such as, but not limited to, a T cell, B cell, NK cell, or other immune cell comprising a member of the pair.


The targeting moiety and effector binding/modulating moiety are physically tethered, covalently or non-covalently, directly or through a linker entity, to one another, e.g., as a member of the same protein molecule in a therapeutic protein molecule. In some embodiments, the targeting and effector moieties are provided in a therapeutic protein molecule, e.g., a fusion protein, typically as separate domains. In some embodiments, the targeting moiety, the effector binding/modulating moiety, or both each comprises a single domain antibody molecule, e.g., a camelid antibody VHH molecule or human soluble VH domain. It may also contain a single-chain fragment variable (scFv) or a Fab domain. In some embodiments, the therapeutic protein molecule, or a nucleic acid, e.g., an mRNA or DNA, encoding the therapeutic protein molecule, can be administered to a subject. In some embodiments, the targeting and effector molecule binding/modulating moieties are linked to a third entity, e.g., a carrier, e.g., a polymeric carrier, a dendrimer, or a particle, e.g., a nanoparticle. The therapeutic compounds can be used to down regulate an immune response at or in a tissue at a selected target or site while having no or substantially less immunosuppressive function systemically. The target or site can comprise donor tissue or autologous tissue.


Provided herein are methods of providing site-specific immune privilege for a transplanted donor tissue, e.g., an allograft tissue, e.g., a tissue described herein, e.g., an allograft liver, an allograft kidney, an allograft heart, an allograft pancreas, an allograft thymus or thymic tissue, allograft skin, or an allograft lung, with therapeutic compounds disclosed herein. In embodiments the treatment minimizes rejection of, minimizes immune effector cell mediated damage to, prolongs acceptance of, or prolongs the functional life of, donor transplant tissue.


Also provided herein are methods of inhibiting graft versus host disease (GVHD) by minimizing the ability of donor immune cells, e.g., donor T cells, to mediate immune attack of recipient tissue, with therapeutic compounds disclosed herein.


Also provided herein are methods of treating, e.g., therapeutically treating or prophylactically treating (or preventing), an auto-immune disorder or autoimmune response in a subject by administration of a therapeutic compound disclosed herein, e.g., to provide site or tissue specific modulation of the immune system. In some embodiments, the method provides tolerance to, minimization of the rejection of, minimization of immune effector cell mediated damage to, or prolonging a function of, subject tissue. In some embodiments, the therapeutic compound includes a targeting moiety that targets, e.g., specifically targets, the tissue under, or at risk for, autoimmune attack. Non-limiting exemplary tissues include, but are not limited to, the pancreas, myelin, salivary glands, synoviocytes, and myocytes.


In some embodiments, administration of the therapeutic compound begins after the disorder is apparent. In some embodiments, administration of the therapeutic compound, begins prior to onset, or full onset, of the disorder. In some embodiments, administration of the therapeutic compound, begins prior to onset, or full onset, of the disorder, e.g., in a subject having the disorder, a high-risk subject, a subject having a biomarker for risk or presence of the disorder, a subject having a family history of the disorder, or other indicator of risk of, or asymptomatic presence of, the disorder. For example, in some embodiments, a subject having islet cell damage but which is not yet diabetic, is treated.


While not wishing to be bound by theory, it is believed that the targeting moiety functions to bind and accumulate the therapeutic compound to a target selectively expressed at the anatomical site where immune privilege is desired. In some embodiments, e.g., in the context of donor tissue transplantation, the target moiety binds to a target, e.g., an allelic product, present in the donor tissue but not the recipient. For treatment of autoimmune disorders, the targeting moiety binds a target preferentially expressed at the anatomical site where immune privilege is desired, e.g., in the pancreas. For treatment of GVHD, the targeting moiety targets the host tissue, and protects the host against attack from transplanted immune effector cells derived from transplanted tissue.


Again, while not wishing to be bound by theory it is believed that the effector binding/modulating moiety serves to deliver an immunosuppressive signal or otherwise create an immune privileged environment.


Effector, as that term is used herein, refers to an entity, e.g., a cell or molecule, e.g., a soluble or cell surface molecule, which mediates an immune response.


Effector ligand binding molecule, as used herein, refers to a polypeptide that has sufficient sequence from a naturally occurring counter-ligand of an effector, that it can bind the effector with sufficient specificity that it can serve as an effector binding/modulating molecule. In some embodiments, it binds to effector with at least 10, 20, 30, 40, 50, 60, 70, 80, 90, or 95% of the affinity of the naturally occurring counter-ligand. In some embodiments, it has at least 60, 70, 80, 90, 95, 99, or 100% sequence identity, or substantial sequence identity, with a naturally occurring counter-ligand for the effector.


Effector specific binding polypeptide, as used herein, refers to a polypeptide that can bind with sufficient specificity that it can serve as an effector binding/modulating moiety. In some embodiments, a specific binding polypeptide comprises an effector ligand binding molecule.


Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which these embodiments belong. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present embodiments, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. Headings, sub-headings or numbered or lettered elements, e.g., (a), (b), (i) etc., are presented merely for ease of reading. The use of headings or numbered or lettered elements in this document does not require the steps or elements be performed in alphabetical order or that the steps or elements are necessarily discrete from one another. Other features, objects, and advantages of the embodiments will be apparent from the description and drawings, and from the claims.


Additional Definitions

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the embodiments pertains. In describing and claiming the present embodiments, the following terminology and terminology otherwise referenced throughout the present application will be used according to how it is defined, where a definition is provided.


It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.


Antibody molecule, as that term is used herein, refers to a polypeptide, e.g., an immunoglobulin chain or fragment thereof, comprising at least one functional immunoglobulin variable domain sequence. An antibody molecule encompasses antibodies (e.g., full-length antibodies) and antibody fragments. In some embodiments, an antibody molecule comprises an antigen binding or functional fragment of a full length antibody, or a full length immunoglobulin chain. For example, a full-length antibody is an immunoglobulin (Ig) molecule (e.g., an IgG antibody) that is naturally occurring or formed by normal immunoglobulin gene fragment recombinatorial processes). In embodiments, an antibody molecule refers to an immunologically active, antigen-binding portion of an immunoglobulin molecule, such as an antibody fragment. An antibody fragment, e.g., functional fragment, comprises a portion of an antibody, e.g., Fab, Fab′, F(ab′)2, F(ab)2, variable fragment (Fv), domain antibody (dAb), or single chain variable fragment (scFv). A functional antibody fragment binds to the same antigen as that recognized by the intact (e.g., full-length) antibody. The terms “antibody fragment” or “functional fragment” also include isolated fragments consisting of the variable regions, such as the “Fv” fragments consisting of the variable regions of the heavy and light chains or recombinant single chain polypeptide molecules in which light and heavy variable regions are connected by a peptide linker (“scFv proteins”). In some embodiments, an antibody fragment does not include portions of antibodies without antigen binding activity, such as Fc fragments or single amino acid residues. Exemplary antibody molecules include full length antibodies and antibody fragments, e.g., dAb (domain antibody), single chain, Fab, Fab′, and F(ab′)2 fragments, and single chain variable fragments (scFvs).


Immunoglobulin chains exhibit the same general structure of relatively conserved framework regions (FR) joined by three hypervariable regions, also called complementarity determining regions or CDRs. The CDRs from the two chains of each pair are aligned by the framework regions, enabling binding to a specific epitope. From N-terminus to C-terminus, both light and heavy chains comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The assignment of amino acids to each domain is in accordance with the definitions of Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk J. Mol. Biol. 196:901-917 (1987); Chothia et al. Nature 342:878-883 (1989). In some embodiments, the antibodies provided herein comprise the same FRs and different CDRs. In some embodiments, the antibodies provided herein comprise the same CDRs and different FRs. In some embodiments, mutations in the FR are in the heavy chain. In some embodiments, mutations in the FR are in the FR1 of the heavy chain. In some embodiments, mutations in the FR are in the FR2 of the heavy chain. In some embodiments, mutations in the FR are in the FR3 of the heavy chain. In some embodiments, mutations in the FR are in the FR4 of the heavy chain. In some embodiments, mutations in the FR are in the light chain. In some embodiments, mutations in the FR are in the FR1 of the light chain. In some embodiments, mutations in the FR are in the FR2 of the light chain. In some embodiments, mutations in the FR are in the FR3 of the light chain. In some embodiments, mutations in the FR are in the FR4 of the light chain. In some embodiments, mutations in the FR are in the heavy and light chains. In some embodiments, mutations in the FR are in any one or more of the FRs of the heavy and light chains.


The term “antibody molecule” also encompasses whole or antigen binding fragments of domain, or single domain, antibodies, which can also be referred to as “sdAb” or “VHH.” Domain antibodies comprise either VH or VL that can act as stand-alone, antibody fragments. Additionally, domain antibodies include heavy-chain-only antibodies (HCAbs). Domain antibodies also include a CH2 domain of an IgG as the base scaffold into which CDR loops are grafted. It can also be generally defined as a polypeptide or protein comprising an amino acid sequence that is comprised of four framework regions interrupted by three complementarity determining regions. This is represented as FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. sdAbs can be produced in camelids such as llamas, but can also be synthetically generated using techniques that are well known in the art. The numbering of the amino acid residues of a sdAb or polypeptide is according to the general numbering for VH domains given by Kabat et al. (“Sequence of proteins of immunological interest,” US Public Health Services, NIH Bethesda, MD, Publication No. 91, which is hereby incorporated by reference). According to this numbering, FR1 of a sdAb comprises the amino acid residues at positions 1-30, CDR1 of a sdAb comprises the amino acid residues at positions 31-36, FR2 of a sdAb comprises the amino acids at positions 36-49, CDR2 of a sdAb comprises the amino acid residues at positions 50-65, FR3 of a sdAb comprises the amino acid residues at positions 66-94, CDR3 of a sdAb comprises the amino acid residues at positions 95-102, and FR4 of a sdAb comprises the amino acid residues at positions 103-113. Domain antibodies are also described in WO2004041862 and WO2016065323, each of which is hereby incorporated by reference. The domain antibodies can be a targeting moiety as described herein.


Antibody molecules can be monospecific (e.g., monovalent or bivalent), bispecific (e.g., bivalent, trivalent, tetravalent, pentavalent, or hexavalent), trispecific (e.g., trivalent, tetravalent, pentavalent, hexavalent), or with higher orders of specificity (e.g., tetraspecific) and/or higher orders of valency beyond hexavalency. An antibody molecule can comprise a functional fragment of a light chain variable region and a functional fragment of a heavy chain variable region, or heavy and light chains may be fused together into a single polypeptide.


Examples of formats for multispecific therapeutic compounds, e.g., bispecific antibody molecules are shown in the following non-limiting examples. Although illustrated with antibody molecules, they can be used as platforms for therapeutic molecules that include other non-antibody moieties as specific binding or effector moieties. In some embodiments, these non-limiting examples are based upon either a symmetrical or asymmetrical Fc formats.


For example, the figures illustrate non-limiting and varied symmetric homodimer approach. In some embodiments, the dimerization interface centers around human IgG1 CH2-CH3 domains, which dimerize via a contact interface spanning both CH2/CH2 and CH3/CH3. The resulting bispecific antibodies shown have a total valence comprised of four binding units with two identical binding units at the N-terminus on each side of the dimer and two identical units at the C-terminus on each side of the dimer. In each case the binding units at the N-terminus of the homo-dimer are different from those at the C-terminus of the homo-dimer. Using this type of bivalency for both an inhibitory T cell receptor at either terminus of the molecule and bivalency for a tissue tethering antigen can be achieved at either end of the molecule.


For example, in FIG. 3A, a non-limiting embodiment is illustrated. The N-terminus of the homodimer contains two identical Fab domains comprised of two identical light chains, which are separate polypeptides, interfaced with the n-terminal VH-CH1 domains of each heavy chain via the VH/VL interaction and Ckappa or Clambda interaction with CH1. The native disulfide bond between the Ckappa or Clambda with CH1 is present providing a covalent anchor between the light and heavy chains. At the c-terminus of this design are two identical scFv units where by (in this example) the c-terminus of the CH3 domain of the Fc, is followed by a flexible, hydrophilic linker typically comprised of (but not limited to) serine, glycine, alanine, and/or threonine residues, which is followed by the VH domain of each scFv unit, which is followed by a glycine/serine rich linker, followed by a VL domain. These tandem VH and VL domains associate to form a single chain fragment variable (scFv) appended at the c-terminus of the Fc. Two such units exist at the c-terminus of this molecule owing to the homodimeric nature centered at the Fc. The domain order of scFvs may be configured to be from N to C terminus either VH-Linker-VL or VL-Linker-VH.


A non-limiting example of a molecule that has different binding regions on the different ends includes a molecule that comprises a PD-1 agonist at one end and an antibody that provides target specificity, particularly, an anti-MAdCAM-1 antibody at the other end. This can be illustrated as shown, for example, in FIG. 3B, which illustrates the molecules in different orientations. For example, FIG. 1 depicts a bi-specific therapeutic compund in a tandem scFv-Fc format containing a targeting scFv domain and an effector domain consisting of either an scFv or a sequence corresponding to the endogenous ligand. FIG. 2 depicts a T cell bound to therapeutic componds disclosed herein. In state 1 the effector domain of a bi-specific binds inhibitory receptors of T cells while in systemic circulation, with neither agonism or antagonism of the receptor occurring. In state 2, the targeting domain of bi-specific binds to target organ leading to bi-specific multimerization on the target organ surface. During T cell recognition of target organ, multimerized effector domains bind, cluster and signal through T cell inhibitory molecules.


In some embodiments, the MAdCAM antibody is a blocking or non-blocking antibody as described elsewhere herein. Without being bound to any theory, MAdCAM has been shown to interact with the headpiece of the integrin α4β7 expressed on lymphocytes via multiple residues within its two Ig superfamily I-set domains and the atomic level structural basis for that interaction has been described (Viney J L et al. (1996). J Immunol. 157, 2488-2497; Yu Y et al (2013). J Biol Chem. 288, 6284-6294; Yu Y et al (2012). J Cell Biol. 196, 131-146, each of which is incorporated by reference in its entirety). It has been shown in great structural, mechanistic and functional detail in both human (Chen J et al (2003). Nat Struct Biol. 10, 995-1001; de Chateau M et al (2001). Biochemistry. 40, 13972-13979) and mouse (Day E S et al (2002). Cell Commun Adhes. 9, 205-219; Hoshino H et al (2011). J Histochem Cytochem. 59, 572-583) molecular systems that any interaction of MAdCAM with α4β7 is dependent on three dication binding sites present in the integrin beta 7 subunit I-like domain and that these metal binding sites can coordinate with Ca2+, Mn2+, and Mg2+. Using cell adhesion assays, flow cytometry, and/or flow chamber assays in the presence of high levels of Ca2+ with or without Mg2+ or Mn2+, the MAdCAM/α4β7 interaction is shown to be of a lower functional affinity and permits rolling adhesion of lymphocytes, whereas in low Ca2+ but higher Mg2+ or Mn2+ which activates the integrin, the MAdCAM/α4β7 interaction is of a higher functional affinity and mediates firm lymphocyte adhesion (Chen J et al (2003). Nat Struct Biol. 10, 995-1001). A number of groups have shown that various cell:cell, cell:membrane prep, and/or cell:protein based adhesion/interaction assays can be utilized, with FACS, cell flow chamber based counts, or IHC based read-outs to monitor the impact of anti-MAdCAM or anti-α4β7 antibodies upon the interaction of MAdCAM with α4β7, allowing one to identify blocking or non-blocking antibodies (Nakache, M et al (1989). Nature. 337, 179-181; Streeter, P R et al (1988). Nature. 331. 41-46; Yang Y et al (1995). Scand J Immunol. 42. 235-247; Leung E et al (2004). Immunol Cell Biol. 82. 400-409; Pullen N et al (2009). B J Pharmacol. 157. 281-293; Soler D et al (2009). J Pharmacol Exp Ther. 330. 864-875; Qi J et al (2012). J Biol Chem. 287. 15749-15759).


This has been exemplified in the mouse system setting with the identification of anti-mouse MAdCAM antibodies such as MECA-89 (non-blocking) and MECA-367 (blocking)) Nakache, M et al (1989). Nature. 337, 179-181; Streeter, P R et al (1988). Nature. 331. 41-46; Yang Y et al (1995). Scand J Immunol. 42. 235-247). In a human system, antibodies have been identified that block the interaction of human MAdCAM with human α4β7 such as anti-human MAdCAM PF-00547659 (Pullen N et al (2009). B J Pharmacol. 157. 281-293) and anti-human α4β7 vedolizumab (Soler D et al (2009). J Pharmacol Exp Ther. 330. 864-875), as well as antibodies that do not block the interaction such as anti-human MAdCAM clone 17F5 (Soler D et al (2009). J Pharmacol Exp Ther. 330. 864-875), and anti-human α4β7 clone J19 (Qi J et al (2012). J Biol Chem. 287. 15749-15759). Thus, the antibody can either be blocking or non-blocking based upon the desired effect. In some embodiments, the antibody is a non-blocking MAdCAM antibody. In some embodiments, the antibody is a blocking MAdCAM antibody. One non-limiting example of demonstrating whether an antibody is blocking or non-blocking can be found throughout the examples, but any method can be used. Each of the references described herein are incorporated by reference in its entirety. In some embodiments, the PD-1 Agonist is replaced with an IL-2 mutein, such as, but not limited to, the ones described herein.


In another example, and as depicted in FIG. 4, the N-terminus of the homodimer contains two identical Fab domains comprised of two identical light chains, which are separate polypeptides, interfaced with the n-terminal VH-CH1 domains of each heavy chain via the VH/VL interaction and Ckappa or Clambda interaction with CH1. The native disulfide bond between the Ckappa or Clambda with CH1 is present providing a covalent anchor between the light and heavy chains. At the C-terminus of this design are two identical VH units (though non-antibody moieties could also be substituted here or at any of the four terminal attachment/fusion points) where by (in this example) the C-terminus of the CH3 domain of the Fc, is followed by a flexible, hydrophilic linker typically comprised of (but not limited to) serine, glycine, alanine, and/or threonine residues, which is followed by a soluble independent VH3 germline family based VH domain. Two such units exist at the C-terminus of this molecule owing to the homodimeric nature centered at the Fc.


In another non-limiting example, as depicted in FIG. 5, the N-terminus of the homodimer contains two identical Fab domains comprised of two identical light chains, which, unlike FIG. 3A and FIG. 4, are physically conjoined with the heavy chain at the N-terminus via a linker between the C-terminus of Ckappa or Clambda and the N-terminus of the VH. The linker may be 36-80 amino acids in length and comprised of serine, glycine, alanine and threonine residues. The physically conjoined N-terminal light chains interface with the n-terminal VH-CH1 domains of each heavy chain via the VH/VL interaction and Ckappa or Clambda interaction with CH1. The native disulfide bond between the Ckappa or Clambda with CH1 is present providing additional stability between the light and heavy chains. At the c-terminus of this design are two identical Fab units where by (in this example) the C-terminus of the CH3 domain of the Fc, is followed by a flexible, hydrophilic linker typically comprised of (but not limited to) serine, glycine, alanine, and/or threonine residues, which is followed by a CH1 domain, followed by a VH domain at the C-terminus. The light chain that is designed to pair with the C-terminal CH1/VH domains is expressed as a separate polypeptide, unlike the N-terminal light chain which is conjoined to the n-terminal VH/CH1 domains as described. The C-terminal light chains form an interface at between VH/VL and Ckappa or Clambda with CH1. The native disulfide anchors this light chain to the heavy chain. Again, any of the antibody moieties at any of the four attachment/fusion points can be substituted with a non-antibody moiety, e.g., an effector binding/modulating moiety that does not comprise an antibody molecule.


The bispecific antibodies can also be asymmetric as shown in the following non-limiting examples. Non-limiting example are also depicted in FIG. 6, FIG. 7, and FIG. 8, which illustrate an asymmetric/heterodimer approach. Again, in any of these formats, any of the antibody moieties at any of the four attachment/fusion points can be substituted with a non-antibody moiety, e.g., an effector binding/modulating moiety that does not comprise an antibody molecule. In some embodiments, the dimerization interface centers around the human IgG1 CH2-CH3 domains, which dimerize via a contact interface spanning both CH2/CH2 and CH3/CH3. However, in order to achieve heterodimerization instead of homodimerization of each heavy chain, mutations are introduced in each CH3 domain. The heterodimerizing mutations include T366W mutation (kabat) in one CH3 domain and T366S, L368A, and Y407V (kabat) mutations in the other CH3 domain. The heterodimerizing interface may be further stabilized with de novo disulfide bonds via mutation of native residues to cysteine residues such as S354 and Y349 on opposite sides of the CH3/CH3 interface. The resulting bispecific antibodies shown have a total valence comprised of four binding units. With this approach, the overall molecule can be designed to have bispecificity at just one terminus and monospecificity at the other terminus (trispecificity overall) or bispecificity at either terminus with an overall molecular specificity of 2 or 4. In the illustrative examples below, the C-terminus comprises two identical binding domains which could, for example, provide bivalent monospecificity for a tissue tethering target. At the N-terminus of all three of the illustrative examples, both binding domains comprise different recognition elements/paratopes and which could achieve recognition of two different epitopes on the same effector moiety target, or could recognize for examples a T cell inhibitory receptor and CD3. In some embodiments, the N-terminal binding moieties may be interchanged with other single polypeptide formats such as scFv, single chain Fab, tandem scFv, VH or VHH domain antibody configurations for example. Other types of recognition element may be used also, such as linear or cyclic peptides.


An example of an asymmetric molecule is depicted in FIG. 6. Referring to FIG. 6, the N-terminus of the molecule is comprised of a first light chain paired with a first heavy chain via VH/VL and Ckappa or Clambda/CH1 interactions and a covalent tether comprised of the native heavy/light chain disulfide bond. On the opposite side of this heterodimeric molecule at the N-terminus is a second light chain and a second heavy chain which are physically conjoined via a linker between the C-terminus of Ckappa or Clambda and the N-terminus of the VH. The linker may be 36-80 amino acids in length and comprised of serine, glycine, alanine and threonine residues. The physically conjoined N-terminal light chains interface with the N-terminal VH-CH1 domains of each heavy chain via the VH/VL interaction and Ckappa or Clambda interaction with CH1. The native disulfide bond between the Ckappa or Clambda with CH1 is present providing additional stability between the light and heavy chains. At the C-terminus of the molecule are two identical soluble VH3 germline family VH domains joined via an N-terminal glycine/serine/alanine/threonine based linker to the C-terminus of the CH3 domain of both heavy chain 1 and heavy chain 2.


In some embodiments, an asymmetric molecule can be as illustrated as depicted in FIG. 7. For example, the N-terminus of the molecule is comprised of two different VH3 germlined based soluble VH domains linked to the human IgG1 hinge region via a glycine/serine/alanine/threonine based linker. The VH domain connected to the first heavy chain is different to the VH domain connected to the second heavy chain. At the c-terminus of each heavy chain is an additional soluble VH3 germline based VH domain, which is identical on each of the two heavy chains. The heavy chain heterodimerizes via the previously described knobs into holes mutations present at the CH3 interface of the Fc module.


In some embodiments, an asymmetric molecule can be as illustrated in FIG. 8. This example is similar to the molecule shown in FIG. 7, except both N-terminal Fab units are configured in a way that light chain 1 and light chain 2 are physically conjoined with heavy chain 1 and heavy chain 2 via a linker between the c-terminus of Ckappa or Clambda and the N-terminus of each respective VH. The linker in each case may be 36-80 amino acids in length and comprised of serine, glycine, alanine and threonine residues. The physically conjoined N-terminal light chains interface with the N-terminal VH-CH1 domains of each heavy chain via the VH/VL interaction and Ckappa or Clambda interaction with CH1. The native disulfide bond between the Ckappa or Clambda with CH1 is present providing additional stability between the light and heavy chains.


Bi-specific molecules can also have a mixed format. This is illustrated, for example, in FIG. 9, FIG. 10, and FIG. 11.


For example, FIG. 9, illustrates a homodimer Fc based approach (see FIGS. 3, 4, and 5), combined with the moiety format selection of FIG. 7, whereby the total molecular valency is four, but specificity is restricted to two specificities. The N-terminus is comprised of two identical soluble VH3 germline based VH domains and the c-terminus is comprised of two identical soluble VH3 germlined based VH domains of different specificity to the N-terminal domains. Therefore, each specificity has a valence of two. Again, in this format, any of the antibody moieties at any of the four attachment/fusion points can be substituted with a non-antibody moiety, e.g., an effector binding/modulating moiety that does not comprise an antibody molecule.



FIG. 10 illustrates another example of a bispecific molecule having a mixed format. In this example, the molecule is comprised of four VH3 germline based soluble VH domains. The first two domains have the same specificity (for example an inhibitory receptor), the 3rd domain from the N-terminus may have specificity for a tissue antigen and the fourth domain from the N-terminus may have specificity for human serum albumin (HSA), thereby granting the molecule extended half-life in the absence of an Ig Fc domain. Three glycine, serine, alanine and/or threonine rich linkers exists between domains 1 and 2, domains 2 and 3, and domains 3 and 4. This format may be configured with up to tetraspecificity, but monovalent in each case, or to have bispecificity with bivalency in each case. The order of domains can be changed. Again, in this format, any of the antibody moieties can be substituted with a non-antibody moiety, e.g., a effector binding/modulating moiety that does not comprise an antibody molecule.



FIG. 11 illustrates yet another approach. This example is similar to FIGS. 3 and 4, in that it is Fc homodimer based with two identical Fab units (bivalent mono specificity) at the N-terminus of the molecule. This example differs from FIGS. 3 and 4 in that the C-terminus of each heavy chain is appended with a tandem-scFv. Thus, in each case the C-terminus of the CH3 domain of the Fc is linked via a glycine/serine/alanine/threonine based linker to the N-terminus of a first VH domain, which is linked via the C-terminus by a 12-15 amino acid glycine/serine rich linker to the N-terminus of a first VL domain, which linked via a 25-35 amino acid glycine/serine/alanine/threonine based linker at the C-terminus to the N-terminus of a second VH domain, which is linked via the C-terminus with a 12-15 amino acid glycine/serine based linker to the N-terminus of a 2nd VL domain. In this Fc homodimer based molecule there are therefore two identical tandem scFvs at the C-terminus of the molecule offering either tetravalency for a single tissue antigen for example or bivalency to two different molecules. This format could also be adapted with a heterodimer Fc core allowing two different tandem-scFvs at the C-terminus of the Fc allowing for monovalent tetraspecificity at the C-terminus while retaining either bivalent monospecificity at the N-terminus or monovalent bispecificity at the N-terminal via usage of single chain Fab configurations as in FIGS. 5, 6, and 7. This molecule can therefore be configured to have 2, 3, 4, 5, or 6 specificities. The domain order of scFvs within the tandem-scFv units may be configured to be from N to C terminus either VH-Linker-VL or VL-Linker-VH. Again, in this format, any of the antibody moieties at any of the four attachment/fusion points can be substituted with a non-antibody moiety, e.g., an effector binding/modulating moiety that does not comprise an antibody molecule.


Bi-specific antibodies can also be constructed to have, for example, shorter systemic PK while having increased tissue penetration. These types of antibodies can be based upon, for example, a human VH3 based domain antibody format. These are illustrated, for example, in FIGS. 12, 13, and 14. FIGS. 12, 13, and 14 each comprised a soluble VH3 germline family based VH domain modules. Each domain is approximately 12.5 kDa allowing for a small overall MW, which, without being bound to any particular theory, should be beneficial for enhanced tissue penetration. In these examples, none of the VH domains recognize any half-life extending targets such as FcRn or HSA. As illustrated in FIG. 12, the molecule is comprised of two VH domains joined with a flexible hydrophilic glycine/serine based linker between the C-terminus of the first domain and N-terminus of the second domain. In this example one domain may recognize a T cell co-stimulatory receptor and the second may recognize a tissue tethering antigen. As illustrated in FIG. 13, the molecule is comprised of three VH domains with N-C terminal linkages of hydrophilic glycine/serine based linkers. The molecule may be configured to be trispecific but monovalent for each target. It may be bispecific with bivalency for one target and monovalency for another. As illustrated in FIG. 14, the molecule is comprised of four VH domains with N-C terminal Glycine/Serine rich linkers between each domain. This molecule may be configured to be tetraspecific, trispecific, or bispecific with varying antigenic valencies in each case. Again, in this format, any of the antibody moieties at can be substituted with a non-antibody moiety, e.g., an effector binding/modulating moiety that does not comprise an antibody molecule.


Other embodiments of bi-specific antibodies are illustrated in FIGS. 15 and 16. FIGS. 15 and 16 are comprised of the naturally heterodimerizing core of the human IgG CH1/Ckappa interface, including the C-terminal heavy/light disulfide bond which covalently anchors the interaction. This format does not contain an Fc or any moieties for half-life extension. As illustrated in FIG. 15, the molecule, at the N-terminus of the constant kappa domain is appended with an scFv fragment consisting of an N-terminal VH domain, linked at its C-terminus to the N-terminus of a VL domain via a 12-15 amino acid gly/ser based linker, which is linked by its C-terminus to the N-terminus of the constant kappa domain via the native VL-Ckappa elbow sequence. The CH1 domain is appended at the N-terminus with an scFv fragment consisting of an N-terminal VL domain linked at its c-terminus via a 12-15 amino acid gly/ser linker to the N-terminus of a VH domain, which is linked at its C-terminus to the N-terminus of the CH1 domains via the natural VH-CH1 elbow sequence. As illustrated in FIG. 16, the molecule has the same N-terminal configuration to Example 13. However the C-terminus of the constant kappa and CH1 domains are appended with scFv modules which may be in either the VH-VL or VL-VH configuration and may be either specific for the same antigen or specific for two different antigens. The VH/VL inter-domain linkers may be 12-15 amino acids in length and consisting of gly/ser residues. The scFv binding sub-units may be swapped for soluble VH domains, or peptide recognition elements, or even tandem-scFv elements. This approach can also be configured to use variable lambda and/or constant lambda domains. Again, in this format, any of the antibody moieties at any of the attachment/fusion points can be substituted with a non-antibody moiety, e.g., an effector binding/modulating moiety that does not comprise an antibody molecule.



FIG. 17 illustrates another embodiment. FIG. 17 represents a tandem scFv format consisting of a first N-terminal VL domain linked at its C-terminus to the N-terminus of a first VH domain with a 12-15 amino acid gly/ser rich linker, followed at the first VH c-terminus by a 25-30 amino acid gly/ser/ala/thr based linker to the N-terminus of a second VL domain. The second VL domain is linked at the C-terminus to the N-terminus of a 2nd VH domain by a 12-15 amino acid gly/ser linker. Each scFv recognizes a different target antigen such as a co-stimulatory T cell molecule and a tissue tethering target. Again, in this format, any of the antibody moieties can be substituted with a non-antibody moiety, e.g., an effector binding/modulating moiety that does not comprise an antibody molecule.



FIG. 18 illustrates another embodiment. FIG. 18 is a F(ab′)2 scFv fusion. This consists of two identical Fab components joined via two disulfide bonds in the native human IgG1 hinge region C-terminal of the human IgG CH1 domain. The human IgG1 CH2 and CH3 domains are absent. At the C-terminus of heavy chains 1 and 2 are two identical scFv fragments linked via a gly/ser/ala/thr rich linker to the c-terminus of the huIgG1 hinge region. In the configuration shown, the VH is N-terminal in each scFv unit and linked via a 12-15 amino acid gly/ser rich linker to the N-terminus of a VL domain. An alternative configuration is N-term-VL-Linker-VH-C-term. In this design, the construct is bispecific with bivalency for reach target. Again, in this format, any of the antibody moieties at any of the four attachment/fusion points can be substituted with a non-antibody moiety, e.g., an effector binding/modulating moiety that does not comprise an antibody molecule.


CD39 molecule, as that term as used herein, refers to a polypeptide having sufficient CD39 sequence that, as part of a therapeutic compound, it phosphohydrolyzes ATP to AMP. In some embodiments, a CD39 molecule phosphohydrolizes ATP to AMP equivalent to, or at least, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 95% of the rate of a naturally occurring CD39, e.g., the CD39 from which the CD39 molecule was derived. In some embodiments, a CD39 molecule has at least 60, 70, 80, 90, 95, 99, or 100% sequence identity, or substantial sequence identity, with a naturally occurring CD39.


Any functional isoform can be used (with CD39 or other proteins discussed herein). Exemplary CD39 sequence include Genbank accession #NP_001767.3 or a mature form from the following sequence:









(SEQ ID NO: 1)


MEDTKESNVKTFCSKNILAILGESSIIAVIALLAVGLTQNKALPENVK





YGIVLDAGSSHTSLYIYKWPAEKENDTGVVHQVEECRVKGPGISKEVQ





KVNEIGIYLTDCMERAREVIPRSQHQETPVYLGATAGMRLLRMESEEL





ADRVLDVVERSLSNYPFDFQGARIITGQEEGAYGWITINYLLGKFSQK





TRWFSIVPYETNNQETFGALDLGGASTQVTFVPQNQTIESPDNALQFR





LYGKDYNVYTHSFLCYGKDQALWQKLAKDIQVASNEILRDPCFHPGYK





KVVNVSDLYKTPCTKRFEMTLPFQQFEIQGIGNYQQCHQSILELENTS





YCPYSQCAFNGIFLPPLQGDFGAFSAFYFVMKFLNLTSEKVSQEKVTE





MMKKFCAQPWEEIKTSYAGVKEKYLSEYCESGTYILSLLLQGYHFTAD





SWEHIHFIGKIQGSDAGWTLGYMLNLTNMIPAEQPLSTPLSHSTYVFL





MVLFSLVLFTVAIIGLLIFHKPSYFWKDMV.






In some embodiments, a CD39 molecule comprises a soluble catalytically active form of CD39 found to circulate in human or murine serum, see, e.g., Metabolism of circulating ADP in the bloodstream is mediated via integrated actions of soluble adenylate kinase-1 and NTPDase1/CD39 activities, Yegutkin et al. FASEB J. 2012 September; 26(9):3875-83. A soluble recombinant CD39 fragment is also described in Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39, Gayle, et al., J Clin Invest. 1998 May 1; 101(9): 1851-1859.


CD73 molecule, as that term as used herein, refers to a polypeptide having sufficient CD73 sequence that, as part of a therapeutic compound, it dephosphorylates extracellular AMP to adenosine. In some embodiments, a CD73 molecule dephosphorylates extracellular AMP to adenosine equivalent to, or at least, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 95% of the rate of a naturally occurring CD73, e.g., the CD73 from which the CD73 molecule was derived. In some embodiments, a CD73 molecule has at least 60, 70, 80, 90, 95, 99, or 100% sequence identity, or substantial sequence identity, with a naturally occurring CD73. Exemplary CD73 sequences include GenBank AAH65937.1 5′-nucleotidase, ecto (CD73) [Homo sapiens] or a mature form from the following sequence,









(SEQ ID NO: 2)


MCPRAARAPATLLLALGAVLWPAAGAWELTILHTNDVHSRLEQTSEDS





SKCVNASRCMGGVARLFTKVQQIRRAEPNVLLLDAGDQYQGTIWFTVY





KGAEVAHFMNALRYDAMALGNHEFDNGVEGLIEPLLKEAKFPILSANI





KAKGPLASQISGLYLPYKVLPVGDEVVGIVGYTSKETPFLSNPGTNLV





FEDEITALQPEVDKLKTLNVNKIIALGHSGFEMDKLIAQKVRGVDVVV





GGHSNTFLYTGNPPSKEVPAGKYPFIVTSDDGRKVPVVQAYAFGKYLG





YLKIEFDERGNVISSHGNPILLNSSIPEDPSIKADINKWRIKLDNYST





QELGKTIVYLDGSSQSCRFRECNMGNLICDAMINNNLRHADETFWNHV





SMCILNGGGIRSPIDERNNGTITWENLAAVLPFGGTFDLVQLKGSTLK





KAFEHSVHRYGQSTGEFLQVGGIHVVYDLSRKPGDRVVKLDVLCTKCR





VPSYDPLKMDEVYKVILPNFLANGGDGFQMIKDELLRHDSGDQDINVV





STYISKMKVIYPAVEGRIKESTGSHCHGSFSLIFLSLWAVIFVLYQ.






In some embodiments, a CD73 molecule comprises a soluble form of CD73 which can be shed from the membrane of endothelial cells by proteolytic cleavage or hydrolysis of the GPI anchor by shear stress see, e.g., Reference: Yegutkin G, Bodin P, Bumstock G. Effect of shear stress on the release of soluble ecto-enzymes ATPase and 5′-nucleotidase along with endogenous ATP from vascular endothelial cells. Br J Pharmacol 2000; 129: 921-6. For CD73 function see Colgan et al., Physiological roles for ecto-5′-nucleotidase (CD73), Purinergic Signalling, June 2006, 2:351.


Cell surface molecule binder, as that term is used herein, refers to a molecule, typically a polypeptide, that binds, e.g., specifically, to a cell surface molecule on a cell, e.g., an immunosuppressive immune cell, e.g., a Treg. In some embodiments, the cell surface binder has sufficient sequence from a naturally occurring ligand of the cell surface molecule, that it can specifically bind the cell surface molecule (a cell surface molecule ligand). In some embodiments, the cell surface binding is an antibody molecule that binds, e.g., specifically binds, the cell surface molecule.


Donor specific targeting moiety, as that term is used herein, refers to a moiety, e.g., an antibody molecule, that as a component of a therapeutic compound, localizes the therapeutic compound preferentially to an implanted donor tissue, as opposed to tissue of a recipient. As a component of a therapeutic compound, the donor specific targeting moiety provides site-specific immune privilege for a transplant tissue, e.g., an organ, from a donor.


In some embodiments, a donor specific targeting moiety it binds to the product, e.g., a polypeptide product, of an allele present at a locus, which allele is not present at the locus in the (recipient) subject. In some embodiments, a donor specific targeting moiety binds to an epitope on product, which epitope is not present in the (recipient) subject.


In some embodiments, a donor specific targeting moiety, as a component of a therapeutic compound, preferentially binds to a donor target or antigen, e.g., has a binding affinity for the donor target that is greater for donor antigen or tissue, e.g., at least 2, 4, 5, 10, 50, 100, 500, 1,000, 5,000, or 10,000 fold greater, than its affinity for than for subject antigen or tissue. In some embodiments, a donor specific targeting moiety, has a binding affinity for a product of an allele of a locus present in donor tissue (but not present in the subject) at least 2, 4, 5, 10, 50, 100, 500, 1,000, 5,000, or 10,000 fold greater, than its affinity for the product of the allele of the locus present in the subject (which allele is not present in donor tissue). Affinity of a therapeutic compound of which the donor specific moiety is a component, can be measured in a cell suspension, e.g., the affinity for suspended cells having the allele is compared with its affinity for suspended cells not having the allele. In some embodiments, the binding affinity for the donor allele cells is below 10 nM. In some embodiments, the binding affinity for the donor allele cells is below 100 pM, 50 pM, or 10 pM.


In some embodiments, the specificity for a product of a donor allele is sufficient that when the donor specific targeting moiety is coupled to an immune-down regulating effector: i) immune attack of the implanted tissue, e.g., as measured by histological inflammatory response, infiltrating T effector cells, or organ function, in the clinical setting—e.g. creatinine for the kidney, is substantially reduced, e.g., as compared to what would be seen in an otherwise similar implant but lacking the donor specific targeting moiety is coupled to an immune-down regulating effector; and/or ii) immune function in the recipient, outside or away from the implanted tissue, is substantially maintained. In some embodiments, one or more of the following is seen: at therapeutic levels of therapeutic compound, peripheral blood lymphocyte counts are not substantially impacted, e.g., the level of T cells is within 25, 50, 75, 85, 90, or 95% of normal, the level of B cells is within 25, 50, 75, 85, 90, or 95% of normal, and/or the level of granuloctyes (PMNs) cells is within 25, 50, 75, 85, 90, or 95% of normal, or the level of monocytes is within 25, 50, 75, 85, 90, or 95% of normal; at therapeutic levels of therapeutic compound, the ex vivo proliferative function of PBMCs (peripheral blood mononuclear cells) against non-disease relevant antigens is substantially normal or is within 70, 80, or 90% of normal; at therapeutic levels of therapeutic compound, the incidence or risk of risk of opportunistic infections and cancers associated with immunosuppression is not substantially increased over normal; or at therapeutic levels of therapeutic compound, the incidence or risk of risk of opportunistic infections and cancers associated with immunosuppression is substantially less than would be seen with standard of care, or non-targeted, immunosuppression. In some embodiments, the donor specific targeting moiety comprises an antibody molecule, a target specific binding polypeptide, or a target ligand binding molecule.


Elevated risk, as used herein, refers to the risk of a disorder in a subject, wherein the subject has one or more of a medical history of the disorder or a symptom of the disorder, a biomarker associated with the disorder or a symptom of the disorder, or a family history of the disorder or a symptom of the disorder.


Functional antibody molecule to an effector or inhibitory immune checkpoint molecule, as that term is used herein, refers to an antibody molecule that when present as the ICIM binding/modulating moiety of a multimerized therapeutic compound, can bind and agonize the effector or inhibitory immune checkpoint molecule. In some embodiments, the anti-effector or inhibitory immune checkpoint molecule antibody molecule, when binding as a monomer (or binding when the therapeutic compound is not multimerized), to the effector or inhibitory immune checkpoint molecule, does not antagonize, substantially antagonize, prevent binding, or prevent substantial binding, of an endogenous counter ligand of the inhibitory immune checkpoint molecule to inhibitory immune checkpoint molecule. In some embodiments, the anti-effector or inhibitory immune checkpoint molecule antibody molecule when binding as a monomer (or binding when the therapeutic compound is not multimerized), to the inhibitory immune checkpoint molecule, does not agonize or substantially agonize, the effector or inhibitory molecule.


ICIM binding/modulating moiety, as that term is used herein, refers to an effector binding/modulating moiety that, as part of a therapeutic compound, binds and agonizes a cell surface inhibitory molecule, e.g., an inhibitory immune checkpoint molecule, e.g., PD-1, or binds or modulates cell signaling, e.g., binds a FCRL, e.g., FCRL1-6, or binds and antagonizes a molecule that promotes immune function.


IIC binding/modulating moiety, as that term is used herein, refers to an effector binding/modulating moiety that, as part of a therapeutic compound, binds an immunosuppressive immune cell. In some embodiments, the IIC binding/modulating moiety increases the number or concentration of an immunosuppressive immune cell at the binding site.


ICSM binding/modulating moiety, as that term is used herein, refers to an effector binding/modulating moiety that antagonizes an immune stimulatory effect of a stimulatory, e.g., co-stimulatory, binding pair. A stimulatory or co-stimulatory binding pair, as that term is used herein, comprises two members, 1) a molecule on the surface of an immune cell; and 2) the binding partner for that cell molecule, which may be an additional immune cell, or a non-immune cell. Ordinarily, upon binding of one member to the other, assuming other requirements are met, the member on the immune cell surfaces stimulates the immune cell, e.g., a costimulatory molecule, and an immune response is promoted. In situations where the costimulatory molecule and the costimulatory molecule counter structure are both expressed on immune cells, bi-directional activation of both cells may occur. In an embodiment an ICSM binding/modulating moiety binds and antagonizes the immune cell expressed member of a binding pair. For example, it binds and antagonizes OX40. In another embodiment, an ICSM binding/modulating moiety binds and antagonizes the member of the binding pair that itself binds the immune cell expressed member, e.g., it binds and antagonizes OX40L. In either case, inhibition of stimulation or co-stimulation of an immune cell is achieved. In an embodiment the ICSM binding/modulating moiety decreases the number or the activity of an immunostimulating immune cell at the binding site.


Inhibitory Immune Checkpoint Molecules

An “inhibitory immune checkpoint molecule ligand molecule,” as that term is used herein, refers to a polypeptide having sufficient inhibitory immune checkpoint molecule ligand sequence, e.g., in the case of a PD-L1 molecule, sufficient PD-L1 sequence, that when present as an ICIM binding/modulating moiety of a multimerized therapeutic compound, can bind and agonize its cognate inhibitory immune checkpoint molecule, e.g., again in the case of a PD-L1 molecule, PD-1.


In some embodiments, the inhibitory immune checkpoint molecule ligand molecule, e.g., a PD-L1 molecule, when binding as a monomer (or binding when the therapeutic compound is not multimerized), to its cognate ligand, e.g., PD-1, does not antagonize or substantially antagonize, or prevent binding, or prevent substantial binding, of an endogenous inhibitory immune checkpoint molecule ligand to the inhibitory immune checkpoint molecule. E.g., in the case of a PD-L1 molecule, the PD-L1 molecule does not antagonize binding of endogenous PD-L1 to PD-1.


In some embodiments, the inhibitory immune checkpoint molecule ligand when binding as a monomer, to its cognate inhibitory immune checkpoint molecule does not agonize or substantially agonize the inhibitory immune checkpoint molecule. By way of example, e.g., a PD-L1 molecule when binding to PD-1, does not agonize or substantially agonize PD-1.


In some embodiments, an inhibitory immune checkpoint molecule ligand molecule has at least 60, 70, 80, 90, 95, 99, or 100% sequence identity, or substantial sequence identity, with a naturally occurring inhibitory immune checkpoint molecule ligand.


Exemplary inhibitory immune checkpoint molecule ligand molecules include: a PD-L1 molecule, which binds to inhibitory immune checkpoint molecule PD-1, and in embodiments has at least 60, 70, 80, 90, 95, 99, or 100% sequence identity, or substantial sequence identity, with a naturally occurring PD-L1, e.g., the PD-L1 molecule comprising the sequence of









(SEQ ID NO: 3)


MRIFAVFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPVEKQL





DLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGN





AALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVV





DPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLEN





VTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERTH





LVILGAILLCLGVALTFIERLRKGRMMDVKKCGIQDTNSKKQSDTHLE





ET,







or an active fragment thereof; in some embodiments, the active fragment comprises residues 19 to 290 of the PD-L1 sequence; an HLA-G molecule, which binds to any of inhibitory immune checkpoint molecules KIR2DL4, LILRB1, and LILRB2, and in embodiments has at least 60, 70, 80, 90, 95, 99, or 100% sequence identity, or substantial sequence identity, with a naturally occurring HLA-G. Exemplary HLA-G sequences include, e.g., a mature form found in the sequence at GenBank P17693.1 RecName: Full=HLA class I histocompatibility antigen, alpha chain G; AltName: Full=HLA G antigen; AltName: Full=MHC class I antigen G; Flags: Precursor, or in the sequence









(SEQ ID NO: 4)


MVVMAPRTLFLLLSGALTLTETWAGSHSMRYFSAAVSRPGRGEPRFIA





MGYVDDTQFVRFDSDSACPRMEPRAPWVEQEGPEYWEEETRNTKAHAQ





TDRMNLQTLRGYYNQSEASSHTLQWMIGCDLGSDGRLLRGYEQYAYDG





KDYLALNEDLRSWTAADTAAQISKRKCEAANVAEQRRAYLEGTCVEWL





HRYLENGKEMLQRADPPKTHVTHHPVEDYEATLRCWALGFYPAEIILT





WQRDGEDQTQDVELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHE





GLPEPLMLRWKQSSLPTIPIMGIVA.






Inhibitory molecule counter ligand molecule, as that term is used herein, refers to a polypeptide having sufficient inhibitory molecule counter ligand sequence such that when present as the ICIM binding/modulating moiety of a multimerized therapeutic compound, can bind and agonize a cognate inhibitory molecule. In some embodiments, the inhibitory molecule counter ligand molecule, when binding as a monomer (or binding when the therapeutic compound is not multimerized), to the inhibitory molecule, does not antagonize, substantially antagonize, prevent binding, or prevent substantial binding, of an endogenous counter ligand of the inhibitory molecule to the inhibitory molecule. In some embodiments, the inhibitory molecule counter ligand molecule when binding as a monomer (or binding when the therapeutic compound is not multimerized), to the inhibitory molecule, does not agonize or substantially agonize, the inhibitory molecule.


Sequence identity, percentage identity, and related terms, as those terms are used herein, refer to the relatedness of two sequences, e.g., two nucleic acid sequences or two amino acid or polypeptide sequences. In the context of an amino acid sequence, the term “substantially identical” is used herein to refer to a first amino acid that contains a sufficient or minimum number of amino acid residues that are i) identical to, or ii) conservative substitutions of aligned amino acid residues in a second amino acid sequence such that the first and second amino acid sequences can have a common structural domain and/or common functional activity. For example, amino acid sequences that contain a common structural domain having at least about 85%, 90%. 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a reference sequence, e.g., a sequence provided herein.


In the context of nucleotide sequence, the term “substantially identical” is used herein to refer to a first nucleic acid sequence that contains a sufficient or minimum number of nucleotides that are identical to aligned nucleotides in a second nucleic acid sequence such that the first and second nucleotide sequences encode a polypeptide having common functional activity, or encode a common structural polypeptide domain or a common functional polypeptide activity. For example, nucleotide sequences having at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a reference sequence, e.g., a sequence provided herein.


The term “functional variant” refers to polypeptides that have a substantially identical amino acid sequence to the naturally-occurring sequence, or are encoded by a substantially identical nucleotide sequence, and are capable of having one or more activities of the naturally-occurring sequence.


Calculations of homology or sequence identity between sequences (the terms are used interchangeably herein) are performed as follows.


To determine the percent identity of two amino acid sequences, or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid “identity” is equivalent to amino acid or nucleic acid “homology”).


The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.


The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch ((1970) J. Mol. Biol. 48:444-453) algorithm which has been incorporated into the GAP program in the GCG software package (available at http://www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at http://www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A particularly preferred set of parameters (and the one that should be used unless otherwise specified) are a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.


The percent identity between two amino acid or nucleotide sequences can be determined using the algorithm of E. Meyers and W. Miller ((1989) CABIOS, 4:11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.


The nucleic acid and protein sequences described herein can be used as a “query sequence” to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12 to obtain nucleotide sequences homologous to for example any a nucleic acid sequence provided herein. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to protein molecules provided herein. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25:3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See http://www.ncbi.nlm.nih.gov. As used herein, the term “hybridizes under low stringency, medium stringency, high stringency, or very high stringency conditions” describes conditions for hybridization and washing. Guidance for performing hybridization reactions can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6, which is incorporated by reference. Aqueous and nonaqueous methods are described in that reference and either can be used. Specific hybridization conditions referred to herein are as follows: 1) low stringency hybridization conditions in 6× sodium chloride/sodium citrate (SSC) at about 45° C., followed by two washes in 0.2×SSC, 0.1% SDS at least at 50° C. (the temperature of the washes can be increased to 55° C. for low stringency conditions); 2) medium stringency hybridization conditions in 6×SSC at about 45° C., followed by one or more washes in 0.2×SSC, 0.1% SDS at 60° C.; 3) high stringency hybridization conditions in 6×SSC at about 45° C., followed by one or more washes in 0.2×SSC, 0.1% SDS at 65° C.; and preferably 4) very high stringency hybridization conditions are 0.5M sodium phosphate, 7% SDS at 65° C., followed by one or more washes at 0.2×SSC, 1% SDS at 65° C. Very high stringency conditions (4) are the preferred conditions and the ones that should be used unless otherwise specified.


It is understood that the molecules and compounds of the present embodiments may have additional conservative or non-essential amino acid substitutions, which do not have a substantial effect on their functions.


The term “amino acid” is intended to embrace all molecules, whether natural or synthetic, which include both an amino functionality and an acid functionality and capable of being included in a polymer of naturally-occurring amino acids. Exemplary amino acids include naturally-occurring amino acids; analogs, derivatives and congeners thereof; amino acid analogs having variant side chains; and all stereoisomers of any of any of the foregoing. As used herein the term “amino acid” includes both the D- or L-optical isomers and peptidomimetics.


A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). CD39 molecule, a CD73 molecule, a Cell surface molecule binder, Donor specific targeting moiety Effector ligand binding molecule, ICIM binding/modulating moiety IIC binding/modulating moiety, an inhibitory immune checkpoint molecule ligand molecule, Inhibitory molecule counter ligand molecule, SM binding/modulating moiety, or ICSM binding/modulating moiety.


SM binding/modulating moiety, as that term is used herein, refers to an effector binding/modulating moiety that, as part of a therapeutic compound, promotes an immuno-suppressive local microenvironment, e.g., by providing in the proximity of the target, a substance that inhibits or minimizes attack by the immune system of the target. In some embodiments, the SM binding/modulating moiety comprises, or binds, a molecule that inhibits or minimizes attack by the immune system of the target. In some embodiments, a therapeutic compound comprises an SM binding/modulating moiety that binds and accumulates a soluble substance, e.g., an endogenous or exogenous substance, having immunosuppressive function. In some embodiments, a therapeutic compound comprises an SM binding/modulating moiety that binds and inhibits, sequesters, degrades or otherwise neutralizes a substance, e.g., a soluble substance, typically and endogenous soluble substance, that promotes immune attack. In some embodiments, a therapeutic compound comprises an SM binding/modulating moiety that comprises an immune-suppressive substance, e.g. a fragment of protein known to be immunosuppressive. By way of example, an effector molecule binding moiety that binds, or comprises, a substance e.g., a CD39 molecule or a CD73 molecule, that depletes a component, that promotes immune effector cell function, e.g., ATP or AMP.


Specific targeting moiety, as that term is used herein, refers to donor specific targeting moiety or a tissue specific targeting moiety.


Subject, as that term is used herein, refers to a mammalian subject, e.g., a human subject. In some embodiments, the subject is a non-human mammal, e.g., a horse, dog, cat, cow, goat, or pig.


Target ligand binding molecule, as used herein, refers to a polypeptide that has sufficient sequence from a naturally occurring counter-ligand of a target ligand that it can bind the target ligand on a target tissue (e.g., donor tissue or subject target tissue) with sufficient specificity that it can serve as a specific targeting moiety. In some embodiments, it binds to target tissue or cells with at least 10, 20, 30, 40, 50, 60, 70, 80, 90, or 95% of the affinity of the naturally occurring counter-ligand. In some embodiments, it has at least 60, 70, 80, 90, 95, 99, or 100% sequence identity, or substantial sequence identity, with a naturally occurring counter-ligand for the target ligand.


Target site, as that term is used herein, refers to a site which contains the entity, e.g., epitope, bound by a targeting moiety. In some embodiments, the target site is the site at which immune privilege is established.


Tissue specific targeting moiety, as that term is used herein, refers to a moiety, e.g., an antibody molecule, that as a component of a therapeutic molecule, localizes the therapeutic molecule preferentially to a target tissue, as opposed to other tissue of a subject. As a component of a therapeutic compound, the tissue specific targeting moiety provides site-specific immune privilege for a target tissue, e.g., an organ or tissue undergoing or at risk for autoimmune attack. In some embodiments, a tissue specific targeting moiety binds to a product, e.g., a polypeptide product, which is not present outside the target tissue, or is present at sufficiently low levels that, at therapeutic concentrations of therapeutic molecule, unacceptable levels of immune suppression are absent or substantially absent. In some embodiments, a tissue specific targeting moiety binds to an epitope, which epitope is not present outside, or not substantially present outside, the target site.


In some embodiments, a tissue specific targeting moiety, as a component of a therapeutic compound, preferentially binds to a target tissue or target tissue antigen, e.g., has a binding affinity for the target tissue or antigen that is greater for target antigen or tissue, e.g., at least 2, 4, 5, 10, 50, 100, 500, 1,000, 5,000, or 10,000 fold greater, than its affinity for than for non-target tissue or antigen present outside the target tissue. Affinity of a therapeutic compound of which the tissue specific moiety is a component, can be measured in a cell suspension, e.g., the affinity for suspended cells having the target antigen is compared with its affinity for suspended cells not having the target antigen. In some embodiments, the binding affinity for the target antigen bearing cells is below 10 nM.


In some embodiments, the binding affinity for the target antigen bearing cells is below 100 pM, 50 pM, or 10 pM. In some embodiments, the specificity for a target antigen is sufficient, that when the tissue specific targeting moiety is coupled to an immune-down regulating effector: i) immune attack of the target tissue, e.g., as measured by histological inflammatory response, infiltrating T effector cells, or organ function, in the clinical setting—e.g. creatinine for kidney, is substantially reduced, e.g., as compared to what would be seen in an otherwise similar implant but lacking the tissue specific targeting moiety is coupled to an immune-down regulating effector; and/or ii) immune function in the recipient, outside or away from the target tissue, is substantially maintained.


In some embodiments, one or more of the following is seen: at therapeutic levels of therapeutic compound, peripheral blood lymphocyte counts are not substantially impacted, e.g., the level of T cells is within 25, 50, 75, 85, 90, or 95% of normal, the level of B cells is within 25, 50, 75, 85, 90, or 95% of normal, and/or the level of granulocytes (PMNs) cells is within 25, 50, 75, 85, 90, or 95% of normal, or the level of monocytes is within 25, 50, 75, 85, 90, or 95% of normal 1; at therapeutic levels of therapeutic compound, the ex vivo proliferative function of PBMCs (peripheral blood mononuclear cells) against non-disease relevant antigens is substantially normal or is within 70, 80, or 90% of normal; at therapeutic levels of therapeutic compound, the incidence or risk of risk of opportunistic infections and cancers associated with immunosuppression is not substantially increased over normal; or at therapeutic levels of therapeutic compound, the incidence or risk of risk of opportunistic infections and cancers associated with immunosuppression is substantially less than would be seen with standard of care, or non-targeted, immunosuppression. In some embodiments, the tissue specific targeting moiety comprises an antibody molecule. In some embodiments, the donor specific targeting moiety comprises an antibody molecule, a target specific binding polypeptide, or a target ligand binding molecule. In some embodiments, the tissue specific targeting moiety binds a product, or a site on a product, that is present or expressed exclusively, or substantially exclusively, on target tissue.


ICIM Binding/Modulating Moieties: Effector Binding/Modulating Moieties that Bind Inhibitory Receptors


Methods and compounds described herein provide for a therapeutic compound having an effector binding/modulating moiety comprising an ICIM binding/modulating moiety, that directly binds and activates an inhibitory receptor on the surface of an immune cell, e.g., to reduce or eliminate, or substantially eliminate, the ability of the immune cell to mediate immune attack. Coupling of the ICIM binding/modulating moiety to a targeting entity, promotes site-specific or local down regulation of the immune cell response, e.g., confined substantially to the locations having binding sites for the targeting moiety. Thus, normal systemic immune function is substantially retained. In some embodiments, an ICIM binding/modulating moiety comprises an inhibitory immune checkpoint molecule counter ligand molecule, e.g., a natural ligand, or fragment of a natural ligand (e.g., PD-L1 or HLA-G) of the inhibitory immune checkpoint molecule. In some embodiments, an ICIM binding/modulating moiety comprises a functional antibody molecule, e.g., a functional antibody molecule comprising an scFv binding domain, that engages inhibitory immune checkpoint molecule.


In some embodiments, the ICIM binding/modulating moiety, comprising, e.g., a functional antibody molecule, or inhibitory immune checkpoint molecule ligand molecule, binds the inhibitory receptor but does not prevent binding of a natural ligand of the inhibitory receptor to the inhibitory receptor. In embodiments a format is used wherein a targeting moiety is coupled, e.g., fused, to an ICIM binding/modulating moiety, comprising, e.g., an scFv domain, and configured so that upon binding of an inhibitory receptor while in solution (e.g., in blood or lymph) (and presumably in a monomeric format), the therapeutic molecule: i) fails to agonize, or fails to substantially agonize (e.g., agonizes at less than 30, 20, 15, 10, or 5% of the level seen with a full agonizing molecule) the inhibitory receptor on the immune cell; and/or ii) fails to antagonize, or fails to substantially antagonize (e.g., antagonizes at less than 30, 20, 15, 10, or 5% of the level seen with a full antagonizing molecule) the inhibitory receptor on the immune cell. A candidate molecule can be evaluated for its ability to agonize or not agonize by its ability to either increase or decrease the immune response in an in vitro cell based assay wherein the target is not expressed, e.g., using an MLR-based assay (mixed lymphocyte reaction).


In some embodiments, candidate ICIM binding/modulating moieties can reduce, completely or substantially eliminate systemic immunosuppression and systemic immune activation. In some embodiments, the targeting domain of the therapeutic compound, when bound to target, will serve to cluster or multimerize the therapeutic compound on the surface of the tissue desiring immune protection. In some embodiments, the ICIM binding/modulating moiety, e.g., an ICIM binding/modulating moiety comprising a scFv domain, requires a clustered or multimeric state to be able to deliver an agonistic and immunosuppressive signal, or substantial levels of such signal, to local immune cells. This type of therapeutic can, for example, provide to a local immune suppression whilst leaving the systemic immune system unperturbed or substantially unperturbed. That is, the immune suppression is localized to where the suppression is needed as opposed to being systemic and not localized to a particular area or tissue type.


In some embodiments, upon binding to the target e.g., a target organ, tissue or cell type, the therapeutic compound coats the target, e.g., target organ, tissue or cell type. When circulating lymphocytes attempt to engage and destroy the target, this therapeutic will provide an ‘off’ signal only at, or to a greater extent at, the site of therapeutic compound accumulation.


A candidate therapeutic compound can be evaluated for the ability to bind, e.g., specifically bind, its target, e.g., by ELISA, a cell based assay, or surface plasmon resonance. This property should generally be maximized, as it mediates the site-specificity and local nature of the immune privilege. A candidate therapeutic compound can be evaluated for the ability to down regulate an immune cell when bound to target, e.g., by a cell based activity assay. This property should generally be maximized, as it mediates the site-specificity and local nature of the immune privilege. The level of down regulation effected by a candidate therapeutic compound in monomeric (or non-bound) form can be evaluated, e.g., by a cell based activity assay. This property should generally be minimized, as could mediate systemic down regulation of the immune system. The level of antagonism of a cell surface inhibitory molecule, e.g., an inhibitory immune checkpoint molecule, effected by a candidate therapeutic compound in monomeric (or non-bound) form can be evaluated, e.g., by, e.g., by a cell based activity assay. This property should generally be minimized, as could mediate systemic unwanted activation of the immune system. Generally, the properties should be selected and balanced to produce a sufficiently robust site specific immune privilege without unacceptable levels of non-site specific agonism or antagonism of the inhibitory immune checkpoint molecule.


The PD-L1/PD-1 Pathway

Programmed cell death protein 1, (often referred to as PD-1) is a cell surface receptor that belongs to the immunoglobulin superfamily. PD-1 is expressed on T cells and other cell types including, but not limited to, B cells, myeloid cells, dendritic cells, monocytes, T regulatory cells, iNK T cells. PD-1 binds two ligands, PD-L1 and PD-L2, and is an inhibitory immune checkpoint molecule. Engagement with a cognate ligand, PD-L1 or PD-L2, in the context of engagement of antigen loaded MCH with the T Cell Receptor on a T cell minimizes or prevents the activation and function of T cells. The inhibitory effect of PD-1 can include both promoting apoptosis (programmed cell death) in antigen specific T-cells in lymph nodes and reducing apoptosis in regulatory T cells (suppressor T cells).


In some embodiments, a therapeutic compound comprises an ICIM binding/modulating moiety which agonizes PD-1 inhibition. An ICIM binding/modulating moiety can include an inhibitory molecule counter ligand molecule, e.g., comprising a fragment of a ligand of PD-1 (e.g., a fragment of PD-L1 or PD-L2) or another moiety, e.g., a functional antibody molecule, comprising, e.g., an scFv domain that binds PD-1.


In some embodiments, a therapeutic compound comprises a targeting moiety that is preferentially binds a donor antigen not present in, present in substantially lower levels in the subject, e.g., a donor antigen from Table 2, and is localized to donor graft tissue in a subject. In some embodiments, it does not bind, or does not substantially bind, other tissues. In some embodiments, a therapeutic compound can include a targeting moiety that is specific for HLA-A2 and specifically binds donor allograft tissue but does not bind, or does not substantially bind, host tissues. In some embodiments, the therapeutic compound comprises an ICIM binding/modulating moiety, e.g., an inhibitory molecule counter ligand molecule, e.g., comprising a fragment of a ligand of PD-1 (e.g., a fragment of PD-L1 or PD-L2) or another moiety, e.g., a functional antibody molecule, comprising, e.g., an scFv domain that binds PD-1, such that the therapeutic compound, e.g., when bound to target, activates PD-1. The therapeutic compound targets an allograft and provides local immune privilege to the allograft.


In some embodiments, a therapeutic compound comprises a targeting moiety that is preferentially binds to an antigen of Table 3, and is localized to the target in a subject, e.g., a subject having an autoimmune disorder, e.g., an autoimmune disorder of Table 3. In some embodiments, it does not bind, or does not substantially bind, other tissues. In some embodiments, the therapeutic compound comprises an ICIM binding/modulating moiety, e.g., an inhibitory molecule counter ligand molecule, e.g., comprising a fragment of a ligand of PD-1 (e.g., a fragment of PD-L1 or PD-L2) or another moiety, e.g., a functional antibody molecule, comprising, e.g., an scFv domain that binds PD-1, such that the therapeutic compound, e.g., when bound to target, activates PD-1. The therapeutic compound targets a tissue subject to autoimmune attack and provides local immune privilege to the tissue.


PD-L1 and PDL2, or polypeptides derived therefrom, can provide candidate ICIM binding moieties. However, in monomer form, e.g., when the therapeutic compound is circulating in blood or lymph, this molecule could have an undesired effect of antagonizing the PD-L1/PD-1 pathway, and may only agonize the PD-1 pathway when clustered or multimerized on the surface of a target, e.g., a target organ. In some embodiments, a therapeutic compound comprises an ICIM binding/modulating moiety comprising a functional antibody molecule, e.g., a scFv domain, that is inert, or substantially inert, to the PD-1 pathway in a soluble form but which agonizes and drives an inhibitory signal when multimerized (by the targeting moiety) on the surface of a tissue.


The antibodies that bind to PD-1 that are provided for herein can be linked or associated with a targeting moiety as provided for herein. These can be used to modulate the PD-1/PD-L1 pathway as provided for herein.


IL-2 Mutein Molecules: IL2 Receptor Binders that Activate Tregs


IL-2 mutein molecule, as that term is used herein, refers to an IL2 variant that binds with high affinity to the CD25 (IL-2R alpha chain) and with low affinity to the other IL-2R signaling components CD122 (IL-2R beta) and CD132 (IL-2R gamma). Such an IL-2 mutein molecule preferentially activates Treg cells. In embodiments, either alone, or as a component of a therapeutic compound, an IL-2 mutein activates Tregs at least 2, 5, 10, or 100 fold more than cytotoxic or effector T cells. Exemplary IL-2 mutein molecules are described in WO2010085495, WO2016/164937, US2014/0286898A1, WO2014153111A2, WO2010/085495, cytotoxic WO2016014428A2, WO2016025385A1, and US20060269515. Muteins disclosed in these references that include additional domains, e.g., an Fc domain, or other domain for extension of half-life can be used in the therapeutic compounds and methods described herein without such additional domains. In another embodiment an IIC binding/modulating moiety comprises an IL-2 mutein, or active fragment thereof, coupled, e.g., fused, to another polypeptide, e.g., a polypeptide that extends in vivo half-life, e.g., an immunoglobulin constant region, or a multimer or dimer thereof, e.g., AMG 592. In an embodiment the therapeutic compound comprises the IL-2 portion of AMG 592. In an embodiment the therapeutic compound comprises the IL-2 portion but not the immunoglobulin portion of AMG 592. In some embodiments, the mutein does not comprise a Fc region. For some IL-2 muteins, the muteins are engineered to contain a Fc region because such region has been shown to increase the half-life of the mutein. In some embodiments, the extended half-life is not necessary for the methods described and embodied herein. In some embodiments, the Fc region that is fused with the IL-2 mutein comprises a N297 mutations, such as, but not limited to, N297A. In some embodiments, the Fc region that is fused with the IL-2 mutein does not comprise a N297 mutation, such as, but not limited to, N297A.


IL-2 mutein molecules that preferentially expand or stimulate Treg cells (over cytotoxic T cells) can be used as an IIC binding/modulating moiety. In some embodiments, the IL-2 mutein can be linked to a PD-1 agonist antibody as provided for herein. Although such molecule may not be targeted to a specific tissue, it could be used to systemically regulate the immune system by targeting both the PD-1 pathway and the IL-2 pathway.


In some embodiments, IIC binding/modulating moiety comprises an IL-2 mutein molecule. As used herein, the term “IL-2 mutein molecule” or “IL-2 mutein” refers to an IL-2 variant that preferentially activates Treg cells. In some embodiments, either alone, or as a component of a therapeutic compound, an IL-2 mutein molecule activates Tregs at least 2, 5, 10, or 100 fold more than cytotoxic T cells. A suitable assay for evaluating preferential activation of Treg cells can be found in U.S. Pat. No. 9,580,486 at, for example, Examples 2 and 3, or in WO2016014428 at, for example, Examples 3, 4, and 5, each of which is incorporated by reference in its entirety. The sequence of mature IL-2 is











(SEQ ID NO: 6)



APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTF







KFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRD







LISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQ







SIISTLT (mature IL-2 sequence)






The immature sequence of IL-2 can be represented by











(SEQ ID NO: 15)



MYRMQLLSCIALSLALVTNSAPTSSSTKKTQLQLEHLLLDLQ







MILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELK







PLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTEMCE







YADETATIVEFLNRWITFCQSIISTLT.






In some embodiments, an IIC binding/modulating moiety comprises an IL-2 mutein, or active fragment thereof, coupled, e.g., fused, to another polypeptide, e.g., a polypeptide that extends in vivo half-life, e.g., an immunoglobulin constant region, or a multimer or dimer thereof.


An IL-2 mutein molecule can be prepared by mutating one or more of the residues of IL-2. Non-limiting examples of IL-2-muteins can be found in WO2016/164937, U.S. Pat. Nos. 9,580,486, 7,105,653, 9,616,105, 9,428,567, US2017/0051029, US2014/0286898A1, WO2014153111A2, WO2010/085495, WO2016014428A2, WO2016025385A1, and US20060269515, each of which are incorporated by reference in its entirety.


In some embodiments, the alanine at position 1 of the sequence above is deleted. In some embodiments, the IL-2 mutein molecule comprises a serine substituted for cysteine at position 125 of the mature IL-2 sequence. Other combinations of mutations and substitutions that are IL-2 mutein molecules are described in US20060269515, which is incorporated by reference in its entirety. In some embodiments, the cysteine at position 125 is also substituted with a valine or alanine. In some embodiments, the IL-2 mutein molecule comprises a V91K substitution. In some embodiments, the IL-2 mutein molecule comprises a N88D substitution. In some embodiments, the IL-2 mutein molecule comprises a N88R substitution. In some embodiments, the IL-2 mutein molecule comprises a substitution of H16E, D84K, V91N, N88D, V91K, or V91R, any combinations thereof. In some embodiments, these IL-2 mutein molecules also comprise a substitution at position 125 as described herein. In some embodiments, the IL-2 mutein molecule comprises one or more substitutions selected from the group consisting of. T3N, T3A, L12G, L12K, L12Q, L12S, Q13G, E15A, E15G, E15S, H16A, H16D, H16G, H16K, H16M, H16N, H16R, H16S, H16T, H16V, H16Y, L19A, L19D, L19E, L19G, L19N, L19R, L19S, L19T, L19V, D20A, D20E, D20H, D20I, D20Y, D20F, D20G, D20T, D20W, M23R, R81A, R81G, R81S, R81T, D84A, D84E, D84G, D84I, D84M, D84Q D84R, D84S, D84T, S87R, N88A, N88D, N88E, N88I, N88F, N88G, N88M, N88R, N88S, N88V, N88W, V91D, V91E, V91G, V91S, I92K, I92R, E95G, and Q126. In some embodiments, the amino acid sequence of the IL-2 mutein molecule differs from the amino acid sequence set forth in mature IL-2 sequence with a C125A or C125S substitution and with one substitution selected from T3N, T3A, L12G, L12K, L12Q L12S, Q13G, E15A, E15G, E15S, H16A, H16D, H16G, H16K, H16M, H16N, H16R, H16S, H16T, H16V, H16Y, L19A, L19D, L19E, L19G, L19N, L19R, L19S, L19T, L19V, D20A, D20E, D20F, D20G, D20T, D20W, M23R, R81A, R81G, R81S, R81T, D84A, D84E, D84G, D84I, D84M, D84Q, D84R, D84S, D84T, S87R, N88A, N88D, N88E, N88F, N88I, N88G, N88M, N88R, N88S, N88V, N88W, V91D, V91E, V91G, V91S, I92K, I92R, E95G, Q126I, Q126L, and Q126F. In some embodiments, the IL-2 mutein molecule differs from the amino acid sequence set forth in mature IL-2 sequence with a C125A or C125S substitution and with one substitution selected from D20H, D20I, D20Y, D20E, D20G, D20W, D84A, D84S, H16D, H16G, H16K, H16R, H16T, H16V, I92K, I92R, L12K, L19D, L19N, L19T, N88D, N88R, N88S, V91D, V91G, V91K, and V91S. In some embodiments, the IL-2 mutein comprises N88R and/or D20H mutations.


In some embodiments, the IL-2 mutein molecule comprises a mutation in the polypeptide sequence at a position selected from the group consisting of amino acid 30, amino acid 31, amino acid 35, amino acid 69, and amino acid 74. In some embodiments, the mutation at position 30 is N30S. In some embodiments, the mutation at position 31 is Y31H. In some embodiments, the mutation at position 35 is K35R. In some embodiments, the mutation at position 69 is V69A. In some embodiments, the mutation at position 74 is Q74P. In some embodiments, the mutein comprises a V69A mutation, a Q74P mutation, a N88D or N88R mutation, and one or more of L53I, L56I, L80I, or L118I mutations. In some embodiments, the mutein comprises a V69A mutation, a Q74P mutation, a N88D or N88R mutation, and a L to I mutation selected from the group consisting of: L53I, L56I, L80I, and L118I mutation. In some embodiments, the IL-2 mutein comprises a V69A, a Q74P, a N88D or N88R mutation, and a L53I mutation. In some embodiments, the IL-2 mutein comprises a V69A, a Q74P, a N88D or N88R mutation, and a L56I mutation. In some embodiments, the IL-2 mutein comprises a V69A, a Q74P, a N88D or N88R mutation, and a L80I mutation. In some embodiments, the IL-2 mutein comprises a V69A, a Q74P, a N88D or N88R mutation, and a L118I mutation. As provided for herein, the muteins can also comprise a C125A or C125S mutation.


In some embodiments, the mutein comprises a T3A mutation. The full length IL-2 muteins provided herein may not be illustrated with a T3A or other mutations provided for herein, but such mutations can be added into the muteins provided herein as is the case for any of the other mutations illustrated herein. Accordingly, In some embodiments, the mutein comprises a T3N mutation. In some embodiments, the mutein comprises a T3A mutation. In some embodiments, the mutein comprises a L12G mutation. In some embodiments, the mutein comprises a L12K mutation. In some embodiments, the mutein comprises a L12Q mutation. In some embodiments, the mutein comprises a L12S mutation. In some embodiments, the mutein comprises a Q13G mutation. In some embodiments, the mutein comprises a E15A mutation. In some embodiments, the mutein comprises a E15G mutation. In some embodiments, the mutein comprises a E15S mutation. In some embodiments, the mutein comprises a H16A mutation. In some embodiments, the mutein comprises a H16D mutation. In some embodiments, the mutein comprises a H16G mutation. In some embodiments, the mutein comprises a H16K mutation. In some embodiments, the mutein comprises a H16M mutation. In some embodiments, the mutein comprises a H16N mutation. In some embodiments, the mutein comprises a H16R mutation. In some embodiments, the mutein comprises a H16S mutation. In some embodiments, the mutein comprises a H16T mutation. In some embodiments, the mutein comprises a HT6V mutation. In some embodiments, the mutein comprises a H16Y mutation. In some embodiments, the mutein comprises a L19A mutation. In some embodiments, the mutein comprises a L19D mutation. In some embodiments, the mutein comprises a L19E mutation. In some embodiments, the mutein comprises a L19G mutation. In some embodiments, the mutein comprises a L19N mutation. In some embodiments, the mutein comprises a L19R mutation. In some embodiments, the mutein comprises a L19S mutation. In some embodiments, the mutein comprises a L19T mutation. In some embodiments, the mutein comprises a L19V mutation. In some embodiments, the mutein comprises a D20A mutation. In some embodiments, the mutein comprises a D20E mutation. In some embodiments, the mutein comprises a D20H mutation. In some embodiments, the mutein comprises a D20I mutation. In some embodiments, the mutein comprises a D20Y mutation. In some embodiments, the mutein comprises a D20F mutation. In some embodiments, the mutein comprises a D20G mutation. In some embodiments, the mutein comprises a D20T mutation. In some embodiments, the mutein comprises a D20W mutation. In some embodiments, the mutein comprises a M23R mutation. In some embodiments, the mutein comprises a R81A mutation. In some embodiments, the mutein comprises a R81G mutation. In some embodiments, the mutein comprises a R81S mutation. In some embodiments, the mutein comprises a R81T mutation. In some embodiments, the mutein comprises a D84A mutation. In some embodiments, the mutein comprises a D84E mutation. In some embodiments, the mutein comprises a D84G mutation. In some embodiments, the mutein comprises a D84I mutation. In some embodiments, the mutein comprises a D84M mutation. In some embodiments, the mutein comprises a D84Q mutation. In some embodiments, the mutein comprises a D84R mutation. In some embodiments, the mutein comprises a D84S mutation. In some embodiments, the mutein comprises a D84T mutation. In some embodiments, the mutein comprises a S87R mutation. In some embodiments, the mutein comprises a N88A mutation. In some embodiments, the mutein comprises a N88D mutation. In some embodiments, the mutein comprises a N88E mutation. In some embodiments, the mutein comprises a N88I mutation. In some embodiments, the mutein comprises a N88F mutation. In some embodiments, the mutein comprises a N88G mutation. In some embodiments, the mutein comprises a N88M mutation. In some embodiments, the mutein comprises a N88R mutation. In some embodiments, the mutein comprises a N88S mutation. In some embodiments, the mutein comprises a N88V mutation. In some embodiments, the mutein comprises a N88W mutation. In some embodiments, the mutein comprises a V91D mutation. In some embodiments, the mutein comprises a V91E mutation. In some embodiments, the mutein comprises a V91G mutation. In some embodiments, the mutein comprises a V91S mutation. In some embodiments, the mutein comprises a I92K mutation. In some embodiments, the mutein comprises a I92R mutation. In some embodiments, the mutein comprises a E95G mutation. In some embodiments, the mutein comprises a Q126 mutation.


Although the mutations are illustrated in list form, this is simply for convenience and the muteins may have one or more of the substitutions provided herein.


In some embodiments, the IL-2 mutein molecule comprises a substitution selected from the group consisting of: N88R, N88I, N88G, D20H, D109C, Q126L, Q126F, D84G, or D84I relative to mature human IL-2 sequence provided above. In some embodiments, the IL-2 mutein molecule comprises a substitution of D109C and one or both of a N88R substitution and a C125S substitution. In some embodiments, the cysteine that is in the IL-2 mutein molecule at position 109 is linked to a polyethylene glycol moiety, wherein the polyethylene glycol moiety has a molecular weight of between 5 and 40 kDa.


In some embodiments, any of the substitutions described herein are combined with a substitution at position 125. The substitution can be a C125S, C125A, or C125V substitution.


In addition to the substitutions or mutations described herein, in some embodiments, the IL-2 mutein has a substitution/mutation at one or more of positions 73, 76, 100, or 138 that correspond to SEQ ID NO: 15 or positions at one or more of positions 53, 56, 80, or 118 that correspond to SEQ ID NO: 6. In some embodiments, the IL-2 mutein comprises a mutation at positions 73 and 76; 73 and 100; 73 and 138; 76 and 100; 76 and 138; 100 and 138; 73, 76, and 100; 73, 76, and 138; 73, 100, and 138; 76, 100 and 138; or at each of 73, 76, 100, and 138 that correspond to SEQ ID NO: 15. In some embodiments, the IL-2 mutein comprises a mutation at positions 53 and 56; 53 and 80; 53 and 118; 56 and 80; 56 and 118; 80 and 118; 53, 56, and 80; 53, 56, and 118; 53, 80, and 118; 56, 80 and 118; or at each of 53, 56, 80, and 118 that correspond to SEQ ID NO: 6. As the IL-2 can be fused or tethered to other proteins, as used herein, the term corresponds to as reference to a SEQ ID NOs: 6 or 15 refer to how the sequences would align with default settings for alignment software, such as can be used with the NCBI website. In some embodiments, the mutation is leucine to isoleucine. Thus, the IL-2 mutein can comprise one more isoleucines at positions 73, 76, 100, or 138 that correspond to SEQ ID NO: 15 or positions at one or more of positions 53, 56, 80, or 118 that correspond to SEQ ID NO: 6. In some embodiments, the mutein comprises a mutation at L53 that correspond to SEQ ID NO: 6. In some embodiments, the mutein comprises a mutation at L56 that correspond to SEQ ID NO: 6. In some embodiments, the mutein comprises a mutation at L80 that correspond to SEQ ID NO: 6. In some embodiments, the mutein comprises a mutation at L118 that correspond to SEQ ID NO: 6. In some embodiments, the mutation is leucine to isoleucine. In some embodiments, the mutein also comprises a mutation as position 69, 74, 88, 125, or any combination thereof in these muteins that correspond to SEQ ID NO: 6. In some embodiments, the mutation is a V69A mutation. In some embodiments, the mutation is a Q74P mutation. In some embodiments, the mutation is a N88D or N88R mutation. In some embodiments, the mutation is a C125A or C125S mutation.


In some embodiments, the IL-2 mutein comprises a mutation at one or more of positions 49, 51, 55, 57, 68, 89, 91, 94, 108, and 145 that correspond to SEQ ID NO: 15 or one or more positions 29, 31, 35, 37, 48, 69, 71, 74, 88, and 125 that correspond to SEQ ID NO: 6. The substitutions can be used alone or in combination with one another. In some embodiments, the IL-2 mutein comprises substitutions at 2, 3, 4, 5, 6, 7, 8, 9, or each of positions 49, 51, 55, 57, 68, 89, 91, 94, 108, and 145. Non-limiting examples such combinations include, but are not limited to, a mutation at positions 49, 51, 55, 57, 68, 89, 91, 94, 108, and 145; 49, 51, 55, 57, 68, 89, 91, 94, and 108; 49, 51, 55, 57, 68, 89, 91, and 94; 49, 51, 55, 57, 68, 89, and 91; 49, 51, 55, 57, 68, and 89; 49, 51, 55, 57, and 68; 49, 51, 55, and 57; 49, 51, and 55; 49 and 51; 51, 55, 57, 68, 89, 91, 94, 108, and 145; 51, 55, 57, 68, 89, 91, 94, and 108; 51, 55, 57, 68, 89, 91, and 94; 51, 55, 57, 68, 89, and 91; 51, 55, 57, 68, and 89; 55, 57, and 68; 55 and 57; 55, 57, 68, 89, 91, 94, 108, and 145; 55, 57, 68, 89, 91, 94, and 108; 55, 57, 68, 89, 91, and 94; 55, 57, 68, 89, 91, and 94; 55, 57, 68, 89, and 91; 55, 57, 68, and 89; 55, 57, and 68; 55 and 57; 57, 68, 89, 91, 94, 108, and 145; 57, 68, 89, 91, 94, and 108; 57, 68, 89, 91, and 94; 57, 68, 89, and 91; 57, 68, and 89; 57 and 68; 68, 89, 91, 94, 108, and 145; 68, 89, 91, 94, and 108; 68, 89, 91, and 94; 68, 89, and 91; 68 and 89; 89, 91, 94, 108, and 145; 89, 91, 94, and 108; 89, 91, and 94; 89 and 91; 91, 94, 108, and 145; 91, 94, and 108; 91, and 94; or 94 and 108. Each mutation can be combined with one another. The same substitutions can be made in SEQ ID NO: 6, but the numbering would adjust appropriately as is clear from the present disclosure (20 less than the numbering for SEQ ID NO: 15 corresponds to the positions in SEQ ID NO: 6).


In some embodiments, the IL-2 mutein comprises a mutation at one or more positions of 35, 36, 42, 104, 115, or 146 that correspond to SEQ ID NO: 15 or the equivalent positions at SEQ ID NO: 6 (e.g. positions 15, 16, 22, 84, 95, or 126). These mutations can be combined with the other leucine to isoleucine mutations described herein or the mutation at positions 73, 76, 100, or 138 that correspond to SEQ ID NO: 15 or at one or more of positions 53, 56, 80, or 118 that correspond to SEQ ID NO: 6. In some embodiments, the mutation is a E35Q, H36N, Q42E, D104N, E115Q, or Q146E, or any combination thereof. In some embodiments, one or more of these substitutions is wild type. In some embodiments, the mutein comprises a wild-type residue at one or more of positions 35, 36, 42, 104, 115, or 146 that correspond to SEQ ID NO: 15 or the equivalent positions at SEQ ID NO: 6 (e.g. positions 15, 16, 22, 84, 95, and 126).


The mutations at these positions can be combined with any of the other mutations described herein, including, but not limited to substitutions at positions 73, 76, 100, or 138 that correspond to SEQ ID NO: 15 or positions at one or more of positions 53, 56, 80, or 118 that correspond to SEQ ID NO: 6 described herein and above. In some embodiments, the IL-2 mutein comprises a N49S mutation that corresponds to SEQ ID NO: 15. In some embodiments, the IL-2 mutein comprises a Y51S or a Y51H mutation that corresponds to SEQ ID NO: 15. In some embodiments, the IL-2 mutein comprises a K55R mutation that corresponds to SEQ ID NO: 15. In some embodiments, the IL-2 mutein comprises a T57A mutation that corresponds to SEQ ID NO: 15. In some embodiments, the IL-2 mutein comprises a K68E mutation that corresponds to SEQ ID NO: 15. In some embodiments, the IL-2 mutein comprises a V89A mutation that corresponds to SEQ ID NO: 15. In some embodiments, the IL-2 mutein comprises a N91R mutation that corresponds to SEQ ID NO: 15. In some embodiments, the IL-2 mutein comprises a Q94P mutation that corresponds to SEQ ID NO: 15. In some embodiments, the IL-2 mutein comprises a N108D or a N108R mutation that corresponds to SEQ ID NO: 15. In some embodiments, the IL-2 mutein comprises a C145A or C145S mutation that corresponds to SEQ ID NO: 15. These substitutions can be used alone or in combination with one another. In some embodiments, the mutein comprises each of these substitutions. In some embodiments, the mutein comprises 1, 2, 3, 4, 5, 6, 7, or 8 of these mutations. In some embodiments, the mutein comprises a wild-type residue at one or more of positions 35, 36, 42, 104, 115, or 146 that correspond to SEQ ID NO: 15 or the equivalent positions at SEQ ID NO: 6 (e.g. positions 15, 16, 22, 84, 95, and 126).


In some embodiments, the IL-2 mutein comprises a N29S mutation that corresponds to SEQ ID NO: 6. In some embodiments, the IL-2 mutein comprises a Y31S or a Y31H mutation that corresponds to SEQ ID NO: 6. In some embodiments, the IL-2 mutein comprises a K35R mutation that corresponds to SEQ ID NO: 6. In some embodiments, the IL-2 mutein comprises a T37A mutation that corresponds to SEQ ID NO: 6. In some embodiments, the IL-2 mutein comprises a K48E mutation that corresponds to SEQ ID NO: 6. In some embodiments, the IL-2 mutein comprises a V69A mutation that corresponds to SEQ ID NO: 6. In some embodiments, the IL-2 mutein comprises a N71R mutation that corresponds to SEQ ID NO: 6. In some embodiments, the IL-2 mutein comprises a Q74P mutation that corresponds to SEQ ID NO: 6. In some embodiments, the IL-2 mutein comprises a N88D or a N88R mutation that corresponds to SEQ ID NO: 6. In some embodiments, the IL-2 mutein comprises a C125A or C125S mutation that corresponds to SEQ ID NO: 6. These substitutions can be used alone or in combination with one another. In some embodiments, the mutein comprises 1, 2, 3, 4, 5, 6, 7, or 8 of these mutations. In some embodiments, the mutein comprises each of these substitutions. In some embodiments, the mutein comprises a wild-type residue at one or more of positions 35, 36, 42, 104, 115, or 146 that correspond to SEQ ID NO: 15 or the equivalent positions at SEQ ID NO: 6 (e.g. positions 15, 16, 22, 84, 95, and 126).


For any of the IL-2 muteins described herein, in some embodiments, one or more of positions 35, 36, 42, 104, 115, or 146 that correspond to SEQ ID NO: 15 or the equivalent positions at SEQ ID NO: 6 (e.g. positions 15, 16, 22, 84, 95, or 126) are wild-type (e.g. are as shown in SEQ ID NOs: 6 or 15). In some embodiments, 2, 3, 4, 5, 6, or each of positions 35, 36, 42, 104, 115, or 146 that correspond to SEQ ID NO: 15 or the equivalent positions at SEQ ID NO: 6 (e.g. positions 15, 16, 22, 84, 95, and 126) are wild-type.


In some embodiments, the IL-2 mutein comprises a sequence of:











(SEQ ID NO: 16)



MYRMQLLSCIALSLALVTNSAPTSSSTKKTQLQLEHLLLDLQ







MILNGISNHKNPRLARMLTFKFYMPEKATEIKHLQCLEEELK







PLEEALRLAPSKNFHLRPRDLISDINVIVLELKGSETTEMCE







YADETATIVEFLNRWITFSQSIISTLT.






In some embodiments, the IL-2 mutein comprises a sequence of:











(SEQ ID NO: 17)



MYRMQLLSCIALSLALVINSAPTSSSTKKTQLQLEHLLLDLQ







MILNGISNHKNPRLARMLTFKFYMPEKATELKHIQCLEEELK







PLEEALRLAPSKNFHLRPRDLISDINVIVLELKGSETTEMCE







YADETATIVEFLNRWITFSQSIISTLT.






In some embodiments, the IL-2 mutein comprises a sequence of:









(SEQ ID NO: 18)


MYRMQLLSCIALSLALVTNSAPTSSSTKKTQLQLEHLLLDLQMILNGISN





HKNPRLARMLTFKFYMPEKATELKHLQCLEEELKPLEEALRLAPSKNFHI





RPRDLISDINVIVLELKGSETTEMCEYADETATIVEFLNRWITFSQSIIS





TLT.






In some embodiments, the IL-2 mutein comprises a sequence of:









(SEQ ID NO: 19)


MYRMQLLSCIALSLALVINSAPTSSSTKKTQLQLEHLLLDLQMILNGISN





HKNPRLARMLTFKFYMPEKATELKHLQCLEEELKPLEEALRLAPSKNFHL





RPRDLISDINVIVLELKGSETTEMCEYADETATIVEFINRWITFSQSIIS





TLT.






In some embodiments, the IL-2 mutein sequences described herein do not comprise the IL-2 leader sequence. The IL-2 leader sequence can be represented by the sequence of MYRMQLLSCIALSLALVTNS (SEQ ID NO: 20). Therefore, in some embodiments, the sequences illustrated above can also encompass peptides without the leader sequence. Although SEQ ID NOs; 16-20 are illustrated with only mutation at one of positions 73, 76, 100, or 138 that correspond to SEQ ID NO: 15 or positions at one or more of positions 53, 56, 80, or 118 that correspond to SEQ ID NO: 6, the peptides can comprise one, two, three or 4 of the mutations at these positions. In some embodiments, the substitution at each position is isoleucine or other type of conservative amino acid substitution. In some embodiments, the leucine at the recited positions are substituted with, independently, isoleucine, valine, methionine, or phenylalanine.


In some embodiments, the IL-2 mutein molecule is fused to a Fc Region or other linker region as described herein. Examples of such fusion proteins can be found in U.S. Pat. Nos. 9,580,486, 7,105,653, 9,616,105, 9,428,567, US2017/0051029, WO2016/164937, US2014/0286898A1, WO2014153111A2, WO2010/085495, WO2016014428A2, WO2016025385A1, US2017/0037102, and US2006/0269515, each of which are incorporated by reference in its entirety.


In some embodiments, the Fc Region comprises what is known as the LALA mutation. Using the Kabat numbering of the Fc region, this would correspond to L247A, L248A, and G250A. In some embodiments, using the EU numbering of the Fc region, the Fc region comprises a L234A mutation, a L235A mutation, and/or a G237A mutation. Regardless of the numbering system used, in some embodiments, the Fc portion can comprise mutations that correspond to these residues. In some embodiments, the Fc Region comprises N297G or N297A (kabat numbering) mutations. The Kabat numbering is based upon a full-length sequence, but would be used in a fragment based upon a traditional alignment used by one of skill in the art for the Fc region.


In some embodiments, the Fc Region comprises a sequence of:









(SEQ ID NO: 21)


DKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMISRTPEVTCVVVDVSHED





PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK





CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK





GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG





NVFSCSVMHEALHNHYTQKSLSLSPG.


or





(SEQ ID NO: 28)


DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED





PEVKENWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK





CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK





GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG





NVFSCSVMHEALHNHYTQKSLSLSPG.






In some embodiments, the IL-2 mutein is linked to the Fc Region. Non-limiting examples of linkers are glycine/serine linkers. For example, a glycine/serine linkers can be a sequence of GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 22) or GGGGSGGGGSGGGGS (SEQ ID NO: 30). This is simply a non-limiting example and the linker can have varying number of GGGGS (SEQ ID NO: 23) or GGGGA repeats (SEQ ID NO: 29). In some embodiments, the linker comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the GGGGS (SEQ ID NO: 23) or GGGGA repeats (SEQ ID NO: 29) repeats (repeats disclosed as SEQ ID NOs: 1750 and 1748, respectively, in order of appearance). In some embodiments, the linker is 10 amino acids in length. In some embodiments, the linker is 5 amino acids in length. In some embodiments, the linker is 15 amino acids in length. In some embodiments, the linker is 20 amino acids in length. In some embodiments, the linker is 25 amino acids in length. In some embodiments, the linker is 30 amino acids in length. In some embodiments, the linker is 35 amino acids in length. In some embodiments, the linker is from 5-50 amino acids in length.


Thus, the IL-2/Fc Fusion can be represented by the formula of ZIL-2M-Lgs-ZFe, wherein ZIL-2M is an IL-2 mutein as described herein, Lgs is a linker sequence as described herein (e.g. glycine/serine linker) and ZFe is a Fc region described herein or known to one of skill in the art. In some embodiments, the formula can be in the reverse orientation ZFe-Lgs-ZIL-2M.


In some embodiments, the IL-2/Fc fusion comprises a sequence of









(SEQ ID NO: 24)


MYRMQLLSCIALSLALVTNSAPTSSSTKKTQLQLEHLLLDLQMILNGISN





HKNPRLARMLTFKFYMPEKATEIKHLQCLEEELKPLEEALRLAPSKNFHL





RPRDLISDINVIVLELKGSETTEMCEYADETATIVEFLNRWITESQSIIS





TLTGGGGSGGGGSGGGGSGGGGSDKTHTCPPCPAPEAAGAPSVELFPPKP





KDTLMISRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNAKTKPREEQYN





STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ





VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV





LDSDGSFFLYSKLTVDKSRWQQGNVESCSVMHEALHNHYTQKSLSLSPG;





(SEQ ID NO: 25)


MYRMQLLSCIALSLALVTNSAPTSSSTKKTQLQLEHLLLDLQMILNGISN





HKNPRLARMLTFKFYMPEKATELKHIQCLEEELKPLEEALRLAPSKNFHL





RPRDLISDINVIVLELKGSETTEMCEYADETATIVEFLNRWITFSQSIIS





TLTGGGGSGGGGSGGGGSGGGGSDKTHTCPPCPAPEAAGAPSVELFPPKP





KDTLMISRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNAKTKPREEQYN





STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ





VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV





LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG;





(SEQ ID NO: 26)


MYRMQLLSCIALSLALVINSAPTSSSTKKTQLQLEHLLLDLQMILNGISN





HKNPRLARMLTFKFYMPEKATELKHLQCLEEELKPLEEALRLAPSKNFHI





RPRDLISDINVIVLELKGSETTEMCEYADETATIVEFLNRWITFSQSIIS





TLTGGGGSGGGGSGGGGSGGGGSDKTHTCPPCPAPEAAGAPSVELFPPKP





KDTLMISRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNAKTKPREEQYN





STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ





VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV





LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG;


or





(SEQ ID NO: 27)


MYRMQLLSCIALSLALVTNSAPTSSSTKKTQLQLEHLLLDLQMILNGISN





HKNPRLARMLTFKFYMPEKATELKHLQCLEEELKPLEEALRLAPSKNFHL





RPRDLISDINVIVLELKGSETTEMCEYADETATIVEFINRWITFSQSIIS





TLTGGGGSGGGGSGGGGSGGGGSDKTHTCPPCPAPEAAGAPSVELFPPKP





KDTLMISRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNAKTKPREEQYN





STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ





VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV





LDSDGSFFLYSKLTVDKSRWQQGNVESCSVMHEALHNHYTQKSLSLSPG.






In some embodiments, the IL-2/Fc Fusion comprises a sequence selected from the following table, Table 3:









TABLE 3







IL-2/Fc Fusion Protein Amino Acid Sequences








Sequence



Identification
Sequence





SEQ ID NO: 7
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEE



ELKPLEEVLNLAQSKNFHLRPRDLISRINVIVLELKGSETTEMCEYADETATIVEFLNRWI



TFSQSIISTLTGGGGAGGGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC



VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCK



VSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES



NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS



PGK





SEQ ID NO: 8
APTSSSTKKTQLQLEHLLLHLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEE



ELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTEMCEYADETATIVEFLNRWI



TFSQSIISTLTVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQ



FNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKT



ISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP



MLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK





SEQ ID NO: 9
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEE



ELKPLEEVLNLAQSKNFHLRPRDLISRINVIVLELKGSETTEMCEYADETATIVEFLNRWI



TFSQSIISTLTDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED



PEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP



IEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK



TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG





SEQ ID NO: 10
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEE



ELKPLEEVLNLAQSKNFHLRPRDLISRINVIVLELKGSETTEMCEYADETATIVEFLNRWI



TFSQSIISTLTGGGGSDKTHTCPPCPAPELLGGPSVELFPPKPKDTLMISRTPEVTCVVVD



VSHEDPEVKENWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNK



ALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP



ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG





SEQ ID NO: 11
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEE



ELKPLEEVLNLAQSKNFHLRPRDLISRINVIVLELKGSETTEMCEYADETATIVEFLNRWI



TFSQSIISTLTGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT



CVVVDVSHEDPEVKENWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKC



KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWE



SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL



SPG





SEQ ID NO: 12
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTEKFYMPKKATELKHLQCLEE



ELKPLEEVLNLAQSKNFHLRPRDLISRINVIVLELKGSETTEMCEYADETATIVEFLNRWI



TFSQSIISTLTGGGGGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR



TPEVTCVVVDVSHEDPEVKENWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNG



KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDI



AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVESCSVMHEALHNYHTQ



KSLSLSPG





SEQ ID NO: 13
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEE



ELKPLEEVLNLAQSKNFHLRPRDLISRINVIVLELKGSETTEMCEYADETATIVEFLNRWI



TFSQSIISTLTGGGGSGGGGSGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDT



LMISRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQ



DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGE



YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH



NHYTQKSLSLSPG





SEQ ID NO: 14
APTSSSTKKTQLQLEHLLLHLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEE



ELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTEMCEYADETATIVEFLNRWI



TFSQSIISTLTGGGGSGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR



TPEVTCVVVDVSHEDPEVKENWYVDGVEVHNAKTKPREEQYASTYPVVSVLTVLHQDWLNG



KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDI



AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ



KSLSLSPG









In some embodiments, the IL-2 muteins comprises one or more of the sequences provided in the following table, which, in some embodiments, shows the IL-2 mutein fused with other proteins or linkers. The table also provides sequences for a variety of Fc domains or variants that the IL-2 can be fused with:














SEQ ID
Brief



NO:
Description
Amino Acid Sequence







31
Human IL-2
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA



with C125S
TELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSE



mutation
TTFMCEYADETATIVEFLNRWITFSQSIISTLT





32
Human IL-2
APASSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA



with C125S
TELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSE



and T3A
TTFMCEYADETATIVEFLNRWITFSQSIISTLT



mutations






33
Human IL-2
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA



with N88R and
TELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISRINVIVLELKGSE



C125S
TTFMCEYADETATIVEFLNRWITFSQSIISTLT





34
Human IL-2
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA



with V69A,
TELKHLQCLEEELKPLEEALNLAPSKNFHLRPRDLISNINVIVLELKGSE



Q74P and
TTFMCEYADETATIVEFLNRWITFSQSIISTLT



C125S




mutations






35
Human IL-2
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA



with V69A,
TELKHLQCLEEELKPLEEALNLAPSKNFHLRPRDLISDINVIVLELKGSE



Q74P, N88D
TTFMCEYADETATIVEFLNRWITESQSIISTLT



and C125S




mutations






36
Human IL-2
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA



with V69A,
TELKHLQCLEEELKPLEEALNLAPSKNFHLRPRDLISRINVIVLELKGSE



Q74P, N88R
TTFMCEYADETATIVEFLNRWITFSQSIISTLT



and C125S




mutations






37
Human IL-2
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA



with N88D and
TELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISDINVIVLELKGSE



C125S
TTFMCEYADETATIVEFLNRWITFSQSIISTLT





38
Human IL-2
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA



with L53I,
TEIKHLQCLEEELKPLEEALNLAPSKNFHLRPRDLISDINVIVLELKGSE



V69A, Q74?,
TTFMCEYADETATIVEFLNRWITFSQSIISTLT



N88D and




C125S




mutations






39
Human IL-2
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA



with L56I,
TELKHIQCLEEELKPLEEALNLAPSKNFHLRPRDLISDINVIVLELKGSE



V69A, Q74P,
TTFMCEYADETATIVEFLNRWITESQSIISTLT



N88D and




C125S




mutations






40
Human IL-2
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA



with V69A,
TELKHLQCLEEELKPLEEALNLAPSKNFHIRPRDLISDINVIVLELKGSE



Q74P, L80I,
TTFMCEYADETATIVEFLNRWITFSQSIISTLT



N88D and




C125S




mutations






41
Human IL-2
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA



with V69A,
TELKHLQCLEEELKPLEEALNLAPSKNFHLRPRDLISDINVIVLELKGSE



Q74P, N88D,
TTFMCEYADETATIVEFINRWITFSQSIISTLT



L118I, and




C125S




mutations






21
Human IgG1 Fc
DKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMISRTPEVTCVVVDVSHED



(N-terminal
PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK



fusions) with
CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK



L234A, L235A,
GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG



and G237A
NVFSCSVMHEALHNHYTQKSLSLSPG



mutations






30
GGGGSGGGGSGGG
GGGGSGGGGSGGGGS



GS linker (15




amino acids)






22
GGGGSGGGGSGGG
GGGGSGGGGSGGGGSGGGGS



GSGGGGS




linker (20




amino acids)






23
GGGGS linker
GGGGS



(5 amino




acids )






43
Human IgG1 Fc
DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED



(truncated)
PEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYK



with N297G
CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK



mutation
GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG




NVFSCSVMHEALHNHYTQKSLSLSPG





44
Antibody
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV



Heavy Chain
HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP



CH1-CH2-CH3
KSCDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMISRTPEVTCVVVDVS



domains
HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK



(human IgG1
EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC



with L234A,
LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW



L235A, and
QQGNVFSCSVMHEALHNHYTQKSLSLSPG



G237A)






45
Antibody
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG



Kappa
NSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTK



Constant
SENRGEC



Domain




(human)






46
IL-2-G4Sx3-Fc
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA




TELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSE




TTFMCEYADETATIVEFLNRWITFSQSIISTLTGGGGSGGGGSGGGGSDK




THTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE




VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK




VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF




YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV




FSCSVMHEALHNHYTQKSLSLSPG





47
IL-2 T3A-
APASSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA



G4Sx3-Fc
TELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSE




TTFMCEYADETATIVEFLNRWITFSQSIISTLTGGGGSGGGGSGGGGSDK




THTCPPCPAPEAAGAPSVELFPPKPKDTLMISRTPEVTCVVVDVSHEDPE




VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK




VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF




YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV




FSCSVMHEALHNHYTQKSLSLSPG





48
IL-2 N88R-
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA



G4Sx3-Fc
TELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISRINVIVLELKGSE




TTFMCEYADETATIVEFLNRWITFSQSIISTLTGGGGSGGGGSGGGGSDK




THTCPPCPAPEAAGAPSVELFPPKPKDTLMISRTPEVTCVVVDVSHEDPE




VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK




VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF




YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV




FSCSVMHEALHNHYTQKSLSLSPG





49
IL-2 V69A,
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA



Q74P,-G4Sx3-
TELKHLQCLEEELKPLEEALNLAPSKNFHLRPRDLISNINVIVLELKGSE



Fc
TTFMCEYADETATIVEFLNRWITFSQSIISTLTGGGGSGGGGSGGGGSDK




THTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE




VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK




VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGE




YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV




FSCSVMHEALHNHYTQKSLSLSPG





50
IL-2 N88D
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA



V69A, Q74P-
TELKHLQCLEEELKPLEEALNLAPSKNFHLRPRDLISDINVIVLELKGSE



G4Sx3-Fc
TTFMCEYADETATIVEFLNRWITESQSIISTLTGGGGSGGGGSGGGGSDK




THTCPPCPAPEAAGAPSVELFPPKPKDTLMISRTPEVTCVVVDVSHEDPE




VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK




VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF




YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV




FSCSVMHEALHNHYTQKSLSLSPG





51
IL-2 N88R
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA



V69A, Q74P-
TELKHLQCLEEELKPLEEALNLAPSKNFHLRPRDLISRINVIVLELKGSE



G4Sx3-Fc
TTEMCEYADETATIVEFLNRWITFSQSIISTLTGGGGSGGGGSGGGGSDK




THTCPPCPAPEAAGAPSVELFPPKPKDTLMISRTPEVTCVVVDVSHEDPE




VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK




VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF




YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV




FSCSVMHEALHNHYTQKSLSLSPG





52
IL-2 N88D-
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA



G4Sx3-Fc
TELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISDINVIVLELKGSE




TTFMCEYADETATIVEFLNRWITFSQSIISTLTGGGGSGGGGSGGGGSDK




THTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE




VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK




VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF




YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV




FSCSVMHEALHNHYTQKSLSLSPG





53
IL-2 L53I
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA



N88D V69A,
TEIKHLQCLEEELKPLEEALNLAPSKNFHLRPRDLISDINVIVLELKGSE



Q74P,C125S-
TTFMCEYADETATIVEFLNRWITFSQSIISTLTGGGGSGGGGSGGGGSGG



G4Sx4-Fc
GGSDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMISRTPEVTCVVVDVS




HEDPEVKENWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK




EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC




LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW




QQGNVFSCSVMHEALHNHYTQKSLSLSPG





54
IL-2 L56I
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA



N88D V69A,
TELKHIQCLEEELKPLEEALNLAPSKNFHLRPRDLISDINVIVLELKGSE



Q74P, C125S
TTFMCEYADETATIVEFLNRWITFSQSIISTLTGGGGSGGGGSGGGGSGG



G4Sx4-Fc
GGSDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMISRTPEVTCVVVDVS




HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK




EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC




LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW




QQGNVFSCSVMHEALHNHYTQKSLSLSPG





55
IL-2 L80I
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA



N88D V69A,
TELKHLQCLEEELKPLEEALNLAPSKNFHIRPRDLISDINVIVLELKGSE



C125S Q74P-
TTFMCEYADETATIVEFLNRWITESQSIISTLTGGGGSGGGGSGGGGSGG



G4Sx4-Fc
GGSDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMISRTPEVTCVVVDVS




HEDPEVKENWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK




EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC




LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW




QQGNVFSCSVMHEALHNHYTQKSLSLSPG





56
IL-2 L118I
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA



N88D V69A,
TELKHLQCLEEELKPLEEALNLAPSKNFHLRPRDLISDINVIVLELKGSE



Q74P, C125S-
TTFMCEYADETATIVEFINRWITFSQSIISTLTGGGGSGGGGSGGGGSGG



G4Sx4-Fc
GGSDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMISRTPEVTCVVVDVS




HEDPEVKENWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK




EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC




LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW




QQGNVFSCSVMHEALHNHYTQKSLSLSPG





57
IL-2 N88D
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA



V69A, Q74P-
TELKHLQCLEEELKPLEEALNLAPSKNFHLRPRDLISDINVIVLELKGSE



G4Sx4-Fc
TTFMCEYADETATIVEFLNRWITFSQSIISTLTGGGGSGGGGSGGGGSGG




GGSDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMISRTPEVTCVVVDVS




HEDPEVKENWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK




EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC




LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW




QQGNVFSCSVMHEALHNHYTQKSLSLSPG





58
Fc-G4S-IL-2
DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED



N88D V69A,
PEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYK



Q74P
CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK




GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG




NVFSCSVMHEALHNHYTQKSLSLSPGGGGGSAPTSSSTKKTQLQLEHLLL




DLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEA




LNLAPSKNFHLRPRDLISDINVIVLELKGSETTEMCEYADETATIVEFLN




RWITFAQSIISTLT





59
IL-2 N88D
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA



V69A, Q74P,
TEX1KHX2QCLEEELKPLEEALNLAPSKNFHX3RPRDLISDINVIVLELK



C125S-G4Sx4-
GSETTEMCEYADETATIVEFX4NRWITFSQSIISTLTGGGGSGGGGSGGG



Fc, wherein
GSGGGGSDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMISRTPEVTCVV



at least one
VDVSHEDPEVKENWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW



of X1, X2, X3,
LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV



and X4 is I
SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD



and the
KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG



remainder are




L or I.






60
IL-2 N88D
APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA



V69A, Q74P,
TEX1KHX2QCLEEELKPLEEALNLAPSKNFHX3RPRDLISDINVIVLELK



C125S,
GSETTEMCEYADETATIVEFX4NRWITFSQSIISTLT



wherein at




least one of




X1, X2, X3,




and X4 is I




and the




remainder are




L or I.









In some embodiments, the sequences shown in the table or throughout comprise one or mutations that correspond to positions L53, L56, L80, and L118. In some embodiments, the sequences shown in the table or throughout do not comprise one or more mutations that correspond to positions L53, L56, L80, and L118. In some embodiments, the sequences shown in the table or throughout the present application comprise or one or more mutations that correspond to positions L59I, L63I, I24L, L94I, L96I or L1321 or other substitutions at the same positions. In some embodiments, the sequences shown in the table or throughout the present application do not comprise one or more mutations that correspond to positions L59I, L63I, I24L, L94I, L96I or L132I or other substitutions at the same positions. In some embodiments, the mutation is leucine to isoleucine. In some embodiments, the mutein does not comprise other mutations than as shown or described herein. In some embodiments, the peptide comprises a sequence of SEQ ID NO: 21, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, or SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, or SEQ ID NO: 60.


In some embodiments, the protein comprises an IL-2 mutein as provided for herein. In some embodiments, a polypeptide is provided comprising SEQ ID NO: 59 or SEQ ID NO: 60, wherein at least one of X1, X2, X3, and X4 is I and the remainder are L or I. In some embodiments, X1, X2, and X3 are L and X4 is I. In some embodiments, X1, X2, and X4 are L and X3 is I. In some embodiments, X2, X3, and X4 are L and X1 is I. In some embodiments, X1, X3, and X4 are L and X2 is I. In some embodiments, X1 and X2 are L and X3 and X4 are I. In some embodiments, X1 and X3 are L and X2 and X4 are I. In some embodiments, X1 and X4 are L and X2 and X3 are I. In some embodiments, X2 and X3 are L and X1 and X4 are I. In some embodiments, X2 and X4 are L and X1 and X3 are I. In some embodiments, X3 and X4 are L and X1 and X2 are I. In some embodiments, X1, X2, and X3 are L and X4 is I. In some embodiments, X2, X3, and X4 are L and X1 is I. In some embodiments, X1, X3, and X4 are L and X2 is I. In some embodiments, X1, X2, and X4 are L and X3 is I.


In some embodiments, the Fc portion of the fusion is not included. In some embodiments, the peptide consists essentially of an IL-2 mutein provided for herein. In some embodiments, the protein is free of a Fc portion.


For illustrative purposes only, embodiments of IL-2 mutein fused with a Fc and with an effector moiety are illustrated in FIG. 19.


The sequences are for illustrative purposes only and are not intended to be limiting. In some embodiments, the compound comprises an amino acid sequence of SEQ ID NO: 53, 54, 55, or 56. In some embodiments, the compound comprises an amino acid sequence of SEQ ID NO: 53, 54, 55, or 56 with or without a C125A or C125S mutation. In some embodiments, the residue at position 125 is C, S, or A. In some embodiments, the compound comprises an amino acid sequence of SEQ ID NO: 59 or SEQ ID NO: 60, wherein at least one of X1, X2, X3, and X4 is I and the remainder are L or I. In some embodiments, the protein comprises an IL-2 mutein as provided for herein. In some embodiments, a polypeptide is provided comprising SEQ ID NO: 59 or SEQ ID NO: 60, wherein at least one of X1, X2, X3, and X4 is I and the remainder are L or I. In some embodiments, X1, X2, and X3 are L and X4 is I. In some embodiments, X1, X2, and X4 are L and X3 is I. In some embodiments, X2, X3, and X4 are L and X1 is I. In some embodiments, X1, X3, and X4 are L and X2 is I. In some embodiments, X1 and X2 are L and X3 and X4 are I. In some embodiments, X1 and X3 are L and X2 and X4 are I. In some embodiments, X1 and X4 are L and X2 and X3 are I. In some embodiments, X2 and X3 are L and X1 and X4 are I. In some embodiments, X2 and X4 are L and X1 and X3 are I. In some embodiments, X3 and X4 are L and X1 and X2 are I. In some embodiments, X1, X2, and X3 are L and X4 is I. In some embodiments, X2, X3, and X4 are L and X1 is I. In some embodiments, X1, X3, and X4 are L and X2 is I. In some embodiments, X1, X2, and X4 are L and X3 is I.


Each of the proteins may also be considered to have the C125S and the LALA and/or G237A mutations as provided for herein. The C125 substitution can also be C125A as described throughout the present application.


In an embodiment, an IL-2 mutein molecule comprises at least 60, 70, 80, 85, 90, 95, or 97% sequence identity or homology with a naturally occurring human IL-2 molecule, e.g., a naturally occurring IL-2 sequence disclosed herein or those that incorporated by reference.


The proteins can be produced with or without a C125A or C125S mutation in the IL-2 mutein. Examples of IL-2 muteins that can be included are illustrated herein, such as, but not limited to, a sequence of SEQ ID NO: 59 or SEQ ID NO: 60.


In some embodiments, the constant kappa domain in any of the light chains can be replaced with a constant lambda domain.


Donor Tissue

Therapeutic compounds and methods described herein can be used in conjunction with a transplantation of donor tissue into a subject and can minimizes rejection of, minimizes immune effector cell mediated damage to, prolongs acceptance of, or prolongs the functional life of, donor transplant tissue. The tissue can be xenograft or allograft tissue. Transplanted tissue can comprise all or part of an organ, e.g., a liver, kidney, heart, pancreas, thymus, skin or lung.


In embodiments, therapeutic compounds described herein reduce, or eliminate the need for systemic immune suppression. Therapeutic compounds and methods described herein can also be used to treat GVHD. In some embodiments, host cells are coated with a therapeutic compound that comprises, as an effector binding/modulating moiety, a PD-L1 molecule.


Table 2 provides target molecules for transplant indications. A target molecule is the target to which a targeting moiety binds. For example, the PD-1 antibodies provided herein can be used and targeted towards a transplanted tissue or organ. As discussed elsewhere herein, In some embodiments, a targeting moiety is selected that binds a product of an allele present on donor tissue and which is not expressed by the subject (recipient) or at expressed at a different level (e.g. reduced or substantially reduced).









TABLE 5







Target Molecules for Transplant Indications










Organ/



Indication
cell type
Target





Allograft transplant tissue,
All
HLA-A, HLA-B, HLA-C,


e.g., allograft solid organ

HLA-DP, HLA-DQ or HLA-


transplant, GvHD

DR


Transplant
Kidney
Antigens expressed in the




kidney where immune




cells infiltrate, for example




including but not limited to




the tubular interstitial




region e.g. Uromodulin,




SLC22A2, SLC22A6, FXYD4,




SLC5A10, SLC6A13, AQP6,




SLC13A3, TMEM72, BSND,




NPR3, and the proximal




and distal tubular




epithelium, such as OAT1,




OCT2









Auto-Immune Disorders

Therapeutic compounds and methods described herein can be used to treat a subject having or at risk for having an unwanted autoimmune response, e.g., an auto immune response in Type 1 Diabetes, Multiple Sclerosis, Cardiomyositis, vitiligo, alopecia, inflammatory bowel disease (IBD, e.g. Crohn's disease or ulcerative colitis), Sjogren's syndrome, focal segmented glomerular sclerosis (FSGS), scleroderma/systemic sclerosis (SSc) or rheumatoid arthritis. In some embodiments, the treatment minimizes rejection of, minimizes immune effector cell mediated damage to, prolongs the survival of subject tissue undergoing, or a risk for, autoimmune attack. Table 3 provides target molecules for several autoimmune indications and organ/cell types. A target molecule is the target to which a targeting moiety binds.









TABLE 2







Target Molecules for autoimmune indications









Indication
Organ/cell type
Target Molecule





Type 1 Diabetes and
Pancreas/Pancreatic islets,
SEZ6L2, LRP11, DISP2,


Transplant
beta cells
SLC30A8, FXYD2




TSPAN7 TMEM27




(reference Hald et al. 2012




Diabetelogia 55: 154);




FXYD2; GPR119;




HEPACAM2,




DPP6, or MAdCAM


Multiple Sclerosis
CNS/myelin sheath of
MOG, PLP, MBP



oligodendrocytes


Cardiomyositis, rheumatoid
Cardiomyocytes, monocytes,
SIRPA (CD172a)


arthritis
macrophages, myeloid cells


Inflammatory bowel disease
Intestine
MAdCAM


(ulcerative colitis, Crohn's


disease) or GVHD; Celiac


disease


Autoimmune hepatitis
liver
MAdCAM


(AIH); Primary Sclerosing


Cholangitis (PSC);


Primary Biliary Sclerosis;


(PBC);


transplant


Focal Segmented
Kidney, podocytes, tubules,
COL1A1, Cadherin 2,


Glomerular Sclerosis
epithelial cells
VCAM-1, Thy1, Podocin,


(FSGS) and other diseases

KIM1 (Hodgin et al, Am J


that can affect kidney for

Pathol 177: 1675 2010);


example lupus nephritis,

PLA2R; OAT1; OCT2; K-


systemic scleroderma,

cadherin 6; CDH16


membranous glomerular


nephropathy (MGN);


Membranous nephropathy


(MN); Minimal Change


Disease (MCD); IgA


nephropathy; ANCA-


associated vasculitis (AAV)


Sjogren's syndrome
Salivary glands, epithelial
FCGR3B, HLAB, KIM1



cells, kidney
(Hu et al Arth and Rheum




56: 3588 2007


Scleroderma, systemic
skin, kidney, lung,
Collagen I, III, VI, VII,


sclerosis (SSc)
Fibroblasts, connective tissue
fibronectin (Wang et al Arth




and Rheum 54: 2271 2006)


vitiligo
Skin, epidermis, Langerhans
COL17A1, CD1A, CD207,



cells, keratinocytes,
desmoglein 1-4, keratin 1



melanocytes


Alopecia areata
Skin, Hair follicle/hair bulb,
CD133 (Yang and



dermis
Cotsarelis, J Dermatol Sci




57: 2 2010)









Accordingly, the PD-1 antibodies provided for herein can be linked to binding partners that bind to the targets listed in the table above.


Other examples of autoimmune disorders and diseases that can be treated with the compounds described herein include, but are not limited to, Myocarditis, Postmyocardial infarction syndrome, Postpericardiotomy syndrome, Subacute bacterial endocarditis, Anti-Glomerular Basement Membrane nephritis, Interstitial cystitis, Lupus nephritis, membranous glomerulonephropathy, Chronic Kidney Disease (“CKD”), Autoimmune hepatitis, Primary biliary cirrhosis, Primary sclerosing cholangitis, Antisynthetase syndrome, alopecia areata, autoimmune angioedema, autoimmune progesterone dermatitis, autoimmune urticaria, bullous pemphigoid, cicatricial pemphigoid, dermatitis herpetiformis, discoid lupus erythematosus, epidermolysis bullosa acquisita, erythema nodosum, gestational pemphigoid, hidradenitis suppurativa, lichen planus, lichen sclerosus, linear iga disease (lad), morphea, pemphigus vulgaris, pityriasis lichenoides et varioliformis acuta, mucha-habermann disease, psoriasis, systemic scleroderma, vitiligo, Addison's disease, Autoimmune polyendocrine syndrome (APS) type 1, Autoimmune polyendocrine syndrome (APS) type 2, Autoimmune polyendocrine syndrome (APS) type 3, Autoimmune pancreatitis (AIP), Diabetes mellitus type 1, Autoimmune thyroiditis, Ord's thyroiditis, Graves' disease, Autoimmune Oophoritis, Endometriosis, Autoimmune orchitis, Sjogren's syndrome, Autoimmune enteropathy, Coeliac disease, Crohn's disease, Microscopic colitis, Ulcerative colitis, thrombocytopenia, Adiposis, dolorosa, Adult-onset Still's, disease, Ankylosing, Spondylitis, CREST syndrome, Drug-induced lupus, Enthesitis-related arthritis, Eosinophilic fasciitis, Felty syndrome, IgG4-related disease, Juvenile, Arthritis, Lyme disease (Chronic), Mixed connective tissue disease (MCTD), Palindromic rheumatism, Parry Romberg syndrome, Parsonage-Turner syndrome, Psoriatic arthritis, Reactive arthritis, Relapsing polychondritis, Retroperitoneal fibrosis, Rheumatic fever, Rheumatoid arthritis, Sarcoidosis, Schnitzler syndrome, Systemic Lupus Erythematosus (SLE), Undifferentiated connective tissue disease (UCTD), Dermatomyositis, Fibromyalgia, Inclusion body myositis, Myositis, Myasthenia gravis, Neuromyotonia, Paraneoplastic cerebellar degeneration, Polymyositis, Acute disseminated encephalomyelitis (ADEM), Acute motor axonal neuropathy, Anti-N-Methyl-D-Aspartate (anti-NMDA) Receptor Encephalitis, Balo concentric sclerosis, Bickerstaff's encephalitis, Chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, Hashimoto's encephalopathy, Idiopathic inflammatory demyelinating diseases, Lambert-Eaton myasthenic syndrome, Multiple sclerosis, Oshtoran syndrome, Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus (PANDAS), Progressive inflammatory neuropathy, Restless leg syndrome, Stiff person syndrome, Sydenham chorea, Transverse myelitis, Autoimmune retinopathy, Autoimmune uveitis, Cogan syndrome, Graves ophthalmopathy, Intermediate uveitis, Ligneous conjunctivitis, Mooren's ulcer, Neuromyelitis optica, Opsoclonus myoclonus syndrome, Optic neuritis, Scleritis, Susac's syndrome, Sympathetic ophthalmia, Tolosa-Hunt syndrome, Autoimmune inner ear disease (AIED), Meniere's disease, Behcet's disease, Eosinophilic granulomatosis with polyangiitis (EGPA), Giant cell arteritis, Granulmatosis with polyangiitis (GPA), IgA vasculitis (IgAV), Kawasaki's disease, Leukocytoclastic vasculitis, Lupus vasculitis, Rheumatoid vasculitis, Microscopic polyangiitis (MPA), Polyarteritis nodosa (PAN), Polymyalgia rheumaticia, Vasculitis, Primary Immune Deficiency, and the like.


Other examples of potential autoimmune disorders and diseases, as well as autoimmune comorbidities that can be treated with the compounds described herein include, but are not limited to, Chronic fatigue syndrome, Complex regional pain syndrome, Eosinophilic esophagitis, Gastirtis, Interstitial lung disease, POEMS syndrome, Raynaud's phenomenon, Primary immunodeficiency, Pyoderma gangrenosum, Agammaglobulinemia, Anyloidosis, Anyotrophic lateral sclerosis, Anti-tubular basement membrane nephritis, Atopic allergy, Atopic dermatitis, Autoimmune peripheral neuropathy, Blau syndrome, Castleman's disease, Chagas disease, Chronic obstructive pulmonary disease, Chronic recurrent multifocal osteomyelitis, Complement component 2 deficiency, Contact dermatitis, Cushing's syndrome, Cutaneous leukocytoclastic angiitis, Dego' deiase, Eczema, Eosinophilic gastroenteritis, Eosinophilic pneumonia, Erythroblastosis fetalsis, Fibrodysplasia ossificans progressive, Gastrointestinal pemphigoid, Hypogammaglobulinemia, Idiopathic giant-cell myocarditis, Idiopathic pulmonary fibrosis, IgA nephropathy, Immunregulatory lipoproteins, IPEX syndrome, Ligenous conjunctivitis, Majeed syndrome, Narcolepsy, Rasmussen's encephalitis, Schizophrenia, Serum sickness, Spondyloathropathy, Sweet's syndrome, Takayasu's arteritis, and the like.


In some embodiments, the autoimmune disorder does not comprise pemphigus Vulgaris, pemphigus. In some embodiments, the autoimmune disorder does not comprise pemphigus foliaceus. In some embodiments, the autoimmune disorder does not comprise bullous pemphigoid. In some embodiments, the autoimmune disorder does not comprise Goodpasture's Disease. In some embodiments, the autoimmune disorder does not comprise psoriasis. In some embodiments, the autoimmune disorder does not comprise a skin disorder. In some embodiments, the disorder does not comprise a neoplastic disorder, e.g., cancer.


Therapeutic Compounds

A therapeutic compound comprises a specific targeting moiety functionally associated with an effector binding/modulating moiety. In some embodiments, the specific targeting moiety and effector binding/modulating moiety are linked to one another by a covalent or noncovalent bond, e.g., a covalent or non-covalent bond directly linking the one to the other. In other embodiments, a specific targeting moiety and effector binding/modulating moiety are linked, e.g., covalently or noncovalently, through a linker moiety. E.g., in the case of a fusion polypeptide, a polypeptide sequence comprising the specific targeting moiety and a polypeptide sequence can be directly linked to one another or linked through one or more linker sequences. In some embodiments, the linker moiety comprises a polypeptide. Linkers are not, however, limited to polypeptides. In some embodiments, a linker moiety comprises other backbones, e.g., anon-peptide polymer, e.g., a PEG polymer. In some embodiments, a linker moiety can comprise a particle, e.g., a nanoparticle, e.g., a polymeric nanoparticle. In some embodiments, a linker moiety can comprise a branched molecule, or a dendrimer. However, in embodiments where the effector binding/modulating moiety comprises an ICIM binding/modulating moiety (which binds an effector like PD-1) structures that result in clustering in the absence of target binding should be avoided as they may cause clustering in the absence of target binding. Thus in embodiments, the therapeutic compound has a structure, e.g., the copies of an ICIM are sufficiently limited, such that clustering in the absence of target binding is minimized or substantially eliminated, or eliminated, or is sufficiently minimized that substantial systemic immune suppression does not occur.


In some embodiments, a therapeutic compound comprises a polypeptide comprising a specific targeting moiety covalently or non-covalently conjugated to an effector binding/modulating moiety. In some embodiments, a therapeutic molecule comprises a fusion protein having comprising a specific targeting moiety fused, e.g., directly or through a linking moiety comprising one or more amino acid residues, to an effector binding/modulating moiety. In some embodiments, a therapeutic molecule comprises a polypeptide comprising a specific targeting moiety linked by a non-covalent bond or a covalent bond, e.g., a covalent bond other than a peptide bond, e.g., a sulfhydryl bond, to an effector binding/modulating moiety.


In some embodiments, a therapeutic compound comprises polypeptide, e.g., a fusion polypeptide, comprising:

    • 1.a) a specific targeting moiety comprising a target specific binding polypeptide;
    • 1.b) a specific targeting moiety comprising a target ligand binding molecule;
    • 1.c) a specific targeting moiety comprising an antibody molecule;
    • 1.d) a specific targeting moiety comprising a single chain antibody molecule, e.g., a scFv domain; or
    • 1.e) a specific targeting moiety comprising a first of the light or heavy chain variable region of an antibody molecule, and wherein the other variable region is covalently or non covalently associated with the first;
    • and
    • 2.a) an effector binding/modulating moiety comprising an effector specific binding polypeptide;
    • 2.b) an effector binding/modulating moiety comprising an effector ligand binding molecule;
    • 2.c) an effector binding/modulating moiety comprising an antibody molecule;
    • 2.d) an effector binding/modulating moiety comprising a single chain antibody molecule, e.g., a scFv domain; or
    • 2.e) an effector binding/modulating moiety comprising a first of the light or heavy chain variable region of an antibody molecule, and wherein the other variable region is covalently or non covalently associated with the first.


In some embodiments, a therapeutic compound comprises 1.a and 2.a.


In some embodiments, a therapeutic compound comprises 1.a and 2.b.


In some embodiments, a therapeutic compound comprises 1.a and 2.c.


In some embodiments, a therapeutic compound comprises 1.a and 2.d.


In some embodiments, a therapeutic compound comprises 1.a and 2.e.


In some embodiments, a therapeutic compound comprises 1.b and 2.a.


In some embodiments, a therapeutic compound comprises 1.b and 2.b.


In some embodiments, a therapeutic compound comprises 1.b and 2.c.


In some embodiments, a therapeutic compound comprises 1.b and 2.d.


In some embodiments, a therapeutic compound comprises 1.b and 2.e.


In some embodiments, a therapeutic compound comprises 1.c and 2.a.


In some embodiments, a therapeutic compound comprises 1.c and 2.b.


In some embodiments, a therapeutic compound comprises 1.c and 2.c.


In some embodiments, a therapeutic compound comprises 1.c and 2.d.


In some embodiments, a therapeutic compound comprises 1.c and 2.e.


In some embodiments, a therapeutic compound comprises 1.d and 2.a.


In some embodiments, a therapeutic compound comprises 1.d and 2.b.


In some embodiments, a therapeutic compound comprises 1.d and 2.c.


In some embodiments, a therapeutic compound comprises 1.d and 2.d.


In some embodiments, a therapeutic compound comprises 1.d and 2.e.


In some embodiments, a therapeutic compound comprises 1.e and 2.a.


In some embodiments, a therapeutic compound comprises 1.e and 2.b.


In some embodiments, a therapeutic compound comprises 1.e and 2.c.


In some embodiments, a therapeutic compound comprises 1.e and 2.d.


In some embodiments, a therapeutic compound comprises 1.e and 2.e.


Therapeutic compounds disclosed herein can, for example, comprise a plurality of effector binding/modulating and specific targeting moieties. Any suitable linker or platform can be used to present the plurality of moieties. The linker is typically coupled or fused to one or more effector binding/modulating and targeting moieties.


In some embodiments, two (or more) linkers associate, either covalently or non-covelaently, e.g., to form a hetero or homo-dimeric therapeutic compound. E.g., the linker can comprise an Fc region and two Fc regions associate with one another. In some embodiments of a therapeutic compound comprising two linker regions, the linker regions can self-associate, e.g., as two identical Fc regions. In some embodiments of a therapeutic compound comprising two linker regions, the linker regions are not capable of, or not capable of substantial, self-association, e.g., the two Fc regions can be members of a knob and hole pair.


Non-limiting exemplary configurations of therapeutic compounds comprise the following (e.g., in N to C terminal order):

    • R1-Linker Region A-R2
    • R3-Linker Region B-R4,


      wherein,
    • R1, R2, R3, and R4, each independently comprises an effector binding/modulating moiety, e.g., an ICIM binding/modulating moiety, an IIC binding/modulating moiety, ICSM binding/modulating moiety, or an SM binding/modulating moiety; a specific targeting moiety; or is absent, provided that at least one of R1 and R2 is not absent, and at least one of R3 and R4 is not absent;
    • Linker Region A and Linker B comprise moieties that can associate with one another, e.g., Linker A and Linker B each comprises an Fc moiety provided that an effector binding/modulating moiety and a specific targeting moiety are present.


In some embodiments:

    • R1 comprises an effector binding/modulating moiety, e.g., an ICIM binding/modulating moiety, an IIC binding/modulating moiety, ICSM binding/modulating moiety, or an SM binding/modulating moiety, or is absent;
    • R2 comprises a specific targeting moiety, or is absent;
    • R3 comprises an effector binding/modulating moiety, e.g., an ICIM binding/modulating moiety, an IIC binding/modulating moiety, ICSM binding/modulating moiety, or an SM binding/modulating moiety, or is absent;
    • R4 comprises a specific targeting moiety, or is absent;


Linker Region A and Linker B comprise moieties that can associate with one another, e.g., Linker A and Linker B each comprises an Fc moiety, provided that one of R1 or R3 is present and one of R2 or R4 is present.


In some embodiments:

    • R1 comprises a specific targeting moiety, or is absent;
    • R2 comprises an effector binding/modulating moiety, e.g., an ICIM binding/modulating moiety, an IIC binding/modulating moiety, ICSM binding/modulating moiety, or an SM binding/modulating moiety, or is absent;
    • R3 comprises a specific targeting moiety, or is absent;
    • R4 comprises an effector binding/modulating moiety, e.g., an ICIM binding/modulating moiety, an IIC binding/modulating moiety, ICSM binding/modulating moiety, or an SM binding/modulating moiety, or is absent;


Linker Region A and Linker B comprise moieties that can associate with one another, e.g., Linker A and Linker B each comprises an Fc moiety, provided that one of R1 or R3 is present and one of R2 or R4 is present.


Non-limiting examples include, but are not limited to:



















Linker


Linker





Region


Region




R1
A
R2
R3
B
R4
Other







HCVR and
Fc
scFv
HCVR
Fc
scFv
Self-Pairing


LCVR
Region

and
Region

Linker





LCVR


Regions


HCVR and
Fc
scFv
HCVR
Fc
scFv
Non-Self


LCVR
Region

and
Region

Pairing linker





LCVR


regions


HCVR and
Fc
scFv
HCVR
Fc
scFv
Self-Pairing


LCVR (or
Region

and
Region

Linker


absent)


LCVR


Regions





(or


One of R1 or





absent)


R3 is absent.


HCVR and
Fc
scFv
HCVR
Fc
scFv
Non-Self


LCVR (or
Region

and
Region

Pairing


absent)


LCVR


Linker





(or


Regions





absent)


One of R1 or








R3 is absent.


HCVR and
Fc
scFv
HCVR
Fc
scFv
Self-Pairing


LCVR
Region
(or
and
Region
(or
linker regions




absent)
LCVR

absent)
One of R2 or








R4 is absent.


HCVR and
Fc
scFv
HCVR
Fc
scFv
Non-Self


LCVR
Region
(or
and
Region
(or
Pairing linker




absent)
LCVR

absent)
regions








One of R2 or








R4 is absent.


HCVR and
Fc
scFv
HCVR
Fc
scFv
Self-Pairing


LCVR
Region

and
Region

Linker





LCVR


Regions








R1 and R3








are the same


HCVR and
Fc
scFv
HCVR
Fc
scFv
Non-Self


LCVR
Region

and
Region

Pairing linker





LCVR


regions








Rland R3 are








different


HCVR and
Fc
scFv
HCVR
Fc
scFv
Self-Pairing


LCVR
Region

and
Region

Linker





LCVR


Regions








R2 and R4








are the same


HCVR and
Fc
scFv
HCVR
Fc
scFv
Non-Self


LCVR
Region

and
Region

Pairing linker





LCVR


regions








R2and R4 are








different





HCVR and LCVR: refers to a moiety comprising an antigen binding portion of a heavyand light chain variable region, typically with the heavy chain fused to the Linker region.


Self-pairing: wherein a liker region can pair with itself, e.g., an Fc region that can paira copy of itself.


Non-Self Pairing: wherein a Linker Region does not pair with itself, or does not substantially pair with itself, e.g., an Fc region does not or does not significantly pair with itself, e.g., wherein Linker Region A and Linker Region B are members of a knoband hole pair.






In some embodiments:

    • R1, R2, R3 and R4 each independently comprise: an effector binding modulating moiety that activates an inhibitory receptor on an immune cell, e.g., a T cell or a B cell, e.g., a PD-L1 molecule or a functional anti-PD-1 antibody molecule (an agonist of PD-1); a specific targeting moiety; or is absent, provided that at least one of R1 and R2 is not absent, and at least one of R3 and R4 is not absent;
    • provided that an effector binding moiety and a specific targeting moiety are present.


In some embodiments, Linker A and Linker B comprise Fc moieties (e.g., self-pairing Fc moieties).


In some embodiments:

    • R1 and R3 independently comprise an effector binding modulating moiety that activates an inhibitory receptor on an immune cell, e.g., a T cell or a B cell, e.g., a PD-L1 molecule or a functional anti-PD-1 antibody molecule (an agonist of PD-1); and
    • R2 and R4 independently comprise specific targeting moieties, e.g., scFv molecules against a tissue antigen.


In some embodiments, Linker A and Linker B comprise Fc moieties (e.g., self-pairing Fc moieties).


In some embodiments:

    • R1 and R3 independently comprise a functional anti-PD-1 antibody molecule (an agonist of PD-1); and
    • R2 and R4 independently comprise specific targeting moieties, e.g., scFv molecules against a tissue antigen.


In some embodiments, Linker A and Linker B comprise Fc moieties (e.g., self-pairing Fc moieties).


In some embodiments:

    • R1 and R3 independently comprise specific targeting moieties, e.g., an anti-tissue antigen antibody; and
    • R2 and R4 independently comprise a functional anti-PD-1 antibody molecule (an agonist of PD-1), e.g., an scFv molecule.


In some embodiments, Linker A and Linker B comprise Fc moieties (e.g., self-pairing Fc moieties).


In some embodiments:

    • R1 and R3 independently comprise a PD-L1 molecule (an agonist of PD-1); and
    • R2 and R4 independently comprise specific targeting moieties, e.g., scFv molecules against a tissue antigen; and


In some embodiments, Linker A and Linker B comprise Fc moieties (e.g., self-pairing Fc moieties).


In some embodiments:

    • R1 and R3 independently comprise specific targeting moieties, e.g., an anti-tissue antigen antibody; and
    • R2 and R4 independently comprise a PD-L1 molecule (an agonist of PD-1).


In some embodiments, Linker A and Linker B comprise Fc moieties (e.g., self-pairing Fc moieties).


Linker Regions

As discussed elsewhere herein specific targeting and effector binding/modulating moieties can be linked by linker regions. Any linker region described herein can be used as a linker. For example, linker Regions A and B can comprise Fc regions. In some embodiments, a therapeutic compound comprises a Linker Region that can self-associate. In some embodiments, a therapeutic compound comprises a Linker Region that has a moiety that minimizes self-association, and typically Linker Region A and Linker Region B are heterodimers. Linkers also include glycine/serine linkers. In some embodiments, the linker can comprise one or more repeats of GGGGS (SEQ ID NO: 23). In some embodiments, the linker comprises 1, 2, 3, 4, or 5 repeats of SEQ ID NO: 23 (repeats disclosed as SEQ ID NO: 1749). In some embodiments, the linker comprises or GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 22) GGGGSGGGGSGGGGS (SEQ ID NO: 30). These linkers can be used in any of the therapeutic compounds or compositions provided herein. The linker can also be a GGGGE (SEQ ID NO: 1741) linker or AAAKA (SEQ ID NO: 1742) linker and the like. In some embodiments, the linker comprises 1, 2, 3, 4, or 5 units of the 5-mer linkers. The linker region can comprise a Fc region that has been modified (e.g. mutated) to produce a heterodimer. In some embodiments, the CH3 domain of the Fc region can be mutated. Examples of such Fc regions can be found in, for example, U.S. Pat. No. 9,574,010, which is hereby incorporated by reference in its entirety. The Fc region as defined herein comprises a CH3 domain or fragment thereof, and may additionally comprise one or more addition constant region domains, or fragments thereof, including hinge, CH1, or CH2. It will be understood that the numbering of the Fc amino acid residues is that of the EU index as in Kabat et al., 1991, NIH Publication 91-3242, National Technical Information Service, Springfield, Va. The “EU index as set forth in Kabat” refers to the EU index numbering of the human IgG1 Kabat antibody. For convenience, Table B of U.S. Pat. No. 9,574,010 provides the amino acids numbered according to the EU index as set forth in Kabat of the CH2 and CH3 domain from human IgG1, which is hereby incorporated by reference. Table 1.1 of U.S. Pat. No. 9,574,010 provides mutations of variant Fc heterodimers that can be used as linker regions. Table 1.1 of U.S. Pat. No. 9,574,010 is hereby incorporated by reference.


In some embodiments, the Linker Region A comprises a first CH3 domain polypeptide and a the Linker Region B comprises a second CH3 domain polypeptide, the first and second CH3 domain polypeptides independently comprising amino acid modifications as compared to a wild-type CH3 domain polypeptide, wherein the first CH3 domain polypeptide comprises amino acid modifications at positions T350, L351, F405, and Y407, and the second CH3 domain polypeptide comprises amino acid modifications at positions T350, T366, K392 and T394, wherein the amino acid modification at position T350 is T350V, T3501, T350L or T350M; the amino acid modification at position L351 is L351Y; the amino acid modification at position F405 is F405A, F405V, F405T or F405S; the amino acid modification at position Y407 is Y407V, Y407A or Y407I; the amino acid modification at position T366 is T366L, T366I, T366V, or T366M, the amino acid modification at position K392 is K392F, K392L or K392M, and the amino acid modification at position T394 is T394W, and wherein the numbering of amino acid residues is according to the EU index as set forth in Kabat.


In some embodiments, the amino acid modification at position K392 is K392M or K392L. In some embodiments, the amino acid modification at position T350 is T350V. In some embodiments, the first CH3 domain polypeptide further comprises one or more amino acid modifications selected from Q347R and one of S400R or S400E. In some embodiments, the second CH3 domain polypeptide further comprises one or more amino acid modifications selected from L351Y, K360E, and one of N390R, N390D or N390E. In some embodiments, the first CH3 domain polypeptide further comprises one or more amino acid modifications selected from Q347R and one of S400R or S400E, and the second CH3 domain polypeptide further comprises one or more amino acid modifications selected from L351Y, K360E, and one of N390R, N390D or N390E. In some embodiments, the amino acid modification at position T350 is T350V. In some embodiments, the amino acid modification at position F405 is F405A. In some embodiments, the amino acid modification at position Y407 is Y407V. In some embodiments, the amino acid modification at position T366 is T366L or T366I. In some embodiments, the amino acid modification at position F405 is F405A, the amino acid modification at position Y407 is and Y407V, the amino acid modification at position T366 is T366L or T366I, and the amino acid modification at position K392 is K392M or K392L. In some embodiments, the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400E, F405V and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, T366L, N390R, K392M and T394W. In some embodiments, the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400E, F405T and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, T366L, N390R, K392M and T394W. In some embodiments, the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400E, F405S and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, T366L, N390R, K392M and T394W. In some embodiments, the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400E, F405A and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, T366L, N390R, K392M and T394W. In some embodiments, the first CH3 domain polypeptide comprises the amino acid modifications Q347R, T350V, L351Y, S400E, F405A and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, K360E, T366L, N390R, K392M and T394W. In some embodiments, the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400R, F405A and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, T366L, N390D, K392M and T394W. In some embodiments, the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400R, F405A and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, T366L, N390E, K392M and T394W. In some embodiments, the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400E, F405A and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, T366L, N390R, K392L and T394W. In some embodiments, the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400E, F405A and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, T366L, N390R, K392F and T394W.


In some embodiments, an isolated heteromultimer comprising a heterodimeric CH3 domain comprising a first CH3 domain polypeptide and a second CH3 domain polypeptide, the first CH3 domain polypeptide comprising amino acid modifications at positions F405 and Y407, and the second CH3 domain polypeptide comprising amino acid modifications at positions T366 and T394, wherein: (i) the first CH3 domain polypeptide further comprises an amino acid modification at position L351, and (ii) the second CH3 domain polypeptide further comprises an amino acid modification at position K392, wherein the amino acid modification at position F405 is F405A, F405T, F405S or F405V; and the amino acid modification at position Y407 is Y407V, Y407A, Y407L or Y407I; the amino acid modification at position T394 is T394W; the amino acid modification at position L351 is L351Y; the amino acid modification at position K392 is K392L, K392M, K392V or K392F, and the amino acid modification at position T366 is T366I, T366L, T366M or T366V, wherein the heterodimeric CH3 domain has a melting temperature (Tm) of about 70.degree. C. or greater and a purity greater than about 90%, and wherein the numbering of amino acid residues is according to the EU index as set forth in Kabat.


In some embodiments, the Linker Region A comprises a first CH3 domain polypeptide and a t Linker Region B comprises a second CH3 domain polypeptide, wherein the first CH3 domain polypeptide comprising amino acid modifications at positions F405 and Y407, and the second CH3 domain polypeptide comprising amino acid modifications at positions T366 and T394, wherein: (i) the first CH3 domain polypeptide further comprises an amino acid modification at position L351, and (ii) the second CH3 domain polypeptide further comprises an amino acid modification at position K392, wherein the amino acid modification at position F405 is F405A, F405T, F405S or F405V; and the amino acid modification at position Y407 is Y407V, Y407A, Y407L or Y407I; the amino acid modification at position T394 is T394W; the amino acid modification at position L351 is L351Y; the amino acid modification at position K392 is K392L, K392M, K392V or K392F, and the amino acid modification at position T366 is T366I, T366L, T366M or T366V, wherein the heterodimeric CH3 domain has a melting temperature (Tm) of about 70 C. or greater and a purity greater than about 90%, and wherein the numbering of amino acid residues is according to the EU index as set forth in Kabat. In some embodiments, the amino acid modification at position F405 is F405A. In some embodiments, the amino acid modification at position T366 is T366I or T366L. In some embodiments, the amino acid modification at position Y407 is Y407V. In some embodiments, the amino acid modification at position F405 is F405A, the amino acid modification at position Y407 is Y407V, the amino acid modification at position T366 is T366I or T366L, and the amino acid modification at position K392 is K392L or K392M. In some embodiments, the amino acid modification at position F405 is F405A, the amino acid modification at position Y407 is Y407V, the amino acid modification at position T366 is T366L, and the amino acid modification at position K392 is K392M. In some embodiments, the amino acid modification at position F405 is F405A, the amino acid modification at position Y407 is Y407V, the amino acid modification at position T366 is T366L, and the amino acid modification at position K392 is K392L. In some embodiments, the amino acid modification at position F405 is F405A, the amino acid modification at position Y407 is Y407V, the amino acid modification at position T366 is T366I, and the amino acid modification at position K392 is K392M. In some embodiments, the amino acid modification at position F405 is F405A, the amino acid modification at position Y407 is Y407V, the amino acid modification at position T366 is T366I, and the amino acid modification at position K392 is K392L. In some embodiments, the first CH3 domain polypeptide further comprises an amino acid modification at position S400 selected from S400D and S400E, and the second CH3 domain polypeptide further comprises the amino acid modification N390R. In some embodiments, the amino acid modification at position F405 is F405A, the amino acid modification at position Y407 is Y405V, the amino acid modification at position S400 is S400E, the amino acid modification at position T366 is T366L, and the amino acid modification at position K392 is K392M.


In some embodiments, the modified first and second CH3 domains are comprised by an Fc construct based on a type G immunoglobulin (IgG). The IgG can be an IgG1, IgG2, IgG3 or IgG4.


Other Linker Region A and Linger Region B comprising variant CH3 domains are described in U.S. Pat. Nos. 9,499,634 and 9,562,109, each of which is incorporated by reference in its entirety.


A Linker Region A and Linker Region B can be complementary fragments of a protein, e.g., a naturally occurring protein such as human serum albumin. In embodiments, one of Linker Region A and Linker Region B comprises a first, e.g., an N terminal fragment of the protein, e.g., hSA, and the other comprises a second, e.g., a C terminal fragment of the protein, e.g., has. In an embodiment the fragments comprise an N terminal and a C terminal fragment. In an embodiment the fragments comprise two internal fragments. Typically the fragments do not overlap. In an embodiment the First and second fragment, together, provide the entire sequence of the original protein, e.g., hSA. The first fragment provides a N terminus and a C terminus for linking, e.g., fusing, to other sequences, e.g., sequences of R1, R2, R3, or R4 (as defined herein).


The Linker Region A and the Linker Region B can be derived from albumin polypeptide. In some embodiments, the albumin polypeptide is selected from native human serum albumin polypeptide and human alloalbumin polypeptide. The albumin polypeptide can be modified such that the Linker Region A and Linker Region B interact with one another to form heterodimers. Examples of modified albumin polypeptides are described in U.S. Pat. Nos. 9,388,231 and 9,499,605, each of which is hereby incorporated by reference in its entirety.


Accordingly, provided herein are multifunctional heteromultimer proteins of the formula R1-Linker Region A-R2 and R3-Linker Region B-R4, wherein the Linker Region A and Linker Region B form a heteromultimer. In some embodiments, the Linker Region A comprises a first polypeptide and the Linker Region B comprises a second polypeptide; wherein each of said first and second polypeptides comprises an amino acid sequence comprising a segment of an albumin polypeptide selected from native human serum albumin polypeptide and human alloalbumin polypeptide; wherein said first and second polypeptides are obtained by segmentation of said albumin polypeptide at a segmentation site, such that the segmentation results in a deletion of zero to 3 amino acid residues at the segmentation site; wherein said first polypeptide comprises at least one mutation selected from A194C, L198C, W214C, A217C, L331C and A335C, and said second polypeptide comprises at least one mutation selected from L331C, A335C, V343C, L346C, A350C, V455C, and N458C; and wherein said first and second polypeptides self-assemble to form a quasi-native structure of the monomeric form of the albumin polypeptide.


In some embodiments, the segmentation site resides on a loop of the albumin polypeptide that has a high solvent accessible surface area (SASA) and limited contact with the rest of the albumin structure, b) the segmentation results in a complementary interface between the transporter polypeptides. These segmentation sites are described, for example, in U.S. Pat. No. 9,388,231, which is hereby incorporated by reference in its entirety.


In some embodiments, the first polypeptide comprises residues 1-337 or residues 1-293 of the albumin polypeptide with one or more of the mutations described herein. In some embodiments, the second polypeptide comprises residues of 342-585 or 304-585 of the albumin polypeptide with one or more of the mutations described herein. In some embodiments, the first polypeptide comprises residues 1-339, 1-300, 1-364, 1-441, 1-83, 1-171, 1-281, 1-293, 1-114, 1-337, or 1-336 of the albumin protein. In some embodiments, the second polypeptide comprises residues 301-585, 365-585, 442-585, 85-585, 172-585, 282-585, or 115-585, 304-585, 340-585, or 342-585 of the albumin protein.


In some embodiments, the first and second polypeptide comprise the residues of the albumin protein as shown in the table below. The sequence of the albumin protein is described below.
















First Polypeptide Residues
Second Polypeptide Residues









1-300
301-585



1-364
365-585



1-441
442-585



1-83 
 85-585



1-171
172-585



1-281
282-585



1-114
115-585



1-339
340-585



1-337
342-585



1-293
304-585



1-336
342-585










In some embodiments, the first and second polypeptides comprise a linker that can form a covalent bond with one another, such as a disulfide bond. A non-limiting example of the linker is a peptide linker. In some embodiments, the peptide linker comprises GGGGS (SEQ ID NO: 23). The linker can be fused to the C-terminus of the first polypeptide and the N-terminus of the second polypeptide. The linker can also be used to attach the moieties described herein without abrogating the ability of the linkers to form a disulfide bond. In some embodiments, the first and second polypeptides do not comprise a linker that can form a covalent bond. In some embodiments, the first and second polypeptides have the following substitutions.
















First Polypeptide Substitution
Second Polypeptide Substitution









A217C
V343C



L331C
A350C



A217C
L346C



W214C
V343C



A335C
L346C



L198C
V455C



A217C
A335C



A217C
L331C



L198C
N458C



A194C
V455C










The sequence of the albumin polypeptide can be The sequence of human albumin is as shown, in the post-protein form with the N-terminal signaling residues removed (MKWVTFISLLFLFSSAYSRGVFRR SEQ ID NO: 1743)









DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFA





KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE





CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY





APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC





ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL





LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA





DLPSLAADEVESKDVCKNYAEAKDVELGMELYEYARRHPDYSVVLLLRLA





KTYETTLEKCCAAADPHECYAKVEDEFKPLVEEPQNLIKQNCELFEQLGE





YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE





DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPK





EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDD





FAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL (human





albumin, SEQ ID NO: 42)






In some embodiments, the Linker Region A and the Linker Region B form a heterodimer as described herein.


In some embodiments, the polypeptide comprises at the N-terminus an antibody comprised of F(ab′)2 on an IgG1 Fc backbone fused with scFvs on the C-terminus of the IgG Fc backbone. In some embodiments, the IgG Fc backbone is a IgG1 Fc backbone. In some embodiments, the IgG1 backbone is replaced with a IgG4 backbone, IgG2 backbone, or other similar IgG backbone. The IgG backbones described in this paragraph can be used throughout this application where a Fc region is referred to as part of the therapeutic compound. Thus, in some embodiments, the antibody comprised of F(ab′)2 on an IgG1 Fc backbone can be an anti-MAdCAM antibody or an anti-PD-1 antibody on an IgG1 Fc or any other targeting moiety or effector binding/modulating moiety provided herein. In some embodiments, the scFV segments fused to the C-terminus could be an anti-PD-1 antibody, if the N-terminus region is an anti-MAdCAM antibody, or anti-MAdCAM antibody, if the N-terminus region is an anti-PD-1 antibody. In this non-limiting example, the N-terminus can be the targeting moiety, such as any one of the ones provided for herein, and the C-terminus can be the effector binding/modulating moiety, such as any of the ones provided for herein. Alternatively, in some embodiments, the N-terminus can be the effector binding/modulating moiety, such as any one of the ones provided for herein, and the C-terminus can be the targeting moiety, such as any of the ones provided for herein.


In some embodiments, the N-terminus can be the targeting moiety, such as any one of the ones provided for herein, and the C-terminus can be the effector binding/modulating moiety, such as any of the ones provided for herein.


In some embodiments, the therapeutic compound comprises two polypeptides that homodimerize. In some embodiments, the N-terminus of the polypeptide comprises an effector binding/modulating moiety that is fused to a human IgG1 Fc domain (e.g. CH2 and/or CH3 domains). In some embodiments, the C-terminus of the Fc domain is another linker that is fused to the targeting moiety. Thus, in some embodiments, the molecule could be represented using the formula of R1-Linker A-Fc Region-Linker B-R2, wherein R1 can be an effector binding/modulating moiety, R2 is a targeting moiety, Linker A and Linker B are independently linkers as provided for herein. In some embodiments, Linker 1 and Linker 2 are different.


In some embodiments, the molecule could be represented using the formula of R1-Linker A-Fc Region-Linker B-R2, wherein R1 can be a targeting moiety, R2 is an effector binding/modulating moiety, Linker A and Linker B are independently linkers as provided for herein. In some embodiments, Linker A and Linker B are different. The linkers can be chosen from the non-limiting examples provided for herein. In some embodiments, R1 and R2 are independently selected from F(ab′)2 and scFV antibody domains. In some embodiments, R1 and R2 are different antibody domains. In some embodiments, the scFV is in the VL-VH domain orientation.


In some embodiments, the therapeutic compound is a bispecific antibody. In some embodiments, the bispecific antibodies are comprised of four polypeptide chains comprising the following:

    • Chain 1: nt-VH1-CH1-CH2-CH3-Linker A-scFv[VL2-Linker B-VH2]-ct
    • Chain 2: nt-VH1-CH1-CH2-CH3-Linker A-scFv[VL2-Linker B-VH2]-ct
    • Chain 3: nt-VL1-CL-ct
    • Chain 4: nt-VL1-CL-ct,
    • wherein chains 1 and 2 are identical to each other, and chains 3 and 4 are identical to each other,
    • wherein chain 1 forms a homodimer with chain 2; and chain 3 and 4 associate with chain 1 and chain 2. That is, when each light chain associates with each heavy chain, VL1 associates with VH1 and CL associates with CH1 to form two functional Fab units. Without being bound to any particular theory, each scFv unit is intrinsically functional since VL2 and VH2 are covalently linked in tandem with a linker as provided herein (e.g. GGGGS (SEQ ID NO: 23), GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 22), or GGGGSGGGGSGGGGS (SEQ ID NO: 30). The sequences of Linker A and Linker B, which are independent of one another can be the same or different and as otherwise described throughout the present application. Thus, in some embodiments, Linker A comprises GGGGS (SEQ ID NO: 23), or two repeats thereof, GGGGSGGGGSGGGGS (SEQ ID NO: 30), or GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 22). In some embodiments, Linker B comprises GGGGS (SEQ ID NO: 23), or two repeats thereof, GGGGSGGGGSGGGGS (SEQ ID NO: 30), or GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 22). The scFv may be arranged in the NT-VH2-VL2-CT or NT-VL2-VH2-CT orientation. NT or nt stands for N-terminus and CT or ct stands for C-terminus of the protein. CH1, CH2, and CH3 are the domains from the IgG Fc region, and CL stands for Constant Light chain, which can be either kappa or lambda family light chains. The other definitions stand for the way they are normally used in the art.


In some embodiments, the VH1 and VL1 domains are derived from the effector molecule and the VH2 and VL2 domains are derived from the targeting moiety. In some embodiments the VH1 and VL1 domains are derived from a targeting moiety and the VH2 and VL2 domains are derived from an effector binding/modulating moiety.


In some embodiments, the VH1 and VL1 domains are derived from an anti-PD-1 antibody, and the VH2 and VL2 domains are derived from an anti-MAdCAM antibody. In some embodiments the VH1 and VL1 domains are derived from an anti-MAdCAM antibody and the VH2 and VL2 domains are derived from an anti-PD-1 antibody.


In some embodiments, Linker A comprises 1, 2, 3, 4, or 5 GGGGS (SEQ ID NO: 23) repeats (repeats disclosed as SEQ ID NO: 1749). In some embodiments, Linker B comprises 1, 2, 3, 4, or 5 GGGGS (SEQ ID NO: 23) repeats (repeats disclosed as SEQ ID NO: 1749). For the avoidance of doubt, the sequences of Linker A and Linker B, which are used throughout this application, are independent of one another. Therefore, in some embodiments, Linker A and Linker B can be the same or different. In some embodiments, Linker A comprises GGGGS (SEQ ID NO: 23), or two repeats thereof, GGGGSGGGGSGGGGS (SEQ ID NO: 30), or GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 22). In some embodiments, Linker B comprises GGGGS (SEQ ID NO: 23), or two repeats thereof, GGGGSGGGGSGGGGS (SEQ ID NO: 30), or GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 22).


In some embodiments, the therapeutic compound comprises a light chain and a heavy chain. In some embodiments, the light and heavy chain begin at the N-terminus with the VH domain of a targeting moiety followed by the CH1 domain of a human IgG1, which is fused to a Fc region (e.g. CH2-CH3) of human IgG1. In some embodiments, at the c-terminus of the Fc region is fused to a linker as provided herein, such as but not limited to, GGGGS (SEQ ID NO: 23), or two or three repeats thereof, or GGGGSGGGGSGGGGS (SEQ ID NO: 30). The linker can then be fused to an effector binding/modulating moiety, such as any one of the effector moieties provided for herein. The polypeptides can homodimerize because through the heavy chain homodimerization, which results in a therapeutic compound having two effector moieties, such as two anti-PD-1 antibodies. In this orientation, the targeting moiety is an IgG format, there are two Fab arms that each recognize binding partner of the targeting moiety, for example, MAdCAM being bound by the anti-MAdCAM targeting moiety.


In some embodiments, the therapeutic or polypeptide comprises a formula of: An antibody (targeting moiety) with a variable heavy chain and a variable light chain, in an IgG isotype, for example, with an effector molecule, such as an IL-2 mutein. In some embodiments, the IL-2 mutein is fused at the c-terminus of the variable heavy chain. This can be represented by the formula of VL and VH-IgGConstantDomain-L1-E, wherein L1 is a linker, such as a glycine/serine linker as provided herein, E is an effector molecule, such as an IL-2 mutein and VL and VH are the variable light and heavy chains. The VL domain can be a kappa domain. In some embodiments, the IgG Constant domain comprises the sequence of:









(SEQ ID NO: 44)


ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV





HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP





KSCDKTHTCPPCPAPEAAGAPSVELEPPKPKDTLMISRTPEVTCVVVDVS





HEDPEVKENWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK





EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC





LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW





QQGNVESCSVMHEALHNHYTQKSLSLSPG







In some embodiments, the linker comprises GGGGS (SEQ ID NO: 23). In some embodiments, the IL-2 mutein comprises the IL-2 muteins provided herein, such as one of SEQ ID NOs: 31-41, which can also have a Fc molecule appended to the N- or C-terminus of the IL-2 mutein. The Fc domain can comprise SEQ ID NO: 21 or 43. In some embodiments, the IL-2 mutein comprises one of SEQ ID NO: 47-60. In some embodiments, the IL-2 mutein comprises SEQ ID NO: 41 or SEQ ID NO: 56. In some embodiments, the IL-2 mutein comprises SEQ ID NO: 40 or SEQ ID NO: 55.


In some embodiments, the targeting moiety is a MAdCAM antibody.


In some embodiments, the MAdCAM antibody is selected from the following table
















TABLE 6





Clone









ID
HCDR1
HCDR2
HCDR3
LCDR1
LCDR2
LCDR3
ScFv






















1.
FTES
AVIS
CTTS
QASQDI
AASSLQS
CQQGYSTPLTF
EVQLLESGGGLVQPGGSLRLSCAA



SYGM
DDGS
KYYY
SKSLN
(SEQ ID
(SEQ ID NO:
SGFTFSSYGMHWVRQAPGKGLEWV



H
DKYY
YYGM
(SEQ
NO: 65)
66)
AVISDDGSDKYYADSVKGRFTISR



(SEQ
A
DVW
ID NO:


DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
(SEç
64)


TTSKYYYYYGMDVWGQGTTVTVSS



NO:
ID
ID



GGGGSGGGGSGGGGSGGGGSDIQM



61)
NO:
NO:



TQSPSSLSASVGDRVTITCQASQD




62)
63)



ISKSLNWYQQKPGKAPKLLIYAAS









SLQSGVPSRESGSGSGTDETLTIS









SLQPEDFATYYCQQGYSTPLTFGG









GTKVEIK (SEQ ID NO: 67)





2.
YPFI
GIIN
CARE
RASQSI
GASTLES
CQQTWGPPFTF
QVQLVQSGAEVKKPGASVKVSCKA



GYYL
PSGG
GRLS
SSYLA
(SEQ ID
(SEQ ID NO:
SGYPFIGYYLHWVRQAPGQGLEWM



H
STSY
YGMD
(SEQ
NO: 72)
73)
GIINPSGGSTSYAQKFQGRVTMTR



(SEQ
A
AW
ID NO:


DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
(SEQ
71)


AREGRLSYGMDAWGQGTLVTVSSG



NO:
ID
ID



GGGSGGGGSGGGGSGGGGSDIQMT



68)
NO:
NO:



QSPSSLSASVGDRVTITCRASQSI




69)
70)



SSYLAWYQQKPGKAPKLLIYGAST









LESGVPSRFSGSGSGTDFTLTISS









LQPEDFATYYCQQTWGPPFTFGQG









TKLEIK (SEQ ID NO: 74)





3.
YPFI
GIIN
CARE
RASQSI
GASTLES
CQQTWGPPFTF
QVQLVQSGAEVKKPGASVKVSCKA



GQYL
PSGG
GRLS
SSYLA
(SEQ ID
(SEQ ID NO:
SGYPFIGQYLHWVRQAPGQGLEWM



H
STSY
YGMD
(SEQ
NO: 72)
73)
GIINPSGGSTSYAQKFQGRVTMTR



(SEQ
A
AW
ID NO:


DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
(SEQ
71)


AREGRLSYGMDAWGQGTLVTVSSG



NO:
ID
ID



GGGSGGGGSGGGGSGGGGSDIQMT



75)
NO:
NO:



QSPSSLSASVGDRVTITCRASQSI




69)
70)



SSYLAWYQQKPGKAPKLLIYGAST









LESGVPSRESGSGSGTDETLTISS









LQPEDFATYYCQQTWGPPFTFGQG









TKLEIK (SEQ ID NO: 76)





4.
GTES
GSIN
CAKD
QASQDI
AASSLQS
CQQSYSSVITF
QVQLVQSGAEVKKPGASVKVSCKA



SYAI
PSGD
KAQW
SNSLN
(SEQ ID
(SEQ ID NO:
SGGTFSSYAISWVRQAPGQGLEWM



S
TTSY
LVGY
(SEQ
NO: 65)
81)
GSINPSGDTTSYAQKFQGRVTMTR



(SEQ
A
FDYW
ID NO:


DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
(SEQ
80)


AKDKAQWLVGYFDYWGQGTLVTVS



NO:
ID
ID



SGGGGSGGGGSGGGGSGGGGSDIQ



77)
NO:
NO:



MTQSPSSLSASVGDRVTITCQASQ




78)
79)



DISNSLNWYQQKPGKAPKLLIYAA









SSLQSGVPSRFSGSGSGTDETLTI









SSLQPEDFATYYCQQSYSSVITFG









QGTKVEIK (SEQ ID NO: 82)





5.
FTES
SSIS
CARE
RASQGI
GASSLQS
CQQANSFPFTF
EVQLLESGGGLVQPGGSLRLSCAA



SYWM
PGGS
VQLS
SNSLA
(SEQ ID
(SEQ ID NO:
SGFTESSYWMHWVRQAPGKGLEWV



H
NIDY
HYDY
(SEQ
NO: 87)
88)
SSISPGGSNIDYADSVKGRFTISR



(SEQ
A
W
ID NO:


DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
(SEQ
86)


AREVQLSHYDYWGQGTLVTVSSGG



NO:
ID
ID



GGSGGGGSGGGGSGGGGSDIQMTQ



83)
NO:
NO:



SPSSLSASVGDRVTITCRASQGIS




84)
85)



NSLAWYQQKPGKAPKLLIYGASSL









QSGVPSRFSGSGSGTDETLTISSL









QPEDFATYYCQQANSFPFTFGQGT









KVEIK (SEQ ID NO: 89)





6.
FTFN
SRIN
CARE
RASQII
GASSLQS
CQQSYRLPFTF
EVQLLESGGGLVQPGGSLRLSCAA



NYAF
SYGT
GPVA
GTNLA
(SEQ ID
(SEQ ID NO:
SGFTFNNYAFHWVRQAPGKGLEWV



H
STTY
GYWY
SEQ
NO: 87)
94)
SRINSYGTSTTYADSVKGRETISR



(SEQ
A
FDLW
ID NO:


DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
(SEQ
93)


AREGPVAGYWYFDLWGQGTLVTVS



NO:
ID
ID



SGGGGSGGGGSGGGGSGGGGSDIQ



90)
NO:
NO:



MTQSPSSLSASVGDRVTITCRASQ




91)
92)



IIGTNLAWYQQKPGKAPKLLIYGA









SSLQSGVPSRFSGSGSGTDETLTI









SSLQPEDFATYYCQQSYRLPFTFG









QGTKVEIK (SEQ ID NO: 95)





7.
YTFT
GIIN
CAKD
RASQNI
AASSLQS
CQQSYTTPYTF
QVQLVQSGAEVKKPGASVKVSCKA



GYHI
PSGG
WSSW
SSSLN
(SEQ ID
(SEQ ID NO:
SGYTFTGYHIHWVRQAPGQGLEWM



H
STIY
YLGP
(SEQ
NO: 65)
100)
GIINPSGGSTIYAQKFQGRVTMTR



(SEQ
A
FDYW
ID NO:


DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
(SEQ
99)


AKDWSSWYLGPFDYWGQGTLVTVS



NO:
ID
ID



SGGGGSGGGGSGGGGSGGGGSDIQ



96)
NO:
NO:



MTQSPSSLSASVGDRVTITCRASQ




97)
98)



NISSSLNWYQQKPGKAPKLLIYAA









SSLQSGVPSRFSGSGSGTDETLTI









SSLQPEDFATYYCQQSYTTPYTFG









QGTKVEIK (SEQ ID NO: 









101)





8.
FMFG
SAIS
CAKD
RASQGI
DASSLES
CQQTHSFPSTF
EVQLLESGGGLVQPGGSLRLSCAA



DYAM
GSGG
LVVA
SNNLN
(SEQ ID
(SEQ ID NO:
SGFMFGDYAMHWVRQAPGKGLEWV



H
STYY
GIWY
(SEQ
NO:
107)
SAISGSGGSTYYADSVKGRETISR



(SEQ
A
FDLW
ID NO:
106)

DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
(SEQ
105)


AKDLVVAGIWYFDLWGRGTLVTVS



NO:
ID
ID



SGGGGSGGGGSGGGGSGGGGSDIQ



102)
NO:
NO:



MTQSPSSLSASVGDRVTITCRASQ




103)
104



GISNNLNWYQQKPGKAPKLLIYDA









SSLESGVPSRFSGSGSGTDETLTI









SSLQPEDFATYYCQQTHSFPSTFG









QGTKLEIK (SEQ ID NO: 









108)





9.
FTFS
SVIG
CAAD
RASQGI
AASTLOS
CQQSYSTPWTF
EVQLLESGGGLVQPGGSLRLSCAA



DYYM
ESGG
PVSR
SSSLA
(SEQ ID
(SEQ ID NO:
SGFTFSDYYMNWVRQAPGKGLEWV



N
STYY
WPKH
(SEQ
NO:
114)
SVIGESGGSTYYADSVKGRFTISR



(SEQ
A
GGGD
ID NO:
113)

DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
YW
112)


AADPVSRWPKHGGGDYWGQGTLVT



NO:
ID
(SEQ



VSSGGGGSGGGGSGGGGSGGGGSD



109)
NO:
ID



IQMTQSPSSLSASVGDRVTITCRA




110)
NO:



SQGISSSLAWYQQKPGKAPKLLIY





111)



AASTLQSGVPSRFSGSGSGTDETL









TISSLQPEDFATYYCQQSYSTPWT









FGQGTKVEIK (SEQ ID NO:









115)





10.
YTLT
GWIN
CAKG
RASDNI
AASSLQS
CQQGYSTPPTF
QVQLVQSGAEVKKPGASVKVSCKA



TWYM
PNRG
DLWG
GSWLA
(SEQ ID
(SEQ ID NO:
SGYTLTTWYMYWVRQAPGQGLEWM



Y
ATNY
AMDV
(SEQ
NO: 65)
120)
GWINPNRGATNYAQKFQGRVTMTR



(SEQ
A
W
ID NO:


DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
(SEQ
119)


AKGDLWGAMDVWGQGTLVTVSSGG



NO:
ID
ID



GGSGGGGSGGGGSGGGGSDIQMTQ



116)
NO:
NO:



SPSSLSASVGDRVTITCRASDNIG




117)
118



SWLAWYQQKPGKAPKLLIYAASSL









QSGVPSRFSGSGSGTDETLTISSL









QPEDFATYYCQQGYSTPPTFGQGT









KVEIK (SEQ ID NO: 121)





11.
YTFT
GGED
CARH
RASESI
AASTLOS
CQQSYSVPFTF
QVQLVQSGAEVKKPGASVKVSCKA



TYYM
PEDG
AVAG
SNWLA
(SEQ ID
(SEQ ID NO:
SGYTFTTYYMHWVRQAPGQGLEWM



H
ETIY
AVGA
(SEQ
NO:
126)
GGFDPEDGETIYAQKFQGRVTMTR



(SEç
A
GYYY
ID NO:
113)

DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
YGMD
125)


ARHAVAGAVGAGYYYYGMDVWGQG



NO:
ID
VW



TMVTVSSGGGGSGGGGSGGGGSGG



122)
NO:
(SEQ



GGSDIQMTQSPSSLSASVGDRVTI




123)
ID



TCRASESISNWLAWYQQKPGKAPK





NO:



LLIYAASTLQSGVPSRFSGSGSGT





124)



DETLTISSLQPEDFATYYCQQSYS









VPFTFGPGTKVDIK (SEQ ID









NO: 127)





12.
YTFT
GWIG
CARD
RSSQSL
SSSNRAP
CMQALHIPLTF
QVQLVQSGAEVKKPGASVKVSCKA



GYYM
PNSG
LDHN
LHSNGY
(SEQ ID
(SEQ ID NO:
SGYTFTGYYMHWVRQAPGQGLEWM



H
DTNY
WYFD
NYLD
NO:
133)
GWIGPNSGDTNYAQKFQGRVTMTR



(SEQ
A
LW
(SEQ
132)

DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
(SEQ
ID NO:


ARDLDHNWYFDLWGRGTLVTVSSG



NO:
ID
ID
131)


GGGSGGGGSGGGGSGGGGSDIVMT



128)
NO:
NO:



QSPLSLPVTPGEPASISCRSSQSL




129)
130)



LHSNGYNYLDWYLQKPGQSPQLLI









YSSSNRAPGVPDRESGSGSGTDET









LKISRVEAEDVGVYYCMQALHIPL









TFGGGTKVEIK (SEQ ID NO:









134)





13.
FTFD
SYID
CAKD
QASQDI
KASTLES
CQQSYSTPITF
EVQLLESGGGLVQPGGSLRLSCAA



DYAM
ASGT
QAAA
SNYLN
(SEQ ID
(SEQ ID NO:
SGFTEDDYAMHWVRQAPGKGLEWV



H
TIYY
GYWY
(SEQ
NO:
140)
SYIDASGTTIYYADSVKGRFTISR



(SEQ
A
FDLW
ID NO:
139

DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
(SEQ
138)


AKDQAAAGYWYFDLWGRGTLVTVS



NO:
ID
ID



SGGGGSGGGGSGGGGSGGGGSDIQ



135)
NO:
NO:



MTQSPSSLSASVGDRVTITCQASQ




136)
137)



DISNYLNWYQQKPGKAPKLLIYKA









STLESGVPSRFSGSGSGTDFTLTI









SSLQPEDFATYYCQQSYSTPITFG









QGTRLEIK (SEQ ID NO:









141)





14.
YTFT
GGIV
CAKD
RSSQSL
SAYNRAS
CMQALQTPLTF
QVQLVQSGAEVKKPGSSVKVSCKA



DYHI
PRSG
ESSG
LHSNGY
(SEQ ID
(SEQ ID NO:
SGYTFTDYHIHWVRQAPGQGLEWM



H
STTY
WYYF
NYLD
NO:
146)
GGIVPRSGSTTYAQKFQGRVTITA



(SEQ
A
DYW
(SEQ
145)

DESTSTAYMELSSLRSEDTAVYYC



ID
(SEQ
(SEQ
ID NO:


AKDESSGWYYFDYWGQGTLVTVSS



NO:
ID
ID
131)


GGGGSGGGGSGGGGSGGGGSDIVM



142)
NO:
NO:



TQSPLSLPVTPGEPASISCRSSQS




143)
144)



LLHSNGYNYLDWYLQKPGQSPQLL









IYSAYNRASGVPDRESGSGSGTDE









TLKISRVEAEDVGVYYCMQALQTP









LTFGQGTKVEIK (SEQ ID NO:









147)





15.
YTFT
GGII
CAKG
QANQDI
RASKLEA
CQQSSEIPYSF
QVQLVQSGAEVKKPGSSVKVSCKA



NYYM
PIVD
RYTV
SNYLN
(SEQ ID
(SEQ ID NO:
SGYTFTNYYMHWVRQAPGQGLEWM



H
RVKY
NYYY
(SEQ
NO:
153)
GGIIPIVDRVKYAQKFQGRVTITA



(SEQ
A
GMDV
ID NO:
152)

DESTSTAYMELSSLRSEDTAVYYC



ID
(SEQ
W
151)


AKGRYTVNYYYGMDVWGQGTTVTV



NO:
ID
(SEQ



SSGGGGSGGGGSGGGGSGGGGSDI



148)
NO:
ID



QMTQSPSSLSASVGDRVTITCQAN




149)
NO:



QDISNYLNWYQQKPGKAPKLLIYR





150)



ASKLEAGVPSRFSGSGSGTDFTLT









ISSLQPEDFATYYCQQSSEIPYSF









GQGTKLEIK (SEQ ID NO:









154)





16.
FTFE
SYLN
CAKD
RASQSI
DASNLET
CQQSYTIPITF
EVQLLESGGGLVQPGGSLRLSCAA



DYAM
SDGG
YCTN
STYLN
(SEQ ID
(SEQ ID NO:
SGFTFEDYAMHWVRQAPGKGLEWV



H
STSY
GVCA
(SEQ
NO:
160)
SYLNSDGGSTSYADSVKGRFTISR



(SEQ
A
FDYW
ID NO:
159)

DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
(SEQ
158)


AKDYCTNGVCAFDYWGQGTLVTVS



NO:
ID
ID



SGGGGSGGGGSGGGGSGGGGSDIQ



155)
NO:
NO:



MTQSPSSLSASVGDRVTITCRASQ




156)
157)



SISTYLNWYQQKPGKAPKLLIYDA









SNLETGVPSRFSGSGSGTDFTLTI









SSLQPEDFATYYCQQSYTIPITFG









QGTRLEIK (SEQ ID NO:









161)





17.
FTES
SAIS
CVSD
RASQSI
AASRLEG
CQQANSFPLTF
EVQLLESGGGLVQPGGSLRLSCAA



DSAM
GSGS
IAVA
STFLN
(SEQ ID
(SEQ ID NO:
SGFTFSDSAMHWVRQAPGKGLEWV



H
TIYY
GHWY
(SEQ
NO:
167)
SAISGSGSTIYYADSVKGRFTISR



(SEQ
A
FDLW
ID NO:
166)

DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
(SEQ
165)


VSDIAVAGHWYFDLWGRGTLVTVS



NO:
ID
ID



SGGGGSGGGGSGGGGSGGGGSDIQ



162)
NO:
NO:



MTQSPSSLSASVGDRVTITCRASQ




163)
164)



SISTFLNWYQQKPGKAPKLLIYAA









SRLEGGVPSRFSGSGSGTDETLTI









SSLQPEDFATYYCQQANSFPLTFG









PGTKVDIK (SEQ ID NO:









168)





18.
FTES
SYIS
CARA
RASQSI
AASSLQS
CQQSYSTPLTF
EVQLVESGGGLVKPGGSLRLSCAA



SYWM
GDSG
NSSG
SSYLN
(SEQ ID
(SEQ ID NO:
SGFTFSSYWMSWVRQAPGKGLEWV



S
YTNY
WYDW
(SEQ
NO: 65)
173)
SYISGDSGYTNYAAPVKGRFTISR



(SEQ
A
YFDL
ID NO:


DDSKNTLYLQMNSLKTEDTAVYYC



ID
(SEQ
W
172)


ARANSSGWYDWYFDLWGRGTLVTV



NO:
ID
(SEQ



SSGGGGSGGGGSGGGGSGGGGSDI



169)
NO:
ID



QMTQSPSSLSASVGDRVTITCRAS




170)
NO:



QSISSYLNWYQQKPGKAPKLLIYA





171)



ASSLQSGVPSRFSGSGSGTDFTLT









ISSLQPEDFATYYCQQSYSTPLTF









GGGTKVEIK (SEQ ID NO:









174)





19.
FTED
SGIS
CAKD
QASQDI
DASNLET
CQQSYSTPLTF
EVQLLESGGGLVQPGGSLRLSCAA



DYAM
WNSG
IVAA
SNYLN
(SEQ ID
(SEQ ID NO:
SGFTEDDYAMHWVRQAPGKGLEWV



H
SIGY
GHYY
(SEQ
NO:
173)
SGISWNSGSIGYADSVKGRETISR



(SEQ
A
YGMD
ID NO:
159)

DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
VW
138)


AKDIVAAGHYYYGMDVWGQGTTVT



NO:
ID
(SEQ



VSSGGGGSGGGGSGGGGSGGGGSD



135)
NO:
ID



IQMTQSPSSLSASVGDRVTITCQA




175)
NO:



SQDISNYLNWYQQKPGKAPKLLIY





176)



DASNLETGVPSRFSGSGSGTDFTL









TISSLQPEDFATYYCQQSYSTPLT









FGGGTKVEIK (SEQ ID NO:









177)





20.
FTFD
SYID
CARD
QAGQDI
DASNLET
CQQTYSTPITF
EVQLLESGGGLVQPGGSLRLSCAA



DYAM
TSSS
EAAA
SNYLN
(SEQ ID
(SEQ ID NO:
SGFTEDDYAMHWVRQAPGKGLEWV



H
HLYY
GYYG
(SEQ
NO:
181)
SYIDTSSSHLYYADSVKGRFTISR



(SEQ
A
MDVW
ID NO:
159)

DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
(SEQ
180)


ARDEAAAGYYGMDVWGQGTTVTVS



NO:
ID
ID



SGGGGSGGGGSGGGGSGGGGSDIQ



135)
NO:
NO:



MTQSPSSLSASVGDRVTITCQAGO




178)
179)



DISNYLNWYQQKPGKAPKLLIYDA









SNLETGVPSRFSGSGSGTDETLTI









SSLQPEDFATYYCQQTYSTPITFG









QGTKLEIK (SEQ ID NO:









182)


21.
FTFS
STIV
CARD
RASQDI
AASSLQS
CQQSYSIPPTF
EVQLLESGGGLVQPGGSLRLSCAA



NAWM
GNGG
NPLR
SNYLN
(SEQ ID
(SEQ ID NO:
SGFTFSNAWMSWVRQAPGKGLEWV



S
ATYY
WQGM
(SEQ
NO: 65)
187)
STIVGNGGATYYADSVKGRETISR



(SEQ
A
DVW
ID NO:


DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
(SEQ
186)


ARDNPLRWQGMDVWGQGTLVTVSS



NO:
ID
ID



GGGGSGGGGSGGGGSGGGGSDIQM



183)
NO:
NO:



TQSPSSLSASVGDRVTITCRASQD




184)
185)



ISNYLNWYQQKPGKAPKLLIYAAS









SLQSGVPSRFSGSGSGTDETLTIS









SLQPEDFATYYCQQSYSIPPTFGP









GTKVDIK (SEQ ID NO: 188)





22.
FTES
SYIS
CARA
RASQSI
AASSLQS
CQQSYSTPLTF
EVQLLESGGGLVQPGGSLRLSCAA



SYQM
SSST
NSSS
SSYLN
(SEQ ID
(SEQ ID NO:
SGFTFSSYQMSWVRQAPGKGLEWV



S
YTNY
WYDW
SEQ
NO: 65)
173
SYISSSSTYTNYADSVKGRETISR



(SEQ
A
YFDL
ID NO:


DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
W
172)


ARANSSSWYDWYFDLWGQGTLVTV



NO:
ID
(SE



SSGGGGSGGGGSGGGGSGGGGSDI



189)
NO:
ID



QMTQSPSSLSASVGDRVTITCRAS




190)
NO:



QSISSYLNWYQQKPGKAPKLLIYA





191)



ASSLQSGVPSRESGSGSGTDETLT









ISSLQPEDFATYYCQQSYSTPLTF









GGGTKVEIK (SEQ ID NO:









192)





23.
FTES
SGIS
CATS
RASQSI
AASNLQR
CQQSYSIPITF
EVQLLESGGGLVQPGGSLRLSCAA



SYAM
GSGG
QAPV
SSWLA
(SEQ ID
(SEQ ID NO:
SGFTESSYAMHWVRQAPGKGLEWV



H
SAYY
DYYY
(SEQ
NO:
198)
SGISGSGGSAYYADSVKGRFTISR



(SEQ
A
YGMD
ID NO:
197)

DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
VW
196)


ATSQAPVDYYYYGMDVWGQGTTVT



NO:
ID
(SEQ



VSSGGGGSGGGGSGGGGSGGGGSD



193)
NO:
ID



IQMTQSPSSLSASVGDRVTITCRA




194
NO:



SQSISSWLAWYQQKPGKAPKLLIY





195)



AASNLQRGVPSRFSGSGSGTDETL









TISSLQPEDFATYYCQQSYSIPIT









FGQGTKVEIK (SEQ ID NO:









199)





24.
FTES
SYIS
CARV
RASQSI
AASSLQS
CQQSYSTPLTF
EVQLVESGGGLVKPGGSLRLSCAA



SYWM
GSSS
GSSG
SSYLN
(SEQ ID
(SEQ ID NO:
SGFTFSSYWMSWVRQAPGKGLEWV



S
YTNY
WYDW
(SEQ
NO: 65)
173)
SYISGSSSYTNYAAPVKGRETISR



(SEQ
A
YFDL
ID NO:


DDSKNTLYLQMNSLKTEDTAVYYC



ID
(SEQ
W
172)


ARVGSSGWYDWYFDLWGRGTLVTV



NO:
ID
(SEQ



SSGGGGSGGGGSGGGGSGGGGSDI



169)
NO:
ID



QMTQSPSSLSASVGDRVTITCRAS




200)
NO:



QSISSYLNWYQQKPGKAPKLLIYA





201)



ASSLQSGVPSRFSGSGSGTDETLT









ISSLQPEDFATYYCQQSYSTPLTE









GQGTKVEIK (SEQ ID NO:









202)





25.
YTLT
GWIN
CAKG
RASDNI
AASSLQS
CQQGYSTPPTF
QVQLVQSGAEVKKPGASVKVSCKA



TWYM
PNRG
DLWG
GSWLA
(SEQ ID
(SEQ ID NO:
SGYTLTTWYMYWVRQAPGQGLEWM



Y
ATNY
AMDV
(SEQ
NO: 65)
120)
GWINPNRGATNYAQKFQGRVTMTR



(SEQ
A
W
ID NO:


DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
(SEQ
119)


AKGDLWGAMDVWGQGTLVTVSSGG



NO:
ID
ID



GGSGGGGSGGGGSGGGGSDIQMTQ



116)
NO:
NO:



SPSSLSASVGDRVTITCRASDNIG




117)
118)



SWLAWYQQKPGKAPKLLIYAASSL









QSGVPSRESGSGSGTDETLTISSL









QPEDFATYYCQQGYSTPPTFGQGT









KVEIK (SEQ ID NO: 121)





26.
YTLT
GWIN
CAKG
RASDNI
AASSLQS
CQQGYSTPPTF
QVQLVQSGAEVKKPGASVKVSCKA



TWYM
PNRG
DLWG
GSWLA
(SEQ ID
(SEQ ID NO:
SGYTLTTWYMYWVRQAPGQGLEWM



Y
ATNY
AMDV
SEQ
NO: 65)
120)
GWINPNRGATNYAQKFQGRVTMTR



(SEQ
A
W
ID NO:


DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
(SEQ
119)


AKGDLWGAMDVWGQGTTVTVSSGG



NO:
ID
ID



GGSGGGGSGGGGSGGGGSDIQMTQ



116)
NO:
NO:



SPSSLSASVGDRVTITCRASDNIG




117)
118)



SWLAWYQQKPGKAPKLLIYAASSL









QSGVPSRFSGSGSGTDETLTISSL









QPEDFATYYCQQGYSTPPTFGQGT









KVEIK (SEQ ID NO: 203)





27.
YTFT
GWMN
CARD
RASQSI
AASSLQS
CQQSYTAPYTF
QVQLVQSGAEVKKPGASVKVSCKA



GYYI
PNSG
PGFL
SSYLH
(SEQ ID
(SEQ ID NO:
SGYTFTGYYIHWVRQAPGQGLEWM



H
NTGY
GYCS
(SEQ


GWMNPNSGNTGYAQKFQGRVTMTR



(SEQ
A
GGSC



DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
YDGW



ARDPGFLGYCSGGSCYDGWFDPWG



NO:
ID




QGTLVTVSSGGGGSGGGGSGGGGS



204)
NO:
FDPW
ID NO:
NO: 65)
208)
GGGGSDIQMTQSPSSLSASVGDRV




205)
(SEQ
207)


TITCRASQSISSYLHWYQQKPGKA





ID



PKLLIYAASSLQSGVPSRESGSGS





NO:



GTDFTLTISSLQPEDFATYYCQQS





206)



YTAPYTFGQGTKLEIK(SEQ ID









NO: 209)





28.
YTFT
GWMN
CARE
RASQGI
DASNLET
CQQSYSTPLTF
QVQLVQSGAEVKKPGASVKVSCKA



DYFL
PTSG
GEGS
NSWLA
(SEQ ID
(SEQ ID NO:
SGYTFTDYFLHWVRQAPGQGLEWM



H
NTGY
GFDY
(SEQ
NO:
173)
GWMNPTSGNTGYAQKFQGRVTMTR



(SEQ
A
W
ID NO:
159)

DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
(SEQ
213)


AREGEGSGFDYWGQGTLVTVSSGG



NO:
ID
ID



GGSGGGGSGGGGSGGGGSDIQMTQ



210)
NO:
NO:



SPSSLSASVGDRVTITCRASQGIN




211)
212)



SWLAWYQQKPGKAPKLLIYDASNL









ETGVPSRFSGSGSGTDETLTISSL









QPEDFATYYCQQSYSTPLTFGGGT









KVEIK (SEQ ID NO: 214)





29.
YTFT
AWMN
CARD
RASQGI
AASSLQS
CQQSYSTPWTF
QVQLVQSGAEVKKPGASVKVSCKA



SYYM
PNSG
YDFW
SNYLA
(SEQ ID
(SEQ ID NO:
SGYTFTSYYMHWVRQAPGQGLEWM



H
NTGY
SGSL
(SEQ
NO: 65)
114)
AWMNPNSGNTGYAQKFQGRVTMTR



(SEQ
A
GYW
ID NO:


DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
(SEQ
218)


ARDYDFWSGSLGYWGQGTLVTVSS



NO:
ID
ID



GGGGSGGGGSGGGGSGGGGSDIQM



215)
NO:
NO:



TQSPSSLSASVGDRVTITCRASQG




216)
217)



ISNYLAWYQQKPGKAPKLLIYAAS









SLQSGVPSRFSGSGSGTDETLTIS









SLQPEDFATYYCQQSYSTPWTFGQ









GTKVEIK (SEQ ID NO: 219)





30.
YTLT
GWIN
CAKG
RASDNI
AASSLQS
CQQGYSTPPTF
QVQLVQSGAEVKKPGASVKVSCKA



TWYM
PNRG
DLWG
GSWLA
(SEQ ID
(SEQ ID NO:
SGYTLTTWYMYWVRQAPGQGLEWM



Y
ATNY
AMDV
(SEQ
NO: 65)
120)
GWINPNRGATNYAQKFQGRVTMTR



(SEQ
A
W
ID NO:


DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
(SEQ
119)


AKGDLWGAMDVWGQGTLVTVSSGG



NO:
ID
ID



GGSGGGGSGGGGSGGGGSDIQMTQ



116)
NO:
NO:



SPSSLSASVGDRVTITCRASDNIG




117)
118)



SWLAWYQQKPGKAPKLLIYAASSL









QSGVPSRFSGSGSGTDETLTISSL









QPEDFATYYCQQGYSTPPTFGQGT









KVEIK (SEQ ID NO: 121)





31.
YTFT
GIIN
CARD
RASQSI
DASNLQS
CQQSYSIPITF
QVQLVQSGAEVKKPGASVKVSCKA



SYYM
PSGG
TGYS
GRWLA
(SEQ ID
(SEQ ID NO:
SGYTFTSYYMHWVRQAPGQGLEWM



H
STSY
YGRY
(SEQ
NO:
198)
GIINPSGGSTSYAQKFQGRVTMTR



(SEQ
A
YYYG
ID NO:
222)

DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
MDVW
221)


ARDTGYSYGRYYYYGMDVWGQGTL



NO:
ID
(SEQ



VTVSSGGGGSGGGGSGGGGSGGGG



215)
NO:
ID



SDIQMTQSPSSLSASVGDRVTITC




69)
NO:



RASQSIGRWLAWYQQKPGKAPKLL





220)



IYDASNLQSGVPSRFSGSGSGTDE









TLTISSLQPEDFATYYCQQSYSIP









ITFGQGTKVEIK (SEQ ID NO:









223)





32.
YTLT
GIIN
CARE
RASQGI
AASSLQS
CQQSYSTPLTF
QVQLVQSGAEVKKPGASVKVSCKA



DYYM
PSGG
EYSS
SSWLA
(SEQ ID
(SEQ ID NO:
SGYTLTDYYMHWVRQAPGQGLEWM



H
STSY
SSGY
(SEQ
NO: 65)
173)
GIINPSGGSTSYAQKFQGRVTMTR



(SEQ
A
FDYW
ID NO:


DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
(SEQ
226)


AREEYSSSSGYFDYWGQGTLVTVS



NO:
ID
ID



SGGGGSGGGGSGGGGSGGGGSDIQ



224)
NO:
NO:



MTQSPSSLSASVGDRVTITCRASQ




69)
225)



GISSWLAWYQQKPGKAPKLLIYAA









SSLQSGVPSRFSGSGSGTDETLTI









SSLQPEDFATYYCQQSYSTPLTFG









QGTKVEIK (SEQ ID NO: 









227)





33.
YTFT
GWMH
CARD
RASQSI
AASSLQS
CQQSYSVPITF
QVQLVQSGAEVKKPGASVKVSCKA



SYGI
PKSG
TPYY
SSWLA
(SEQ ID
(SEQ ID NO:
SGYTFTSYGISWVRQAPGQGLEWM



S
DTGL
YYGM
(SEQ
NO: 65)
231)
GWMHPKSGDTGLTQKFQGRVTMTR



(SEQ
T
DVW
ID NO:


DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
SEQ
196)


ARDTPYYYYGMDVWGQGTTVTVSS



NO:
ID
ID



GGGGSGGGGSGGGGSGGGGSDIQM



228)
NO:
NO:



TQSPSSLSASVGDRVTITCRASQS




229)
230)



ISSWLAWYQQKPGKAPKLLIYAAS









SLQSGVPSRFSGSGSGTDETLTIS









SLQPEDFATYYCQQSYSVPITFGQ









GTKVEIK (SEQ ID NO: 232)





34.
FTFG
SYIS
CARD
RASQSI
AASSLQS
CQQSYSTPLTF
EVQLVESGGGLVKPGGSLRLSCAA



DYAM
GDIG
VAAT
SSYLN
(SEQ ID
(SEQ ID NO:
SGFTFGDYAMSWVRQAPGKGLEWV



S
YTNY
GNWY
(SEQ
NO: 65)
173)
SYISGDIGYTNYAAPVKGRFTISR



(SEQ
A
FDLW
ID NO:


DDSKNTLYLQMNSLKTEDTAVYYC



ID
(SEQ
(SEQ
172)


ARDVAATGNWYFDLWGRGTLVTVS



NO:
ID
ID



SGGGGSGGGGSGGGGSGGGGSDIQ



233)
NO:
NO:



MTQSPSSLSASVGDRVTITCRASQ




234)
235)



SISSYLNWYQQKPGKAPKLLIYAA









SSLQSGVPSRFSGSGSGTDETLTI









SSLQPEDFATYYCQQSYSTPLTFG









GGTKVEIK (SEQ ID NO: 









236)





35.
FSFS
SFIT
CARD
RASQSV
GASTRAT
CQQYGSSPLTF
EVQLLESGGGLVQPGGSLRLSCAA



SYTM
SSSR
RRGD
RNYLA
(SEQ ID
(SEQ ID NO:
SGFSFSSYTMNWVRQAPGKGLEWV



N
TIYY
YGDS
(SEQ
NO:
242)
SFITSSSRTIYYADSVKGRFTISR



(SEQ
A
WYFD
ID NO:
241)

DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
LW
240)


ARDRRGDYGDSWYFDLWGRGTLVT



NO:
ID
(SEQ



VSSGGGGSGGGGSGGGGSGGGGSE



237)
NO:
ID



IVMTQSPATLSVSPGERATLSCRA




238)
NO:



SQSVRNYLAWYQQKPGQAPRLLIY





239)



GASTRATGIPARFSGSGSGTEFTL









TISSLQSEDFAVYYCQQYGSSPLT









FGGGTKVEIK (SEQ ID NO: 









243)





36.
YTFT
GIIN
CARD
RASQSI
DASNLOS
CQQSYSIPITF
QVQLVQSGAEVKKPGASVKVSCKA



GHYM
PSGG
TGYS
GRWLA
(SEQ ID
(SEQ ID NO:
SGYTFTGHYMHWVRQAPGQGLEWM



H
STSY
YGRY
(SEQ
NO:
198)
GIINPSGGSTSYAQKFQGRVTMTR



(SEQ
A
YYYG
ID NO:
222)

DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
MDVW
221)


ARDTGYSYGRYYYYGMDVWGQGTT



NO:
ID
(SEQ



VTVSSGGGGSGGGGSGGGGSGGGG



244)
NO:
ID



SDIQMTQSPSSLSASVGDRVTITC




69)
NO:



RASQSIGRWLAWYQQKPGKAPKLL





220)



IYDASNLQSGVPSRFSGSGSGTDF









TLTISSLQPEDFATYYCQQSYSIP









ITFGGGTKVEIK (SEQ ID NO:









245)





37.
YTES
GWMN
CARG
RASQSI
AASTLOS
CQQSYSTPWTF
QVQLVQSGAEVKKPGASVKVSCKA



KHFV
PNSG
EGGY
SSWLA
(SEQ ID
(SEQ ID NO:
SGYTFSKHFVHWVRQAPGQGLEWM



H
NSGY
YYYG
(SEQ
NO:
114)
GWMNPNSGNSGYAQKFQGRVTMTR



(SEQ
A
MDVW
ID NO:
113)

DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
(SEQ
196)


ARGEGGYYYYGMDVWGQGTLVTVS



NO:
ID
ID



SGGGGSGGGGSGGGGSGGGGSDIQ



246)
NO:
NO:



MTQSPSSLSASVGDRVTITCRASQ




247)
248



SISSWLAWYQQKPGKAPKLLIYAA









STLQSGVPSRFSGSGSGTDETLTI









SSLQPEDFATYYCQQSYSTPWTFG









QGTKVEIK (SEQ ID NO: 









249)





38.
FTFG
SAIG
CAKG
RASQPL
AASSLQS
CQQAISFPLTF
EVQLLESGGGLVQPGGSLRLSCAA



SYSM
TGGG
TPYY
SNWLA
(SEQ ID
(SEQ ID NO:
SGFTFGSYSMSWVRQAPGKGLEWV



S
TYYA
YYYG
(SEQ
NO: 65)
254)
SAIGTGGGTYYADSVKGRFTISRD



(SEQ
(SEQ
MDVW
ID NO:


NSKNTLYLQMNSLRAEDTAVYYCA



ID
ID
(SEQ
253)


KGTPYYYYYGMDVWGQGTMVTVSS



NO:
NO:
ID



GGGGSGGGGSGGGGSGGGGSDIQM



250)
251)
NO:



TQSPSSLSASVGDRVTITCRASQP





252)



LSNWLAWYQQKPGKAPKLLIYAAS









SLQSGVPSRESGSGSGTDETLTIS









SLQPEDFATYYCQQAISFPLTFGG









GTKVEIK (SEQ ID NO: 255)





39.
YTFT
GWMN
CARD
QSSEDI
AASSLQI
CQQTYSTPYTF
QVQLVQSGAEVKKPGASVKVSCKA



SYYM
PNSG
LGYY
SSSLN
(SEQ ID
(SEQ ID NO:
SGYTFTSYYMHWVRQAPGQGLEWM



H
NTGY
DSSG
(SEQ
NO:
259)
GWMNPNSGNTGYAQKFQGRVTMTR



(SEQ
A
YFGA
ID NO:
258)

DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
FDIW
257)


ARDLGYYDSSGYFGAFDIWGQGTT



NO:
ID
(SEQ



VTVSSGGGGSGGGGSGGGGSGGGG



215)
NO:
ID



SDIQMTQSPSSLSASVGDRVTITC




205)
NO:



QSSEDISSSLNWYQQKPGKAPKLL





256)



IYAASSLQIGVPSRFSGSGSGTDE









TLTISSLQPEDFATYYCQQTYSTP









YTFGQGTKVEIK (SEQ ID NO:









260)





40.
YTFT
GIIN
CARG
RASQGI
AASNLET
CQQIHSYPLTF
QVQLVQSGAEVKKPGASVKVSCKA



SYGI
PRGG
TRSS
GNWLA
(SEQ ID
(SEQ ID NO:
SGYTFTSYGISWVRQAPGOGLEWM



S
STIF
GWYG
(SEQ
NO:
265)
GIINPRGGSTIFAQKFQGRVTMTR



(SEQ
A
WEDP
ID NO:
264)

DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
W
263)


ARGTRSSGWYGWFDPWGQGTLVTV



NO:
ID
(SEQ



SSGGGGSGGGGSGGGGSGGGGSDI



228)
NO:
ID



QMTQSPSSLSASVGDRVTITCRAS




261)
NO:



QGIGNWLAWYQQKPGKAPKLLIYA





262)



ASNLETGVPSRESGSGSGTDFTLT









ISSLQPEDFATYYCQQIHSYPLTF









GGGTKVEIK (SEQ ID NO: 









266)





41.
FTFD
SYIS
CARE
RASQSI
AASSLQS
CQQSYSTPLTF
EVQLLESGGGLVQPGGSLRLSCAA



DYGM
SSSS
IAAA
SSYLN
(SEQ ID
(SEQ ID NO:
SGFTEDDYGMSWVRQAPGKGLEWV



S
YIYY
GFYG
(SEQ
NO: 65)
173)
SYISSSSSYIYYADSVKGRFTISR



(SEQ
A
MDVW
ID NO:


DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
(SEQ
172)


AREIAAAGFYGMDVWGQGTTVTVS



NO:
ID
ID



SGGGGSGGGGSGGGGSGGGGSDIQ



267)
NO:
NO:



MTQSPSSLSASVGDRVTITCRASQ




268 )
269)



SISSYLNWYQQKPGKAPKLLIYAA









SSLQSGVPSRESGSGSGTDFTLTI









SSLQPEDFATYYCQQSYSTPLTFG









GGTKVEIK (SEQ ID NO: 









270)





42.
GTLS
GGII
CARD
RASQSV
GASTRAT
CQQYGSSPITF
QVQLVQSGAEVKKPGSSVKVSCKA



RYGV
PIFG
RVYY
SSSYLA
(SEQ ID
(SEQ ID NO:
SGGTLSRYGVSWVRQAPGQGLEWM



S
TTNY
DSSG
(SEQ
NO:
275)
GGIIPIFGTTNYAQKFQGRVTITA



(SEQ
A
YPTW
ID NO:
241)

DESTSTAYMELSSLRSEDTAVYYC



ID
(SEQ
YFDL
274)


ARDRVYYDSSGYPTWYFDLWGRGT



NO:
ID




LVTVSSGGGGSGGGGSGGGGSGGG



271)
NO:
W



GSEIVMTQSPATLSVSPGERATLS




272)
(SEQ



CRASQSVSSSYLAWYQQKPGQAPR





ID



LLIYGASTRATGIPARFSGSGSGT





NO:



EFTLTISSLQSEDFAVYYCQQYGS





273)



SPITFGQGTKVEIK (SEQ ID









NO: 276)





43.
FTFD
SGIS
CARD
QASQDI
KASTLES
CQQANSFPLTF
EVQLLESGGGLVQPGGSLRLSCAA



DEAM
GNGD
ASYG
RNYLN
(SEQ ID
(SEQ ID NO:
SGFTFDDFAMHWVRQAPGKGLEWV



H
SRYY
GNYG
(SEQ
NO:
167)
SGISGNGDSRYYADSVKGRFTISR



(SEQ
A
MDVW
ID NO:
139)

DNSKNTLYLOMNSLRAEDTAVYYC



ID
(SEQ
(SEQ
280)


ARDASYGGNYGMDVWGQGTTVTVS



NO:
ID
ID



SGGGGSGGGGSGGGGGGGGSDIQ



277)
NO:
NO:



MTQSPSSLSASVGDRVTITCQASQ




278)
279)



DIRNYLNWYQQKPGKAPKLLIYKA









STLESGVPSRFSGSGSGTDETLTI









SSLQPEDFATYYCQQANSFPLTFG









PGTKVDIK (SEQ ID NO: 









281)





44.
FTES
SAIG
CARE
RASQSI
GASNLQS
CQQSYST PWTF
EVQLVESGGGLVKPGGSLRLSCAA



SYWM
TGGG
WLVP
SRWLA
(SEQ ID
(SEQ ID NO:
SGFTFSSYWMSWVRQAPGKGLEWV



S
TYYA
YYGM
(SEQ
NO:
114)
SAIGTGGGTYYAAPVKGRFTISRD



(SEQ
(SEQ
DVW
ID NO:
284)

DSKNTLYLQMNSLKTEDTAVYYCA



ID
ID
(SEQ
283)


REWLVPYYGMDVWGQGTTVTVSSG



NO:
NO:
ID



GGGSGGGGSGGGGSGGGGSDIQMT



169)
251)
NO:



QSPSSLSASVGDRVTITCRASQSI





282)



SRWLAWYQQKPGKAPKLLIYGASN









LQSGVPSRFSGSGSGTDFTLTISS









LQPEDFATYYCQQSYSTPWTFGQG









TKVEIK (SEQ ID NO: 285)





45.
FSVS
AGIS
CARS
KSSQSV
WASTROS
CHQYYGHPPTF
EVQLLESGGGLVQPGGSLRLSCAA



SNYM
YDGS
RGIA
LYSSNN
(SEQ ID
(SEQ ID NO:
SGFSVSSNYMSWVRQAPGKGLEWV



S
SKPY
ARPL
KNYLA
NO:
291)
AGISYDGSSKPYADSVKGRFTISR



(SEQ
A
QHW
(SEQ
290)

DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
(SEQ
ID NO:


ARSRGIAARPLQHWGQGTLVTVSS



NO:
ID
ID
289)


GGGGSGGGGSGGGGSGGGGSDIVM



286)
NO:
NO:



TQSPDSLAVSLGERATINCKSSQS




287)
288)



VLYSSNNKNYLAWYQQKPGQPPKL









LIYWASTRQSGVPDRFSGSGSGTD









FTLTISSLQAEDVAVYYCHQYYGH









PPTFGGGTKVEIK (SEQ ID









NO: 292)





46.
FSVS
AGIS
CARS
KSSQSV
QASTROS
CHQYYGHPPTF
EVQLLESGGGLVQPGGSLRLSCAA



SNYM
YDGS
RGIA
LYSSNN
(SEQ ID
(SEQ ID NO:
SGFSVSSNYMSWVRQAPGKGLEWV



S
SKPY
ARPL
KNYLA
NO:
291)
AGISYDGSSKPYADSVKGRFTISR



(SEQ
A
QHW
(SEQ
293)

DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
(SEQ
ID NO:


ARSRGIAARPLQHWGQGTLVTVSS



NO:
ID
ID
289)


GGGGSGGGGSGGGGSGGGGSDIVM



286)
NO:
NO:



TQSPDSLAVSLGERATINCKSSQS




287)
288)



VLYSSNNKNYLAWYQQKPGQPPKL









LIYQASTROSGVPDRESGSGSGTD









FTLTISSLQAEDVAVYYCHQYYGH









PPTFGGGTKVEIK (SEQ ID









NO: 294)





47.
FSFS
SAIS
CARD
RASQGI
DASNLET
CQQSYSTPLTF
EVQLLESGGGLVQPGGSLRLSCAA



DYGM
GSGG
GGWQ
SNNLN
(SEQ ID
(SEQ ID NO:
SGFSFSDYGMHWVRQAPGKGLEWV



H
STYY
PAAI
(SEQ
NO:
173
SAISGSGGSTYYADSVKGRETISR



(SEQ
A
LDYW
ID NO:
159)

DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
(SEQ
105)


ARDGGWQPAAILDYWGQGTLVTVS



NO:
ID
ID



SGGGGSGGGGSGGGGSGGGGSDIQ



295)
NO:
NO:



MTQSPSSLSASVGDRVTITCRASQ




103)
296)



GISNNLNWYQQKPGKAPKLLIYDA









SNLETGVPSRFSGSGSGTDFTLTI









SSLQPEDFATYYCQQSYSTPLTFG









GGTKVEIK (SEQ ID NO:









297)





48.
FTES
SVIY
CARD
RASQGI
DASNLET
CQQSYSTCYTF
EVQLLESGGGLVQPGGSLRLSCAA



DHGM
GGES
PAVA
SNYLA
(SEQ ID
(SEQ ID NO:
SGFTFSDHGMHWVRQAPGKGLEWV



H
TYYA
GGGI
(SEQ
NO:
301)
SVIYGGESTYYADSVKGRFTISRD



(SEQ
(SEQ
FDYW
ID NO:
159)

NSKNTLYLQMNSLRAEDTAVYYCA



ID
ID
(SEQ
218)


RDPAVAGGGIFDYWGQGTLVTVSS



NO:
NO:
ID



GGGGSGGGGSGGGGSGGGGSDIQM



298)
299)
NO:



TQSPSSLSASVGDRVTITCRASQG





300)



ISNYLAWYQQKPGKAPKLLIYDAS









NLETGVPSRESGSGSGTDETLTIS









SLQPEDFATYYCQQSYSTCYTFGQ









GTKLEIK (SEQ ID NO: 302)





49.
DTFT
GWIN
CARS
RASQTI
DASTLQS
CQQYSSYPLTF
QVQLVQSGAEVKKPGASVKVSCKA



GYYI
PNSG
GLWL
SIWLA
(SEQ ID
(SEQ ID NO:
SGDTFTGYYIHWVRQAPGQGLEWM



H
GTNY
GSYY
(SEQ
NO:
308)
GWINPNSGGTNYAQKFQGRVTMTR



(SEQ
A
GMDV
ID NO:
307)

DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
W
306)


ARSGLWLGSYYGMDVWGQGTLVTV



NO :
ID
(SEQ



SSGGGGSGGGGSGGGGSGGGGSDI



303)
NO:
ID



QMTQSPSSLSASVGDRVTITCRAS




304
NO:



QTISIWLAWYQQKPGKAPKLLIYD





305)



ASTLQSGVPSRESGSGSGTDFTLT









ISSLQPEDFATYYCQQYSSYPLTF









GQGTKVEIK (SEQ ID NO:









309)





50.
YTFT
GWIN
CARS
RASHFI
AASTLOS
CQQSYSGISF
QVQLVQSGAEVKKPGASVKVSCKA



SYDI
PNSG
PYYY
SRWVA
(SEQ ID
(SEQ ID NO:
SGYTFTSYDINWVRQAPGQGLEWM



N
TTGY
YGMD
(SEç
NO:
314)
GWINPNSGTTGYAQKFQGRVTMTR



(SEQ
A
VW
ID NO:
113)

DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
(SEQ
313)


ARSPYYYYGMDVWGQGTTVTVSSG



NO:
ID
ID



GGGSGGGGSGGGGSGGGGSDIQMT



310)
NO:
NO:



QSPSSLSASVGDRVTITCRASHFI




311)
312)



SRWVAWYQQKPGKAPKLLIYAAST









LQSGVPSRFSGSGSGTDFTLTISS









LQPEDFATYYCQQSYSGISFGPGT









KVDIK (SEQ ID NO: 315)





51.
FTEN
SRIN
CARG
RASQSV
ATSSRAS
CQQYYSGLTF
EVQLLESGGGLVQPGGSLRLSCAA



NYGM
SDGS
AYYY
SGSYLA
(SEQ ID
(SEQ ID NO:
SGFTFNNYGMNWVRQAPGKGLEWV



N
STSY
YYMD
(SEQ
NO:
321)
SRINSDGSSTSYADSVKGRFTISR



(SEQ
A
VW
ID NO:
320)

DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
(SEQ
319)


ARGAYYYYYMDVWGQGTLVTVSSG



NO:
ID
ID



GGGSGGGGSGGGGSGGGGSEIVMT



316)
NO:
NO:



QSPATLSVSPGERATLSCRASQSV




317)
318)



SGSYLAWYQQKPGQAPRLLIYATS









SRASGIPARFSGSGSGTEFTLTIS









SLQSEDFAVYYCQQYYSGLTFGQG









TKVEIK (SEQ ID NO: 322)





52.
FTES
AHIW
CARD
RASQDI
DASSLET
CQQATSLPLTF
EVQLLESGGGLVQPGGSLRLSCAA



NSDM
NDGS
RTDP
RNYLG
(SEQ ID
(SEQ ID NO:
SGFTFSNSDMNWVRQAPGKGLEWV



N
QKYY
GYSS
(SEQ
NO:
328)
AHIWNDGSQKYYADSVKGRFTISR



(SEQ
A
AMDV
ID NO:
327)

DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
W
326)


ARDRTDPGYSSAMDVWGQGTTVTV



NO:
ID
(SEQ



SSGGGGSGGGGSGGGGSGGGGSDI



323)
NO:
ID



QMTQSPSSLSASVGDRVTITCRAS




324)
NO:



QDIRNYLGWYQQKPGKAPKLLIYD





325)



ASSLETGVPSRFSGSGSGTDETLT









ISSLQPEDFATYYCQQATSLPLTE









GGGTKVEIK (SEQ ID NO:









329)





53.
YTFT
GWMN
CAKD
RASQDI
QASSLES
CQQSYTIPLTF
QVQLVQSGAEVKKPGASVKVSCKA



SYDI
PNSG
SDYS
TNDLG
(SEQ ID
(SEQ ID NO:
SGYTFTSYDINWVRQAPGQGLEWM



N
NTGY
NLLW
(SEQ
NO:
333)
GWMNPNSGNTGYAQKFQGRVTMTR



(SEQ
A
DYW
ID NO:
332)

DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
(SEQ
331)


AKDSDYSNLLWDYWGQGTLVTVSS



NO:
ID
ID



GGGGGGGGSGGGGSGGGGSDIQM



310)
NO:
NO:



TQSPSSLSASVGDRVTITCRASQD




205)
330)



ITNDLGWYQQKPGKAPKLLIYQAS









SLESGVPSRFSGSGSGTDETLTIS









SLQPEDFATYYCQQSYTIPLTFGQ









GTKVEIK (SEQ ID NO: 334)





54.
FTFG
AVVS
CAKD
RASQNI
DASNLET
CQQANSFPPTF
EVQLLESGGGLVQPGGSLRLSCAA



DYAM
YDGT
ICSS
NNYVN
(SEQ ID
(SEQ ID NO:
SGFTFGDYAMSWVRQAPGKGLEWV



S
NKYY
TSCY
(SEQ
NO:
338)
AVVSYDGTNKYYADSVKGRFTISR



(SEQ
A
FDLW

159)

DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
(SEQ
ID NO:


AKDICSSTSCYFDLWGRGTLVTVS



NO:
ID
ID
337)


SGGGGSGGGGSGGGGSGGGGSDIQ



233)
NO:
NO:



MTQSPSSLSASVGDRVTITCRASQ




335)
336)



NINNYVNWYQQKPGKAPKLLIYDA









SNLETGVPSRFSGSGSGTDETLTI









SSLQPEDFATYYCQQANSFPPTFG









QGTRLEIK (SEQ ID NO:









339)





55.
YTFT
GIID
CARE
RASQGI
ATSSLQT
CQQTYSIPITF
QVQLVQSGAEVKKPGASVKVSCKA



SYYM
PSGG
EWSS
SSYLA
(SEQ ID
(SEQ ID NO:
SGYTFTSYYMHWVRQAPGQGLEWM



H
STSY
GGVG
(SEQ
NO:
344)
GIIDPSGGSTSYAQKFQGRVTMTR



(SEQ
A
YFDY
ID NO:
343)

DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
W
342)


AREEWSSGGVGYFDYWGQGTLVTV



NO:
ID
(SEQ



SSGGGGSGGGGSGGGGSGGGGSDI



215)
NO:
ID



QMTQSPSSLSASVGDRVTITCRAS




340)
NO:



QGISSYLAWYQQKPGKAPKLLIYA





341)



TSSLQTGVPSRFSGSGSGTDETLT









ISSLQPEDFATYYCQQTYSIPITF









GQGTRLEIK (SEQ ID NO:









345)





56.
FTED
SAIS
CARD
QASQDI
KASSLES
CQQANSYPVTF
EVQLLESGGGLVQPGGSLRLSCAA



DYAM
GGGE
ASYG
RNYLN
(SEQ ID
(SEQ ID NO:
SGFTEDDYAMHWVRQAPGKGLEWV



H
DTYY
GNYG
(SEQ
NO:
348)
SAISGGGEDTYYADSVKGRFTISR



(SEQ
A
MDVW
ID NO:
347)

DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
(SEQ
280)


ARDASYGGNYGMDVWGQGTTVTVS



NO:
ID
ID



SGGGGSGGGGSGGGGSGGGGSDIQ



135)
NO:
NO:



MTQSPSSLSASVGDRVTITCQASQ




346)
279)



DIRNYLNWYQQKPGKAPKLLIYKA









SSLESGVPSRESGSGSGTDETLTI









SSLQPEDFATYYCQQANSYPVTFG









GGTKVEIK (SEQ ID NO:









349)





57.
YTFT
GIIN
CARD
RASQGI
AASSLQG
CQQSYSLPYTF
QVQLVQSGAEVKKPGASVKVSCKA



SYYM
PSGG
SVAG
SNYFA
(SEQ ID
(SEQ ID NO:
SGYTFTSYYMHWVRQAPGQGLEWM



H
STSY
TGGR
(SEQ
NO:
353)
GIINPSGGSTSYAQKFQGRVTMTR



(SEQ
A
YYGM
ID NO:
352)

DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
DVW
351)


ARDSVAGTGGRYYGMDVWGQGTLV



NO:
ID
(SEQ



TVSSGGGGSGGGGSGGGGSGGGGS



215)
NO:
ID



DIQMTQSPSSLSASVGDRVTITCR




69)
NO:



ASQGISNYFAWYQQKPGKAPKLLI





350)



YAASSLOGGVPSRESGSGSGTDET









LTISSLQPEDFATYYCQQSYSLPY









TFGQGTKLEIK (SEQ ID NO:









354)





58.
YTFT
GIIN
CTTA
RASQGI
AASSLQS
CQQYYSNADF
QVQLVQSGAEVKKPGASVKVSCKA



GYYM
PSGG
DYYY
SNYLA
(SEQ ID
(SEQ ID NO:
SGYTFTGYYMHWVRQAPGQGLEWM



H
NTKY
YMDV
(SEQ
NO: 65)
357)
GIINPSGGNTKYAQKFQGRVTMTR



(SEQ
A
W
ID NO:


DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
(SEQ
218)


TTADYYYYMDVWGKGTTVTVSSGG



NO:
ID
ID



GGSGGGGSGGGGSGGGGSDIQMTQ



128)
NO:
NO:



SPSSLSASVGDRVTITCRASQGIS




355
356)



NYLAWYQQKPGKAPKLLIYAASSL









QSGVPSRFSGSGSGTDETLTISSL









QPEDFATYYCQQYYSNADFGQGTK









VEIK (SEQ ID NO: 358)





59.
FTES
SYIS
CARD
RASQSV
SSLQS
QQYKSYPVT
EVQLLESGGGLVQPGGSLRLSCAA



DFWM
GDSG
RPYY
SRSLA
(SEQ ID
(SEQ ID NO:
SGFTFSDFWMHWVRQAPGKGLEWI



H
YTNY
YYMD
(SEQ
NO:
363)
SYISGDSGYTNYADSVKGRFTISR



(SEQ
A
VW
ID NO:
362)

DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
(SEQ
361)


ARDRPYYYYMDVWGKGTTVTVSSG



NO:
ID
ID



GGGSGGGGSGGGGSGGGGSDIQMT



359)
NO:
NO:



QSPSSLSASVGDRVTITCRASQSV




170)
360)



SRSLAWYQQKPGKAPKLLIYAASS









LQSGVPSRFSGSGSGTDFTLTISS









LQPEDFATYYCQQYKSYPVTFGQG









TKVEIK (SEQ ID NO: 364)





60.
FTFD
SDIS
CAKD
QASQDI
SYLQS
QQAHNYPIT
EVQLLESGGGLVQPGGSLRLSCAA



DYTM
GSGG
VVVA
SNYLN
(SEQ ID
(SEQ ID NO:
SGFTFDDYTMHWVRQAPGKGLEWV



H
STYY
GTPL
(SEQ
NO:
369)
SDISGSGGSTYYADSVKGRFTISR



(SEQ
A
HFDY
ID NO:
368)

DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
W
138)


AKDVVVAGTPLHFDYWGQGTLVTV



NO:
ID
(SEQ



SSGGGGSGGGGSGGGGSGGGGSDI



365)
NO:
ID



QMTQSPSSLSASVGDRVTITCQAS




366)
NO:



QDISNYLNWYQQKPGKAPKLLIYA





367)



ASYLQSGVPSRFSGSGSGTDETLT









ISSLQPEDFATYYCQQAHNYPITF









GQGTRLEIK (SEQ ID NO:









370)





61.
FTFS
ASIS
CARE
RASQSI
SSLQS
QQANAFPPT
EVQLLESGGGLVQPGGSLRLSCAA



NAWM
STSA
VVGA
STWLA
(SEQ ID
(SEQ ID NO:
SEFTFSNAWMSWVRQAPGKGLEWV



S
YIDY
TTED
(SEQ
NO:
374)
ASISSTSAYIDYADSVKGRETISR



(SEQ
A
YW
ID NO:
362)

DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
(SEQ
373)


AREVVGATTFDYWGQGTLVTVSSG



NO:
ID
ID



GGGSGGGGSGGGGSGGGGSDIQMT



183)
NO:
NO:



QSPSSLSASVGDRVTITCRASQSI




371)
372)



STWLAWYQQKPGKAPKLLIYAASS









LQSGVPSRFSGSGSGTDETLTISS









LQPEDFATYYCQQANAFPPTFGQG









TRLEIK (SEQ ID NO: 375)





62.
GTES
GWME
CAKG
KSSQSV
STRES
QQYYSTPPT
QVQLVQSGAEVKKPGSSVKVSCKA



SYAI
PHTG
GFSW
LYSSNN
(SEQ ID
(SEQ ID NO:
SGGTFSSYAISWVRQAPGQGLEWM



S
NTRY
FDPW
KNYLA
NO:
379)
GWMEPHTGNTRYAQKFQGRVTITA



(SEQ
A
(SEQ
(SEQ
378)

DESTSTAYMELSSLRSEDTAVYYC



ID
(SEQ
ID
ID NO:


AKGGFSWFDPWGQGTLVTVSSGGG



NO:
ID
NO:
289)


GSGGGGSGGGGSGGGGSDIVMTQS



77)
NO:
377)



PDSLAVSLGERATINCKSSQSVLY




376)




SSNNKNYLAWYQQKPGQPPKLLIY









WASTRESGVPDRESGSGSGTDETL









TISSLQAEDVAVYYCQQYYSTPPT









FGQGTRLEIK (SEQ ID NO:









380)





63.
FTED
ASIT
CARE
RASQGI
STRAT
QQYYTYPPT
EVQLLESGGGLVKPGGSLRLSCAA



DYAM
SSSA
RVDW
SNSYLA
(SEQ ID
(SEQ ID NO:
SGFTEDDYAMHWVRQAPGKGLEWV



H
FIDY
NSYF
(SEQ
NO:
385)
ASITSSSAFIDYAASVKGRFTISR



(SEQ
A
DLW
ID NO:
384)

DDSKNTLYLQMNSLKTEDTAVYYC



ID
(SEQ
(SEQ
383)


ARERVDWNSYFDLWGRGTLVTVSS



NO:
ID
ID



GGGGSGGGGSGGGGSGGGGSEIVM



135)
NO:
NO:



TQSPATLSVSPGERATLSCRASQG




381)
382)



ISNSYLAWYQQKPGQAPRLLIYGA









STRATGIPARFSGSGSGTEFTLTI









SSLQSEDFAVYYCQQYYTYPPTFG









PGTKVDIK (SEQ ID NO:









386)





64.
FAFS
AGTS
CARE
RASQGI
ANLEG
QQSDIFPPT
EVQLLESGGGLVKPGGSLRLSCAA



SHWM
GSGE
TYYY
SNYLA
(SEQ ID
(SEQ ID NO:
SGFAFSSHWMHWVRQAPGKGLEWV



H
SRDY
YYMD
SEQ
NO:
391)
AGTSGSGESRDYADFVKGRFTISR



(SEQ
A
VW
ID NO:
390)

DDSKNTLYLQMNSLKTEDTAVYYC



ID
(SEQ
SEQ
218)


ARETYYYYYMDVWGKGTTVTVSSG



NO:
ID
ID



GGGSGGGGSGGGGSGGGGSDIQMT



387)
NO:
NO:



QSPSSLSASVGDRVTITCRASQGI




388)
389)



SNYLAWYQQKPGKAPKLLIYDAAN









LEGGVPSRESGSGSGTDETLTISS









LQPEDFATYYCQQSDIFPPTFGQG









TKVEIK (SEQ ID NO: 392)





65.
YTFT
GWIN
CARE
RASQSI
SSLQS
QQSNSFPLT
QVQLVQSGAEVKKPGASVKVSCKA



RHWI
VKTG
SSGW
SNYLA
(SEQ ID
(SEQ ID NO:
SGYTFTRHWIHWVRQAPGQGLEWM



H
GAGY
YGTD
SEQ
NO:
397)
GWINVKTGGAGYAQKFQGRVTMTR



(SEQ
A
VW
ID NO:
362)

DTSTSTVYMELSSLRSEDTAVYYC



ID
(SEQ
(SEQ
396)


ARESSGWYGTDVWGQGTTVTVSSG



NO:
ID
ID



GGGSGGGGSGGGGSGGGGSDIQMT



393)
NO:
NO:



QSPSSLSASVGDRATITCRASQSI




394)
395)



SNYLAWYQQKPGKAPKLLIYAASS









LQSGVPSRFSGSGSGTDFTLTISS









LQPEDFATYYCQQSNSFPLTFGGG









TKVEIK (SEQ ID NO: 398)





66.
FTES
AAIS
CARE
QASQDI
NLRS
QQANSFPVT
EVQLLESGGGLVQPGGSLRLSCAA



SYWM
YDGK
NKQW
SNFVN
(SEQ ID
(SEQ ID NO:
SGFTFSSYWMHWVRQAPGKGLEWV



H
YKDY
LASF
(SEQ
NO:
403)
AAISYDGKYKDYEDSVKGRETISR



(SEQ
E
DYW
ID NO:
402)

DNSKNTLYLQMNSLRAEDTAVYYC



ID
(SEQ
(SEQ
401)


ARENKQWLASFDYWGQGTLVTVSS



NO:
ID
ID



GGGGSGGGGSGGGGSGGGGSDIQM



83)
NO:
NO:



TQSPSSLSASVGDRVTITCQASQD




399)
400)



ISNFVNWYQQKPGKAPKLLIYAAN









LRSGVPSRFSGSGSGTDETLTISS









LQPEDFATYYCQQANSFPVTFGPG









TKVDIK (SEQ ID NO: 404)









In some embodiments, the antibody comprises a CDR set as set forth in Table 6 or Table 7. In some embodiments, the antibody comprises the CDRs of Clone ID: 6, Clone ID: 59, or Clone ID: 63 of Table 6.


The antibodies, can be in a scFv format, which are also illustrated in a non-limiting embodiment in Table 6.


In some embodiments, the MAdCAM antibody is selected from the following table, which can be in a IgG format as illustrated in Table 7.

















TABLE 7





Clone










ID
HCDR1
HCDR2
HCDR3
LCDR1
LCDR2
LCDR3
VH
VK























1.
FTFSSY
AVISDD
CTTSKYYYY
QASQDI
AASSL
CQQGYS
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



GMH
GSDKYY
YGMDVW
SKSLN
QS
TPLTF
SLRLSCAASGFTESSY
GDRVTITCQASQDIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
GMHWVRQAPGKGLEWV
KSLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 63)
ID NO:
ID
ID NO:
AVISDDGSDKYYADSV
LLIYAASSLQSGVPS



61)
62)

64)
NO:
66)
KGRFTISRDNSKNTLY
RFSGSGSGTDETLTI







65)

LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









TTSKYYYYYGMDVWGQ
GYSTPLTFGGGTKVE









GTTVTVSS (SEQ ID
IK (SEQ ID NO:









NO: 405)
406)





2.
YPFIGY
GIINPS
CAREGRLSY
RASQSI
GASTL
CQQTWG
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YLH
GGSTSY
GMDAW
SSYLA
ES
PPFTF
SVKVSCKASGYPFIGY
GDRVTITCRASQSIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
YLHWVRQAPGQGLEWM
SYLAWYQQKPGKAPK



ID NO:
ID NO:
NO: 70)
ID NO:
ID
ID NO:
GIINPSGGSTSYAQKF
LLIYGASTLESGVPS



68)
69)

71)
NO:
73)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI







72)

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









AREGRLSYGMDAWGQG
TWGPPFTFGQGTKLE









TLVTVSS (SEQ ID
IK (SEQ ID NO:









NO: 407)
408)





3.
YPFIGQ
GIINPS
CAREGRLSY
RASQSI
GASTL
CQQTWG
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YLH
GGSTSY
GMDAW
SSYLA
ES
PPFTE
SVKVSCKASGYPFIGQ
GDRVTITCRASQSIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
YLHWVRQAPGQGLEWM
SYLAWYQQKPGKAPK



ID NO:
ID NO:
NO: 70)
ID NO:
ID
ID NO:
GIINPSGGSTSYAQKF
LLIYGASTLESGVPS



75
69)

71)
NO:
73)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI







72)

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









AREGRLSYGMDAWGQG
TWGPPFTFGQGTKLE









TLVTVSS (SEQ ID
IK (SEQ ID NO:









NO: 409)
408)





4.
GTFSSY
GSINPS
CAKDKAQWL
QASQDI
AASSL
CQQSYS
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



AIS
GDTTSY
VGYFDYW
SNSLN
QS
SVITE
SVKVSCKASGGTESSY
GDRVTITCQASQDIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
AISWVRQAPGQGLEWM
NSLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 79)
ID NO:
ID
ID NO:
GSINPSGDTTSYAQKF
LLIYAASSLQSGVPS



77)
78)

80)
NO:
81)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI







65)

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









AKDKAQWLVGYFDYWG
SYSSVITFGQGTKVE









QGTLVTVSS SEQ
IK (SEQ ID NO:









ID NO: 410)
411)





5.
FTFSSY
SSISPG
CAREVQLSH
RASQGI
GASSL
CQQANS
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



WMH
GSNIDY
YDYW (SEQ
SNSLA
QS
FPFTF
SLRLSCAASGFTESSY
GDRVTITCRASQGIS



(SEQ
A (SEQ
ID NO:
(SEQ
(SEQ
(SEQ
WMHWVRQAPGKGLEWV
NSLAWYQQKPGKAPK



ID NO:
ID NO:
85)
ID NO:
ID
ID NO:
SSISPGGSNIDYADSV
LLIYGASSLQSGVPS



83)
84)

86)
NO:
88)
KGRFTISRDNSKNTLY
RFSGSGSGTDFTLTI







87)

LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









AREVQLSHYDYWGQGT
ANSFPFTFGQGTKVE









LVTVSS (SEQ ID
IK (SEQ ID NO:









NO: 412)
413)





6.
FTENNY
SRINSY
CAREGPVAG
RASQII
GASSL
CQQSYR
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



AFH
GTSTTY
YWYFDLW
GTNLA
QS
LPFTF
SLRLSCAASGFTENNY
GDRVTITCRASQIIG



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
AFHWVRQAPGKGLEWV
TNLAWYQQKPGKAPK



ID NO:
ID NO:
NO: 92)
ID NO:
ID
ID NO:
SRINSYGTSTTYADSV
LLIYGASSLQSGVPS



90)
91)

93)
NO:
94)
KGRFTISRDNSKNTLY
RFSGSGSGTDETLTI







87)

LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









AREGPVAGYWYFDLWG
SYRLPFTFGQGTKVE









QGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 414)
415)





7.
FTFSDY
AIISHA
CAKPYSSGW
RASRGI
STLQS
QQAYSF
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



QMS
DGGFKD
SAVYYFDYW
TNDLG
(SEQ
PWT
SLRLSCAASGFTESDY
GDRVTITCRASRGIT



(SEQ
YA
(SEQ ID
(SEQ
ID
(SEQ
QMSWVRQAPGKGLEWV
NDLGWYQQKPGKAPK



ID NO:
(SEç
NO: 418)
ID NO:
NO :
ID NO:
AIISHADGGFKDYADS
LLIYAASTLQSGVPS



416)
ID NO:

419)
420)
421)
VKGRFTISRDNSKNTL
RFSGSGSGTDETLTI




417)




YLQMNSLRAEDTAVYY
SSLQPEDFATYYCQQ









CAKPYSSGWSAVYYED
AYSFPWTFGQGTKVE









YWGQGTLVTVSS
IK (SEQ ID NO:









(SEQ ID NO: 422)
423)





8.
YTFTGY
GIINPS
CAKDWSSWY
RASQNI
AASSL
CQQSYT
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



HIH
GGSTIY
LGPFDYW
SSSLN
QS
TPYTF
SVKVSCKASGYTFTGY
GDRVTITCRASQNIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
HIHWVRQAPGQGLEWM
SSLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 98)
ID NO:
ID
ID NO:
GIINPSGGSTIYAQKF
LLIYAASSLQSGVPS



96)
97)

99)
NO:
100)
QGRVTMTRDTSTSTVY
RFSGSGSGTDFTLTI







65)

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









AKDWSSWYLGPFDYWG
SYTTPYTFGQGTKVE









QGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 424)
425)





9.
YTFTSY
GIINHS
CARPYSGWY
RASQSI
STLQS
QQSYST
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YMH
GGSTSY
FAFDIW
SSSLN
(SEQ
PLT
SVKVSCKASGYTFTSY
GDRVTITCRASQSIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
ID
(SEQ
YMHWVRQAPGQGLEWM
SSLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 427)
ID NO:
NO:
ID NO:
GIINHSGGSTSYAQKF
LLIYAASTLQSGVPS



215)
426)

428)
420)
429)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI









MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









ARPYSGWYFAFDIWGQ
SYSTPLTFGQGTKVE









GTLVTVSS (SEQ ID
IK (SEQ ID NO:









NO: 430)
431)





10.
FMFGDY
SAISGS
CAKDLVVAG
RASQGI
DASSL
CQQTHS
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



AMH
GGSTYY
IWYFDLW
SNNLN
ES
FPSTF
SLRLSCAASGFMFGDY
GDRVTITCRASQGIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
AMHWVRQAPGKGLEWV
NNLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 104)
ID NO:
ID
ID NO:
SAISGSGGSTYYADSV
LLIYDASSLESGVPS



102)
103)

105)
NO:
107)
KGRFTISRDNSKNTLY
RFSGSGSGTDFTLTI







106)

LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









AKDLVVAGIWYFDLWG
THSFPSTFGQGTKLE









RGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 432)
433)





11.
FTESDY
SVIGES
CAADPVSRW
RASQGI
AASTL
CQQSYS
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



YMN
GGSTYY
PKHGGGDYW
SSSLA
QS
TPWTF
SLRLSCAASGFTESDY
GDRVTITCRASQGIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
YMNWVRQAPGKGLEWV
SSLAWYQQKPGKAPK



ID NO:
ID NO:
NO: 111)
ID NO:
ID
ID NO:
SVIGESGGSTYYADSV
LLIYAASTLQSGVPS



109)
110)

112)
NO:
114)
KGRFTISRDNSKNTLY
RFSGSGSGTDETLTI







113)

LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









AADPVSRWPKHGGGDY
SYSTPWTFGQGTKVE









WGQGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 434)
435)





12.
YTLTTW
GWINPN
CAKGDLWGA
RASDNI
AASSL
CQQGYS
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YMY
RGATNY
MDVW (SEQ
GSWLA
QS
TPPTF
SVKVSCKASGYTLTTW
GDRVTITCRASDNIG



(SEQ
A (SEQ
ID NO:
(SEQ
(SEQ
(SEQ
YMYWVRQAPGQGLEWM
SWLAWYQQKPGKAPK





118)

ID

GWINPNRGATNYAQKF
LLIYAASSLQSGVPS



ID NO:
ID NO:

ID NO:
NO:
ID NO:
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI



116)
117)

119)
65)
120)
MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









AKGDLWGAMDVWGQGT
GYSTPPTFGQGTKVE









LVTVSS (SEQ ID
IK (SEQ ID NO:









NO: 436)
437)





13.
YTFTTY
GGFDPE
CARHAVAGA
RASESI
AASTL
CQQSYS
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YMH
DGETIY
VGAGYYYYG
SNWLA
QS
VPFTF
SVKVSCKASGYTFTTY
GDRVTITCRASESIS



(SEQ
A (SEQ
MDVW (SEQ
(SEQ
(SEQ
(SEQ
YMHWVRQAPGQGLEWM
NWLAWYQQKPGKAPK



ID NO:
ID NO:
ID NO:
ID NO:
ID
ID NO:
GGFDPEDGETIYAQKE
LLIYAASTLQSGVPS



122)
123)
124)
125)
NO:
126)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI







113)

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









ARHAVAGAVGAGYYYY
SYSVPFTFGPGTKVD









GMDVWGQGTMVTVSS
IK (SEQ ID NO:









(SEQ ID NO: 438)
439)





14.
YTFTNY
GGIIPI
CAKGQFTGN
QANQDI
SKLEA
QQSSEI
QVQLVQSGAEVKKPGS
DIQMTQSPSSLSASV



YMH
VDGVKY
YYYGMDYW
SNYLN
(SEQ
PYS
SVKVSCKASGYTFTNY
GDRVTITCQANODIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
ID
(SEQ
YMHWVRQAPGQGLEWM
NYLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 441)
ID NO:
NO:
ID NO:
GGIIPIVDGVKYAQKF
LLIYRASKLEAGVPS



148)
440)

151)
442)
443)
QGRVTITADESTSTAY
RFSGSGSGTDFTLTI









MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









AKGQFTGNYYYGMDYW
SSEIPYSFGQGTKVE









GQGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 444)
445)





15.
YTFTGY
GWIGPN
CARDLDHNW
RSSQSL
SSSNR
CMQALH
QVQLVQSGAEVKKPGA
DIVMTQSPLSLPVTP



YMH
SGDTNY
YFDLW
LHSNGY
AP
IPLTE
SVKVSCKASGYTFTGY
GEPASISCRSSQSLL



(SEQ
A (SEQ
(SEQ ID
NYLD
(SEQ
(SEQ
YMHWVRQAPGQGLEWM
HSNGYNYLDWYLQKP



ID NO:
ID NO:
NO: 130)
(SEQ
ID
ID NO:
GWIGPNSGDTNYAQKF
GOSPQLLIYSSSNRA



128)
129)

ID NO:
NO:
133)
QGRVTMTRDTSTSTVY
PGVPDRESGSGSGTD






131)
132)

MELSSLRSEDTAVYYC
FTLKISRVEAEDVGV









ARDLDHNWYFDLWGRG
YYCMQALHIPLTFGG









TLVTVSS (SEQ ID
GTKVEIK(SEQID









NO: 446)
NO:447)





16.
FTEDDY
SYIDAS
CAKDQAAAG
QASQDI
KASTL
CQQSYS
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



AMH
GTTIYY
YWYFDLW
SNYLN
ES
TPITF
SLRLSCAASGFTEDDY
GDRVTITCQASQDIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
AMHWVRQAPGKGLEWV
NYLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 137)
ID NO:
ID
ID NO:
SYIDASGTTIYYADSV
LLIYKASTLESGVPS



135)
136)

138)
NO:
140)
KGRFTISRDNSKNTLY
RFSGSGSGTDFTLTI







139)

LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









AKDQAAAGYWYFDLWG
SYSTPITFGQGTRLE









RGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 448)
449)





17.
YTFTDY
GGIVPR
CAKDESSGW
RSSQSL
SAYNR
CMQALQ
QVQLVQSGAEVKKPGS
DIVMTQSPLSLPVTP



HIH
SGSTTY
YYFDYW
LHSNGY
AS
TPLTF
SVKVSCKASGYTFTDY
GEPASISCRSSQSLL



(SEQ
A (SEQ
(SEQ ID
NYLD
(SEQ
(SEQ
HIHWVRQAPGQGLEWM
HSNGYNYLDWYLQKP



ID NO:
ID NO:
NO: 144)
(SEQ
ID
ID NO:
GGIVPRSGSTTYAQKF
GQSPQLLIYSAYNRA



142)
143)

ID NO:
NO:
146)
QGRVTITADESTSTAY
SGVPDRFSGSGSGTD






131)
145)

MELSSLRSEDTAVYYC
FTLKISRVEAEDVGV









AKDESSGWYYFDYWGQ
YYCMQALQTPLTFGQ









GTLVTVSS (SEQ ID
GTKVEIK(SEQID









NO: 450)
NO:451)





18.
YTFTNY
GGIIPI
CAKGRYTVN
QANQDI
RASKL
CQQSSE
QVQLVQSGAEVKKPGS
DIQMTQSPSSLSASV



YMH
VDRVKY
YYYGMDVW
SNYLN
EA
IPYSF
SVKVSCKASGYTFTNY
GDRVTITCQANQDIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
YMHWVRQAPGQGLEWM
NYLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 150)
ID NO:
ID
ID NO:
GGIIPIVDRVKYAQKF
LLIYRASKLEAGVPS



148)
149)

151)
NO:
153)
QGRVTITADESTSTAY
RFSGSGSGTDETLTI







152)

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









AKGRYTVNYYYGMDVW
SSEIPYSFGQGTKLE









GQGTTVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 452)
453)





19.
FTFEDY
SYLNSD
CAKDYCTNG
RASQSI
DASNL
CQQSYT
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



AMH
GGSTSY
VCAFDYW
STYLN
ET
IPITE
SLRLSCAASGFTFEDY
GDRVTITCRASQSIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
AMHWVRQAPGKGLEWV
TYLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 157)
ID NO:
ID
ID NO:
SYLNSDGGSTSYADSV
LLIYDASNLETGVPS



155)
156)

158)
NO:
160)
KGRFTISRDNSKNTLY
RFSGSGSGTDETLTI







159)

LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









AKDYCTNGVCAFDYWG
SYTIPITFGQGTRLE









QGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 454)
455)





20.
FTFSDS
SAISGS
CVSDIAVAG
RASQSI
AASRL
CQQANS
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



AMH
GSTIYY
HWYFDLW
STELN
EG
FPLTF
SLRLSCAASGFTESDS
GDRVTITCRASQSIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
AMHWVRQAPGKGLEWV
TFLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 164)
ID NO:
ID
ID NO:
SAISGSGSTIYYADSV
LLIYAASRLEGGVPS



162)
163)

165)
NO:
167)
KGRFTISRDNSKNTLY
RFSGSGSGTDETLTI







166)

LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









VSDIAVAGHWYFDLWG
ANSFPLTFGPGTKVD









RGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 456)
457)





21.
FTFSSY
SYISGD
CARANSSGW
RASQSI
AASSL
CQQSYS
EVQLVESGGGLVKPGG
DIQMTQSPSSLSASV



WMS
SGYTNY
YDWYFDLW
SSYLN
QS
TPLTF
SLRLSCAASGFTESSY
GDRVTITCRASQSIS



(SEQ
A (SEQ
(SEQ ID
(SEç
(SEQ
(SEQ
WMSWVRQAPGKGLEWV
SYLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 171)
ID NO:
ID
ID NO:
SYISGDSGYTNYAAPV
LLIYAASSLQSGVPS



169)
170)

172)
NO:
173)
KGRFTISRDDSKNTLY
RFSGSGSGTDFTLTI







65)

LQMNSLKTEDTAVYYC
SSLQPEDFATYYCQQ









ARANSSGWYDWYFDLW
SYSTPLTFGGGTKVE









GRGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 458)
459)





22.
FTEDDY
SGISWN
CAKDIVAAG
QASQDI
DASNL
CQQSYS
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



AMH
SGSIGY
HYYYGMDVW
SNYLN
ET
TPLTF
SLRLSCAASGFTEDDY
GDRVTITCQASQDIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
AMHWVRQAPGKGLEWV
NYLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 176)
ID NO:
ID
ID NO:
SGISWNSGSIGYADSV
LLIYDASNLETGVPS



135)
175)

138)
NO:
173)
KGRFTISRDNSKNTLY
RFSGSGSGTDFTLTI







159)

LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









AKDIVAAGHYYYGMDV
SYSTPLTFGGGTKVE









WGQGTTVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 460)
461)





23.
FTEDDY
SYIDTS
CARDEAAAG
QAGQDI
DASNL
CQQTYS
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



AMH
SSHLYY
YYGMDVW
SNYLN
ET
TPITE
SLRLSCAASGFTEDDY
GDRVTITCQAGQDIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
AMHWVRQAPGKGLEWV
NYLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 179)
ID NO:
ID
ID NO:
SYIDTSSSHLYYADSV
LLIYDASNLETGVPS



135)
178)

180)
NO:
181)
KGRFTISRDNSKNTLY
RFSGSGSGTDETLTI







159)

LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









ARDEAAAGYYGMDVWG
TYSTPITFGQGTKLE









QGTTVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 462)
463)





24.
FTFSSY
SRISSD
CARGTSYCT
RASQSI
SNLQS
QQSYSI
EVQLVESGGGLVKPGG
DIQMTQSPSSLSASV



WMS
GRITTY
GGVCDIDYW
GRNLN
(SEQ
PLT
SLRLSCAASGFTESSY
GDRVTITCRASQSIG



(SEQ
A (SEQ
(SEQ ID
(SEQ
ID
(SEQ
WMSWVRQAPGKGLEWV
RNLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 465)
ID NO:
NO:
ID NO:
SRISSDGRITTYAAPV
LLIYSASNLQSGVPS



169)
464)

466)
467)
468)
KGRFTISRDDSKNTLY
RFSGSGSGTDETLTI









LQMNSLKTEDTAVYYC
SSLQPEDFATYYCQQ









ARGTSYCTGGVCDIDY
SYSIPLTFGPGTKVD









WGQGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 469)
470)





25.
FTFSNA
STIVGN
CARDNPLRW
RASQDI
AASSL
CQQSYS
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



WMS
GGATYY
QGMDVW
SNYLN
QS
IPPTF
SLRLSCAASGFTESNA
GDRVTITCRASQDIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
WMSWVRQAPGKGLEWV
NYLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 185)
ID NO:
ID
ID NO:
STIVGNGGATYYADSV
LLIYAASSLQSGVPS



183)
184)

186)
NO:
187)
KGRFTISRDNSKNTLY
RFSGSGSGTDETLTI







65)

LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









ARDNPLRWQGMDVWGQ
SYSIPPTFGPGTKVD









GTLVTVSS (SEQ ID
IK (SEQ ID NO:









NO: 471)
472)





26.
FTFSSY
SYISSS
CARANSSSW
RASQSI
SGLQS
QQSYST
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



AMS
STYTNY
YDWYFDLW
SSYLN
(SEQ
PLT
SLRLSCAASGFTESSY
GDRVTITCRASQSIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
ID
(SEQ
AMSWVRQAPGKGLEWV
SYLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 191)
ID NO:
NO:
ID NO:
SYISSSSTYTNYADSV
LLIYAASGLQSGVPS



473)
190)

172)
474)
429)
KGRFTISRDNSKNTLY
RFSGSGSGTDETLTI









LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









ARANSSSWYDWYFDLW
SYSTPLTFGGGTKVE









GQGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 475)
476)





27.
FTESSY
SYISSS
CARANSSSW
RASQSI
SGLQS
QQSYST
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



QMS
STYTNY
YDWYFDLW
SSYLN
(SEQ
PLT
SLRLSCAASGFTESSY
GDRVTITCRASQSIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
ID
(SEQ
QMSWVRQAPGKGLEWV
SYLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 191)
ID NO:
NO:
ID NO:
SYISSSSTYTNYADSV
LLIYAASGLQSGVPS



189)
190)

172)
474)
429)
KGRFTISRDNSKNTLY
RFSGSGSGTDETLTI









LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









ARANSSSWYDWYFDLW
SYSTPLTFGGGTKVE









GQGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 477)
476)





28.
FTFSSY
SYISSS
CARANSSSW
RASQSI
SSLQS
QQSYST
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



AMS
STYTNY
YDWYFDLW
SSYLN
(SEQ
PLT
SLRLSCAASGFTESSY
GDRVTITCRASQSIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
ID
(SEQ
AMSWVRQAPGKGLEWV
SYLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 191)
ID NO:
NO:
ID NO:
SYISSSSTYTNYADSV
LLIYAASSLQSGVPS



473)
190)

172)
362)
429)
KGRFTISRDNSKNTLY
RFSGSGSGTDETLTI









LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









ARANSSSWYDWYFDLW
SYSTPLTFGGGTKVE









GQGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 475)
459)





29.
FTFSSY
SYISSS
CARANSSSW
RASQSI
AASSL
CQQSYS
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



QMS
STYTNY
YDWYFDLW
SSYLN
QS
TPLTF
SLRLSCAASGFTESSY
GDRVTITCRASQSIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
QMSWVRQAPGKGLEWV
SYLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 191)
ID NO:
ID
ID NO:
SYISSSSTYTNYADSV
LLIYAASSLQSGVPS



189)
190)

172)
NO:
173)
KGRFTISRDNSKNTLY
RFSGSGSGTDETLTI







65)

LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









ARANSSSWYDWYFDLW
SYSTPLTFGGGTKVE









GQGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 477)
459)





30.
FTFSSY
SGISGS
CATSQAPVD
RASQSI
AASNL
CQQSYS
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



AMH
GGSAYY
YYYYGMDVW
SSWLA
QR
IPITE
SLRLSCAASGFTESSY
GDRVTITCRASQSIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
AMHWVRQAPGKGLEWV
SWLAWYQQKPGKAPK



ID NO:
ID NO:
NO: 195)
ID NO:
ID
ID NO:
SGISGSGGSAYYADSV
LLIYAASNLQRGVPS



193)
194)

196)
NO:
198)
KGRFTISRDNSKNTLY
RFSGSGSGTDFTLTI







197)

LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









ATSQAPVDYYYYGMDV
SYSIPITFGQGTKVE









WGQGTTVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 478)
479)





31.
FTFSSY
SYISGS
CARVGSSGW
RASQSI
AASSL
CQQSYS
EVQLVESGGGLVKPGG
DIQMTQSPSSLSASV



WMS
SSYTNY
YDWYFDLW
SSYLN
QS
TPLTF
SLRLSCAASGFTESSY
GDRVTITCRASQSIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
WMSWVRQAPGKGLEWV
SYLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 201)
ID NO:
ID
ID NO:
SYISGSSSYTNYAAPV
LLIYAASSLQSGVPS



169)
200)

172)
NO:
173)
KGRFTISRDDSKNTLY
RFSGSGSGTDFTLTI







65)

LQMNSLKTEDTAVYYC
SSLQPEDFATYYCQQ









ARVGSSGWYDWYFDLW
SYSTPLTFGQGTKVE









GRGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 480)
481)





32.
YTLTTW
GWINPN
CAKGDLWGA
RASDNI
AASSL
CQQGYS
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YMY
RGATNY
MDVW (SEQ
GSWLA
QS
TPPTE
SVKVSCKASGYTLTTW
GDRVTITCRASDNIG



(SEQ
A (SEQ
ID NO:
(SEQ
(SEQ
(SEQ
YMYWVRQAPGQGLEWM
SWLAWYQQKPGKAPK



ID NO:
ID NO:
118)
ID NO:
ID
ID NO:
GWINPNRGATNYAQKF
LLIYAASSLQSGVPS



116)
117)

119)
NO:
120)
QGRVTMTRDTSTSTVY
RFSGSGSGTDFTLTI







65)

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









AKGDLWGAMDVWGQGT
GYSTPPTFGQGTKVE









LVTVSS (SEQ ID
IK (SEQ ID NO:









NO: 436)
437)





33.
YTLTTW
GWINPN
CAKGDLWGA
RASDNI
AASSL
CQQGYS
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YMY
RGATNY
MDVW (SEQ
GSWLA
QS
TPPTF
SVKVSCKASGYTLTTW
GDRVTITCRASDNIG



(SEQ
A (SEQ
ID NO:
(SEQ
(SEQ
(SEQ
YMYWVRQAPGQGLEWM
SWLAWYQQKPGKAPK



ID NO:
ID NO:
118)
ID NO:
ID
ID NO:
GWINPNRGATNYAQKF
LLIYAASSLQSGVPS



116)
117)

119)
NO:
120)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI







65)

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









AKGDLWGAMDVWGQGT
GYSTPPTFGQGTKVE









TVTVSS (SEQ ID
IK (SEQ ID NO:









NO: 482)
437)





34.
YTFTGY
GWMNPN
CARDPGFLG
RASQSI
AASSL
CQQSYT
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YIH
SGNTGY
YCSGGSCYD
SSYLH
QS
APYTF
SVKVSCKASGYTFTGY
GDRVTITCRASQSIS



(SEQ
A (SEQ
GWFDPW
(SEQ
(SEQ
(SEQ
YIHWVRQAPGQGLEWM
SYLHWYQQKPGKAPK



ID NO:
ID NO:
(SEQ ID
ID NO:
ID
ID NO:
GWMNPNSGNTGYAQKF
LLIYAASSLQSGVPS



204)
205)
NO: 206)
207)
NO:
208)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI







65)

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









ARDPGFLGYCSGGSCY
SYTAPYTFGQGTKLE









DGWFDPWGQGTLVTVS
IK (SEQ ID NO:









S (SEQ ID NO:
484)









483)






35.
YTFTGY
GWMNPN
CARDPGFLG
RASQSI
AASSL
CQQSYT
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YIH
SGNTGY
YSSGGSCYD
SSYLH
QS
APYTF
SVKVSCKASGYTFTGY
GDRVTITCRASQSIS



(SEQ
A (SEQ
GWFDPW
(SEQ
(SEQ
(SEQ
YIHWVRQAPGQGLEWM
SYLHWYQQKPGKAPK



ID NO:
ID NO:
(SEQ ID
ID NO:
ID
ID NO:
GWMNPNSGNTGYAQKF
LLIYAASSLQSGVPS



204)
205)
NO: 485)
207)
NO:
208)
QGRVTMTRDTSTSTVY
RFSGSGSGTDFTLTI







65)

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









ARDPGFLGYSSGGSSY
SYTAPYTFGQGTKLE









DGWEDPWGQGTLVTVS
IK (SEQ ID NO:









S (SEQ ID NO:
484)









486)






36.
FTEDDY
SAISGD
CARDGTVNG
QASQDI
SNLET
QQSYSI
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



ALH
GRSTTY
ATGWFDPW
SKYLN
(SEQ
PFT
SLRLSCAASGFTEDDY
GDRVTITCQASQDIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
ID
(SEQ
ALHWVRQAPGKGLEWV
KYLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 489)
ID NO:
NO:
ID NO:
SAISGDGRSTTYADSV
LLIYDASNLETGVPS



487)
488)

490)
491)
492)
KGRFTISRDNSKNTLY
RFSGSGSGTDETLTI









LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









ARDGTVNGATGWEDPW
SYSIPFTFGPGTKVD









GQGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 493)
494)





37.
FTESDY
SAISGS
CARDGGWQP
RASQGI
SNLET
QQSYST
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



GMP
GGSTYY
AAILDYW
SNNLN
(SEQ
PLT
SLRLSCAASGFTFSDY
GDRVTITCRASQGIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
ID
(SEQ
GMPWVRQAPGKGLEWV
NNLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 296)
ID NO:
NO:
ID NO:
SAISGSGGSTYYADSV
LLIYDASNLETGVPS



495)
103)

105)
491)
429)
KGRFTISRDNSKNTLY
RFSGSGSGTDETLTI









LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









ARDGGWQPAAILDYWG
SYSTPLTFGQGTKVE









QGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 496)
497)





38.
YTFTDY
GWMNPT
CAREGEGSG
RASQGI
DASNL
CQQSYS
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



FLH
SGNTGY
FDYW (SEQ
NSWLA
ET
TPLTF
SVKVSCKASGYTFTDY
GDRVTITCRASQGIN



(SEQ
A (SEQ
ID NO:
(SEQ
(SEQ
(SEQ
FLHWVRQAPGQGLEWM
SWLAWYQQKPGKAPK



ID NO:
ID NO:
212)
ID NO:
ID
ID NO:
GWMNPTSGNTGYAQKF
LLIYDASNLETGVPS



210)
211)

213)
NO:
173)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI







159)

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









AREGEGSGFDYWGQGT
SYSTPLTFGGGTKVE









LVTVSS (SEQ ID
IK (SEQ ID NO:









NO: 498)
499)





39.
YTFTSY
AWMNPN
CARDYDEWS
RASQGI
AASSL
CQQSYS
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YMH
SGNTGY
GSLGYW
SNYLA
QS
TPWTF
SVKVSCKASGYTFTSY
GDRVTITCRASQGIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
YMHWVRQAPGQGLEWM
NYLAWYQQKPGKAPK



ID NO:
ID NO:
NO: 217)
ID NO:
ID
ID NO:
AWMNPNSGNTGYAQKF
LLIYAASSLQSGVPS



215)
216)

218)
NO:
114)
QGRVTMTRDTSTSTVY
RFSGSGSGTDFTLTI







65)

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









ARDYDFWSGSLGYWGQ
SYSTPWTFGQGTKVE









GTLVTVSS (SEQ ID
IK (SEQ ID NO:









NO: 500)
501)





40.
YTLTTW
GWINPN
CAKGDLWGA
RASDNI
AASSL
CQQGYS
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YMY
RGATNY
MDVW (SEQ
GSWLA
QS
TPPTF
SVKVSCKASGYTLTTW
GDRVTITCRASDNIG



(SEQ
A (SEQ
ID NO:
(SEQ
(SEQ
(SEQ
YMYWVRQAPGQGLEWM
SWLAWYQQKPGKAPK



ID NO:
ID NO:
118)
ID NO:
ID
ID NO:
GWINPNRGATNYAQKF
LLIYAASSLQSGVPS



116)
117)

119)
NO :
120)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI







65)

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









AKGDLWGAMDVWGQGT
GYSTPPTFGQGTKVE









LVTVSS (SEQ ID
IK (SEQ ID NO:









NO: 436)
437)





41.
YTFTSY
GIINPS
CARDTGYSY
RASQSI
DASNL
CQQSYS
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YMH
GGSTSY
GRYYYYGMD
GRWLA
QS
IPITE
SVKVSCKASGYTFTSY
GDRVTITCRASQSIG



(SEQ
A (SEQ
VW (SEQ
(SEQ
(SEQ
(SEQ
YMHWVRQAPGQGLEWM
RWLAWYQQKPGKAPK



ID NO:
ID NO:
ID NO:
ID NO:
ID
ID NO:
GIINPSGGSTSYAQKF
LLIYDASNLQSGVPS



215)
69)
220)
221)
NO:
198)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI







222)

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









ARDTGYSYGRYYYYGM
SYSIPITFGQGTKVE









DVWGQGTLVTVSS
IK (SEQ ID NO:









(SEQ ID NO: 502)
503)





42.
YTLTDY
GIINPS
CAREEYSSS
RASQGI
AASSL
CQQSYS
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YMH
GGSTSY
SGYFDYW
SSWLA
QS
TPLTF
SVKVSCKASGYTLTDY
GDRVTITCRASQGIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
YMHWVRQAPGQGLEWM
SWLAWYQQKPGKAPK



ID NO:
ID NO:
NO: 225)
ID NO:
ID
ID NO:
GIINPSGGSTSYAQKF
LLIYAASSLQSGVPS



224)
69)

226)
NO:
173)
QGRVTMTRDTSTSTVY
RFSGSGSGTDFTLTI







65)

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









AREEYSSSSGYEDYWG
SYSTPLTFGQGTKVE









QGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 504)
505)





43.
YTFTSY
GWMHPK
CARDTPYYY
RASQSI
AASSL
CQQSYS
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



GIS
SGDTGL
YGMDVW
SSWLA
QS
VPITF
SVKVSCKASGYTFTSY
GDRVTITCRASQSIS



(SEQ
T (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
GISWVRQAPGQGLEWM
SWLAWYQQKPGKAPK



ID NO:
ID NO:
NO: 230)
ID NO:
ID
ID NO:
GWMHPKSGDTGLTQKF
LLIYAASSLQSGVPS



228)
229)

196)
NO:
231)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI







65)

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









ARDTPYYYYGMDVWGQ
SYSVPITFGQGTKVE









GTTVTVSS (SEQ ID
IK (SEQ ID NO:









NO: 506)
507)





44.
FTFSSY
SAISGS
CAKERFIDY
QASQDI
SSLQS
QQTYSG
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



AMS
GGSTYY
GMDVW
SNYLN
(SEQ
WT
SLRLSCAASGFTESSY
GDRVTITCQASQDIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
ID
(SEQ
AMSWVRQAPGKGLEWV
NYLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 508)
ID NO:
NO:
ID NO:
SAISGSGGSTYYADSV
LLIYAASSLQSGVPS



473)
103)

138)
362)
509)
KGRFTISRDNSKNTLY
RFSGSGSGTDFTLTI









LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









AKERFIDYGMDVWGQG
TYSGWTFGPGTKVDI









TTVTVSS (SEQ ID
K (SEQ ID NO:









NO: 510)
511)





45.
FTFGDY
SYISGD
CARDVAATG
RASQSI
AASSL
CQQSYS
EVQLVESGGGLVKPGG
DIQMTQSPSSLSASV



AMS
IGYTNY
NWYFDLW
SSYLN
QS
TPLTF
SLRLSCAASGFTFGDY
GDRVTITCRASQSIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
AMSWVRQAPGKGLEWV
SYLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 235)
ID NO:
ID
ID NO:
SYISGDIGYTNYAAPV
LLIYAASSLQSGVPS



233)
234)

172)
NO:
173)
KGRFTISRDDSKNTLY
RFSGSGSGTDETLTI







65)

LQMNSLKTEDTAVYYC
SSLQPEDFATYYCQQ









ARDVAATGNWYFDLWG
SYSTPLTFGGGTKVE









RGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 512)
459)





46.
FSFSSY
SFITSS
CARDRRGDY
RASQSV
GASTR
CQQYGS
EVQLLESGGGLVQPGG
EIVMTQSPATLSVSP



TMN
SRTIYY
GDSWYFDLW
RNYLA
AT
SPLTE
SLRLSCAASGFSFSSY
GERATLSCRASQSVR



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
TMNWVRQAPGKGLEWV
NYLAWYQQKPGQAPR



ID NO:
ID NO:
NO: 239)
ID NO:
ID
ID NO:
SFITSSSRTIYYADSV
LLIYGASTRATGIPA



237)
238)

240)
NO:
242)
KGRFTISRDNSKNTLY
RFSGSGSGTEFTLTI







241)

LQMNSLRAEDTAVYYC
SSLQSEDFAVYYCQQ









ARDRRGDYGDSWYFDL
YGSSPLTFGGGTKVE









WGRGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 513)
514)





47.
YTFTGH
GIINPS
CARDTGYSY
RASQSI
DASNL
CQQSYS
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YMH
GGSTSY
GRYYYYGMD
GRWLA
QS
IPITF
SVKVSCKASGYTFSKH
GDRVTITCRASQSIS



(SEQ
A (SEQ
VW (SEQ
(SEQ
(SEQ
(SEQ
FVHWVRQAPGQGLEWM
SWLAWYQQKPGKAPK



ID NO:
ID NO:
ID NO:
ID NO:
ID
ID NO:
GWMNPNSGNSGYAQKF
LLIYAASTLQSGVPS



244)
69)
220)
221)
NO:
198)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI







222)

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









ARGEGGYYYYGMDVWG
SYSTPWTFGQGTKVE









QGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 515)
516)





48.
YTFSKH
GWMNPN
CARGEGGYY
RASQSI
AASTL
CQQSYS
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



FVH
SGNSGY
YYGMDVW
SSWLA
QS
TPWTF
SLRLSCAASGFTFGSY
GDRVTITCRASQPLS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
SMSWVRQAPGKGLEWV
NWLAWYQQKPGKAPK



ID NO:
ID NO:
NO: 248)
ID NO:
ID
ID NO:
SAIGTGGGTYYADSVK
LLIYAASSLQSGVPS



246)
247)

196)
NO:
114)
GRFTISRDNSKNTLYL
RFSGSGSGTDETLTI







113)

QMNSLRAEDTAVYYCA
SSLQPEDFATYYCQQ









KGTPYYYYYGMDVWGQ
AISFPLTFGGGTKVE









GTMVTVSS (SEQ ID
IK (SEQ ID NO:









NO: 517)
518)





49.
FTFGSY
SAIGTG
CAKGTPYYY
RASQPL
AASSL
CQQAIS
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



SMS
GGTYYA
YYGMDVW
SNWLA
QS
FPLTF
SVKVSCKASGYTFTSY
GDRVTITCQSSEDIS



(SEQ
(SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
YMHWVRQAPGQGLEWM
SSLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 252)
ID NO:
ID
ID NO:
GWMNPNSGNTGYAQKF
LLIYAASSLQIGVPS



250)
251)

253)
NO:
254)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI







65)

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









ARDLGYYDSSGYFGAF
TYSTPYTFGQGTKVE









DIWGQGTTVTVSS
IK (SEQ ID NO:









(SEQ ID NO: 519)
520)





50.
YTFTSY
GWMNPN
CARDLGYYD
QSSEDI
AASSL
CQQTYS
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YMH
SGNTGY
SSGYFGAFD
SSSLN
QI
TPYTE
SVKVSCKASGYTFTSY
GDRVTITCRASQGIG



(SEQ
A (SEQ
IW (SEQ
(SEQ
(SEQ
(SEQ
GISWVRQAPGQGLEWM
NWLAWYQQKPGKAPK



ID NO:
ID NO:
ID NO:
ID NO:
ID
ID NO:
GIINPRGGSTIFAQKF
LLIYAASNLETGVPS



215)
205)
256)
257)
NO:
259)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI







258)

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









ARGTRSSGWYGWEDPW
IHSYPLTFGGGTKVE









GQGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 521)
522)





51.
YTFTSY
GIINPR
CARGTRSSG
RASQGI
AASNL
CQQIHS
EVQLVESGGGLVKPGG
DIVMTQSPLSLPVTP



GIS
GGSTIF
WYGWFDPW
GNWLA
ET
YPLTF
SLRLSCAASGFIFQDS
GEPASISCRSSQSLL



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
AIHWVRQAPGKGLEWV
HSNGYNYLDWYLQKP



ID NO:
ID NO:
NO: 262)
ID NO:
ID
ID NO:
SAIGTGGGTYYAAPVK
GOSPQLLIYDASNLE



228)
261)

263)
NO:
265)
GRFTISRDDSKNTLYL
TGVPDRFSGSGSGTD







264)

QMNSLKTEDTAVYYCA
FTLKISRVEAEDVGV









RSYCSGGSCSLGSWGQ
YYCMQALQTPLTFGQ









GTLVTVSS (SEQ ID
GTKVEIK(SEQID









NO: 523)
NO:524)





52.
FTEDDY
SYISSS
CAREIAAAG
RASQSI
AASSL
CQQSYS
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



GMS
SSYIYY
FYGMDVW
SSYLN
QS
TPLTE
SLRLSCAASGFTEDDY
GDRVTITCRASQSIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
GMSWVRQAPGKGLEWV
SYLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 269)
ID NO:
ID
ID NO:
SYISSSSSYIYYADSV
LLIYAASSLQSGVPS



267)
268)

172)
NO:
173)
KGRFTISRDNSKNTLY
RFSGSGSGTDFTLTI







65)

LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









AREIAAAGFYGMDVWG
SYSTPLTFGGGTKVE









QGTTVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 525)
459)





53.
YTFTSY
GWMNPN
CAREGLGYC
RASQGI
SSLQS
QQSYST
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YMH
SGNTGY
TNGVCWNYY
SSWLA
(SEQ
PYT
SVKVSCKASGYTFTSY
GDRVTITCRASQGIS



(SEQ
A (SEQ
GMDVW
(SEQ
ID
(SEQ
YMHWVRQAPGQGLEWM
SWLAWYQQKPGKAPK



ID NO:
ID NO:
(SEQ ID
ID NO:
NO:
ID NO:
GWMNPNSGNTGYAQKF
LLIYGASSLQSGVPS



215)
205)
NO: 526)
226)
362)
527)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI









MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









AREGLGYCTNGVCWNY
SYSTPYTFGQGTKVE









YGMDVWGQGTLVTVSS
IK (SEQ ID NO:









(SEQ ID NO: 528)
529)





54.
GTLSRY
GGIIPI
CARDRVYYD
RASQSV
GASTR
CQQYGS
QVQLVQSGAEVKKPGS
EIVMTQSPATLSVSP



GVS
FGTTNY
SSGYPTWYF
SSSYLA
AT
SPITF
SVKVSCKASGGTLSRY
GERATLSCRASQSVS



(SEQ
A (SEQ
DLW (SEQ
(SEQ
(SEQ
(SEQ
GVSWVRQAPGQGLEWM
SSYLAWYQQKPGQAP



ID NO:
ID NO:
ID NO:
ID NO:
ID
ID NO:
GGIIPIFGTTNYAQKE
RLLIYGASTRATGIP



271)
272)
273)
274)
NO:
275)
QGRVTITADESTSTAY
ARFSGSGSGTEFTLT







241)

MELSSLRSEDTAVYYC
ISSLQSEDFAVYYCQ









ARDRVYYDSSGYPTWY
QYGSSPITFGQGTKV









FDLWGRGTLVTVSS
EIK (SEQ ID NO:









(SEQ ID NO: 530)
531)





55.
FTEDDE
SGISGN
CARDASYGG
QASQDI
KASTL
CQQANS
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



AMH
GDSRYY
NYGMDVW
RNYLN
ES
FPLTF
SLRLSCAASGFTEDDE
GDRVTITCQASQDIR



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
AMHWVRQAPGKGLEWV
NYLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 279)
ID NO:
ID
ID NO:
SGISGNGDSRYYADSV
LLIYKASTLESGVPS



277)
278)

280)
NO:
167)
KGRFTISRDNSKNTLY
RFSGSGSGTDFTLTI







139)

LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









ARDASYGGNYGMDVWG
ANSFPLTFGPGTKVD









QGTTVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 532)
533)





56.
FTESSY
SAIGTG
CAREWLVPY
RASQSI
GASNL
CQQSYS
EVQLVESGGGLVKPGG
DIQMTQSPSSLSASV



WMS
GGTYYA
YGMDVW
SRWLA
QS
TPWTF
SLRLSCAASGFTFSSY
GDRVTITCRASQSIS



(SEQ
(SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
WMSWVRQAPGKGLEWV
RWLAWYQQKPGKAPK



ID NO:
ID NO:
NO: 282)
ID NO:
ID
ID NO:
SAIGTGGGTYYAAPVK
LLIYGASNLQSGVPS



169)
251)

283)
NO:
114)
GRFTISRDDSKNTLYL
RFSGSGSGTDETLTI







284)

QMNSLKTEDTAVYYCA
SSLQPEDFATYYCQQ









REWLVPYYGMDVWGQG
SYSTPWTFGQGTKVE









TTVTVSS (SEQ ID
IK (SEQ ID NO:









NO: 534)
535)





57.
FSVSSN
AGISYD
CARSRGIAA
KSSQSV
WASTR
CHQYYG
EVQLLESGGGLVQPGG
DIVMTQSPDSLAVSL



YMS
GSSKPY
RPLQHW
LYSSNN
QS
HPPTF
SLRLSCAASGFSVSSN
GERATINCKSSQSVL



(SEQ
A (SEQ
(SEQ ID
KNYLA
(SEQ
(SEQ
YMSWVRQAPGKGLEWV
YSSNNKNYLAWYQQK



ID NO:
ID NO:
NO: 288)
(SEQ
ID
ID NO:
AGISYDGSSKPYADSV
PGQPPKLLIYWASTR



286)
287)

ID NO:
NO:
291)
KGRFTISRDNSKNTLY
QSGVPDRFSGSGSGT






289)
290)

LQMNSLRAEDTAVYYC
DETLTISSLQAEDVA









ARSRGIAARPLQHWGQ
VYYCHQYYGHPPTFG









GTLVTVSS (SEQ ID
GGTKVEIK (SEQ









NO: 536)
ID NO: 537)





58.
FSVSSN
AGISYD
CARSRGIAA
KSSQSV
QASTR
CHQYYG
EVQLLESGGGLVQPGG
DIVMTQSPDSLAVSL



YMS
GSSKPY
RPLQHW
LYSSNN
QS
HPPTF
SLRLSCAASGFSVSSN
GERATINCKSSQSVL



(SEQ
A (SEQ
(SEQ ID
KNYLA
(SEQ
(SEQ
YMSWVRQAPGKGLEWV
YSSNNKNYLAWYQQK



ID NO:
ID NO:
NO: 288)
(SEQ
ID
ID NO:
AGISYDGSSKPYADSV
PGQPPKLLIYQASTR



286)
287)

ID NO:
NO:
291)
KGRFTISRDNSKNTLY
QSGVPDRESGSGSGT






289)
293)

LQMNSLRAEDTAVYYC
DFTLTISSLQAEDVA









ARSRGIAARPLQHWGQ
VYYCHQYYGHPPTFG









GTLVTVSS (SEQ ID
GGTKVEIK (SEQ









NO: 536)
ID NO: 538)





59.
FSFSDY
SAISGS
CARDGGWQP
RASQGI
DASNL
CQQSYS
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



GMH
GGSTYY
AAILDYW
SNNLN
ET
TPLTF
SLRLSCAASGFSFSDY
GDRVTITCRASQGIS



SEQ
A (SEQ
(SEQ ID
(SEQ
SEQ
(SEQ
GMHWVRQAPGKGLEWV
NNLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 296)
ID NO:
ID
ID NO:
SAISGSGGSTYYADSV
LLIYDASNLETGVPS



295)
103)

105)
NO:
173)
KGRFTISRDNSKNTLY
RFSGSGSGTDETLTI







159)

LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









ARDGGWQPAAILDYWG
SYSTPLTFGGGTKVE









QGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 539)
540)





60.
FTFSDH
SVIYGG
CARDPAVAG
RASQGI
DASNL
CQQSYS
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



GMH
ESTYYA
GGIFDYW
SNYLA
ET
TCYTE
SLRLSCAASGFTESDH
GDRVTITCRASQGIS



(SEQ
(SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
GMHWVRQAPGKGLEWV
NYLAWYQQKPGKAPK



ID NO:
ID NO:
NO: 300)
ID NO:
ID
ID NO:
SVIYGGESTYYADSVK
LLIYDASNLETGVPS



298)
299)

218)
NO:
301)
GRFTISRDNSKNTLYL
RFSGSGSGTDFTLTI







159)

QMNSLRAEDTAVYYCA
SSLQPEDFATYYCQQ









RDPAVAGGGIFDYWGQ
SYSTCYTFGQGTKLE









GTLVTVSS (SEQ ID
IK (SEQ ID NO:









NO: 541)
542)





61.
DTFTGY
GWINPN
CARSGLWLG
RASQTI
DASTL
CQQYSS
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YIH
SGGTNY
SYYGMDVW
SIWLA
QS
YPLTF
SVKVSCKASGDTFTGY
GDRVTITCRASQTIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
YIHWVRQAPGQGLEWM
IWLAWYQQKPGKAPK



ID NO:
ID NO:
NO: 305)
ID NO:
ID
ID NO:
GWINPNSGGTNYAQKF
LLIYDASTLQSGVPS



303)
304)

306)
NO:
308)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI







307)

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









ARSGLWLGSYYGMDVW
YSSYPLTFGQGTKVE









GQGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 543)
544)





62.
YTFTSY
GWINPN
CARSPYYYY
RASHFI
AASTL
CQQSYS
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



DIN
SGTTGY
GMDVW
SRWVA
QS
GISF
SVKVSCKASGYTFTSY
GDRVTITCRASHFIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
DINWVRQAPGQGLEWM
RWVAWYQQKPGKAPK



ID NO:
ID NO:
NO: 312)
ID NO:
ID
ID NO:
GWINPNSGTTGYAQKF
LLIYAASTLQSGVPS



310)
311)

313)
NO:
314)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI







113)

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









ARSPYYYYGMDVWGQG
SYSGISFGPGTKVDI









TTVTVSS (SEQ ID
K (SEQ ID NO:









NO: 545)
546)





63.
FTENNY
SRINSD
CARGAYYYY
RASQSV
ATSSR
CQQYYS
EVQLLESGGGLVQPGG
EIVMTQSPATLSVSP



GMN
GSSTSY
YMDVW
SGSYLA
AS
GLTF
SLRLSCAASGFTENNY
GERATLSCRASQSVS



(SEQ
A (SEQ
(SEQ ID
(SEç
(SEQ
(SEQ
GMNWVRQAPGKGLEWV
GSYLAWYQQKPGQAP



ID NO:
ID NO:
NO: 318)
ID NO:
ID
ID NO:
SRINSDGSSTSYADSV
RLLIYATSSRASGIP



316)
317)

319)
NO:
321)
KGRFTISRDNSKNTLY
ARFSGSGSGTEFTLT







320)

LQMNSLRAEDTAVYYC
ISSLQSEDFAVYYCQ









ARGAYYYYYMDVWGQG
QYYSGLTFGQGTKVE









TLVTVSS (SEQ ID
IK (SEQ ID NO:









NO: 547)
548)





64.
FTFSNS
AHIWND
CARDRTDPG
RASQDI
DASSL
CQQATS
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



DMN
GSQKYY
YSSAMDVW
RNYLG
ET
LPLTF
SLRLSCAASGFTESNS
GDRVTITCRASQDIR



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
DMNWVRQAPGKGLEWV
NYLGWYQQKPGKAPK



ID NO:
ID NO:
NO: 325)
ID NO:
ID
ID NO:
AHIWNDGSQKYYADSV
LLIYDASSLETGVPS



323)
324)

326)
NO:
328)
KGRFTISRDNSKNTLY
RFSGSGSGTDFTLTI







327)

LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









ARDRTDPGYSSAMDVW
ATSLPLTFGGGTKVE









GQGTTVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 549)
550)





65.
YTFTSY
GWMNPN
CAKDSDYSN
RASQDI
QASSL
CQQSYT
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



DIN
SGNTGY
LLWDYW
TNDLG
ES
IPLTF
SVKVSCKASGYTFTSY
GDRVTITCRASQDIT



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
DINWVRQAPGQGLEWM
NDLGWYQQKPGKAPK



ID NO:
ID NO:
NO: 330)
ID NO:
ID
ID NO:
GWMNPNSGNTGYAQKF
LLIYQASSLESGVPS



310)
205)

331)
NO:
333)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI







332)

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









AKDSDYSNLLWDYWGQ
SYTIPLTFGQGTKVE









GTLVTVSS (SEQ ID
IK (SEQ ID NO:









NO: 51)
552)





66.
YTFTGH
GIINPS
CARDGAWFG
RASQGI
SNLET
QQYYSE
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YMH
GGSTSY
EEYYYGMDV
SNWLA
(SEQ
PLYT
SVKVSCKASGYTFTGH
GDRVTITCRASQGIS



(SEQ
A (SEQ
W (SEQ ID
(SEQ
ID
(SEQ
YMHWVRQAPGQGLEWM
NWLAWYQQKPGKAPK



ID NO:
ID NO:
NO: 553)
ID NO:
NO:
ID NO:
GIINPSGGSTSYAQKF
LLIYDASNLETGVPS



244)
69)

554)
491)
555)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI









MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









ARDGAWFGEEYYYGMD
YYSFPLYTFGQGTKV









VWGQGTTVTVSS
EIK (SEQ ID NO:









(SEQ ID NO: 556)
557)





67.
YTFTGY
GMIYPR
CAMTGWGYG
RASQGI
STLQS
QQSYSA
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YMH
DGSTSY
MDVW (SEQ
NNYLA
(SEQ
PPT
SVKVSCKASGYTFTGY
GDRVTITCRASQGIN



(SEQ
A (SEQ
ID NO:
(SEQ
ID
(SEQ
YMHWVRQAPGQGLEWM
NYLAWYQQKPGKAPK



ID NO:
ID NO:
559)
ID NO:
NO:
ID NO:
GMIYPRDGSTSYAQKE
LLIYDASTLQSGVPS



128)
558)

560)
420)
561)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI









MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









AMTGWGYGMDVWGKGT
SYSAPPTFGQGTKLE









TVTVSS (SEQ ID
IK (SEQ ID NO:









NO: 562)
563)





68.
FTFGDY
AVVSYD
CAKDICSST
RASQNI
DASNL
CQQANS
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



AMS
GTNKYY
SCYFDLW
NNYVN
ET
FPPTE
SLRLSCAASGFTFGDY
GDRVTITCRASQNIN



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
AMSWVRQAPGKGLEWV
NYVNWYQQKPGKAPK



ID NO:
ID NO:
NO: 336)
ID NO:
ID
ID NO:
AVVSYDGTNKYYADSV
LLIYDASNLETGVPS



233)
335)

337)
NO:
338)
KGRFTISRDNSKNTLY
RFSGSGSGTDETLTI







159)

LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









AKDICSSTSCYFDLWG
ANSFPPTFGQGTRLE









RGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 564)
565)





69.
YTFTSY
GIIDPS
CAREEWSSG
RASQGI
ATSSL
CQQTYS
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YMH
GGSTSY
GVGYFDYW
SSYLA
QT
IPITF
SVKVSCKASGYTFTSY
GDRVTITCRASQGIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
(SEQ
(SEQ
YMHWVRQAPGQGLEWM
SYLAWYQQKPGKAPK



ID NO:
ID NO:
NO: 341)
ID NO:
ID
ID NO:
GIIDPSGGSTSYAQKF
LLIYATSSLQTGVPS



215)
340)

342)
NO:
344)
QGRVTMTRDTSTSTVY
RFSGSGSGTDFTLTI







343

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









AREEWSSGGVGYFDYW
TYSIPITFGQGTRLE









GQGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 566)
567)





70.
YPFTDY
GWIKPN
CARDRFVGK
RASQSI
SSLQS
QQSYDT
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YMH
SGDTEY
PDYYYYGMD
SVWLA
(SEQ
PYT
SVKVSCKASGYPFTDY
GDRVTITCRASQSIS



(SEQ
A (SEQ
VW (SEQ
(SEQ
ID
(SEQ
YMHWVRQAPGQGLEWM
VWLAWYQQKPGKAPK



ID NO:
ID NO:
ID NO:
ID NO:
NO:
ID NO:
GWIKPNSGDTEYAQKF
LLIYAASSLQSGVPS



568)
569)
570)
571)
362)
572)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI









MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









ARDRFVGKPDYYYYGM
SYDTPYTFGQGTKLE









DVWGQGTMVTVSS
IK (SEQ ID NO:









(SEQ ID NO: 573)
574)





71.
YTFTSY
GIINPS
CARDSVAGT
RASQGI
AASSL
CQQSYS
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YMH
GGSTSY
GGRYYGMDV
SNYFA
QG
LPYTE
SVKVSCKASGYTFTSY
GDRVTITCRASQGIS



(SEQ
A (SEQ
W (SEQ ID
(SEQ
(SEQ
(SEQ
YMHWVRQAPGQGLEWM
NYFAWYQQKPGKAPK



ID NO:
ID NO:
NO: 350)
ID NO:
ID
ID NO:
GIINPSGGSTSYAQKF
LLIYAASSLOGGVPS



215)
69)

351)
NO:
353)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI







352)

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









ARDSVAGTGGRYYGMD
SYSLPYTFGQGTKLE









VWGQGTLVTVSS
IK (SEQ ID NO:









(SEQ ID NO: 575)
576)





72.
YTFTSY
GVINPI
CASGAPSYY
RASQSI
SYLAT
QQSYST
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YMH
GGTTTY
YYGMDVW
SSYLN
(SEQ
PLT
SVKVSCKASGYTFTSY
GDRVTITCRASQSIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
ID
(SEQ
YMHWVRQAPGQGLEWM
SYLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 578)
ID NO:
NO:
ID NO:
GVINPIGGTTTYAQKF
LLIYGTSYLATGVPS



215)
577)

172)
579)
429)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI









MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









ASGAPSYYYYGMDVWG
SYSTPLTFGQGTKVE









QGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 580)
581)





73.
YTFTSN
GRINPH
CARAGQLWS
QASQDI
TALRT
QQSYSH
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YVH
SGDTSY
DWYFDLW
RNYLN
(SEQ
PLT
SVKVSCKASGYTFTSN
GDRVTITCQASQDIR



(SEQ
A (SEQ
(SEQ ID
(SEQ
ID
(SEQ
YVHWVRQAPGQGLEWM
NYLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 584)
ID NO:
NO:
ID NO:
GRINPHSGDTSYAQKF
LLIYAATALRTGVPS



582)
583)

280)
585)
586)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI









MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









ARAGQLWSDWYFDLWG
SYSHPLTFGQGTKVE









RGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 587)
588)





74.
YTFTGY
GIINPS
CTTADYYYY
RASQGI
AASSL
CQQYYS
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



YMH
GGNTKY
MDVW (SEQ
SNYLA
QS
NADE
SVKVSCKASGYTFTGY
GDRVTITCRASQGIS



(SEQ
A (SEQ
ID NO:
(SEQ
(SEQ
(SEQ
YMHWVRQAPGQGLEWM
NYLAWYQQKPGKAPK



ID NO:
ID NO:
356)
ID NO:
ID
ID NO:
GIINPSGGNTKYAQKF
LLIYAASSLQSGVPS



128)
355)

218)
NO:
357)
QGRVTMTRDTSTSTVY
RFSGSGSGTDFTLTI







65)

MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









TTADYYYYMDVWGKGT
YYSNADFGQGTKVEI









TVTVSS (SEQ ID
K (SEQ ID NO:









NO: 589)
590)





75.
FTESDE
SYISGD
CARDRPYYY
RASQSV
SSLQS
QQYKSY
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



WMH
SGYTNY
YMDVW
SRSLA
(SEQ
PVT
SLRLSCAASGFTESDE
GDRVTITCRASQSVS



(SEQ
A (SEQ
(SEQ ID
(SEQ
ID
(SEQ
WMHWVRQAPGKGLEWI
RSLAWYQQKPGKAPK



ID NO:
ID NO:
NO: 360)
ID NO:
NO:
ID NO:
SYISGDSGYTNYADSV
LLIYAASSLQSGVPS



359)
170)

361)
362)
363)
KGRFTISRDNSKNTLY
RFSGSGSGTDETLTI









LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









ARDRPYYYYMDVWGKG
YKSYPVTFGQGTKVE









TTVTVSS (SEQ ID
IK (SEQ ID NO:









NO: 591)
592)





76.
FTEDDY
SDISGS
CAKDVVVAG
QASQDI
SYLQS
QQAHNY
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



TMH
GGSTYY
TPLHEDYW
SNYLN
(SEQ
PIT
SLRLSCAASGFTEDDY
GDRVTITCQASQDIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
ID
(SEQ
TMHWVRQAPGKGLEWV
NYLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 367)
ID NO:
NO:
ID NO:
SDISGSGGSTYYADSV
LLIYAASYLQSGVPS



365)
366)

138)
368)
369)
KGRFTISRDNSKNTLY
RFSGSGSGTDFTLTI









LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









AKDVVVAGTPLHFDYW
AHNYPITFGQGTRLE









GQGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 593)
594)





77.
FTFSNA
ASISST
CAREVVGAT
RASQSI
SSLQS
QQANAF
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



WMS
SAYIDY
TEDYW
STWLA
(SEQ
PPT
SLRLSCAASEFTESNA
GDRVTITCRASQSIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
ID
(SEQ
WMSWVRQAPGKGLEWV
TWLAWYQQKPGKAPK



ID NO:
ID NO:
NO: 372)
ID NO:
NO:
ID NO:
ASISSTSAYIDYADSV
LLIYAASSLQSGVPS



183)
371)

373)
362)
374)
KGRFTISRDNSKNTLY
RFSGSGSGTDFTLTI









LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









AREVVGATTEDYWGQG
ANAFPPTFGQGTRLE









TLVTVSS (SEQ ID
IK (SEQ ID NO:









NO: 595)
596)





78.
GTFSSY
GWME PH
CAKGGFSWF
KSSQSV
STRES
QQYYST
QVQLVQSGAEVKKPGS
DIVMTQSPDSLAVSL



AIS
TGNTRY
DPW (SEQ
LYSSNN
(SEQ
PPT
SVKVSCKASGGTESSY
GERATINCKSSQSVL



(SEQ
A (SEQ
ID NO:
KNYLA
ID
(SEQ
AISWVRQAPGQGLEWM
YSSNNKNYLAWYQQK



ID NO:
ID NO:
377)
(SEQ
NO:
ID NO:
GWMEPHTGNTRYAQKF
PGQPPKLLIYWASTR



77)
376)

ID NO:
378)
379)
QGRVTITADESTSTAY
ESGVPDRESGSGSGT






289)


MELSSLRSEDTAVYYC
DETLTISSLQAEDVA









AKGGFSWFDPWGQGTL
VYYCQQYYSTPPTFG









VTVSS (SEQ ID
QGTRLEIK(SEQ









NO: 597)
IDNO:598)





79.
FTEDDY
ASITSS
CARERVDWN
RASQGI
STRAT
QQYYTY
EVQLLESGGGLVKPGG
EIVMTQSPATLSVSP



AMH
SAFIDY
SYFDLW
SNSYLA
(SEç
PPT
SLRLSCAASGFTEDDY
GERATLSCRASQGIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
ID
(SEQ
AMHWVRQAPGKGLEWV
NSYLAWYQQKPGQAP



ID NO:
ID NO:
NO: 382)
ID NO:
NO:
ID NO:
ASITSSSAFIDYAASV
RLLIYGASTRATGIP



135)
381)

383)
384)
385)
KGRFTISRDDSKNTLY
ARFSGSGSGTEFTLT









LQMNSLKTEDTAVYYC
ISSLQSEDFAVYYCQ









ARERVDWNSYFDLWGR
QYYTYPPTFGPGTKV









GTLVTVSS (SEQ ID
DIK (SEQ ID NO:









NO: 599)
600)





80.
FTEDDY
SAISGS
CAKDLGVVV
QASQDI
SNLEA
QQSYST
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



AMH
GGSTYY
PAALDYW
SNHLN
(SEQ
PLT
SLRLSCAASGFTEDDY
GDRVTITCQASQDIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
ID
(SEQ
AMHWVRQAPGKGLEWV
NHLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 601)
ID NO:
NO:
ID NO:
SAISGSGGSTYYADSV
LLIYDASNLEAGVPS



135)
103)

602)
603)
429)
KGRFTISRDNSKNTLY
RFSGSGSGTDETLTI









LQMNSLRAEDTAVYYC
SSLQPEDFATYYCQQ









AKDLGVVVPAALDYWG
SYSTPLTFGGGTKVE









QGTTVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 604)
605)





81.
FAFSSH
AGTSGS
CARETYYYY
RASQGI
ANLEG
QQSDIF
EVQLLESGGGLVKPGG
DIQMTQSPSSLSASV



WMH
GESRDY
YMDVW
SNYLA
(SEQ
PPT
SLRLSCAASGFAFSSH
GDRVTITCRASQGIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
ID
(SEQ
WMHWVRQAPGKGLEWV
NYLAWYQQKPGKAPK



ID NO:
ID NO:
NO: 389)
ID NO:
NO:
ID NO:
AGTSGSGESRDYADFV
LLIYDAANLEGGVPS



387)
388)

218)
390)
391)
KGRFTISRDDSKNTLY
RFSGSGSGTDETLTI









LQMNSLKTEDTAVYYC
SSLQPEDFATYYCQQ









ARETYYYYYMDVWGKG
SDIFPPTFGQGTKVE









TTVTVSS (SEQ ID
IK (SEQ ID NO:









NO: 606)
607)





82.
YTFTRH
GWINVK
CARESSGWY
RASQSI
SSLQS
QQSNSF
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



WIH
TGGAGY
GTDVW
SNYLA
(SEQ
PLT
SVKVSCKASGYTFTRH
GDRATITCRASQSIS



(SEQ
A (SEQ
(SEQ ID
(SEQ
ID
SEQ
WIHWVRQAPGQGLEWM
NYLAWYQQKPGKAPK



ID NO:
ID NO:
NO: 395)
ID NO:
NO:
ID NO:
GWINVKTGGAGYAQKF
LLIYAASSLQSGVPS



393)
394)

396)
362)
397)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI









MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









ARESSGWYGTDVWGQG
SNSFPLTFGGGTKVE









TTVTVSS (SEQ ID
IK (SEQ ID NO:









NO: 608)
609)





83.
FTFSSY
AAISYD
CARENKQWL
QASQDI
NLRS
QQANSF
EVQLLESGGGLVQPGG
DIQMTQSPSSLSASV



WMH
GKYKDY
ASFDYW
SNFVN
(SEQ
PVT
SLRLSCAASGFTESSY
GDRVTITCQASQDIS



(SEQ
E (SEQ
(SEQ ID
(SEQ
ID
(SEQ
WMHWVRQAPGKGLEWV
NFVNWYQQKPGKAPK



ID NO:
ID NO:
NO: 400)
ID NO:
NO:
ID NO:
AAISYDGKYKDYEDSV
LLIYAANLRSGVPSR



83)
399)

401)
402)
403)
KGRFTISRDNSKNTLY
FSGSGSGTDETLTIS









LQMNSLRAEDTAVYYC
SLQPEDFATYYCQQA









ARENKQWLASFDYWGQ
NSFPVTFGPGTKVDI









GTLVTVSS (SEQ ID
K (SEQ ID NO:









NO: 610)
611)





84.
GTESSS
GWISAY
CASRVHSGG
QASEHI
SSLQS
QQTDSI
QVQLVQSGAEVKKPGA
DIQMTQSPSSLSASV



AIS
NGYTNY
SYPDDYW
YNYLN
(SEQ
PIT
SVKVSCKASGGTFSSS
GDRVTITCQASEHIY



(SEQ
A (SEQ
(SEQ ID
(SEQ
ID
(SEQ
AISWVRQAPGQGLEWM
NYLNWYQQKPGKAPK



ID NO:
ID NO:
NO: 614)
ID NO:
NO:
ID NO:
GWISAYNGYTNYAQKF
LLIYAASSLQSGVPS



612)
613)

615)
362)
616)
QGRVTMTRDTSTSTVY
RFSGSGSGTDETLTI









MELSSLRSEDTAVYYC
SSLQPEDFATYYCQQ









ASRVHSGGSYPDDYWG
TDSIPITFGQGTKVE









QGTLVTVSS (SEQ
IK (SEQ ID NO:









ID NO: 617)
618)









In some embodiments, the antibody comprises the CDRs of Clone ID: 6, Clone ID: 75, or Clone ID: 79 of Table 7.


The IgG and scFv formats illustrated herein are simply non-limiting examples. The CDRs provided herein can be placed in different formats, including different VH and VL/VK formats and still be able to bind to MAdCAM.


Although the CDRs are illustrated in the tables provided herein, there are other ways to annotate or identify CDRs. For example, in some embodiments, the HCDR2 can have an extra amino acid at the N-terminus. For example, for the HCDR2 of Clone 6 the table indicates that it has a sequence of: SRINSYGTSTTYA (SEQ ID NO: 91) However, in some embodiments, the HCDR2 has a sequence of VSRINSYGTSTTYA (SEQ ID NO: 629), which is shown with an extra residue, a valine, at the N-terminus of the HCDR2. The valine is clearly illustrated in VH peptide of the tables provided herein. Therefore, in some embodiments, the HCDR2 comprises one additional amino acid immediately to the N-terminus of the HCDR2 listed in the table. The residue would be the residue that is immediately to the N-terminus of the HCDR2 found in the VH sequence provided for in the table in the same row. One of skill in the art with this information could immediately envisage the HCDR2 peptide sequence that has the additional amino acid residue immediately to the N-terminus of the HCDR2 listed in the table. These embodiments are sufficiently described and do not require application to list each of these different annotations and one of skill in the art with the guidance and description provided herein could write them out individually without any undue experimentation.


Similarly, the HCDR3 can exclude the cysteine residue. Each of the HCDR3 polypeptides provided for in Tables 6 and 7 begins with a cysteine residue. In some embodiments, the HCDR3 does not include the cysteine. Furthermore, in some embodiments, the HCDR3 does not have the last C-terminal residue illustrated in Table 6 and 7 provided for herein. Therefore, in some embodiments, the HCDR3 does not have the cysteine and/or the last C-terminal residue illustrated in the tables. One of skill in the art with this information could immediately envisage the HCDR3 peptide sequence that does not have the cysteine and/or the last C-terminal residue illustrated in the tables. These embodiments are sufficiently described and do not require application to list each of these different annotations and one of skill in the art with the guidance and description provided herein could write them out individually without any undue experimentation.


In some embodiments, the light chain CDR2 can have one or two extra amino acid residues at the N-terminus. These additional residues would be those that are immediately to the N-terminus of the light chain CDR2 (LCDR2) present in the VL/VK chain provided for herein, in the same row as the CDRs that are listed. For example, the LCDR2 of Clone 6 is provided as GASSLQS (SEQ ID NO: 87), but in some embodiments could be IYGASSLQS (SEQ ID NO: 630) or YGASSLQS (SEQ ID NO: 631). One of skill in the art with this information could immediately envisage the LCDR2 peptide sequence that has one or two extra amino acid residues at the N-terminus of the LCDR2 sequence provided for herein. These embodiments are sufficiently described and do not require application to list each of these different annotations and one of skill in the art with the guidance and description provided herein could write them out individually without any undue experimentation.


There are also alternative systems for annotating CDRs, any of which can be used. For example, CDRs can be chosen based on the Kabat sytem, the IMGT system, or the Chothia system. Other proprietary systems can also be used, which may be based on the predicted 3-dimensional structure of the protein. Accordingly, in some embodiments, the CDRs of Clone ID: 6, Clone ID: 75, or Clone ID: 79 of Table 7 can also be characterized as shown in Table 8. These alternative CDRs can be substituted for these clone referenced in Table 7 or the equivalent clone numbering in Table 6, i.e., Clone 6, Clone 59, and Clone 63.









TABLE 8







Alterative CDRs for Certain Clones














Clone









No.









(Table
Annotation








7)
System
LCDR1
LCDR2
LCDR3
HCDR1
HCDR2
HCDR3





 6
Proprietary
RASQIIG
SSLQS
QQSYRLPFT
FTENNYAFH
SRINSYGTSTTYA
CAREGPVAGY




TNLA
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID NO:
WYFDLW




(SEQ ID
NO: 362)
NO: 632)
NO: 90)
91)
(SEQ ID




NO: 93)




NO: 92)






Other
RASQIIG
GASSLQS
CQQSYRLPFT
FTENNYAFH
SRINSYGTSTTYA
CAREGPVAGY



Annotation
TNLA
(SEQ ID
F (SEQ ID
(SEQ ID
(SEQ ID NO:
WYFDLW




(SEQ ID
NO: 87)
NO: 94)
NO: 90
91)
(SEQ ID




NO: 93)




NO: 92)






Kabat
RASQIIG
GASSLQS
QQSYRLPFT
NYAFH (SEQ
RINSYGTSTTYAD
EGPVAGYWYF




TNLA
(SEQ ID
(SEQ ID
ID NO:
SVKG (SEQ ID
DL (SEQ ID




(SEQ ID
NO: 87)
NO: 632)
633)
NO: 634)
NO: 635)




NO: 93)











IMGT
QIIGTN
GAS
QQSYRLPFT
GFTENNYA
INSYGTST (SEQ
AREGPVAGYW




(SEQ ID

(SEQ ID
(SEQ ID
ID NO: 638)
YFDL (SEQ




NO:

NO: 632)
NO: 637)

ID NO:




636)




639)






CHOTHIA
RASQIIG
GASSLQS
QQSYRLPFT
GFTENNY
NSYGTS (SEQ
EGPVAGYWYF




TNLA
(SEQ ID
(SEQ ID
(SEQ ID
ID NO: 641)
DL (SEQ ID




(SEQ ID
NO: 87)
NO: 632)
NO: 640)

NO: 635)




NO: 93)










75
Proprietary
RASQSVS
SSLQS
QQYKSYPVT
FTFSDFWMH
SYISGDSGYTNYA
CARDRPYYYY




RSLA
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID NO:
MDVW (SEQ




(SEQ ID
NO: 362)
NO: 363)
NO: 359)
170)
ID NO:




NO:




360)




361)











Other
RASQSVS
AASSLQS
CQQYKSYPVT
FTFSDFWMH
SYISGDSGYTNYA
CARDRPYYYY



Annotation
RSLA
(SEQ ID
F (SEQ ID
(SEQ ID
(SEQ ID NO:
MDVW (SEQ




(SEQ ID
NO: 65)
NO: 642)
NO: 359)
170)
ID NO:




NO:




360)




361)











Kabat
RASQSVS
AASSLQS
QQYKSYPVT
DFWMH (SEQ
YISGDSGYTNYAD
DRPYYYYMDV




RSLA
(SEQ ID
(SEQ ID
ID NO:
SVKG (SEQ ID
(SEQ ID




(SEQ ID
NO: 65)
NO: 363)
643)
NO: 644)
NO: 645)




NO:









361)











IMGT
QSVSRS
AAS
QQYKSYPVT
GFTFSDFW
ISGDSGYT (SEQ
ARDRPYYYYM




(SEQ ID

(SEQ ID
(SEQ ID
ID NO: 648)
DV (SEQ ID




NO:

NO: 363)
NO: 647)

NO: 649)




646)











CHOTHIA
RASQSVS
AASSLQS
QQYKSYPVT
GFTFSDE
SGDSGY (SEQ
DRPYYYYMDV




RSLA
(SEQ ID
(SEQ ID
(SEQ ID
ID NO: 651)
(SEQ ID




(SEQ ID
NO: 65)
NO: 363)
NO: 650)

NO: 645)




NO:









361)










79
Proprietary
RASQGIS
STRAT
QQYYTYPPT
FTEDDYAMH
ASITSSSAFIDYA
CARERVDWNS




NSYLA
(SEQ ID
(SEQ ID
(SEQ ID
(SEQ ID NO:
YFDLW (SEQ




(SEQ ID
NO: 384)
NO: 385)
NO: 135)
381)
ID NO:




NO:




382)




383)











Other
RASQGIS
GASTRAT
CQQYYTYPPT
FTFDDYAMH
ASITSSSAFIDYA
CARERVDWNS



Annotation
NSYLA
(SEQ ID
F (SEQ ID
(SEQ ID
(SEQ ID NO:
YFDLW (SEQ




(SEQ ID
NO: 241)
NO: 652)
NO: 135)
381)
ID NO:




NO:




382)




383)











Kabat
RASQGIS
GASTRAT
QQYYTYPPT
DYAMH (SEQ
SITSSSAFIDYAA
ERVDWNSYED




NSYLA
(SEQ ID
(SEQ ID
ID NO:
SVKG (SEQ ID
L (SEQ ID




(SEQ ID
NO: 241)
NO: 385)
653)
NO: 654)
NO: 655)




NO:









383)











IMGT
QGISNSY
GAS
QQYYTYPPT
GFTEDDYA
ITSSSAFI (SEQ
ARERVDWNSY




(SEQ ID

(SEQ ID
(SEQ ID
ID NO: 658)
FDL (SEQ




NO:

NO: 385)
NO: 657)

ID NO:




656)




659)






CHOTHIA
RASQGIS
GASTRAT
QQYYTYPPT
GFTEDDY
TSSSAF (SEQ
ERVDWNSYED




NSYLA
(SEQ ID
(SEQ ID
(SEQ ID
ID NO: 661)
L (SEQ ID




(SEQ ID
NO: 241)
NO: 385)
NO: 660)

NO: 655)




NO:









383)









In some embodiments, the MAdCAM antibody is selected from the following table:

















TABLE 9





Clone










(Fab)
VH Seq
VK Seq
HCDR1
HCDR2
HCDR3
LCDR1
LCDR2
LCDR3







MIAB128
EVQLLESGGGL
DIQMTQSPSS
FTESD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PNYYY
SRSLA
(SEQ
PVT



AASGFTFSDFW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
361)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
1399)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPNYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
NO: 592)









1346)












MIAB128A
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PQYYY
SRSLA
(SEQ
PVT



AASGFTFSDEW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
361)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
1400)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPQYYYMDVWG
YKSYPVTEGO









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1348)
NO: 592)











MIAB129
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PGYYY
SRSLA
(SEQ
PVT



AASGFTFSDFW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
361)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
1401)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPGYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ]









1349)
NO: 592)











MIAB130
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYQ
SRSLA
(SEQ
PVT



AASGFTFSDFW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
361)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
1402)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYQMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1350)
NO: 592)











MIAB131
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYG
SRSLA
(SEQ
PVT



AASGFTFSDFW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
361)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
1403)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYGMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1351)
NO: 592)











MIAB132
EVQLLESGGGL
DIQMTQSPSS
FTFSN
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SRSLA
(SEQ
PVT



AASGFTFSNFW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
361)

363)



GYTNYADSVKG
ASSLQSGVPS
1404)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1352)
NO: 592)











MIAB133
EVQLLESGGGL
DIQMTQSPSS
FTFSS
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SRSLA
(SEQ
PVT



AASGFTFSSFW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
361)

363)



GYTNYADSVKG
ASSLQSGVPS
1405)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1353)
NO: 592)








MIAB134
EVQLLESGGGL
DIQMTQSPSS
FTFSA
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SRSLA
SEQ
PVT



AASGFTFSAFW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
361)

363)



GYTNYADSVKG
ASSLQSGVPS
1406)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1354)
NO: 592)











MIAB135
EVQLLESGGGL
DIQMTQSPSS
FTESD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SRSLA
(SEQ
PVT



AASGFTFSDFW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
361)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSNN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1355)
NO: 592)











MIAB136
EVQLLESGGGL
DIQMTQSPSS
FTFSS
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
YAMS
DSGYT
PYYYY
SRSLA
(SEQ
PVT



AASGFTFSSYA
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MSWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
361)

363)



GYTNYADSVKG
ASSLQSGVPS
473)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1356)
NO: 592)








MIAB137
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SAISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
SGGST
PYYYY
SRSLA
(SEQ
PVT



AASGFTFSDEW
ITCRASQSVS
(SEQ
YYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWVSAISGSG
GKAPKLLIYA
NO:
ID
ID
361)

363)



GSTYYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

103)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1357)
NO: 592)











MIAB138
EVQLLESGGGL
DIQMTQSPSS
FTFSS
SAISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
YAMS
SGGST
PYYYY
SRSLA
(SEQ
PVT



AASGFTESSYA
ITCRASQSVS
(SEQ
YYA
MDVW
(SEQ
ID NO:
(SEQ



MSWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWVSAISGSG
GKAPKLLIYA
NO:
ID
ID
361)

363)



GSTYYADSVKG
ASSLQSGVPS
473)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

103)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1358)
NO: 592)











MIAB139
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSI
SSLQS
QQSYST



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SSYLN
(SEQ
PRT



AASGFTFSDFW
ITCRASQSIS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
SYLNWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
172)

1407)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
SYSTPRTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









591)
NO: 1360)











MIAB140
EVQLLESGGGL
DIQMTQSPSS
FTESS
SAISG
CARDR
RASQSI
SSLQS
QQSYST



VQPGGSLRLSC
LSASVGDRVT
YAMS
SGGST
PYYYY
SSYLN
(SEQ
PRT



AASGFTESSYA
ITCRASQSIS
(SEQ
YYA
MDVW
(SEQ
ID NO:
(SEQ



MSWVRQAPGKG
SYLNWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWVSAISGSG
GKAPKLLIYA
NO:
ID
ID
172)

1407)



GSTYYADSVKG
ASSLQSGVPS
473)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

103)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
SYSTPRTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1358)
NO: 1360)











MIAB141
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSI
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SSYLN
(SEQ
PVT



AASGFTESDEW
ITCRASQSIS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
SYLNWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
172)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









591)
NO: 1361)











MIAB142
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQSYST



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SRSLA
(SEQ
PRT



AASGFTFSDFW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
361)

1407)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
SYSTPRTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









591)
NO: 1362)











MIAB143
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SRSLA
(SEQ
PVT



AASGFTFSDEW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
361)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









591)
NO: 592)











MIAB144
EVQLLESGGGL
DIQMTQSPSS
FTESD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SRSLA
(SEQ
PVT



AASGFTFSDFW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
361)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









591)
NO: 592)











MIAB145
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSI
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SRSLA
(SEQ
PVT



AASGFTESDFW
ITCRASQSIS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1408)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









591)
NO: 1363)











MIAB146
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SSSLA
(SEQ
PVT



AASGFTFSDFW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
SSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1409)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









591)
NO: 1364)











MIAB147
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SRYLA
(SEQ
PVT



AASGETESDEW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RYLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1410)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









591)
NO: 1365)











MIAB148
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SRSLN
(SEQ
PVT



AASGFTFSDFW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLNWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1411)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









591)
NO: 1366)











MIAB149
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSI
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SSSLA
(SEQ
PVT



AASGFTESDFW
ITCRASQSIS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
SSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1412)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









591)
NO: 1367)











MIAB150
EVQLLESGGGL
DIQMTQSPSS
FTESD
SYISG
CARDR
RASQSI
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SRYLA
(SEQ
PVT



AASGFTFSDFW
ITCRASQSIS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RYLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1413)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









591)
NO: 1368)











MIAB151
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSI
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SRSLN
(SEQ
PVT



AASGFTFSDEW
ITCRASQSIS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLNWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1414)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









591)
NO: 1369)











MIAB152
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SSYLA
(SEQ
PVT



AASGFTFSDFW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
SYLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1415)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









591)
NO: 1370)











MIAB153
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SSSLN
(SEQ
PVT



AASGFTESDEW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
SSLNWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1416)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









591)
NO: 1371)











MIAB154
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SRYLN
(SEQ
PVT



AASGFTFSDFW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RYLNWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1417)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









591)
NO: 1372)











MIAB155
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSI
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SSSLN
(SEQ
PVT



AASGFTFSDFW
ITCRASQSIS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
SSLNWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1418)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
SEQ ID









591)
NO: 1373)











MIAB156
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSI
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SRYLN
SEQ
PVT



AASGFTFSDFW
ITCRASQSIS
(SEQ
NYA
MDVW
SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RYLNWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1419)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
SEQ ID









591)
NO: 1374)











MIAB157
EVQLLESGGGL
DIQMTQSPSS
FTESD
SYISG
CARDR
RASQSI
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SSYLA
SEQ
PVT



AASGFTFSDFW
ITCRASQSIS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
SYLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1420)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









591)
NO: 1375)











MIAB158
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SSYLN
(SEQ
PVT



AASGFTFSDFW
ITCRASQSVS
(SEQ
NYA
MDVW
SEQ
ID NO:
(SEQ



MHWVRQAPGKG
SYLNWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1421)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









591)
NO: 1376)











MIAB159
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
ESGYT
PYYYY
SRSLA
(SEQ
PVT



AASGFTFSDEW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGES
GKAPKLLIYA
NO:
ID
ID
361)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

1422)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1377)
NO: 592)








MIAB160
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SRSLA
(SEQ
PVT



AASGFTESDEW
ITCRASQSVS
(SEQ
QYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
361)

363)



GYTQYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

1423)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1378)
NO: 592)











MIAB161
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SRSLA
(SEQ
PVT



AASGFTFSDFW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
361)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDQSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:










1379)
(SEQ ID NO:










592)











MIAB162
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SRSLG
(SEQ
PVT



AASGFTESDEW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLGWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1424)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









591)
NO: 1380)











MIAB163
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SRSLD
(SEQ
PVT



AASGFTESDFW
ITCRASQSVS
(SEQ
NYA
MDVW
SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLDWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1425)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









591)
NO: 1381)











MIAB164
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SRSLT
(SEQ
PVT



AASGFTFSDFW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLTWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1426)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









591)
NO: 1382)











MIAB165
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SRSLS
(SEQ
PVT



AASGFTFSDFW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLSWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1427)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLOP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









591)
NO: 1383)











MIAB166
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SRSLE
(SEQ
PVT



AASGFTFSDFW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLEWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1428)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLOP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:










591)
(SEQ ID










NO: 1384)











MIAB167
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SRSLK
SEQ
PVT



AASGFTFSDFW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLKWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1429)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









591)
NO: 1385)











MIAB168
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SRSLL
(SEQ
PVT



AASGFTFSDEW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLLWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1430)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









591)
NO: 1386)











MIAB169
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYI
SRSLA
(SEQ
PVT



AASGFTFSDEW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
361)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
1431)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYIMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1387)
NO: 592)











MIAB170
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYW
SRSLA
(SEQ
PVT



AASGETFSDEW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
361)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
1432)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYWMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1388)
NO: 592)











MIAB171
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PSYYY
SRSLA
(SEQ
PVT



AASGFTFSDFW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
361)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
1433)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPSYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1389)
NO: 592)











MIAB172
EVQLLESGGGL
DIQMTQSPSS
FTESD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PTYYY
SRSLA
(SEQ
PVT



AASGFTFSDEW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
361)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
1434)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPTYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1390)
NO: 592)











MIAB173
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYY
SRSLA
(SEQ
PVT



AASGFTFSDFW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
361)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









591)
NO: 592)











MIAB174
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
YWMH
DSGYT
PYYYY
SRSLA
(SEQ
PVT



AASGFTFSDYW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
361)

363)



GYTNYADSVKG
ASSLQSGVPS
1435)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1391)
NO: 592)











MIAB175
EVQLLESGGGL
DIQMTQSPSS
FTFSS
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
YWMH
DSGYT
PYYYY
SRSLA
(SEQ
PVT



AASGFTESSYW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
361)

363)



GYTNYADSVKG
ASSLQSGVPS
83)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1392)
NO: 592)











MIAB176
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SAISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
SSGST
PYYYY
SRSLA
(SEQ
PVT



AASGFTFSDFW
ITCRASQSVS
(SEQ
YYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISAISGSS
GKAPKLLIYA
NO:
ID
ID
361)

363)



GSTYYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

1436)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
SEQ ID









1393)
NO: 592)











MIAB177
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SAISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
SGGST
PYYYY
SRSLA
(SEQ
PVT



AASGFTFSDFW
ITCRASQSVS
(SEQ
YYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWVSAISGSG
GKAPKLLIYA
NO:
ID
ID
361)

363)



GSTYYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

103)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1357)
NO: 592)











MIAB178
EVQLLESGGGL
DIQMTQSPSS
FTESS
SAISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
YWMH
SSGST
PYYYY
SRSLA
(SEQ
PVT



AASGFTESSYW
ITCRASQSVS
(SEQ
YYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISAISGSS
GKAPKLLIYA
NO:
ID
ID
361)

363)



GSTYYADSVKG
ASSLQSGVPS
83)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

1436)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1394)
NO: 592)











MIAB179
EVQLLESGGGL
DIQMTQSPSS
FTFSS
SAISG
CARDR
RASQSI
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
YWMH
SGGST
PYYYY
SRYLA
(SEQ
PVT



AASGFTFSSYW
ITCRASQSIS
(SEQ
YYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RYLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWVSAISGSG
GKAPKLLIYA
NO:
ID
ID
1413)

363)



GSTYYADSVKG
ASSLQSGVPS
83)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

103)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1395)
NO: 1368)











MIAB180
EVQLLESGGGL
DIQMTQSPSS
FTFSS
SAISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
YWMH
SGGST
PYYYY
SRSLA
SEQ
PVT



AASGFTESSYW
ITCRASQSVS
(SEQ
YYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWVSAISGSG
GKAPKLLIYA
NO:
ID
ID
361)

363)



GSTYYADSVKG
ASSLQSGVPS
83)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

103)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1395)
NO: 592)











MIAB181
EVQLLESGGGL
DIQMTQSPSS
FTFSS
SAISG
CARDR
RASQSI
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
YWMH
SGGST
PYYYY
SRYLA
(SEQ
PVT



AASGFTESSYW
ITCRASQSIS
(SEQ
YYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RYLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWVSAISGSG
GKAPKLLIYA
NO:
ID
ID
1413)

363)



GSTYYADSVKG
ASSLQSGVPS
83)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

103)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1395)
NO: 1368)











MIAB182
EVQLLESGGGL
DIQMTQSPSS
FTFSS
SAISG
CARDR
RASQSI
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
YWMH
SGGST
PYYYY
SRSLA
(SEQ
PVT



AASGFTFSSYW
ITCRASQSIS
(SEQ
YYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWVSAISGSG
GKAPKLLIYA
NO:
ID
ID
1408)

363)



GSTYYADSVKG
ASSLQSGVPS
83)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

103)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1395)
NO: 1363)











MIAB183
EVQLLESGGGL
DIQMTQSPSS
FTFSS
SAISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
YWMH
SGGST
PYYYY
SSSLA
(SEQ
PVT



AASGFTESSYW
ITCRASQSVS
(SEQ
YYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
SSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWVSAISGSG
GKAPKLLIYA
NO:
ID
ID
1409)

363)



GSTYYADSVKG
ASSLQSGVPS
83)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

103)
360)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1395)
NO: 1364)











MIAB184
EVQLLESGGGL
DIQMTQSPSS
FTFSS
SAISG
CARDR
RASQSI
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
YWMH
SGGST
PYYYY
SSSLA
(SEQ
PVT



AASGFTESSYW
ITCRASQSIS
(SEQ
YYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
SSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWVSAISGSG
GKAPKLLIYA
NO:
ID
ID
1412)

363)



GSTYYADSVKG
ASSLQSGVPS
83)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

103)
360)






TLYLQMNSLRA
FTLTISSLOP









EDTAVYYCARD
EDFATYYCQQ









RPYYYYMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1395)
NO: 1367)











MIAB185
EVQLLESGGGL
DIQMTQSPSS
FTFSS
SYISG
CARDR
RASQSI
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
YWMH
DSGYT
PYYYI
SRSLA
(SEQ
PVT



AASGFTESSYW
ITCRASQSIS
(SEQ
NYA
MDVW
(SEQ
ID NO:
SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1408)

363)



GYTNYADSVKG
ASSLQSGVPS
83)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
1431)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYIMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1396)
NO: 1363)











MIAB186
EVQLLESGGGL
DIQMTQSPSS
FTFSS
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
YWMH
DSGYT
PYYYI
SSSLA
(SEQ
PVT



AASGFTESSYW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
SSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1409)

363)



GYTNYADSVKG
ASSLQSGVPS
83)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
1431)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYIMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1396)
NO: 1364)











MIAB187
EVQLLESGGGL
DIQMTQSPSS
FTFSS
SYISG
CARDR
RASQSI
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
YWMH
DSGYT
PYYYI
SSSLA
(SEQ
PVT



AASGFTESSYW
ITCRASQSIS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
SSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1412)

363)



GYTNYADSVKG
ASSLQSGVPS
83)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
1431)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYIMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1396)
NO: 1367)











MIAB188
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SAISG
CARDR
RASQSI
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
SGGST
PYYYI
SRSLA
(SEQ
PVT



AASGFTFSDFW
ITCRASQSIS
(SEQ
YYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWVSAISGSG
GKAPKLLIYA
NO:
ID
ID
1408)

363)



GSTYYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

103)
1431)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYIMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1397)
NO: 1363)











MIAB189
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SAISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
SGGST
PYYYI
SSSLA
(SEQ
PVT



AASGFTFSDFW
ITCRASQSVS
(SEQ
YYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
SSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWVSAISGSG
GKAPKLLIYA
NO:
ID
ID
1409)

363)



GSTYYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

103)
1431)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYIMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1397)
NO: 1364)











MIAB190
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SAISG
CARDR
RASQSI
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
SGGST
PYYYI
SSSLA
(SEQ
PVT



AASGFTESDEW
ITCRASQSIS
(SEQ
YYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
SSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWVSAISGSG
GKAPKLLIYA
NO:
ID
ID
1412)

363)



GSTYYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

103)
1431)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYIMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
SEQ ID









1397)
NO: 1367)











MIAB191
EVQLLESGGGL
DIQMTQSPSS
FTESS
SAISG
CARDR
RASQSI
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
YWMH
SGGST
PYYYI
SRSLA
(SEQ
PVT



AASGFTFSSYW
ITCRASQSIS
(SEQ
YYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWVSAISGSG
GKAPKLLIYA
NO:
ID
ID
1408)

363)



GSTYYADSVKG
ASSLQSGVPS
83)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

103)
1431)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYIMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1398)
NO: 1363)











MIAB192
EVQLLESGGGL
DIQMTQSPSS
FTESS
SAISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
YWMH
SGGST
PYYYI
SSSLA
(SEQ
PVT



AASGFTESSYW
ITCRASQSVS
(SEQ
YYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
SSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWVSAISGSG
GKAPKLLIYA
NO:
ID
ID
1409)

363)



GSTYYADSVKG
ASSLQSGVPS
83)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

103)
1431)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYIMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1398)
NO: 1364)











MIAB193
EVQLLESGGGL
DIQMTQSPSS
FTFSS
SAISG
CARDR
RASQSI
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
YWMH
SGGST
PYYYI
SSSLA
(SEQ
PVT



AASGFTESSYW
ITCRASQSIS
(SEQ
YYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
SSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWVSAISGSG
GKAPKLLIYA
NO:
ID
ID
1412)

363)



GSTYYADSVKG
ASSLQSGVPS
83)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

103)
1431)






TLYLQMNSLRA
FTLTISSLOP









EDTAVYYCARD
EDFATYYCQQ









RPYYYIMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1398)
NO: 1367)











MIAB194
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSI
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYI
SRSLA
(SEQ
PVT



AASGFTFSDFW
ITCRASQSIS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1408)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
1431)






TLYLQMNSLRA
FTLTISSLOP









EDTAVYYCARD
EDFATYYCQQ









RPYYYIMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID NO:









1387)
1363)











MIAB195
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYI
SSSLA
(SEQ
PVT



AASGFTFSDFW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
SSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1409)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
1431)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYIMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1387)
NO: 1364)











MIAB196
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSI
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYI
SSSLA
(SEQ
PVT



AASGFTFSDFW
ITCRASQSIS
(SEQ
NYA
MDVW
SEQ
ID NO:
(SEQ



MHWVRQAPGKG
SSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1412)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
1431)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYIMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1387)
NO: 1367)











MIAB197
EVQLLESGGGL
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSI
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYI
SRSLA
(SEQ
PVT



AASGFTFSDFW
ITCRASQSIS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
1408)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
1431)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYIMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1387)
NO: 1363)











MIAB198
EVQLLESGGGI
DIQMTQSPSS
FTFSD
SYISG
CARDR
RASQSV
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
FWMH
DSGYT
PYYYI
SRSLA
SEQ
PVT



AASGFTFSDFW
ITCRASQSVS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
RSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
362)
ID NO:



LEWISYISGDS
GKAPKLLIYA
NO:
ID
ID
361)

363)



GYTNYADSVKG
ASSLQSGVPS
359)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

170)
1431)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYIMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1387)
NO: 592)









In some embodiments, the MAdCAM antibody comprises one or more sequences, or a combination thereof, of the sequences presented in Table 9.


In some embodiments, the antibody is linked to another antibody or therapeutic. In some embodiments, the MAdCAM antibody is linked to a PD-1 antibody or an IL-2 mutein as provided herein or that is incorporated by reference.


In some embodiments, the variable light chain MAdCAM antibody comprises a mutation selected from the group comprising V29I; R31S; S32Y; A34N; Y91S; K92Y; Y94T; and V99R.


In some embodiments, the variable heavy chain MAdCAM antibody comprises a mutation selected from the group comprising D31S, F32Y, I48V, Y50A, D54S, Y57S, N59Y, Y103G, V29I, R31S; D31S, F32Y, I48V, Y50A, D54S, Y57S, N59Y, V29I, R31S; D31S, F32Y, I48V, Y50A, D54S, Y57S, N59Y, Y103G, V29I; D31S, F32Y, I48V, Y50A, D54S, Y57S, N59Y, V29I; D31S, F32Y, Y50A, D54S, S55G, Y57S, N59Y, Y103G, V29I, R31S; D31S, F32Y, Y50A, D54S, S55G, Y57S, N59Y, V29I, R31S; D31S, F32Y, Y50A, D54S, S55G, Y57S, N59Y, Y103G, V29I; D31S, F32Y, Y50A, D54S, S55G, Y57S, N59Y, V29I; D31S, F32Y, I48V, Y50A, D54S, S55G, Y57S, N59Y, Y103G, V29I, R31S; D31S, F32Y, I48V, Y50A, D54S, S55G, Y57S, N59Y, V29I, R31S; D31S, F32Y, I48V, Y50A, D54S, S55G, Y57S, N59Y, Y103G, V29I; D31S, F32Y, I48V, Y50A, D54S, S55G, Y57S, N59Y, V29I; D31S, F32Y, I48V, D54S, S55G, Y103G, V29I, R31S; D31S, F32Y, I48V, Y50A, D54S, S55G, Y57S, N59Y, Y105D, V29I, R31S; D31S, F32Y, I48V, D54S, S55G, Y105D, V29I, R31S; D31S, F32Y, I48V, Y50A, D54S, S55G, Y57S, N59Y, Y103G, V29I, R31S; D31S, F32Y, I48V, D54S, S55G, Y105D, V29I, R31S; D31S; F32Y; W33A; H35S; I48V; Y50A; D54S; S55G; Y57S; N59Y; D60A; D60Q; N72A; N72Q; N82A; N82G; and N82Q.


In some embodiments, the MAdCAM antibody comprises one or more sequences as shown in Table 6 or Table 9. In some embodiments, the MAdCAM antibody comprises a combination of one or more sequence as shown in Table 6, or Table 9. In some embodiments, the MAdCAM antibody is in a scFV format as illustrated in Table 6. In some embodiments, the antibody comprises a CDR1 from any one of clones 1-66 of Table 6, a CDR2 from any one of clones 1-84, and a CDR3 from any one of clones 1-66 of Table 6. In some embodiments, the antibody comprises a LCDR1 from any one of clones 1-66 of Table 6, a LCDR2 from any one of clones 1-66 of Table 6, and a LCDR3 from any one of clones 1-66 of Table 6. In some embodiments, the MAdCAM antibody is in a Fab format as illustrated in Table 9. In some embodiments, the antibody comprises a HCDR1 from any one of clones MIAB128-198 of Table 9, a HCDR2 from any one of clones MIAB128-198 of Table 9, and a HCDR3 from any one of clones MIAB128-198 of Table 9. In some embodiments, the antibody comprises a LCDR1 from any one of clones MIAB128-198 of Table 9, a LCDR2 from any one of clones MIAB128-198 of Table 9, and a LCDR3 from any one of clones MIAB128-198 of Table 9. In some embodiments, the amino acid residues of the CDRs shown above contain mutations. In some embodiments, the CDRs contain 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 substitutions or mutations. In some embodiments, the substitution is a conservative substitution.


In some embodiments, the MAdCAM antibody has a VH region selected from any one of clones 1-84 of Table 7 and a VL region selected from any one of clones 1-84 as set forth in of Table 7. In some embodiments, the antibody comprises a CDR1 from any one of clones 1-84 of Table 7, a CDR2 from any one of clones 1-84, and a CDR3 from any one of clones 1-84 of Table 7. In some embodiments, the antibody comprises a LCDR1 from any one of clones 1-84 of Table 7, a LCDR2 from any one of clones 1-84 of Table 7, and a LCDR3 from any one of clones 1-84 of Table 7. In some embodiments, the MAdCAM antibody has a VH region selected from any one of clones MIAB128-198 of Table 9 and a VK region selected from any one of clones MIAB128-198 as set forth in of Table 9. In some embodiments, the antibody comprises a CDR1 from any one of clones MIAB128-198 of Table 9, a CDR2 from any one of clones MIAB128-198, and a CDR3 from any one of clones MIAB128-198 of Table 9. In some embodiments, the antibody comprises a LCDR1 from any one of clones MIAB128-198 of Table 9, a LCDR2 from any one of clones MIAB128-198 of Table 9, and a LCDR3 from any one of clones MIAB128-198 of Table 9.


In some embodiments, the amino acid residues of the CDRs shown above contain mutations. In some embodiments, the CDRs contain 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 substitutions or mutations. In some embodiments, the substitution is a conservative substitution.


In some embodiments, the molecule comprises an antibody that binds to MAdCAM. In some embodiments, the antibody comprises (i) a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of any of the CDR1 sequences set forth in Table 6, Table 7, or Table 9; the heavy chain CDR2 has the amino acid sequence of any of the CDR2 sequences set forth in Table 6, Table 7, or Table 9, and the heavy chain CDR3 has the amino acid sequence of any of the CDR3 sequences set forth in Table 6, Table 7, or Table 9; or variants of any of the foregoing; and (ii) a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of any of the LCDR1 sequences set forth in Table 6, Table 7, or Table 9; the light chain LCDR2 has the amino acid sequence of any of the LCDR2 sequences set forth in Table 6, Table 7, or Table 9, and the light chain CDR3 has the amino acid sequence of any of the LCDR3 sequences set forth in Table 6, Table 7, or Table 9, or variants of any of the foregoing.


In some embodiments, the antibody comprises a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1, CDR2, and CDR3 sequences have the amino acid sequence as set forth in Antibody 6 of Table 6 or Antibody 6 of Table 7, or variants of any of the foregoing; and (ii) a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1, CDR2, and CDR3 sequences have the amino acid sequence as set forth sequence as set forth in Antibody 6 of Table 6 or Antibody 6 of Table 7, or variants of any of the foregoing.


In some embodiments, the antibody comprises a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1, CDR2, and CDR3 sequences have the amino acid sequence as set forth in Antibody 59 of Table 6 or Antibody 75 of Table 7, or variants of any of the foregoing; and (ii) a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1, CDR2, and CDR3 sequences have the amino acid sequence as set forth sequence as set forth in Antibody 59 of Table 6 or Antibody 75 of Table 7, or variants of any of the foregoing.


In some embodiments, the antibody comprises a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1, CDR2, and CDR3 sequences have the amino acid sequence as set forth in Antibody 63 of Table 6 or Antibody 79 of Table 7, or variants of any of the foregoing; and (ii) a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1, CDR2, and CDR3 sequences have the amino acid sequence as set forth sequence as set forth in Antibody 63 of Table 6 or Antibody 79 of Table 7, or variants of any of the foregoing.


In some embodiments, the antibody comprises a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1, CDR2, and CDR3 sequences have the amino acid sequence as set forth in MIAB197 of Table 9, or variants of any of the foregoing; and (ii) a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1, CDR2, and CDR3 sequences have the amino acid sequence as set forth sequence as set forth in MIAB197 of Table 9, or variants of any of the foregoing.


These are non-limiting illustrative examples and the antibodies can have the CDRs as set forth in the tables provided herein and are explicitly referenced without writing out the previous paragraphs for each CDR set.


In some embodiments, the MAdCAM antibody comprises a VH and VL(VK) chain as provided herein, such as those listed in the Table 7, MAdCAM Antibody CDR Table 1, and Table 9. In some embodiments, the VH peptide comprises a sequence of SEQ ID NO: 414, 591, 599, or 1387. In some embodiments, the VK chain comprises a sequence of 415, 592, 600, or 1363. In some embodiments, the antibody comprises a VH of SEQ ID NO: 414 and a VK of SEQ ID NO: 415. In some embodiments, the antibody comprises a VH of SEQ ID NO: 591 and a VK of SEQ ID NO: 592. In some embodiments, the antibody comprises a VH of SEQ ID NO: 599 and a VK of SEQ ID NO: 600. In some embodiments, the antibody comprises a VH of SEQ ID NO: 1387 and a VK of SEQ ID NO: 1363. The VH and VK can also be in a scFV format as illustrated in the Table 6, Table 11, Table 12, and Table 14. The VH and VK can also be in a Fab format as illustrated in the Table 9.


In some embodiments, a therapeutic is provided comprising one or more of the following polypeptides:













SEQ ID NO:
Sequence







620
EVQLLESGGGLVQPGGSLRLSCAASGFTENNYAFHWVRQAPGKGLEWVSRINSYGTSTTYADSVKGRF



TISRDNSKNTLYLQMNSLRAEDTAVYYCAREGPVAGYWYFDLWGQGTLVTVSSASTKGPSVEPLAPSS



KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC



NVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMISRTPEVTCVVVDVSH



EDPEVKENWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI



SKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF



FLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSAPTSSSTKKTQLQLEHLLLDL



QMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEALNLAPSKNFHLRPRDLISDI



NVIVLELKGSETTFMCEYADETATIVEFINRWITFSQSIISTLT





621
DIQMTQSPSSLSASVGDRVTITCRASQIIGTNLAWYQQKPGKAPKLLIYGASSLQSGVPSRESGSGSG



TDFTLTISSLQPEDFATYYCQQSYRLPFTFGQGTKVEIKRRTVAAPSVFIFPPSDEQLKSGTASVVCL



LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSS



PVTKSENRGEC





622
EVQLLESGGGLVQPGGSLRLSCAASGFTFSDFWMHWVRQAPGKGLEWISYISGDSGYTNYADSVKGRE



TISRDNSKNTLYLQMNSLRAEDTAVYYCARDRPYYYYMDVWGKGTTVTVSSASTKGPSVFPLAPSSKS



TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV



NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMISRTPEVTCVVVDVSHED



PEVKENWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK



AKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL



YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSAPTSSSTKKTQLQLEHLLLDLQM



ILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEALNLAPSKNFHLRPRDLISDINV



IVLELKGSETTEMCEYADETATIVEFINRWITFSQSIISTLT





623
DIQMTQSPSSLSASVGDRVTITCRASQSVSRSLAWYQQKPGKAPKLLIYAASSLQSGVPSRESGSGSG



TDFTLTISSLQPEDFATYYCQQYKSYPVTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLL



NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSP



VTKSENRGEC





624
EVQLLESGGGLVKPGGSLRLSCAASGFTEDDYAMHWVRQAPGKGLEWVASITSSSAFIDYAASVKGRF



TISRDDSKNTLYLQMNSLKTEDTAVYYCARERVDWNSYFDLWGRGTLVTVSSASTKGPSVFPLAPSSK



STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN



VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMISRTPEVTCVVVDVSHE



DPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS



KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF



LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSAPTSSSTKKTQLQLEHLLLDLQ



MILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEALNLAPSKNFHLRPRDLISDIN



VIVLELKGSETTEMCEYADETATIVEFINRWITFSQSIISTLT





625
EIVMTQSPATLSVSPGERATLSCRASQGISNSYLAWYQQKPGQAPRLLIYGASTRATGIPARESGSGS



GTEFTLTISSLQSEDFAVYYCQQYYTYPPTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCL



LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSS



PVTKSENRGEC









In some embodiments, the polypeptide comprises one peptide of SEQ ID NO: 620, 622, or 624 and a second peptide of SEQ ID NO: 621, 623, or 625. In some embodiments, a polypeptide is provided comprising a first peptide of SEQ ID NO: 620 and a second peptide comprising a sequence of SEQ ID NO: 621. In some embodiments, a polypeptide is provided comprising a first peptide of SEQ ID NO: 620 and a second peptide comprising a sequence of SEQ ID NO: 623. In some embodiments, a polypeptide is provided comprising a first peptide of SEQ ID NO: 620 and a second peptide comprising a sequence of SEQ ID NO: 625. In some embodiments, a polypeptide is provided comprising a first peptide of SEQ ID NO: 622 and a second peptide comprising a sequence of SEQ ID NO: 621. In some embodiments, a polypeptide is provided comprising a first peptide of SEQ ID NO: 622 and a second peptide comprising a sequence of SEQ ID NO: 623. In some embodiments, a polypeptide is provided comprising a first peptide of SEQ ID NO: 622 and a second peptide comprising a sequence of SEQ ID NO: 625. In some embodiments, a polypeptide is provided comprising a first peptide of SEQ ID NO: 624 and a second peptide comprising a sequence of SEQ ID NO: 621. In some embodiments, a polypeptide is provided comprising a first peptide of SEQ ID NO: 624 and a second peptide comprising a sequence of SEQ ID NO: 623. In some embodiments, a polypeptide is provided comprising a first peptide of SEQ ID NO: 624 and a second peptide comprising a sequence of SEQ ID NO: 625.


In some embodiments, the therapeutic counpound comprises a MAdCAM IgG wherein the IL-2 mutein is fused to the C-terminus of the IgG heavy chain, and is selected from one or more of the following sequences:















TABLE 10







IgG1
Fc-IL-







Constant
2M






VH
Domains
Linker
IL-2M
VK
CK


Ab
Seq
Seq
Seq
Seq
Seq
Seq







MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


128
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPNYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSFNRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1346)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKI
DIQMTQS
RTVAAPS


128A
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPQYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1348)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


129
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVELFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPGYY
MTKNQVSLTCLVKGFYPSDI

WITESQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1349)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


130
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



QMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1350)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


131
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINE
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



GMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSFNRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1351)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


132
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTFSNF
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRFS
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITESQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1352)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


133
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTFSSF
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1353)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


134
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTFSAF
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSFNRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1354)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


135
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVELFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRFS
TEQDSKD



DNSNNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSFNRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1355)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


136
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESSY
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



AMSWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRFS
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITESQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1356)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


137
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWV
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SAISGSGG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



STYYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRFS
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSFNRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1357)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


138
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESSY
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



AMSWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWV
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SAISGSGG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



STYYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1358)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


139
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTEPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
ISSYLNW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVELFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITESQSIIS
TYYCQQS
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
YSTPRTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSFNRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


1360)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


140
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESSY
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



AMSWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
ISSYLNW
LNNFYPR



PGKGLEWV
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SAISGSGG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



STYYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQS
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
YSTPRTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1358)
NO: 44)


1360)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


141
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
ISSYLNW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITESQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


1361)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


142
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQS
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
YSTPRTE
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


1362)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


143
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVELFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


144
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


145
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
ISRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSFNRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


1363)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


146
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSSSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


1364)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


147
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTFSDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRYLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRFS
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


1365)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


148
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLNW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


1366)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


149
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
ISSSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRFS
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
GLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


1367)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


150
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
ISRYLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


1368)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


151
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTEPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
ISRSLNW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSFNRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


1369)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


152
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSSYLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRFS
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


1370)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


153
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSSSLNW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSFNRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


1371)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


154
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRYLNW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSFNRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


1372)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


155
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
ISSSLNW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


1373)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


156
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTEPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
ISRYLNW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


1374)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


157
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
ISSYLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTE
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


1375)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


158
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSSYLNW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVELFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRFS
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


1376)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


159
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGESG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRFS
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSFNRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1377)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


160
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTQYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1378)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


161
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DQSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTE
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1379)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


162
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLGW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


1380)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


163
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTFSDF
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLDW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


1381)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


164
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLTW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITESQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSFNRG



SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


1382)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


165
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLSW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


1383)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


166
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTFSDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLEW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


1384)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


167
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLKW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSFNRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


1385)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


168
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLLW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


1386)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


169
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITESQSIIS
TYYCQQY
YACEVTH



IMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1387)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


170
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



WMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1388)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


171
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRFS
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPSYY
MTKNQVSLTCLVKGFYPSDI

WITESQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSFNRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1389)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


172
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPTYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1390)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


173
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTFSDF
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


174
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDY
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1391)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


175
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESSY
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRFS
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1392)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


176
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SAISGSSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



STYYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1393)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


177
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWV
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SAISGSGG
PSVELFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



STYYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1357)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


178
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESSY
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SAISGSSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



STYYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITESQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1394)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


179
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESSY
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
ISRYLAW
LNNFYPR



PGKGLEWV
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SAISGSGG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



STYYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDEA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1395)
NO: 44)


1368)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


180
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTFSSY
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWV
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SAISGSGG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



STYYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITESQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSFNRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1395)
NO: 44)


592)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


181
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESSY
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
ISRYLAW
LNNFYPR



PGKGLEWV
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SAISGSGG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



STYYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTE
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVESCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1395)
NO: 44)


1368)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


182
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESSY
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
ISRSLAW
LNNFYPR



PGKGLEWV
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SAISGSGG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



STYYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRFS
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTE
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1395)
NO: 44)


1363)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


183
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTFSSY
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSSSLAW
LNNFYPR



PGKGLEWV
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SAISGSGG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



STYYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1395)
NO: 44)


1364)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


184
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTFSSY
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
ISSSLAW
LNNFYPR



PGKGLEWV
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SAISGSGG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



STYYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRFS
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPGSEQ ID


ID NO:
ID NO:



1395)
NO: 44)


1367)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


185
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESSY
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
ISRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



IMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1396)
NO: 44)


1363)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


186
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESSY
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSSSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRFS
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



IMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSFNRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1396)
NO: 44)


1364)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


187
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESSY
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
ISSSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



IMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1396)
NO: 44)


1367)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


188
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
ISRSLAW
LNNFYPR



PGKGLEWV
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SAISGSGG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



STYYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



IMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1397)
NO: 44)


1363)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


189
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTFSDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSSSLAW
LNNFYPR



PGKGLEWV
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SAISGSGG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



STYYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



IMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1397)
NO: 44)


1364)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


190
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
ISSSLAW
LNNFYPR



PGKGLEWV
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SAISGSGG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



STYYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



IMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSFNRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1397)
NO: 44)


1367)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


191
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESSY
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
ISRSLAW
LNNFYPR



PGKGLEWV
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SAISGSGG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



STYYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITESQSIIS
TYYCQQY
YACEVTH



IMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1398)
NO: 44)


1363)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


192
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTFSSY
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSSSLAW
LNNFYPR



PGKGLEWV
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SAISGSGG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



STYYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



IMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1398)
NO: 44)


1364)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


193
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESSY
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
ISSSLAW
LNNFYPR



PGKGLEWV
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SAISGSGG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



STYYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRFS
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTEMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



IMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1398)
NO: 44)


1367)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


194
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTFSDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
ISRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



IMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTE
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1387)
NO: 44)


1363)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


195
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSSSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



IMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1387)
NO: 44)


1364)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


196
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
ISSSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



IMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTE
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1387)
NO: 44)


1367)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


197
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
ISRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



IMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1387)
NO: 44)


1363)
45)





MIAB
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


198
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNFHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITFSQSIIS
TYYCQQY
YACEVTH



IMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO:
QKSLSLSPG (SEQ ID


ID NO:
ID NO:



1387)
NO: 44)


592)
45)





PRNT
EVQLLESG
ASTKGPSVFPLAPSSKSTSG
GGGGS
APTSSSTKKT
DIQMTQS
RTVAAPS


1
GGLVQPGG
GTAALGCLVKDYFPEPVTVS
(SEQ
QLQLEHLLLD
PSSLSAS
VFIFPPS



SLRLSCAA
WNSGALTSGVHTFPAVLQSS
ID NO:
LQMILNGINN
VGDRVTI
DEQLKSG



SGFTESDE
GLYSLSSVVTVPSSSLGTQT
23)
YKNPKLTRML
TCRASQS
TASVVCL



WMHWVRQA
YICNVNHKPSNTKVDKKVEP

TFKFYMPKKA
VSRSLAW
LNNFYPR



PGKGLEWI
KSCDKTHTCPPCPAPEAAGA

TELKHLQCLE
YQQKPGK
EAKVQWK



SYISGDSG
PSVFLFPPKPKDTLMISRTP

EELKPLEEAL
APKLLIY
VDNALQS



YTNYADSV
EVTCVVVDVSHEDPEVKENW

NLAPSKNEHL
AASSLQS
GNSQESV



KGRFTISR
YVDGVEVHNAKTKPREEQYN

RPRDLISDIN
GVPSRES
TEQDSKD



DNSKNTLY
STYRVVSVLTVLHQDWLNGK

VIVLELKGSE
GSGSGTD
STYSLSS



LQMNSLRA
EYKCKVSNKALPAPIEKTIS

TTFMCEYADE
FTLTISS
TLTLSKA



EDTAVYYC
KAKGQPREPQVYTLPPSREE

TATIVEFINR
LQPEDFA
DYEKHKV



ARDRPYYY
MTKNQVSLTCLVKGFYPSDI

WITESQSIIS
TYYCQQY
YACEVTH



YMDVWGKG
AVEWESNGQPENNYKTTPPV

TLT (SEQ
KSYPVTF
QGLSSPV



TTVTVSS
LDSDGSFFLYSKLTVDKSRW

ID NO: 41)
GQGTKVE
TKSENRG



(SEQ ID
QQGNVFSCSVMHEALHNHYT


IK (SEQ
EC (SEQ



NO: 591)
QKSLSLSPG (SEQ ID


ID NO:
ID NO:




NO: 44)


592)
45)









In some embodiments, the therapeutic compound comprises one or more sequences, or a combination thereof, selected from the Table 10. In some embodiments, the therapeutic compound comprises the peptides of SEQ ID NOs: 1387, 44, 23, 41, 1363, and 45.


In additional embodiments, the MAdCAM antibody comprises an IL-2 mutein fused to the N-terminus of an Fc heavy chain, wherein the Fc is further fused at its C-terminus to a MAdCAM scFv, and has one or more of the sequences as set forth in the following table
















TABLE 11







IL-2M-









Fc



Intra





Linker

Fc-scFv
scFv VH
scFv
scFv VK


Ab
IL-2M Seq
Seq
Fc Domain Seq
Linker
Seq
Linker
Seq







MIAB199
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGGS
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
(SEQ ID
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGS
ISRTPEVTCVVVDVSH
NO: 23)
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
(SEQ
EDPEVKFNWYVDGVEV

DFWMHWVRQA
GS
SVSRSLAWY



TFKFYMPKKA
ID NO:
HNAKTKPREEQYNSTY

PGKGLEWISY
(SEQ
QQKPGKAPK



TELKHLQCLE
30)
RVVSVLTVLHQDWLNG

ISGDSGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL

KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTFMCEYADE

WESNGQPENNYKTTPP

PYYYYMDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

QGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 591)

NO: 592)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB200
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGGSGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GGS
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGS
ISRTPEVTCVVVDVSH
(SEQ ID
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
(SEQ
EDPEVKFNWYVDGVEV
NO:
DFWMHWVRQA
GS
SVSRSLAWY



TFKFYMPKKA
ID NO:
HNAKTKPREEQYNSTY
619)
PGKGLEWISY
(SEQ
QQKPGKAPK



TELKHLQCLE

RVVSVLTVLHQDWLNG

ISGDSGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL
30)
KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTFMCEYADE

WESNGQPENNYKTTPP

PYYYYMDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

QGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 591)

NO: 592)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB201
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGGSGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GGSGGGG
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGS
ISRTPEVTCVVVDVSH
S (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
(SEQ
EDPEVKFNWYVDGVEV
ID NO:
DFWMHWVRQA
GS
SVSRSLAWY



TFKFYMPKKA
ID NO:
HNAKTKPREEQYNSTY
30)
PGKGLEWISY
(SEQ
QQKPGKAPK



TELKHLQCLE
30)
RVVSVLTVLHQDWLNG

ISGDSGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL

KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTFMCEYADE

WESNGQPENNYKTTPP

PYYYYMDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

QGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 591)

NO: 592)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB202
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGGS
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
(SEQ ID
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGSGGG
ISRTPEVTCVVVDVSH
NO: 23)
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
GS
EDPEVKFNWYVDGVEV

DFWMHWVRQA
GS
SVSRSLAWY



TFKFYMPKKA
(SEQ
HNAKTKPREEQYNSTY

PGKGLEWISY
(SEQ
QQKPGKAPK



TELKHLQCLE
ID NO:
RVVSVLTVLHQDWLNG

ISGDSGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL
22)
KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTFMCEYADE

WESNGQPENNYKTTPP

PYYYYMDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

QGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 591)

NO: 592)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB203
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGGSGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GGS
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGSGGG
ISRTPEVTCVVVDVSH
(SEQ ID
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
GS
EDPEVKFNWYVDGVEV
NO:
DFWMHWVRQA
GS
SVSRSLAWY



TFKFYMPKKA
(SEQ
HNAKTKPREEQYNSTY
619)
PGKGLEWISY
(SEQ
QQKPGKAPK



TELKHLQCLE
ID NO:
RVVSVLTVLHQDWING

ISGDSGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL
22)
KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTFMCEYADE

WESNGQPENNYKTTPP

PYYYYMDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

QGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 591)

NO: 592)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB204
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGGSGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GGSGGGG
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGSGGG
ISRTPEVTCVVVDVSH
S (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
GS
EDPEVKFNWYVDGVEV
ID NO:
DFWMHWVRQA
GS
SVSRSLAWY



TFKFYMPKKA
(SEQ
HNAKTKPREEQYNSTY
30)
PGKGLEWISY
(SEQ
QQKPGKAPK



TELKHLQCLE
ID NO:
RVVSVLTVLHQDWLNG

ISGDSGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL
22)
KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTFMCEYADE

WESNGQPENNYKTTPP

PYYYYMDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

QGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 591)

NO: 592)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB212
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGGSGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GGSGGGG
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGS
ISRTPEVTCVVVDVSH
S (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
(SEQ
EDPEVKFNWYVDGVEV
ID NO:
SYWMHWVRQA
GS
SISSSLAWY



TFKFYMPKKA
ID NO:
HNAKTKPREEQYNSTY
30)
PGKGLEWVSY
(SEQ
QQKPGKAPK



TELKHLQCLE
30)
RVVSVLTVLHQDWLNG

ISGSGGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL

KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTFMCEYADE

WESNGQPENNYKTTPP

PYYYDMDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

QGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 1445)

NO: 1367)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB213
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGGSGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GGSGGGG
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGS
ISRTPEVTCVVVDVSH
S (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
(SEQ
EDPEVKFNWYVDGVEV
ID NO:
SYWMHWVRQA
GS
SISSSLAWY



TFKFYMPKKA
ID NO:
HNAKTKPREEQYNSTY
30)
PGKGLEWVSY
(SEQ
QQKPGKAPK



TELKHLQCLE
30)
RVVSVLTVLHQDWLNG

ISGSGGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL

KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTFMCEYADE

WESNGQPENNYKTTPP

PYYYDIDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

QGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 1477)

NO: 1367)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB214
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGGSGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GGSGGGG
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGS
ISRTPEVTCVVVDVSH
S (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
(SEQ
EDPEVKFNWYVDGVEV
ID NO:
SYWMHWVRQA
GS
SISSSLAWY



TFKFYMPKKA
ID NO:
HNAKTKPREEQYNSTY
30)
PGKGLEWVSY
(SEQ
QQKPGKAPK



TELKHLQCLE
30)
RVVSVLTVLHQDWLNG

ISGSGGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL

KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTFMCEYADE

WESNGQPENNYKTTPP

PYYYDLDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

QGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 1480)

NO: 1367)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB215
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGGSGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GGSGGGG
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGS
ISRTPEVTCVVVDVSH
S (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
(SEQ
EDPEVKFNWYVDGVEV
ID NO:
SYWMHWVRQA
GS
SISSSLAWY



TFKFYMPKKA
ID NO:
HNAKTKPREEQYNSTY
30)
PGKCLEWVSY
(SEQ
QQKPGKAPK



TELKHLQCLE
30)
RVVSVLTVLHQDWLNG

ISGSGGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL

KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTFMCEYADE

WESNGQPENNYKTTPP

PYYYDMDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

CGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 1542)

NO: 1543)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB216
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGGSGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GGSGGGG
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGS
ISRTPEVTCVVVDVSH
S (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
(SEQ
EDPEVKFNWYVDGVEV
ID NO:
SYWMHWVRQA
GS
SISSSLAWY



TFKFYMPKKA
ID NO:
HNAKTKPREEQYNSTY
30)
PGKCLEWVSY
(SEQ
QQKPGKAPK



TELKHLQCLE
30)
RVVSVLTVLHQDWLNG

ISGSGGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL

KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTFMCEYADE

WESNGQPENNYKTTPP

PYYYDIDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

CGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 1544)

NO: 1543)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB217
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGGSGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GGSGGGG
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGS
ISRTPEVTCVVVDVSH
S (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
(SEQ
EDPEVKFNWYVDGVEV
ID NO:
SYWMHWVRQA
GS
SISSSLAWY



TFKFYMPKKA
ID NO:
HNAKTKPREEQYNSTY
30)
PGKCLEWVSY
(SEQ
QQKPGKAPK



TELKHLQCLE
30)
RVVSVLTVLHQDWLNG

ISGSGGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL

KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTFMCEYADE

WESNGQPENNYKTTPP

PYYYDLDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

CGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 1545)

NO: 1543)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB218
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGSEGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GSEGGGS
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGS
ISRTPEVTCVVVDVSH
E (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
(SEQ
EDPEVKFNWYVDGVEV
ID NO:
SYWMHWVRQA
GS
SISSSLAWY



TFKFYMPKKA
ID NO:
HNAKTKPREEQYNSTY
1546)
PGKGLEWVSY
(SEQ
QQKPGKAPK



TELKHLQCLE
30)
RVVSVLTVLHQDWLNG

ISGSGGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL

KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTFMCEYADE

WESNGQPENNYKTTPP

PYYYDMDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

QGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 1445)

NO: 1367)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB219
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGSEGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GSEGGGS
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGS
ISRTPEVTCVVVDVSH
E (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
(SEQ
EDPEVKFNWYVDGVEV
ID NO:
SYWMHWVRQA
GS
SISSSLAWY



TFKFYMPKKA
ID NO:
HNAKTKPREEQYNSTY
1546)
PGKGLEWVSY
(SEQ
QQKPGKAPK



TELKHLQCLE
30)
RVVSVLTVLHQDWLNG

ISGSGGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL

KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTFMCEYADE

WESNGQPENNYKTTPP

PYYYDIDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

QGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 1477)

NO: 1367)



ID NO: 41)

PG (SEQ ID NO:









21)






MIAB220
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGSEGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GSEGGGS
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGS
ISRTPEVTCVVVDVSH
E (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
(SEQ
EDPEVKFNWYVDGVEV
ID NO:
SYWMHWVRQA
GS
SISSSLAWY



TFKFYMPKKA
ID NO:
HNAKTKPREEQYNSTY
1546)
PGKGLEWVSY
(SEQ
QQKPGKAPK



TELKHLQCLE
30)
RVVSVLTVLHQDWLNG

ISGSGGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL

KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTFMCEYADE

WESNGQPENNYKTTPP

PYYYDLDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

QGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 1480)

NO: 1367)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB221
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGSEGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GSEGGGS
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGS
ISRTPEVTCVVVDVSH
E (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
(SEQ
EDPEVKFNWYVDGVEV
ID NO:
SYWMHWVRQA
GS
SISSSLAWY



TFKFYMPKKA
ID NO:
HNAKTKPREEQYNSTY
1546)
PGKCLEWVSY
(SEQ
QQKPGKAPK



TELKHLQCLE
30)
RVVSVLTVLHQDWLNG

ISGSGGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL

KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTFMCEYADE

WESNGQPENNYKTTPP

PYYYDMDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

CGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 1542)

NO: 1543)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB222
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGSEGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GSEGGGS
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGS
ISRTPEVTCVVVDVSH
E (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
(SEQ
EDPEVKFNWYVDGVEV
ID NO:
SYWMHWVRQA
GS
SISSSLAWY



TFKFYMPKKA
ID NO:
HNAKTKPREEQYNSTY
1546)
PGKCLEWVSY
(SEQ
QQKPGKAPK



TELKHLQCLE
30)
RVVSVLTVLHQDWLNG

ISGSGGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL

KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTFMCEYADE

WESNGQPENNYKTTPP

PYYYDIDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

CGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 1544)

NO: 1543)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB223
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGSEGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GSEGGGS
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGS
ISRTPEVTCVVVDVSH
E (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
(SEQ
EDPEVKFNWYVDGVEV
ID NO:
SYWMHWVRQA
GS
SISSSLAWY



TFKFYMPKKA
ID NO:
HNAKTKPREEQYNSTY
1546)
PGKCLEWVSY
(SEQ
QQKPGKAPK



TELKHLQCLE
30)
RVVSVLTVLHQDWLNG

ISGSGGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL

KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTFMCEYADE

WESNGQPENNYKTTPP

PYYYDLDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

CGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 1545)

NO: 1543)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB224
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGGSGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GGSGGGG
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGSGGG
ISRTPEVTCVVVDVSH
S (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
GS
EDPEVKFNWYVDGVEV
ID NO:
SYWMHWVRQA
GS
SISSSLAWY



TFKFYMPKKA
(SEQ
HNAKTKPREEQYNSTY
30)
PGKGLEWVSY
(SEQ
QQKPGKAPK



TELKHLQCLE
ID NO:
RVVSVLTVLHQDWLNG

ISGSGGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL
22)
KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTFMCEYADE

WESNGQPENNYKTTPP

PYYYDMDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

QGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 1445)

NO: 1367)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB225
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGGSGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GGSGGGG
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGSGGG
ISRTPEVTCVVVDVSH
S (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
GS
EDPEVKFNWYVDGVEV
ID NO:
SYWMHWVRQA
GS
SISSSLAWY



TFKFYMPKKA
(SEQ
HNAKTKPREEQYNSTY
30)
PGKGLEWVSY
(SEQ
QQKPGKAPK



TELKHLQCLE
ID NO:
RVVSVLTVLHQDWLNG

ISGSGGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL
22)
KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTFMCEYADE

WESNGQPENNYKTTPP

PYYYDIDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

QGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 1477)

NO: 1367)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB226
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGGSGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GGSGGGG
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGSGGG
ISRTPEVTCVVVDVSH
S (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
GS
EDPEVKFNWYVDGVEV
ID NO:
SYWMHWVRQA
GS
SISSSLAWY



TFKFYMPKKA
(SEQ
HNAKTKPREEQYNSTY
30)
PGKGLEWVSY
(SEQ
QQKPGKAPK



TELKHLQCLE
ID NO:
RVVSVLTVLHQDWLNG

ISGSGGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL
22)
KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTEMCEYADE

WESNGQPENNYKTTPP

PYYYDLDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

QGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 1480)

NO: 1367)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB227
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGGSGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GGSGGGG
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGSGGG
ISRTPEVTCVVVDVSH
S (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
GS
EDPEVKFNWYVDGVEV
ID NO:
SYWMHWVRQA
GS
SISSSLAWY



TFKFYMPKKA
(SEQ
HNAKTKPREEQYNSTY
30)
PGKCLEWVSY
(SEQ
QQKPGKAPK



TELKHLQCLE
ID NO:
RVVSVLTVLHQDWLNG

ISGSGGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL
22)
KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTEMCEYADE

WESNGQPENNYKTTPP

PYYYDMDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

CGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 1542)

NO: 1543)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB228
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGGSGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GGSGGGG
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGSGGG
ISRTPEVTCVVVDVSH
S (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
GS
EDPEVKFNWYVDGVEV
ID NO:
SYWMHWVRQA
GS
SISSSLAWY



TFKFYMPKKA
(SEQ
HNAKTKPREEQYNSTY
30)
PGKCLEWVSY
(SEQ
QQKPGKAPK



TELKHLQCLE
ID NO:
RVVSVLTVLHQDWLNG

ISGSGGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL
22)
KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTFMCEYADE

WESNGQPENNYKTTPP

PYYYDIDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

CGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 1544)

NO: 1543)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB229
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGGSGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GGSGGGG
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGSGGG
ISRTPEVTCVVVDVSH
S (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
GS
EDPEVKFNWYVDGVEV
ID NO:
SYWMHWVRQA
GS
SISSSLAWY



TFKFYMPKKA
(SEQ
HNAKTKPREEQYNSTY
30)
PGKCLEWVSY
(SEQ
QQKPGKAPK



TELKHLQCLE
ID NO:
RVVSVLTVLHQDWLNG

ISGSGGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL
22)
KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTFMCEYADE

WESNGQPENNYKTTPP

PYYYDLDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

CGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 1545)

NO: 1543)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB230
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGSEGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GSEGGGS
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGSGGG
ISRTPEVTCVVVDVSH
E (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
GS
EDPEVKFNWYVDGVEV
ID NO:
SYWMHWVRQA
GS
SISSSLAWY



TFKFYMPKKA
(SEQ
HNAKTKPREEQYNSTY
1546)
PGKGLEWVSY
(SEQ
QQKPGKAPK



TELKHLQCLE
ID NO:
RVVSVLTVLHQDWLNG

ISGSGGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL
22)
KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTEMCEYADE

WESNGQPENNYKTTPP

PYYYDMDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

QGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 1445)

NO: 1367)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB231
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGSEGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GSEGGGS
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGSGGG
ISRTPEVTCVVVDVSH
E (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
GS
EDPEVKFNWYVDGVEV
ID NO:
SYWMHWVRQA
GS
SISSSLAWY



TFKFYMPKKA
(SEQ
HNAKTKPREEQYNSTY
1546)
PGKGLEWVSY
(SEQ
QQKPGKAPK



TELKHLQCLE
ID NO:
RVVSVLTVLHQDWLNG

ISGSGGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL
22)
KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTEMCEYADE

WESNGQPENNYKTTPP

PYYYDIDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

QGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 1477)

NO: 1367)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB232
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGSEGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GSEGGGS
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGSGGG
ISRTPEVTCVVVDVSH
E (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
GS
EDPEVKFNWYVDGVEV
ID NO:
SYWMHWVRQA
GS
SISSSLAWY



TFKFYMPKKA
(SEQ
HNAKTKPREEQYNSTY
1546)
PGKGLEWVSY
(SEQ
QQKPGKAPK



TELKHLQCLE
ID NO:
RVVSVLTVLHQDWLNG

ISGSGGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL
22)
KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTEMCEYADE

WESNGQPENNYKTTPP

PYYYDLDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

QGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 1480)

NO: 1367)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB233
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGSEGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GSEGGGS
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGSGGG
ISRTPEVTCVVVDVSH
E (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
GS
EDPEVKFNWYVDGVEV
ID NO:
SYWMHWVRQA
GS
SISSSLAWY



TFKFYMPKKA
(SEQ
HNAKTKPREEQYNSTY
1546)
PGKCLEWVSY
(SEQ
QQKPGKAPK



TELKHLQCLE
ID NO:
RVVSVLTVLHQDWLNG

ISGSGGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL
22)
KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTEMCEYADE

WESNGQPENNYKTTPP

PYYYDMDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

CGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 1542)

NO: 1543)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB234
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGSEGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GSEGGGS
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGSGGG
ISRTPEVTCVVVDVSH
E (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
GS
EDPEVKFNWYVDGVEV
ID NO:
SYWMHWVRQA
GS
SISSSLAWY



TFKFYMPKKA
(SEQ
HNAKTKPREEQYNSTY
1546)
PGKCLEWVSY
(SEQ
QQKPGKAPK



TELKHLQCLE
ID NO:
RVVSVLTVLHQDWLNG

ISGSGGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL
22)
KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTEMCEYADE

WESNGQPENNYKTTPP

PYYYDIDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

CGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 1544)

NO: 1543)



ID NO: 41)

PG (SEQ ID NO:









21)









MIAB235
APTSSSTKKT
GGGGSG
DKTHTCPPCPAPEAAG
GGGSEGG
EVQLLESGGG
GGGGSG
DIQMTQSPS



QLQLEHLLLD
GGGSGG
APSVFLFPPKPKDTLM
GSEGGGS
LVQPGGSLRL
GGGSGG
SLSASVGDR



LQMILNGINN
GGSGGG
ISRTPEVTCVVVDVSH
E (SEQ
SCAASGFTFS
GGSGGG
VTITCRASQ



YKNPKLTRML
GS
EDPEVKFNWYVDGVEV
ID NO:
SYWMHWVRQA
GS
SISSSLAWY



TFKFYMPKKA
(SEQ
HNAKTKPREEQYNSTY
1546)
PGKCLEWVSY
(SEQ
QQKPGKAPK



TELKHLQCLE
ID NO:
RVVSVLTVLHQDWING

ISGSGGYTNY
ID NO:
LLIYAASSL



EELKPLEEAL
22)
KEYKCKVSNKALPAPI

ADSVKGRFTI
22)
QSGVPSRFS



NLAPSKNFHL

EKTISKAKGQPREPQV

SRDNSKNTLY

GSGSGTDFT



RPRDLISDIN

YTLPPSREEMTKNQVS

LQMNSLRAED

LTISSLQPE



VIVLELKGSE

LTCLVKGFYPSDIAVE

TAVYYCARDR

DFATYYCQQ



TTFMCEYADE

WESNGQPENNYKTTPP

PYYYDLDVWG

YKSYPVTFG



TATIVEFINR

VLDSDGSFFLYSKLTV

KGTTVTVSS

CGTKVEIK



WITFSQSIIS

DKSRWQQGNVFSCSVM

(SEQ ID

(SEQ ID



TLT (SEQ

HEALHNHYTQKSLSLS

NO: 1545)

NO: 1543)



ID NO: 41)

PG (SEQ ID NO:









21)









In some embodiments, the MAdCAM antibody comprises one or more sequences, or a combination thereof, of the sequences presented in Table 11.


In some embodiments, the polypeptide is referred to as an antibody or antigen binding protein.


In some embodiments, as provided for herein, the MAdCAM antibody, or binding fragment thereof, is linked directly or indirectly to a PD-1 antibody or binding fragment thereof.


In some embodiments, as provided for herein, the MAdCAM antibody, or binding fragment thereof, is linked directly or indirectly to an IL-2 mutein or binding fragment thereof. The IL-2 mutein can be any mutein as provided for herein or other IL-2 muteins known to one of skill in the art.


In some embodiments, if the therapeutic compound comprises a Fc portion, the Fc domain, (portion) bears mutations to render the Fc region “effectorless,” that is unable to bind FcRs. The mutations that render Fc regions effectorless are known. In some embodiments, the mutations in the Fc region, which is according to the known numbering system, are selected from the group consisting of K322A, L234A, L235A, G237A, L234F, L235E, N297, P331S, or any combination thereof. In some embodiments, the Fc mutations comprises a mutation at L234 and/or L235 and/or G237. In some embodiments, the Fc mutations comprise L234A and/or L235A mutations, which can be referred to as LALA mutations. In some embodiments, the Fc mutations comprise L234A, L235A, and G237A mutations.


Disclosed herein are Linker Region polypeptides, therapeutic peptides, and nucleic acids encoding the polypeptides (e.g. therapeutic compounds), vectors comprising the nucleic acid sequences, and cells comprising the nucleic acids or vectors


Therapeutic compounds can comprise a plurality of specific targeting moieties. In some embodiments, the therapeutic compound comprises a plurality one specific targeting moiety, a plurality of copies of a donor specific targeting moiety or a plurality of tissue specific targeting moieties. In some embodiments, a therapeutic compound comprises a first and a second donor specific targeting moiety, e.g., a first donor specific targeting moiety specific for a first donor target and a second donor specific targeting moiety specific for a second donor target, e.g., wherein the first and second target are found on the same donor tissue. In some embodiments, the therapeutic compound comprises e.g., a first specific targeting moiety for a tissue specific target and a second specific targeting moiety for a second target, e.g., wherein the first and second target are found on the same or different target tissue.


In some embodiments, a therapeutic compound comprises a plurality of effector binding/modulating moieties each comprising an ICIM binding/modulating moiety, the number of ICIM binding/modulating moieties is sufficiently low that clustering of the ICIM binding/modulating moiety's ligand on immune cells (in the absence of target binding) is minimized, e.g., to avoid systemic agonizing of immune cells in the absence of binding of the therapeutic compound to target.


In some embodiments, the therapeutic compound has the formula from N-terminus to C-terminus:

    • A1-Linker A-A2-Linker B-A3
    • A3-Linker A-A2-Linker B-A1,


      wherein,
    • A1 and A3, each independently comprises an effector binding/modulating moiety, e.g., an ICIM binding/modulating moiety, an IIC binding/modulating moiety, ICSM binding/modulating moiety, or an SM binding/modulating moiety; or a specific targeting moiety,
    • A2 comprises an Fc region or is absent; and
    • Linker A and Linker B, each are independent linkers.


In some embodiments,

    • A1 comprises an IL-2 mutein molecule,
    • A3 comprises a specific targeting moiety, e.g. anti-human MAdCAM Ab, such as a scFv,
    • A2 comprises an Fc region, and


Linker A and Linker B, each are independent linkers further comprising glycine/serine linkers.


In some embodiments, a polypeptide is provided, wherein the polypeptide comprises a peptide of the formula


Ab-ConstantDomain-LinkerA-IL2Mutein-LinkerB-FcRegion, wherein the Ab is a variable heavy chain domain that binds to MAdCAM, the Constant domain is an Ig constant domain such as IgG1, IgG2, IgG3, or IgG4, Linker A is a linker, such as those provided herein, and the IL2Mutein is an IL-2 mutein, such as those provided for herein. In some embodiments, the variable heavy domain is a variable heavy chain domain as illustrated in Table 7. In some embodiments, the variable heavy chain domain comprises the variable heavy chain domain of Clone ID: 6, 75, or 79 of Table 7; MIAB197 of Table 9, or MIAB204 of Table 11. In some embodiments, the variable heavy chain domain comprises the CDRs of the heavy domain of 6, 75, or 79 of Table 7; or MIAB197 of Table 9. In some embodiments, the VH comprises a sequence of SEQ ID NO: 414, SEQ ID NO: 591, SEQ ID NO: 599, and SEQ ID NO: 1387.


In some embodiments, the ConstantDomain comprises a IgG1 constant domain, such as those provided for herein. In some embodiments, the constant domain comprises mutations to render the constant region “effectorless,” that is unable to bind FcRs. The mutations that render constant regions effectorless are known. In some embodiments, the mutations in the constant region, which is according to the known numbering system, are selected from the group consisting of: K322A, L234A, L235A, G237A, L234F, L235E, N297, P331S, or any combination thereof. In some embodiments, the constant region mutations comprises a mutation at L234 and/or L235 and/or G237. In some embodiments, the constant region mutations comprise L234A and/or L235A mutations, which can be referred to as LALA mutations. In some embodiments, the constant region mutations comprise L234A, L235A, and G237A mutations. In some embodiments, the ConstantDomain comprises SEQ ID NO: 44.


In some embodiments, the MAdCAM antibody is selected from the following table:

















TABLE 15





Clone

scFv VK








(scFv)
scFv VH Seq
Seq
HCDR1
HCDR2
HCDR3
LCDR1
LCDR2
LCDR3







MIAB212
EVQLLESGGGL
DIQMTQSPSS
FTFSS
SYISG
CARDR
RASQSI
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
YWMH
SGGYT
PYYYD
SSSLA
(SEQ
PVT



AASGFTFSSYW
ITCRASQSIS
(SEQ
NYA
MDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
SSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
1497)
ID NO:



LEWVSYISGSG
GKAPKLLIYA
NO:
ID
ID
1502)

1498)



GYTNYADSVKG
ASSLQSGVPS
1499)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

1506)
1507)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYDMDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1445)
NO: 1367)











MIAB213
EVQLLESGGGL
DIQMTQSPSS
FTFSS
SYISG
CARDR
RASQSI
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
YWMH
SGGYT
PYYYD
SSSLA
(SEQ
PVT



AASGFTFSSYW
ITCRASQSIS
(SEQ
NYA
IDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
SSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
1497)
ID NO:



LEWVSYISGSG
GKAPKLLIYA
NO:
ID
ID
1502)

1498)



GYTNYADSVKG
ASSLQSGVPS
1499)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

1506)
1531)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYDIDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1477)
NO: 1367)











MIAB214
EVQLLESGGGL
DIQMTQSPSS
FTFSS
SYISG
CARDR
RASQSI
SSLQS
QQYKSY



VQPGGSLRLSC
LSASVGDRVT
YWMH
SGGYT
PYYYD
SSSLA
(SEQ
PVT



AASGFTFSSYW
ITCRASQSIS
(SEQ
NYA
LDVW
(SEQ
ID NO:
(SEQ



MHWVRQAPGKG
SSLAWYQQKP
ID
(SEQ
(SEQ
ID NO:
1497)
ID NO:



LEWVSYISGSG
GKAPKLLIYA
NO:
ID
ID
1502)

1498)



GYTNYADSVKG
ASSLQSGVPS
1499)
NO:
NO:






RFTISRDNSKN
RFSGSGSGTD

1506)
1532)






TLYLQMNSLRA
FTLTISSLQP









EDTAVYYCARD
EDFATYYCQQ









RPYYYDLDVWG
YKSYPVTFGQ









KGTTVTVSS
GTKVEIK









(SEQ ID NO:
(SEQ ID









1480)
NO: 1367)









Alternative CDR notations for the MAdCAM antibody are also provided for in Table 14 for the same heavy and light chain variable domains.


In some embodiments, the variable heavy chain domain comprises a first CDR of SEQ ID NO: 90, a second CDR of SEQ ID NO: 91, and a third CDR of SEQ ID NO: 92. In some embodiments, the variable heavy chain domain comprises a first CDR of SEQ ID NO: 359, a second CDR of SEQ ID NO: 170, and a third CDR of SEQ ID NO: 360. In some embodiments, the variable heavy chain domain comprises a first CDR of SEQ ID NO: 135, a second CDR of SEQ ID NO: 381, and a third CDR of SEQ ID NO: 382. In some embodiments, the variable heavy chain domain comprises a first CDR of SEQ ID NO: 359, a second CDR of SEQ ID NO: 170, and a third CDR of SEQ ID NO: 1431. These are illustrative only and the CDR sets as set forth herein and in the tables are also provided.


In some embodiments, the LinkerA is a glycine/serine linker, which can be any glycine/serine linker provided for herein. In some embodiments, the linker is a sequence of GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 22) or GGGGSGGGGSGGGGS (SEQ ID NO: 30). These are non-limiting examples and the linker can have varying number of GGGGS (SEQ ID NO: 23) or GGGGA repeats (SEQ ID NO: 29), or a mixture of the two. In some embodiments, the linker comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the GGGGS (SEQ ID NO: 23) and/or GGGGA (SEQ ID NO: 29) repeats (repeats disclosed as SEQ ID NOs: 1750 and 1748, respectively, in order of appearance). In some embodiments, the linker is 10 amino acids in length. In some embodiments, the linker is 5 amino acids in length. In some embodiments, the linker is 15 amino acids in length. In some embodiments, the linker is 20 amino acids in length. In some embodiments, the linker is 25 amino acids in length. In some embodiments, the linker is 30 amino acids in length. In some embodiments, the linker is 35 amino acids in length. In some embodiments, the linker is from 5-50 amino acids in length.


In some embodiments, the IL-2 mutein comprises a sequence of SEQ ID NO: 31. In some embodiments, the IL-2 mutein comprises a sequence of SEQ ID NO: 32. In some embodiments, the IL-2 mutein comprises a sequence of SEQ ID NO: 33. In some embodiments, the IL-2 mutein comprises a sequence of SEQ ID NO: 34. In some embodiments, the IL-2 mutein comprises a sequence of SEQ ID NO: 35. In some embodiments, the IL-2 mutein comprises a sequence of SEQ ID NO: 36. In some embodiments, the IL-2 mutein comprises a sequence of SEQ ID NO: 37. In some embodiments, the IL-2 mutein comprises a sequence of SEQ ID NO: 38. In some embodiments, the IL-2 mutein comprises a sequence of SEQ ID NO: 39. In some embodiments, the IL-2 mutein comprises a sequence of SEQ ID NO: 40. In some embodiments, the IL-2 mutein comprises a sequence of SEQ ID NO: 41. In some embodiments, the IL-2 mutein further comprises a T3A substitution (mutation). In some embodiments, the Fc Region comprises a peptide having a sequence of SEQ ID NO: 21. In some embodiments, the Fc Region comprises a peptide having a sequence of SEQ ID NO: 28. In some embodiments, the C-terminus of the Fc Region is linked to the N-terminus or the C-terminus of the variable heavy chain or IL-2 mutein. In some embodiments, the linker linking the Fc Region to the variable heavy chain or the IL-2 mutein is a glycine/serine or a glycine/alanine linker. In some embodiments, the linker linking the Fc region to the C- or N-terminus of the variable heavy chain or IL-2 mutein is a glycine/serine linker, which can be a sequence of GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 22) or GGGGSGGGGSGGGGS (SEQ ID NO: 30). These are non-limiting examples and the linker can have varying number of GGGGS (SEQ ID NO: 23) or GGGGA (SEQ ID NO: 29) repeats (repeats disclosed as SEQ ID NOs: 1750 and 1748, respectively, in order of appearance), or a mixture of the two. In some embodiments, the linker comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the GGGGS (SEQ ID NO: 23) and/or GGGGA (SEQ ID NO: 29) repeats. In some embodiments, the linker is 10 amino acids in length. In some embodiments, the linker is 5 amino acids in length. In some embodiments, the linker is 15 amino acids in length. In some embodiments, the linker is 20 amino acids in length. In some embodiments, the linker is 25 amino acids in length. In some embodiments, the linker is 30 amino acids in length. In some embodiments, the linker is 35 amino acids in length. In some embodiments, the linker is from 5-50 amino acids in length.


In some embodiments, the polypeptide further comprises a polypeptide of formula VL-ConstantDomainLight, wherein VL is a variable light chain and ConstantDomainLight is a IgG light chain constant domain, wherein the polypeptide can be or is associated with the polypeptide having the formula of Ab-ConstantDomain-LinkerA-IL2Mutein-LinkerB-FcRegion. In some embodiments, the VL comprises one or any sequence of Table 7, Table 9, or Table 12.


In some embodiments, the constant domain also comprises mutations to negate the effector function, such as those provided for herein. In some embodiments, the ConstantDomainLight comprises a sequence of:









(SEQ ID NO: 45)


RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG





NSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTK





SFNRGEC






The different polypeptides of formula IL2Mutein-LinkerA-FcRegion-LinkerB-Ab and VL-ConstantDomainLight can be interchanged with one another.


In some embodiments, compounds are provided comprising the following formula, from N-terminus to C-terminus:


IL2Mutein-LinkerA-FcRegion-LinkerB-Ab, wherein the IL2Mutein is any IL-2 mutein that can, for example, preferentially activate Tregs; the LinkerA and Linker B are, each, independently, a linker as provided herein, the Fc Region can any one of such as provided herein, and the Ab is a tissue targeting moiety, such as those provided herein. In some embodiments, the Ab is an antibody that binds to MAdCAM or another cell surface target as provided herein. In some embodiments, the antibody is in a scFV format. In some embodiments, the antibody in scFV format is an antibody as provided in the Table 6 or Table 14. In some embodiments, the antibody in scFV format is an antibody that comprises the CDRs as set forth in Table 6, Table 7, Table 11, or Table 14.


In some embodiments, the C-terminus of the IL-2 mutein is linked to the N-terminus of the Fc region. In some embodiments, the linkage is direct or through a linker, such as those described herein. In some embodiments, the linker is a glycine/serine linker. In some embodiments, the linker linking the IL-2 mutein to the Fc region is a glycine/serine linker. In some embodiments, the glycine/serine linker comprises or consists of a sequence of GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 22) or GGGGSGGGGSGGGGS (SEQ ID NO: 30). These are non-limiting examples and the linker can have varying number of GGGGS (SEQ ID NO: 23) or GGGGA (SEQ ID NO: 29) repeats, or a mixture of the two. In some embodiments, the linker comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the GGGGS (SEQ ID NO: 23) and/or GGGGA (SEQ ID NO: 29) repeats (repeats disclosed as SEQ ID NOs: 1750 and 1748, respectively, in order of appearance). In some embodiments, the linker is 10 amino acids in length. In some embodiments, the linker is 5 amino acids in length. In some embodiments, the linker is 15 amino acids in length. In some embodiments, the linker is 20 amino acids in length. In some embodiments, the linker is 25 amino acids in length. In some embodiments, the linker is 30 amino acids in length. In some embodiments, the linker is 35 amino acids in length. In some embodiments, the linker is from 5-50 amino acids in length.


In some embodiments, the IL-2 mutein comprises a sequence of SEQ ID NO: 31. In some embodiments, the IL-2 mutein comprises a sequence of SEQ ID NO: 32. In some embodiments, the IL-2 mutein comprises a sequence of SEQ ID NO: 33. In some embodiments, the IL-2 mutein comprises a sequence of SEQ ID NO: 34. In some embodiments, the IL-2 mutein comprises a sequence of SEQ ID NO: 35. In some embodiments, the IL-2 mutein comprises a sequence of SEQ ID NO: 36. In some embodiments, the IL-2 mutein comprises a sequence of SEQ ID NO: 37. In some embodiments, the IL-2 mutein comprises a sequence of SEQ ID NO: 38. In some embodiments, the IL-2 mutein comprises a sequence of SEQ ID NO: 39. In some embodiments, the IL-2 mutein comprises a sequence of SEQ ID NO: 40. In some embodiments, the IL-2 mutein comprises a sequence of SEQ ID NO: 41. In some embodiments, the IL-2 mutein further comprises a T3A substitution (mutation). In some embodiments, the Fc Region comprises a peptide having a sequence of SEQ ID NO: 21. In some embodiments, the Fc Region comprises a peptide having a sequence of SEQ ID NO: 28. In some embodiments, the C-terminus of the Fc Region is linked to the N-terminus of the variable heavy chain. In some embodiments, the linker linking the Fc Region to the variable heavy chain is a glycine/serine or a glycine/alanine linker. In some embodiments, the linker linking the Fc region to the N-terminus of the variable heavy chain is a glycine/serine linker, which can be a sequence of GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 22) or GGGGSGGGGSGGGGS (SEQ ID NO: 30). These are non-limiting examples and the linker can have varying number of GGGGS (SEQ ID NO: 23) or GGGGA (SEQ ID NO: 29) repeats, or a mixture of the two. In some embodiments, the linker comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the GGGGS (SEQ ID NO: 23) and/or GGGGA (SEQ ID NO: 29) repeats (repeats disclosed as SEQ ID NOs: 1750 and 1748, respectively, in order of appearance). In some embodiments, the linker is 10 amino acids in length. In some embodiments, the linker is 5 amino acids in length. In some embodiments, the linker is 15 amino acids in length. In some embodiments, the linker is 20 amino acids in length. In some embodiments, the linker is 25 amino acids in length. In some embodiments, the linker is 30 amino acids in length. In some embodiments, the linker is 35 amino acids in length. In some embodiments, the linker is from 5-50 amino acids in length.


In some embodiments, the variable heavy chain comprises the CDRs as set forth in Table 6, Table 7, Table 9, or Table 14. In some embodiments, the variable heavy chain comprises a HCDR1, HCDR2, and a HCDR3, wherein the HCDR1, HCDR2, and a HCDR3 are as set forth in Table 6, Table 7, Table 9, or Table 14. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 1 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 2 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 3 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 4 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 5 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 6 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 7 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 8 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 9 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 10 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 11 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 12 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 13 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 14 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 15 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 16 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 17 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 1 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 18 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 19 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 20 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 21 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 22 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 23 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 24 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 25 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 26 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 27 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 28 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 29 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 30 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 31 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 32 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 33 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 34 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 35 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 36 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 37 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 38 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 39 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 40 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 41 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 42 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 43 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 44 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 45 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 46 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 47 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 48 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 49 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 50 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 51 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 52 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 53 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 54 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 55 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 56 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 57 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 58 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 59 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 60 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 61 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 62 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 63 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 64 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 65 in Table 6. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 66 in Table 6.


In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 1 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 2 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 3 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 4 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 5 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 6 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 7 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 8 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 9 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 10 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 11 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 12 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 13 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 14 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 15 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 16 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 17 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 1 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 18 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 19 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 20 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 21 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 22 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 23 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 24 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 25 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 26 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 27 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 28 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 29 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 30 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 31 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 32 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 33 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 34 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 35 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 36 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 37 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 38 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 39 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 40 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 41 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 42 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 43 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 44 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 45 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 46 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 47 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 48 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 49 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 50 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 51 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 52 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 53 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 54 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 55 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 56 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 57 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 58 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 59 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 60 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 61 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 62 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 63 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 64 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 65 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 66 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 67 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 68 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 69 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 70 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 71 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 72 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 73 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 74 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 75 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 76 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 77 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 78 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 79 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 80 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 81 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 82 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 83 in Table 7. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for Clone 84 in Table 7.


In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB128 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB128A in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB129 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB130 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB131 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB132 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB133 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB134 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB135 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB136 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB137 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB138 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB139 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB140 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB141 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB142 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB143 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB144 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB145 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB146 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB147 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB148 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB149 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB150 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB151 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB152 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB153 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB154 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB155 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB156 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB157 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB158 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB159 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB160 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB161 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB162 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB163 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB164 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB165 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB166 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB167 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB168 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB169 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB170 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB171 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB172 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB173 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB174 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB175 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB176 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB177 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB178 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB179 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB180 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB181 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB182 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB183 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB184 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB185 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB186 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB187 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB188 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB189 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB190 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB191 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB192 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB193 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB194 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB195 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB196 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB197 in Table 9. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB198 in Table 9.


In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for PMAB61 in Table 14. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for PMAB62 in Table 14. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for PMAB63 in Table 14. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for PMAB64 in Table 14. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for PMAB65 in Table 14. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for PMAB66 in Table 14. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for PMAB67 in Table 14. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for PMAB68 in Table 14.


In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB212 in Table 15. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB213 in Table 15. In some embodiments, the variable heavy chain has a HCDR1, HCDR2, and a HCDR3 as set forth for MIAB214 in Table 15.


In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 1 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 2 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 3 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 4 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 5 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 6 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 7 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 8 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 9 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 10 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 11 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 12 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 13 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 14 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 15 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 16 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 17 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 1 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 18 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 19 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 20 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 21 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 22 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 23 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 24 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 25 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 26 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 27 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 28 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 29 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 30 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 31 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 32 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 33 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 34 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 35 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 36 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 37 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 38 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 39 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 40 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 41 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 42 in Table 6. In some embodiments, the light heavy chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 43 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 44 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 45 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 46 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 47 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 48 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 49 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 50 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 51 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 52 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 53 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 54 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 55 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 56 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 57 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 58 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 59 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 60 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 61 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 62 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 63 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 64 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 65 in Table 6. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 66 in Table 6.


In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 1 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 2 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 3 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 4 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 5 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 6 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 7 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 8 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 9 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 10 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 11 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 12 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 13 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 14 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 15 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 16 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 17 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 1 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 18 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 19 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 20 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 21 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 22 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 23 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 24 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 25 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 26 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 27 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 28 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 29 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 30 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 31 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 32 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 33 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 34 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 35 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 36 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 37 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 38 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 39 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 40 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 41 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 42 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 43 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 44 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 45 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 46 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 47 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 48 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 49 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 50 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 51 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 52 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 53 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 54 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 55 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 56 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 57 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 58 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 59 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 60 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 61 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 62 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 63 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 64 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 65 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 66 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 67 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 68 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 69 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 70 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 71 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 72 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 73 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 74 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 75 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 76 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 77 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 78 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 79 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 80 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 81 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 82 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 83 in Table 7. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for Clone 84 in Table 7.


In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB128 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB128A in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB129 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB130 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB131 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB132 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB133 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB134 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB135 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB136 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB137 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB138 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB139 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB140 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB141 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB142 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB143 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB144 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB145 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB146 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB147 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB148 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB149 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB150 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB151 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB152 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB153 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB154 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB155 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB156 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB157 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB158 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB159 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB160 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB161 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB162 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB163 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB164 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB165 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB166 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB167 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB168 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB169 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB170 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB171 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB172 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB173 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB174 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB175 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB176 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB177 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB178 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB179 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB180 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB181 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB182 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB183 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB184 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB185 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB186 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB187 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB188 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB189 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB190 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB191 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB192 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB193 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB194 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB195 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB196 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB197 in Table 9. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB198 in Table 9.


In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for PMAB61 in Table 14. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for PMAB62 in Table 14. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for PMAB63 in Table 14. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for PMA64 in Table 14. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for PMAB65 in Table 14. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for PMAB66 in Table 14. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for PMAB67 in Table 14. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for PMAB68 in Table 14.


In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB212 in Table 15. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB213 in Table 15. In some embodiments, the variable light chain has a LCDR1, LCDR2, and a LCDR3 as set forth for MIAB214 in Table 15.


In some embodiments, the CDRS are swapped for one another. For example, the HCDR1 of clone 1 can be substituted for the HCDR1 of clone 10, or vice versa. This CDR swapping can be done for any of the HCDRs of the clones provided herein (e.g., HCDR1 for HCDR1; HCDR2 for HCDR2; or HCDR3 for HCDR3) or the LCDRs (e.g., LCDR1 for LCDR1; LCDR2 for LCDR2; or LCDR3 for LCDR3). Therefore, in some embodiments, the antibody comprises a HCDR1 as set forth in any of Clones 1-66 of Table 6, Clones 1-84 of Table 7, MIAB128-198 of Table 9, or PMAB61-68 of Table 13 or Table 14; a HCDR2 as set forth in any of Clones 1-66 of Table 6, Clones 1-84 of Table 7, MIAB128-198 of Table 9, or PMAB61-68 of Table 13 or Table 14; a HCDR3 as set forth in any of Clones 1-66 of Table 6, Clones 1-84 of Table 7, MIAB128-198 of Table 9, or PMAB61-68 of Table 13 or Table 14; a LCDR1 as set forth in any of Clones 1-66 of Table 6, Clones 1-84 of Table 7, MIAB128-198 of Table 9, or PMAB61-68 of Table 13 or Table 14; a LCDR2 as set forth in any of Clones 1-66 of Table 6, Clones 1-84 of Table 7, MIAB128-198 of Table 9, or PMAB61-68 of Table 13 or Table 14; a LCDR3 as set forth in any of Clones 1-66 of Table 6, Clones 1-84 of Table 7, MIAB128-198 of Table 9, or PMAB61-68 of Table 13 or Table 14, or a variant of any of the foregoing.


In some embodiments, the MAdCAM Antibody is a scFV format as shown in clones 6, 59, 63, MIAB199, MIAB200, MIAB201, MIAB202, MIAB203, MIAB204, or PMAB61-231. The linker as shown in those sequences is 20 amino acid residues in length, but could also be 5, 10, or 15 amino acid residues in length. In some embodiments, the linker the links the VH and VL(or VK) sequences of the antibody is a glycine/serine linker, which can be a sequence of GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 22) or GGGGSGGGGSGGGGS (SEQ ID NO: 30). This is simply a non-limiting example and the linker can have varying number of GGGGS (SEQ ID NO: 23) or GGGGA repeats (SEQ ID NO: 29). In some embodiments, the linker comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the GGGGS (SEQ ID NO: 23) or GGGGA (SEQ ID NO: 29) repeats (repeats disclosed as SEQ ID NOs: 1750 and 1748, respectively, in order of appearance). Thus, the linkers shown in Table 6 are non-limiting examples and can be substituted with any other linkers, such as those provided for herein.


In some embodiments, the polypeptide comprises the formula of:









APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA





TELKHLQCLEEELKPLEEALNLAPSKNFHLRPRDLISDINVIVLELKGSE





TTFMCEYADETATIVEFINRWITFSQSIISTLT-Linker1-





DKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED





PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK





CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK





GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG





NVESCSVMHEALHNHYTQKSLSLSPG-Linker2-Ab (SEQ ID NOs:





1745 and 1746, respectively, in order of





appearance),







wherein Linker 1, Linker2, and Ab are as provided herein. In some embodiments, Linker 1 is GGGGSGGGGSGGGGS (SEQ ID NO: 30) or GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 22). In some embodiments, Linker 2 is GGGGS (SEQ ID NO: 23). In some embodiments, Linker 2 is GGGGSGGGGS (SEQ ID NO: 619). In some embodiments, Linker 2 is GGGGSGGGGSGGGGS (SEQ ID NO: 30). In some embodiments, Ab is the scFV as set forth in Table 6, Table 12, or Table 14. In some embodiments, the Ab comprises a sequence of SEQ ID NO: 95. In some embodiments, the Ab comprises a sequence of SEQ ID NO: 364. In some embodiments, the Ab comprises a sequence of SEQ ID NO: 386. In some embodiments, the Ab comprises a sequences of SEQ ID NOs: 1478, 44, 30, 1445, 22, 1367, 1479, 45. In some embodiments, the Ab comprises a sequences of SEQ ID NOs: 1476, 44, 30, 1445, 22, 1367, 1359, 45. In some embodiments, the Ab comprises a VH and a VK or VL segment. In some embodiments, the VH comprises a sequence as set forth in Table 7, Table 9, Table 10, or Table 12. In some embodiments, the VK comprises a sequence as set forth in Table 7, Table 9, Table 10, or Table 12. In some embodiments, the Ab comprises a VH and a VK as set forth for the clones in Table 7, Table 9, Table 10, or Table 12. In some embodiments, the VH and VK are linked by a linker. In some embodiments, the VH and VK are linked by a peptide linker comprising a peptide of GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 22). In some embodiments, the VH and VK are linked by a peptide linker comprising a peptide of GGGGS (SEQ ID NO: 23). In some embodiments, the VH and VK are linked by a peptide linker comprising a peptide of GGGGSGGGGS (SEQ ID NO: 619). In some embodiments, the VH and VK are linked by a peptide linker comprising a peptide of GGGGSGGGGSGGGGS (SEQ ID NO: 30).


In some embodiments, the Ab comprises a VH of SEQ ID NO: 414 and a VK of SEQ ID NO: 415. In some embodiments, the Ab comprises a VH of SEQ ID NO: 591 and a VK of SEQ ID NO: 592. In some embodiments, the Ab comprises a VH of SEQ ID NO: 599 and a VK of SEQ ID NO: 600. In some embodiments, the Ab comprises a VH of SEQ ID NO: 1478 and a VK of SEQ ID NO: 1479. In some embodiments, the Ab comprises a VH of SEQ ID NO: 1445 and a VK of SEQ ID NO: 1367. In some embodiments, the Ab comprises a VH of SEQ ID NO: 1476 and a VK of SEQ ID NO: 1359.


In some embodiments, the peptide comprises:









(SEQ ID NO: 1747)


APTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA





TELKHLQCLEEELKPLEEALNLAPSKNFHLRPRDLISDINVIVLELKGSE





TTFMCEYADETATIVEFINRWITFSQSIISTLT- (GGGGSGGGGSGGGG





S or GGGGSGGGGSGGGGSGGGGS) -DKTHTCPPCPAPEAAGAPSVFL





FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPR





EEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ





PREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK





TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS





LSPG- (GGGGS or GGGGSGGGGS or GGGGSGGGGSGGGGS)-Ab,







wherein Ab is set forth as herein. In some embodiments, the Ab comprises a sequence of SEQ ID NO: 95. In some embodiments, the Ab comprises a sequence of SEQ ID NO: 364. In some embodiments, the Ab comprises a sequence of SEQ ID NO: 386. In some embodiments, the Ab comprises a VH and a VK or VL segment. In some embodiments, the VH comprises a sequence as set forth in Table 7, Table 9, Table 10, Table 12, or Table 14. In some embodiments, the VK comprises a sequence as set forth in Table 7, Table 9, Table 10, Table 12, or Table 14. In some embodiments, the Ab comprises a VH and a VK as set forth for the clones in Table 7, Table 9, Table 10, Table 12, or Table 14. In some embodiments, the VH and VK are linked by a linker. In some embodiments, the VH and VK are linked by a peptide linker comprising a peptide of GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 22). In some embodiments, the VH and VK are linked by a peptide linker comprising a peptide of GGGGS (SEQ ID NO: 23). In some embodiments, the VH and VK are linked by a peptide linker comprising a peptide of GGGGSGGGGS (SEQ ID NO: 619).


In some embodiments, the Ab comprises a VH of SEQ ID NO: 414 and a VK of SEQ ID NO: 415. In some embodiments, the Ab comprises a VH of SEQ ID NO: 591 and a VK of SEQ ID NO: 592. In some embodiments, the Ab comprises a VH of SEQ ID NO: 599 and a VK of SEQ ID NO: 600. In some embodiments, the Ab comprises a VH of SEQ ID NO: 1478 and a VK of SEQ ID NO: 1479. In some embodiments, the Ab comprises a VH of SEQ ID NO: 1445 and a VK of SEQ ID NO: 1367. In some embodiments, the Ab comprises a VH of SEQ ID NO: 1476 and a VK of SEQ ID NO: 1359. These examples are non-limiting the combinations of VH and VK as shown in Table 7, Table 9, Table 10, or Table 12 are also provided.


In some embodiments, the therapeutic compound or polypeptide comprises a formula of an anti-PD-1 heavy and light chain, wherein the PD-1 heavy chain is linked to a MAdCAM antibody (scFV), such as those provided herein at the C-terminus of the PD-1 IgG heavy chain. The polypeptide can have the formula of A1-A2-Linker1-A4-Linker2-A5 and A6, wherein A1 is a PD-1 heavy chain, A6 is a PD-1 light chain; A2 is a IgG constant domain (e.g. IgG1 Constant domain), Linker 1 is as provided herein, such as, but not limited to, a glycine/serine linker, which can be a sequence of GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 22) or GGGGSGGGGSGGGGS (SEQ ID NO: 30), or GGGSEGGGSEGGGSE (SEQ ID NO: 1546) which are simply a non-limiting example and the linker can have varying number of GGGGS (SEQ ID NO: 23) or GGGGA (SEQ ID NO: 29) repeats and in some embodiments, the linker comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the GGGGS (SEQ ID NO: 23) or GGGGA (SEQ ID NO: 29) repeats (repeats disclosed as SEQ ID NOs: 1750 and 1748, respectively, in order of appearance); A4 is VH domain, such as those set forth in Table 7 or Table 12; Linker 2 is as provided herein, such as, but not limited to, a glycine/serine linker, which can be a sequence of GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 22) or GGGGSGGGGSGGGGS (SEQ ID NO: 30), which are simply a non-limiting example and the linker can have varying number of GGGGS (SEQ ID NO: 23) or GGGGA (SEQ ID NO: 29) repeats, and in some embodiments, the linker comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the GGGGS (SEQ ID NO: 23) or GGGGA (SEQ ID NO: 29) repeats (repeats disclosed as SEQ ID NOs: 1750 and 1748, respectively, in order of appearance); and A5 is VK/VL domain, such as those set forth in Table 7 or Table 12. In some embodiments, Linker 2 is GGGGSGGGGSGGGGS (SEQ ID NO: 30). In some embodiments, the A4-Linker2-A5 is a scFV antibody, such as those set forth in Table 6. The linkers shown in Table 6 can be substituted with the linker of GGGGSGGGGSGGGGS (SEQ ID NO: 30). In some embodiments, the A4-Linker2-A5 comprises the HCDR sets (e.g., HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3) sets as set forth in Table 6, Table 7 or Table 12. For the avoidance of doubt, a CDR set refers to the CDRs illustrated for each of the different antibody clones provided for in the tables. In some embodiments, A4 comprises a peptide of SEQ ID NO: 414 and A5 comprises a peptide of SEQ ID NO: 415. In some embodiments, A4 comprises a peptide of SEQ ID NO: 591 and A5 comprises a peptide of SEQ ID NO: 592. In some embodiments, A4 comprises a peptide of SEQ ID NO: 599 and A5 comprises a peptide of SEQ ID NO: 600. In some embodiments, A4 comprises a peptide of SEQ ID NO: 1445 and A5 comprises a peptide of SEQ ID NO: 1367. These examples are non-limiting the combinations of VH and VK as shown in Table 7, or Table 12 are also provided.


In some embodiments, A2 comprises a sequence of









(SEQ ID NO: 44)


ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV





HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP





KSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVS





HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK





EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC





LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW





QQGNVFSCSVMHEALHNHYTQKSLSLSPG.






In some embodiments, once expressed the heavy and light chains of the PD-1 antibody bind to one another to form the compound comprising the anti-PD-1 antibody linked to the anti-MAdCAM antibody. The anti-MAdCAM antibody can be any antibody that binds to MAdCAM, such as those provided for herein.


In some embodiments, the therapeutic compound comprises one or more sequences selected from the sequence in the following table:











TABLE 12








Chain 1
Chain 2
















Fab VH

Linker
scFv VH
Linker
scFv VK
Fab VK
CK


Clone
Seq
CH1-CH3 Seq
Seq
Seq
Seq
Seq
Seq
Seq





PMAB61
EVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
TCRASQS
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
ISSYLAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIINPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO:

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV

1445)

1367)
1479)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1478)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB62
EVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
TCRASQS
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
ISSYLAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIINPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

DLDVWGKG

KSYPVTF
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO:

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV

1480)

1367)
1479)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1478)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB63
EVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
TCRASQS
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
ISSYLAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKCLEWV
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIINPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

DLDVWGKG

KSYPVTE
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GCGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO:

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV

1545)

1543)
1479)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1478)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB64
EVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
TCRASQS
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
ISSYLAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKCLEWV
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIINPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTE
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GCGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO:

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV

1542)

1543)
1479)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1478)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB65
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1476)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB66
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DLDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1480)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1476)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB67
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKCLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DLDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GCGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1545)

1543)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1476)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB68
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKCLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GCGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1542)

1543)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1476)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB69
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



HDSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1547)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB70
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYAMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGISGS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1548)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB71
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYSMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SAISGS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1549)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB72
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYSMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGISGS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1550)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB73
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SAISGS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1551)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB74
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GQSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1552)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB75
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GWSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1553)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB76
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWFDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1554)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB77
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGKGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1555)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB78
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



YYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1556)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB79
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGDTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1557)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB80
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGNTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1558)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB81
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFPFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1559)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB82
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRFSG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1560)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1476)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB83
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRKSG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1561)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1476)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB84
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTWG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1562)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1476)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB85
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPHN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1563)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1476)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB86
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSYS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1564)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1476)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB87
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
LTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1565)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1476)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB88
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TQPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1566)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1476)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB89
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRFSG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTWG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWFDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1567)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1554)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB90
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYKMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGATYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGAGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGFLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1568)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB91
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYAMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGFLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1569)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB92
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYRMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1570)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB93
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYNMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1571)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB94
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYQMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1572)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB95
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYRMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1570)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB96
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYWMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1573)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB97
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



NSAMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQGY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1575)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1574)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB98
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYAMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQGY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGELDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1575)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1569)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB99
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQAY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1576)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1476)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB100
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQGY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1575)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1476)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB101
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQMY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1577)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1476)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB102
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQTY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1578)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1476)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB103
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQVY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1579)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1476)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB104
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYAMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIQ
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQGY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1575)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1580)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB105
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYAMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TGPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



AGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1582)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1581)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB106
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
TCQASRD
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
IKNYLAW
GTASV



TYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIINPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO:

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV

1445)

1367)
1449)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1583)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB107
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
TCQASRD
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
IKNYLAW
GTASV



TYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIIQPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO:

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV

1445)

1367)
1449)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1584)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB108
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
TCQASRD
EQLKS



SGYTFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
IKNYLAW
GTASV



TYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV



592)
1449)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1585)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB109
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
TCQASRD
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
IKNYLAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV



592)
1449)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1586)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB110
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
TCQASRD
EQLKS



SGYTFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
IKNYLAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV



592)
1449)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1587)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB111
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
TCRASRD
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
IKNYLAW
GTASV



TYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV



592)
1589)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1588)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB112
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
TCQASQD
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
IKNYLAW
GTASV



TYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV



592)
1590)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1588)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB113
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
TCQASRS
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
IKNYLAW
GTASV



TYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV



592)
1591)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1588)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB114
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
TCQASRD
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISNYLAW
GTASV



TYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV



592)
1592)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1588)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB115
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
TCQASRD
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
IKSYLAW
GTASV



TYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV



592)
1593)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1588)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB116
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
TCQASRD
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
IKNYLNW
GTASV



TYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV



592)
1594)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1588)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB117
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
TCQASRD
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
IKNYLAW
GTASV



TYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YSTPRTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV



592)
1595)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1588)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB118
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
TCRASQS
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISSYLNW
GTASV



TYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YSTPRTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV



592)
1596)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1588)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB119
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
TCQASRD
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
IKNYLAW
GTASV



TYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV



592)
1449)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1588)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB120
EVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
TCRASQS
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
ISSYLAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GAINPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTE
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO:

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV

1445)

1367)
1479)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1597)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB121
EVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
TCRASQS
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
ISSYLAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIINPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTE
YSTPPTF
YSLSS



SLNSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO:

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV

1445)

1367)
1479)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1598)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB122
EVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
TCRASQS
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
ILSYLAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIINPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTE
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO:

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV

1445)

1367)
1599)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1478)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB123
EVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
TCRASQS
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
INSYLAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIINPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTE
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO:

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV

1445)

1367)
1600)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1478)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB124
EVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
TCRASQS
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
ISSYLAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
YQQKPGA
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIINPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTE
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO:

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV

1445)

1367)
1601)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1478)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB125
EVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
TCRASQS
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
ISSYLAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
YQQKPGN
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIINPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTE
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO:

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV

1445)

1367)
1602)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1478)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB126
EVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
TCRASQS
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
ISSYLAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
YQQKPGS
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIINPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTE
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO:

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV

1445)

1367)
1603)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1478)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB127
EVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDTVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
TCRASQS
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
ISSYLAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIINPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTE
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO:

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV

1445)

1367)
1604)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1478)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB128
EVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
TCRASQS
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
ISSYLAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
APKLLIA
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIINPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTE
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO:

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV

1445)

1367)
1605)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1478)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB129
EVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
TCQASRD
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
IKNYLAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIINPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTE
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO:

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV

1445)

1367)
1449)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1478)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB130
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
TCQASRD
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
IKNYLAW
GTASV



TYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
YQQKPGK
VCLLN



WVRQAP
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
APKLLIY
NFYPR



GKGLEW
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



MGIINP
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



SGGSTS
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



YADSVK
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



GRFTIS
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



RDNSKN
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



TLYLQM
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTE
YSTPPTF
YSLSS



NSLRAE
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



DTAVYY
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



CASGWV
QPREPQVYTLPPSR

NO:

ID NO:
ID NO:
KHKVY



YWGQGT
EEMTKNQVSLTCLV

1445)

1367)
1449)
ACEVT



TVTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1606)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB131
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCQASRD
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
IKNYLAW
GTASV



TYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
YQQKPGQ
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
PPKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPDRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQAEDVA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
VYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTE
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GQGTRLE
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO:

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV

1445)

1367)
1607)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1588)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB132
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCQASRD
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
IKNYLAW
GTASV



TYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
YQQKPGQ
VCLLN



WVRQAP
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
PPKLLIY
NFYPR



GKGLEW
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



MGIINP
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPDRFS
WKVDN



SGGSTS
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



YADSVK
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



GRFTIS
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQAEDVA
VTEQD



RDNSKN
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
VYYCQQS
SKDST



TLYLQM
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTE
YSTPPTF
YSLSS



NSLRAE
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GQGTRLE
TLTLS



DTAVYY
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



CASGWV
QPREPQVYTLPPSR

NO:

ID NO:
ID NO:
KHKVY



YWGQGT
EEMTKNQVSLTCLV

1445)

1367)
1607)
ACEVT



TVTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1606)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB133
EVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCQASRD
EQLKS



SGYSFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
IKNYLAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
YQQKPGQ
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
PPKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GIINPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPDRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQAEDVA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
VYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTE
YSTPPTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GQGTRLE
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



ASGWVY
QPREPQVYTLPPSR

NO:

ID NO:
ID NO:
KHKVY



WGQGTL
EEMTKNQVSLTCLV

1445)

1367)
1607)
ACEVT



VTVSS
KGFYPSDIAVEWES





HQGLS



(SEQ
NGQPENNYKTTPPV





SPVTK



ID NO:
LDSDGSFFLYSKLT





SFNRG



1478)
VDKSRWQQGNVFSC





EC




SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB134
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1438)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB135
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



SSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1608)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB136
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1609)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB137
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSAMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1574)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB138
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SAITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1610)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB139
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGISIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1611)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB140
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITGS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1612)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB141
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



SYAMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SAISGS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1613)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB142
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSSNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1614)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1438)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB143
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
STPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1615)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1438)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB144
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPLTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1616)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1438)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB145
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSSNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
STPLTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1617)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1438)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB146
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTA
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1618)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB147
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGETFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTD
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1619)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB148
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTS
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1620)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB149
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGSGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1621)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB150
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGTGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1622)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB151
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGALDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1623)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB152
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGDLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1624)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB153
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSSNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
STPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




598)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1438)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB154
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
SNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1625)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1438)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB155
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYD
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1626)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1438)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB156
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYS
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1627)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1438)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB157
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLASPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1628)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1438)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB158
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNTLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1629)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1438)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB159
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLISW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1630)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1438)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB160
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYE
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1631)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1438)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB161
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYS
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1632)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1438)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB162
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



AASVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1633)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB163
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



AQSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1634)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB164
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVRG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1635)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB165
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



ASDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1636)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB166
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



QSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1637)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB167
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSSNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
RNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
STPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1638)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1438)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB168
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSSNA
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
RNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
STPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1639)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1438)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB169
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSSNA
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
STPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1640)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1438)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB170
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSSNQ
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
RNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
STPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1641)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1438)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB171
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSSNQ
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
STPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1642)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1438)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB172
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSSNN
GTASV



SYAMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SAISGS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1614)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1613)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB173
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



SYAMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SAISGS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
STPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1615)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1613)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB174
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSSNN
GTASV



SYAMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SAISGS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
STPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




598)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1613)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB175
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1643)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB176
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SAITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1644)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB177
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGISIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1645)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB178
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITGS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1646)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB179
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SAISIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1647)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB180
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SAITGS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1648)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB181
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGISGS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1649)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB182
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



SYAMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGISGS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1650)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB183
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SAISGS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1651)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB184
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SAISGS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1652)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB185
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSSNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SAISIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
STPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




598)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1647)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB186
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSSNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SAITGS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
STPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




598)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1648)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB187
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSSNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGISGS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
STPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




598)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1649)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB188
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSSNN
GTASV



SYAMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGISGS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
STPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




598)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1650)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB189
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSSNN
GTASV



NSDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SAISGS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
STPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




598)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1651)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB190
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSDF
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
VLYSSNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SAISGS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
STPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO: 591)

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV



592)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




598)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1652)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB191
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYGY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1443)

1367)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1643)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB192
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYGY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1443)

1367)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1643)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB193
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSSNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYGY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
STPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1443)

1367)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




598)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1643)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB194
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSSNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYGY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1443)

1367)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1614)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1643)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB195
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYGY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
STPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1443)

1367)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1615)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1643)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB196
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1643)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB197
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTL
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1643)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB198
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYGY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1443)

1367)
ID NO:
ACEVT



WGQGTD
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1653)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB199
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYGY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1443)

1367)
ID NO:
ACEVT



WGQGTT
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1476)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB200
EVQLLE
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIVMTQS
RTVAA



SGGGLV
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PDSLAVS
PSVFI



QPGGSL
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
LGERATI
FPPSD



RLSCAA
SGALTSGVHTFPAV
(SEQ
SGFTFSSY
GS
TCRASQS
NCKSSQS
EQLKS



SGFTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
ISSSLAW
VLYSPNN
GTASV



SYDMSW
VPSSSLGTQTYICN
30)
PGKGLEWV
ID NO:
YQQKPGK
KNYLAWY
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGSGG
22)
APKLLIY
QQKPGQP
NFYPR



KGLEWV
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
PKLLIYW
EAKVQ



SGITIS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
ASTRESG
WKVDN



GGSTYY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
VPDRFSG
ALQSG



ADSVKG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
SGSGTDF
NSQES



RFTISR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
TLTISSL
VTEQD



DNSKNT
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
QAEDVAV
SKDST



LYLQMN
YRVVSVLTVLHQDW

DMDVWGKG

KSYPVTF
YYCQQYY
YSLSS



SLRAED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
TTPPTFG
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
QGTRLEI
KADYE



ARGRGG
QPREPQVYTLPPSR

NO:

ID NO:
K (SEQ
KHKVY



SGWLDY
EEMTKNQVSLTCLV

1445)

1367)
ID NO:
ACEVT



WGQGTD
KGFYPSDIAVEWES




1359)
HQGLS



VTVSS
NGQPENNYKTTPPV





SPVTK



(SEQ
LDSDGSFFLYSKLT





SFNRG



ID NO:
VDKSRWQQGNVFSC





EC



1653)
SVMHEALHNHYTQK





(SEQ




SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB201
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISNWVAW
GTASV



DHYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGRTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1655)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1654)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB202
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTES
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISNWVAW
GTASV



SHYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGRTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1655)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1656)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB203
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTES
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISNWVAW
GTASV



DYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGRTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1655)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1657)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB204
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISNWVAW
GTASV



DHYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GIIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGRTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1655)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1658)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB205
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTFS
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISNWVAW
GTASV



DHYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1655)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1659)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB206
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISNWVAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GIIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1655)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1660)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB207
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTES
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISSWVAW
GTASV



DHYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGRTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1662)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1661)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB208
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTES
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISNYVAW
GTASV



DHYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGRTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1663)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1661)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB209
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTES
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISNWLAW
GTASV



DHYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGRTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1664)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1661)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB210
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTES
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISNWVNW
GTASV



DHYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGRTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1665)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1661)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB211
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTES
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISNWVAW
GTASV



DHYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGRTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1666)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1661)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB212
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTES
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISNWVAW
GTASV



DHYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASSLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGRTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1667)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1661)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB213
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTES
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISNWVAW
GTASV



DHYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGRTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1668)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1661)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB214
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTES
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISNWVAW
GTASV



DHYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGRTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSTPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1669)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1661)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB215
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTES
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISNWVAW
GTASV



DHYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGRTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPRTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1670)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1661)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB216
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTES
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISSYLNW
GTASV



DHYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
AASSLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGRTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
YSTPRTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1596)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1661)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB217
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTES
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISNWVAW
GTASV



DHYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGRTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1655)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1661)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB218
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISNWVAW
GTASV



SHYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGRTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1655)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1671)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB219
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISNWVAW
GTASV



DYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGRTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1655)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1672)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB220
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISNWVAW
GTASV



DHYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1655)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1673)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB221
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISNWVAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGRTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1655)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1674)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB222
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISNWVAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1655)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1675)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB223
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTES
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISSYVAW
GTASV



DHYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGRTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1676)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1661)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB224
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTES
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISSWLAW
GTASV



DHYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGRTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1677)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1661)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB225
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTES
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISSYLAW
GTASV



DHYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGRTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1678)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1661)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB226
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISSYVAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGRTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1676)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1674)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB227
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISSWLAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGRTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1677)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1674)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB228
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISSYLAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGRTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1678)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1674)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB229
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISSYVAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1676)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1675)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB230
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISSWLAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1677)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1675)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)





PMAB231
QVQLVQ
ASTKGPSVFPLAPS
GGGGSG
EVQLLESG
GGGGSG
DIQMTQS
DIQMTQS
RTVAA



SGAEVK
SKSTSGGTAALGCL
GGGSGG
GGLVQPGG
GGGSGG
PSSLSAS
PSSLSAS
PSVFI



KPGASV
VKDYFPEPVTVSWN
GGS
SLRLSCAA
GGSGGG
VGDRVTI
VGDRVTI
FPPSD



KVSCKA
SGALTSGVHTFPAV
(SEQ
SGFTFSDE
GS
TCRASQS
TCRASQS
EQLKS



SGYTFT
LQSSGLYSLSSVVT
ID NO:
WMHWVRQA
(SEQ
VSRSLAW
ISSYLAW
GTASV



SYYMHW
VPSSSLGTQTYICN
30)
PGKGLEWI
ID NO:
YQQKPGK
YQQKPGK
VCLLN



VRQAPG
VNHKPSNTKVDKKV

SYISGDSG
22)
APKLLIY
APKLLIY
NFYPR



QGLEWM
EPKSCDKTHTCPPC

YTNYADSV

AASSLQS
RASTLQS
EAKVQ



GTIAPS
PAPEAAGAPSVELE

KGRFTISR

GVPSRFS
GVPSRFS
WKVDN



GGSTSY
PPKPKDTLMISRTP

DNSKNTLY

GSGSGTD
GSGSGTD
ALQSG



AQKFQG
EVTCVVVDVSHEDP

LQMNSLRA

FTLTISS
FTLTISS
NSQES



RVTMTR
EVKFNWYVDGVEVH

EDTAVYYC

LQPEDFA
LQPEDFA
VTEQD



DTSTST
NAKTKPREEQYNST

ARDRPYYY

TYYCQQY
TYYCQQS
SKDST



VYMELS
YRVVSVLTVLHQDW

YMDVWGKG

KSYPVTF
HSLPLTF
YSLSS



SLRSED
LNGKEYKCKVSNKA

TTVTVSS

GQGTKVE
GPGTKVD
TLTLS



TAVYYC
LPAPIEKTISKAKG

(SEQ ID

IK (SEQ
IK (SEQ
KADYE



AADNGH
QPREPQVYTLPPSR

NO: 591)

ID NO:
ID NO:
KHKVY



ASGWLY
EEMTKNQVSLTCLV



592)
1678)
ACEVT



YYGMDV
KGFYPSDIAVEWES





HQGLS



WGQGTT
NGQPENNYKTTPPV





SPVTK



VTVSS
LDSDGSFFLYSKLT





SFNRG



(SEQ
VDKSRWQQGNVFSC





EC



ID NO:
SVMHEALHNHYTQK





(SEQ



1675)
SLSLSPG (SEQ





ID




ID NO: 44)





NO:










45)









In some embodiments, the therapeutic comprises one or more sequences, or a combination thereof, selected from the Table 12.


In some embodiments, the PD-1 antibody comprises one or more amino acid sequence as provided for in the following table:













TABLE 16





Clone
Fab VH Seq
CH1-CH3 Seq
Fab VK Seq
CK Seq







PMAb6
EVQLLESGGGLV
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIVMTQSPDS
RTVAAPSVFIF


5
QPGGSLRLSCAA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LAVSLGERAT
PPSDEQLKSGT



SGFTFSSYDMSW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
INCKSSQSVL
ASVVCLLNNFY



VRQAPGKGLEWV
CDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMI
YSPNNKNYLA
PREAKVQWKVD



SGITISGGSTYY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
WYQQKPGQPP
NALQSGNSQES



ADSVKGRFTISR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
KLLIYWASTR
VTEQDSKDSTY



DNSKNTLYLQMN
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
ESGVPDRESG
SLSSTLTLSKA



SLRAEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
SGSGTDETLT
DYEKHKVYACE



ARGRGGSGWLDY
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
ISSLQAEDVA
VTHQGLSSPVT



WGQGTTVTVSS
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
VYYCQQYYTT
KSENRGEC



(SEQ ID NO:
NO: 44)
PPTFGQGTRL
(SEQ ID NO:



1476)

EIK (SEQ
45)





ID NO:






1359)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


32
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYTFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASQSIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMI
NYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1679)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1680)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


33
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYTFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASQSIK
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1679)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1681)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVEIF


34
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYTFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASQDIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1679)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1682)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


35
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYTFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASRSIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1679)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1683)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


36
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYTFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCQASQSIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1679)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1684)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


37
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYTFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASQSIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1679)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1479)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


38
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTSYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASQSIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI
NYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1685)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1680)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


39
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTSYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASQSIK
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1685)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1681)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


40
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTSYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASQDIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1685)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1682)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


41
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTSYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASRSIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1685)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1683)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


42
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTSYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCQASQSIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1685)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1684)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


43
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTSYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASQSIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1685)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1479)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


44
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCQASRDIK
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMI
NYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1449)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


45
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYTFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCQASRDIK
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI
NYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1679)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1449)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


46
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTSYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCQASRDIK
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMI
NYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1685)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1449)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


47
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYTFTSYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCQASRDIK
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI
NYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTEGP
KSENRGEC



ID NO: 1686)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1449)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


48
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASQDIK
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMI
NYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1687)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYEP
DIQMTQSPSS
RTVAAPSVFIF


49
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRRVGSIK
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMI
NYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1688)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


50
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASRDIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMI
NYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1689)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYEP
DIQMTQSPSS
RTVAAPSVFIF


51
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASRDIK
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1690)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


52
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCQASQSIK
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI
NYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1691)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


53
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCQASQDIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI
NYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1692)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


54
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCQASQDIK
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1693)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


55
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCQASRSIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMI
NYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1694)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


56
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCQASRSIK
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1695)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


57
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCQASRDIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1696)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


58
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASQSIK
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI
NYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1697)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


59
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASQDIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI
NYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





2ID
45)





NO: 1698)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYEP
DIQMTQSPSS
RTVAAPSVFIF


60
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASQDIK
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTEGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1699)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYEP
DIQMTQSPSS
RTVAAPSVFIF


61
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASRSIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMI
NYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTEGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1700)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


62
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASRSIK
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1701)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


63
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASRDIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1702)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


64
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCQASQSIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMI
NYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1703)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


65
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCQASQSIK
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1704)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIE


66
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCQASQDIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1705)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


67
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCQASRSIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1706)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


68
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASQSIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI
NYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTEGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1680)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


69
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASQSIK
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1681)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


70
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASQDIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1682)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


71
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASRSIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1683)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


72
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCQASQSIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1684)






PMAB2
QVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


73
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASQSIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIIQPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1584)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1479)






PMAB2
EVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


74
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYTFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCQASRDIK
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMI
NYLAWYQQKP
PREAKVQWKVD



GIINPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1707)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1449)






PMAB2
EVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVEIF


75
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTSYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCQASRDIK
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVELFPPKPKDTLMI
NYLAWYQQKP
PREAKVQWKVD



GIINPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1478)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1449)






PMAB2
EVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


76
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCQASRDIK
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI
NYLAWYQQKP
PREAKVQWKVD



GIINPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1708)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1449)






PMAB2
EVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


77
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYTFTTYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASQSIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIINPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1707)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1479)






PMAB2
EVQLVQSGAEVK
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
DIQMTQSPSS
RTVAAPSVFIF


78
KPGASVKVSCKA
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
LSASVGDRVT
PPSDEQLKSGT



SGYSFTSYYMHW
VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS
ITCRASQSIS
ASVVCLLNNFY



VRQAPGQGLEWM
CDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI
SYLAWYQQKP
PREAKVQWKVD



GIINPSGGSTSY
SRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNA
GKAPKLLIYA
NALQSGNSQES



AQKFQGRVTMTR
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
ASSLQSGVPS
VTEQDSKDSTY



DTSTSTVYMELS
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
RFSGSGSGTD
SLSSTLTLSKA



SLRSEDTAVYYC
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
FTLTISSLQP
DYEKHKVYACE



ASGWVYWGQGTL
NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVE
EDFATYYCQQ
VTHQGLSSPVT



VTVSS (SEQ
SCSVMHEALHNHYTQKSLSLSPG (SEQ ID
SYSTPPTFGP
KSENRGEC



ID NO: 1478)
NO: 44)
GTKVDIK
(SEQ ID NO:





(SEQ ID
45)





NO: 1479)









As provided for herein, in some embodiments, a polypeptide comprises a plurality of chain 1 and chain 2 as provided for in the table above. In some embodiments, the polypeptide comprises two identical polypeptides of chain 1 and two identical polypeptides of chain 2. In some embodiments, the two polypeptides of chain 1 are different. In some embodiments, the polypeptides of chain 2 are different. The domains of the scFv antibody can also be linked with a disulfide bond. Without being bound to any particular theory, the disulfide linkage can be used to stabilize the scFv antibody. As provided for herein, in some embodiments, the scFv antibody is an antibody that binds to MAdCAM.


In some embodiments, the therapeutic compound comprises one or more sequences, or a combination thereof, selected from the Table 16.


In some embodiments, a PD-1 antibody or the PD-1 antibody of a PD-1-MAdCAM antibody, such as when the PD-1 antibody is in the FAb format, comprises CDRs as provided for in Table 13.
















TABLE 13






CDR









Annotation








Clone
System
HCDR1
HCDR2
HCDR3
LCDR1
LCDR2
LCDR3







PMAB61
Kabat
SYYMH
IINPSGGST
ASGWVY
RASQSISSY
AASSLQS
QQSYSTP




(SEQ ID
SYAQKFQG
(SEQ
LA (SEQ
(SEQ ID
PT (SEQ




NO:
(SEQ ID
ID NO:
ID NO:
NO:
ID NO:




1709)
NO: 1712)
1715)
1716)
1717)
1718)






IMGT
GYSFTSYY
INPSGGST
ASGWVY
QSISSY
AAS
QQSYSTP




(SEQ ID
(SEQ ID
(SEQ
(SEQ ID

PT (SEQ




NO:
NO: 1713)
ID NO:
NO: 1730)

ID NO:




1710)

1715)


1718)






CHOTHIA
GYSFTSY
NPSGGS
WV
RASQSISSY
AASSLQS
QQSYSTP




(SEQ ID
(SEQ ID

LA (SEQ
(SEQ ID
PT (SEQ




NO:
NO: 1714)

ID NO:
NO:
ID NO:




1711)


1716)
1717)
1718)





PMAB65
Kabat
SYDMS
GITISGGST
ARGRGG
KSSQSVLYS
WASTRES
QQYYTTP




(SEQ ID
YYADSVKG
SGWLDY
PNNKNYLA
(SEQ ID
PT (SEQ




NO:
(SEQ ID
(SEQ
(SEQ ID
NO:
ID NO:




1719)
NO: 1744)
ID NO:
NO: 1726)
1728)
1729)






1724)









IMGT
GFTFSSYD
ITISGGS
ARGRGG
QSVLYS PNN
WAS
QQYYTTP




(SEQ ID
(SEQ ID
SGWLDY
KNY (SEQ

PT (SEQ




NO:
NO: 1722)
(SEQ
ID NO:

ID NO:




1720)

ID NO:
1727)

1729)






1724)









CHOTHIA
GFTESSY
TISGGS
RGGSGW
KSSQSVLYS
WASTRES
QQYYTTP




(SEQ ID
(SEQ ID
LD
PNNKNYLA
(SEQ ID
PT (SEQ




NO:
NO: 1723)
(SEQ
(SEQ ID
NO:
ID NO:




1721)

ID NO:
NO: 1726)
1728)
1729)






1725)








PMAB62
Kabat
SYYMH
IINPSGGST
ASGWVY
RASQSISSY
AASSLQS
QQSYSTP




(SEQ ID
SYAQKFQG
(SEQ
LA (SEQ
(SEQ ID
PT (SEQ




NO:
(SEQ ID
ID NO:
ID NO:
NO:
ID NO:




1709)
NO: 1712)
1715)
1716)
1717)
1718)






IMGT
GYSFTSYY
INPSGGST
ASGWVY
QSISSY
AAS
QQSYSTP




(SEQ ID
(SEQ ID
(SEQ
(SEQ ID

PT (SEQ




NO:
NO: 1713)
ID NO:
NO: 1730)

ID NO:




1710)

1715)


1718)






CHOTHIA
GYSFTSY
NPSGGS
WV
RASQSISSY
AASSLQS
QQSYSTP




(SEQ ID
(SEQ ID

LA (SEQ
(SEQ ID
PT (SEQ




NO:
NO: 1714)

ID NO:
NO:
ID NO:




1711)


1716)
1717)
1718)





PMAB66
Kabat
SYDMS
GITISGGST
ARGRGG
KSSQSVLYS
WASTRES
QQYYTTP




(SEQ ID
YYADSVKG
SGWLDY
PNNKNYLA
(SEQ ID
PT (SEQ




NO:
(SEQ ID
(SEQ
(SEQ ID
NO:
ID NO:




1719)
NO: 1744)
ID NO:
NO: 1726)
1728)
1729)






1724)









IMGT
GFTFSSYD
ITISGGS
ARGRGG
QSVLYSPNN
WAS
QQYYTTP




(SEQ ID
(SEQ ID
SGWLDY
KNY (SEQ

PT (SEQ




NO:
NO: 1722)
(SEQ
ID NO:

ID NO:




1720)

ID NO:
1727)

1729)






1724)









CHOTHIA
GFTESSY
TISGGS
RGGSGW
KSSQSVLYS
WASTRES
QQYYTTP




(SEQ ID
(SEQ ID
LD
PNNKNYLA
(SEQ ID
PT (SEQ




NO:
NO: 1723)
(SEQ
(SEQ ID
NO:
ID NO:




1721)

ID NO:
NO: 1726)
1728)
1729)






1725)








PMAB63
Kabat
SYYMH
IINPSGGST
ASGWVY
RASQSISSY
AASSLQS
QQSYSTP




(SEQ ID
SYAQKFQG
(SEQ
LA (SEQ
(SEQ ID
PT (SEQ




NO:
(SEQ ID
ID NO:
ID NO:
NO:
ID NO:




1709)
NO: 1712)
1715)
1716)
1717)
1718)






IMGT
GYSFTSYY
INPSGGST
ASGWVY
QSISSY
AAS
QQSYSTP




(SEQ ID
(SEQ ID
(SEQ
(SEQ ID

PT (SEQ




NO:
NO: 1713)
ID NO:
NO: 1730)

ID NO:




1710)

1715)


1718)






CHOTHIA
GYSFTSY
NPSGGS
WV
RASQSISSY
AASSLQS
QQSYSTP




(SEQ ID
(SEQ ID

LA (SEQ
(SEQ ID
PT (SEQ




NO:
NO: 1714)

ID NO:
NO:
ID NO:




1711)


1716)
1717)
1718)





PMAB67
Kabat
SYDMS
GITISGGST
ARGRGG
KSSQSVLYS
WASTRES
QQYYTTP




(SEQ ID
YYADSVKG
SGWLDY
PNNKNYLA
(SEQ ID
PT (SEQ




NO:
(SEQ ID
(SEQ
(SEQ ID
NO:
ID NO:




1719)
NO: 1744)
ID NO:
NO: 1726)
1728)
1729)






1724)









IMGT
GFTFSSYD
ITISGGS
ARGRGG
QSVLYSPNN
WAS
QQYYTTP




(SEQ ID
(SEQ ID
SGWLDY
KNY (SEQ

PT (SEQ




NO:
NO: 1722)
(SEQ
ID NO:

ID NO:




1720)

ID NO:
1727)

1729)






1724)









CHOTHIA
GFTFSSY
TISGGS
RGGSGW
KSSQSVLYS
WASTRES
QQYYTTP




(SEQ ID
(SEQ ID
LD
PNNKNYLA
(SEQ ID
PT (SEQ




NO:
NO: 1723)
(SEQ
(SEQ ID
NO:
ID NO:




1721)

ID NO:
NO: 1726)
1728)
1729)






1725)








PMAB64
Kabat
SYYMH
IINPSGGST
ASGWVY
RASQSISSY
AASSLQS
QQSYSTP




(SEQ ID
SYAQKFQG
(SEQ
LA (SEQ
(SEQ ID
PT (SEQ




NO:
(SEQ ID
ID NO:
ID NO:
NO:
ID NO:




1709)
NO: 1712)
1715)
1716)
1717)
1718)






IMGT
GYSFTSYY
INPSGGST
ASGWVY
QSISSY
AAS
QQSYSTP




(SEQ ID
(SEQ ID
(SEQ
(SEQ ID

PT (SEQ




NO:
NO: 1713)
ID NO:
NO: 1730)

ID NO:




1710)

1715)


1718)






CHOTHIA
GYSFTSY
NPSGGS
WV
RASQSISSY
AASSLQS
QQSYSTP




(SEQ ID
(SEQ ID

LA (SEQ
(SEQ ID
PT (SEQ




NO:
NO: 1714)

ID NO:
NO:
ID NO:




1711)


1716)
1717)
1718)





PMAB68
Kabat
SYDMS
GITISGGST
ARGRGG
KSSQSVLYS
WASTRES
QQYYTTP




(SEQ ID
YYADSVKG
SGWLDY
PNNKNYLA
(SEQ ID
PT (SEQ




NO:
(SEQ ID
(SEQ
(SEQ ID
NO:
ID NO:




1719)
NO: 1744)
ID NO:
NO: 1726)
1728)
1729)






1724)









IMGT
GFTFSSYD
ITISGGS
ARGRGG
QSVLYSPNN
WAS
QQYYTTP




(SEQ ID
(SEQ ID
SGWLDY
KNY (SEQ

PT (SEQ




NO:
NO: 1722)
(SEQ
ID NO:

ID NO:




1720)

ID NO:
1727)

1729)






1724)









CHOTHIA
GFTESSY
TISGGS
RGGSGW
KSSQSVLYS
WASTRES
QQYYTTP




(SEQ ID
(SEQ ID
LD
PNNKNYLA
(SEQ ID
PT (SEQ




NO:
NO: 1723)
(SEQ
(SEQ ID
NO:
ID NO:




1721)

ID NO:
NO: 1726)
1728)
1729)






1725)









In some embodiments, the therapeutic compound comprises CDRs of one or more sequences, or a combination thereof, selected from the Table 13.


In some embodiments, the PD-1-MAdCAM antibody comprises scFv CDRs, when the scFV binds to MAdCAM, as provided for in table 14.
















TABLE 14






CDR









Annotation








Clone
System
HCDR1
HCDR2
HCDR3
LCDR1
LCDR2
LCDR3







PMAB61
Kabat
GFTFSSYW
ISGSGGYT
ARDRPY
RASQSISSS
AASSLQS
QQYKSYP




(SEQ ID
(SEQ ID
YYDMDV
LA (SEQ
(SEQ ID
VT (SEQ




NO:
NO: 1732)
(SEQ
ID NO:
NO:
ID NO:




1731)

ID NO:
1736)
1717)
1738)






1734)









IMGT
GFTESSY
SGSGGY
DRPYYY
QSISSS
AAS
QQYKSYP




(SEQ ID
(SEQ ID
DMDV
(SEQ ID

VT (SEQ




NO:
NO: 1733)
(SEQ
NO: 1737)

ID NO:




1721)

ID NO:


1738)






1735)









CHOTHIA
GFTESSY
SGSGGY
DRPYYY
RASQSISSS
AASSLQS
QQYKSYP




(SEQ ID
(SEQ ID
DMDV
LA (SEQ
(SEQ ID
VT (SEQ




NO:
NO: 1733)
(SEQ
ID NO:
NO:
ID NO:




1721)

ID NO:
1736)
1717)
1738)






1735)








PMAB65
Kabat
GFTESSYW
ISGSGGYT
ARDRPY
RASQSISSS
AASSLQS
QQYKSYP




(SEQ ID
(SEQ ID
YYDMDV
LA (SEQ
(SEQ ID
VT (SEQ




NO:
NO: 1732)
(SEQ
ID NO:
NO:
ID NO:




1731)

ID NO:
1736)
1717)
1738)






1734)









IMGT
GFTESSY
SGSGGY
DRPYYY
QSISSS
AAS
QQYKSYP




(SEQ ID
(SEQ ID
DMDV
(SEQ ID

VT (SEQ





NO: 1733)
(SEQ
NO: 1737)






NO:

ID NO:


ID NO:




1721)

1735)


1738)






CHOTHIA
GFTESSY
SGSGGY
DRPYYY
RASQSISSS
AASSLQS
QQYKSYP




(SEQ ID
(SEQ ID
DMDV
LA (SEQ
(SEQ ID
VT (SEQ




NO:
NO: 1733)
(SEQ
ID NO:
NO:
ID NO:




1721)

ID NO:
1736)
1717)
1738)






1735)








PMAB62
Kabat
GFTFSSYW
ISGSGGYT
ARDRPY
RASQSISSS
AASSLQS
QQYKSYP




(SEQ ID
(SEQ ID
YYDLDV
LA (SEQ
(SEQ ID
VT (SEQ




NO:
NO: 1732)
(SEQ
ID NO:
NO:
ID NO:




1731)

ID NO:
1736)
1717)
1738)






1739)









IMGT
GFTESSY
SGSGGY
DRPYYY
QSISSS
AAS
QQYKSYP




(SEQ ID
(SEQ ID
DLDV
(SEQ ID

VT (SEQ




NO:
NO: 1733)
(SEQ
NO: 1737)

ID NO:




1721)

ID NO:


1738)






1740)









CHOTHIA
GFTESSY
SGSGGY
DRPYYY
RASQSISSS
AASSLQS
QQYKSYP




(SEQ ID
(SEQ ID
DLDV
LA (SEQ
(SEQ ID
VT (SEQ




NO:
NO: 1733)
(SEQ
ID NO:
NO:
ID NO:




1721)

ID NO:
1736)
1717)
1738)






1740)








PMAB66
Kabat
GFTESSYW
ISGSGGYT
ARDRPY
RASQSISSS
AASSLQS
QQYKSYP




(SEQ ID
(SEQ ID
YYDLDV
LA (SEQ
(SEQ ID
VT (SEQ




NO:
NO: 1732)
(SEQ
D NO:
NO:
ID NO:




1731)

ID NO:
1736)
1717)
1738)






1739)









IMGT
GFTESSY
SGSGGY
DRPYYY
QSISSS
AAS
QQYKSYP




(SEQ ID
(SEQ ID
DLDV
(SEQ ID

VT (SEQ




NO:
NO: 1733)
(SEQ
NO: 1737)

ID NO:




1721)

ID NO:


1738)






1740)









CHOTHIA
GFTESSY
SGSGGY
DRPYYY
RASQSISSS
AASSLQS
QQYKSYP




(SEQ ID
(SEQ ID
DLDV
LA (SEQ
(SEQ ID
VT (SEQ




NO:
NO: 1733)
(SEQ
ID NO:
NO:
ID NO:




1721)

ID NO:
1736)
1717)
1738)






1740)








PMAB63
Kabat
GFTFSSYW
ISGSGGYT
ARDRPY
RASQSISSS
AASSLQS
QQYKSYP




(SEQ ID
(SEQ ID
YYDLDV
LA (SEQ
(SEQ ID
VT (SEQ




NO:
NO: 1732)
(SEQ
ID NO:
NO:
ID NO:




1731)

ID NO:
1736)
1717)
1738)






1739)









IMGT
GFTESSY
SGSGGY
DRPYYY
QSISSS
AAS
QQYKSYP




(SEQ ID
(SEQ ID
DLDV
(SEQ ID

VT (SEQ




NO:
NO: 1733)
(SEQ
NO: 1737)

ID NO:




1721)

ID NO:


1738)






1740)









CHOTHIA
GFTESSY
SGSGGY
DRPYYY
RASQSISSS
AASSLQS
QQYKSYP




(SEQ ID
(SEQ ID
DLDV
LA (SEQ
(SEQ ID
VT (SEQ




NO:
NO: 1733)
(SEQ
ID NO:
NO:
ID NO:




1721)

ID NO:
1736)
1717)
1738)






1740)








PMAB67
Kabat
GFTESSYW
ISGSGGYT
ARDRPY
RASQSISSS
AASSLQS
QQYKSYP




SEQ ID
(SEQ ID
YYDLDV
LA (SEQ
(SEQ ID
VT (SEQ




NO:
NO: 1732)
(SEQ
ID NO:
NO:
ID NO:




1731)

ID NO:
1736)
1717)
1738)






1739)









IMGT
GFTESSY
SGSGGY
DRPYYY
QSISSS
AAS
QQYKSYP




(SEQ ID
(SEQ ID
DLDV
(SEQ ID

VT (SEQ




NO:
NO: 1733)
(SEQ
NO: 1737)

ID NO:




1721)

ID NO:


1738)






1740)









CHOTHIA
GFTESSY
SGSGGY
DRPYYY
RASQSISSS
AASSLQS
QQYKSYP




(SEQ ID
(SEQ ID
DLDV
LA (SEQ
(SEQ ID
VT (SEQ




NO:
NO: 1733)
(SEQ
ID NO:
NO:
ID NO:




1721)

ID NO:
1736)
1717)
1738)






1740)








PMAB64
Kabat
GFTFSSYW
ISGSGGYT
ARDRPY
RASQSISSS
AASSLQS
QQYKSYP




(SEQ ID
(SEQ ID
YYDMDV
LA (SEQ
(SEQ ID
VT (SEQ




NO:
NO: 1732)
SEQ
ID NO:
NO:
ID NO:




1731)

ID NO:
1736)
1717)
1738)






1734)









IMGT
GFTESSY
SGSGGY
DRPYYY
QSISSS
AAS
QQYKSYP




(SEQ ID
(SEQ ID
DMDV
(SEQ ID

VT (SEQ




NO:
NO: 1733)
SEQ
NO: 1737)

ID NO:




1721)

ID NO:


1738)






1735)









CHOTHIA
GFTESSY
SGSGGY
DRPYYY
RASQSISSS
AASSLQS
QQYKSYP




(SEQ ID
(SEQ ID
DMDV
LA (SEQ
(SEQ ID
VT (SEQ




NO :
NO: 1733)
(SEQ
ID NO:
NO:
ID NO:




1721)

ID NO:
1736)
1717)
1738)






1735)








PMAB68
Kabat
GFTESSYW
ISGSGGYT
ARDRPY
RASQSISSS
AASSLQS
QQYKSYP




(SEQ ID
(SEQ ID
YYDMDV
LA (SEQ
(SEQ ID
VT (SEQ




NO:
NO: 1732)
(SEQ
ID NO:
NO:
ID NO:




1731)

ID NO:
1736)
1717)
1738)






1734)









IMGT
GFTESSY
SGSGGY
DRPYYY
QSISSS
AAS
QQYKSYP




( SEQ ID
(SEQ ID
DMDV
(SEQ ID

VT (SEQ




NO:
NO: 1733)
(SEQ
NO: 1737)

ID NO:




1721)

ID NO:


1738)






1735)









CHOTHIA
GFTESSY
SGSGGY
DRPYYY
RASQSISSS
AASSLQS
QQYKSYP




(SEQ ID
(SEQ ID
DMDV
LA (SEQ
(SEQ ID
VT (SEQ




NO:
NO: 1733)
SEQ
ID NO:
NO:
ID NO:




1721)

ID NO:
1736)
1717)
1738)






1735)









In some embodiments, the therapeutic compound comprises CDRs one or more sequences, or a combination thereof, selected from the Table 14.


In some embodiments, the therapeutic is a Fab PD-1 antibody fused via a linker to a scFv MAdCAM antibody. In some embodiments, the Fab PD-1 antibody is fused to a IgG1 constant domain, wherein said IgG1 constant domain is fused to scFv MAdCAM antibody via a Fc-scFv linker. In some embodiment the scFv MAdCAM antibody comprises an internal scFv linker. In some embodiments, the linker is a peptide linker. In some embodiments, the peptide linker is a glycine/serine linker as provided herein.


In some embodiments, the PD-1-MAdCAM antibody comprises one or more sequences as shown in Table 12. In some embodiments, the MAdCAM antibody comprises a combination of one or more sequence as shown in Table 12. In some embodiments, the anti-PD-1 antibody is in the Fab format and the anti-MAdCAM antibody is in a scFV format as illustrated in Table 12. In some embodiments, the Fab portion of the antibody comprises a CDR1 from any one of clones of Table 13, a CDR2 from any one of clones of Table 13, and a CDR3 from any one of clones of Table 13. In some embodiments, the Fab portion of the antibody comprises a LCDR1 from any one of clones of Table 13, a LCDR2 from any one of clones of Table 13, and a LCDR3 from any one of clones of Table 13. In some embodiments, the scFv portion of the antibody comprises a CDR1 from any one of clones of Table 14, a CDR2 from any one of clones of Table 14, and a CDR3 from any one of clones of Table 14. In some embodiments, the scFc portion of the antibody comprises a LCDR1 from any one of clones of Table 14, a LCDR2 from any one of clones of Table 14, and a LCDR3 from any one of clones of Table 14. In some embodiments, the amino acid residues of the CDRs shown above contain mutations. In some embodiments, the CDRs contain 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 substitutions or mutations. In some embodiments, the substitution is a conservative substitution.


In some embodiments, the PD-1-MAdCAM antibody has a VH region selected from any one of clones PMAB61-231 of Table 12 and a VL region selected from any one of clones PMAB61-231 as set forth in of Table 12. In some embodiments, the antibody comprises a Fab CDR1 from any one of clones of Table 13, a Fab CDR2 from any one of clones of Table 13, and a Fab CDR3 from any one of clones of Table 13, a scFv CDR1 from any one of clones of Table 14, a Fab CDR2 from any one of clones of Table 14, and a Fab CDR3 from any one of clones of Table 14.


In some embodiments, the variable heavy chain has a Fab HCDR1, HCDR2, and a HCDR3 as set forth for PMAB61 in Table 13. In some embodiments, the variable heavy chain has a Fab HCDR1, HCDR2, and a HCDR3 as set forth for PMAB62 in Table 13. In some embodiments, the variable heavy chain has a Fab HCDR1, HCDR2, and a HCDR3 as set forth for PMAB63 in Table 13. In some embodiments, the variable heavy chain has a Fab HCDR1, HCDR2, and a HCDR3 as set forth for PMAB64 in Table 13. In some embodiments, the variable heavy chain has a Fab HCDR1, HCDR2, and a HCDR3 as set forth for PMAB65 in Table 13. In some embodiments, the variable heavy chain has a Fab HCDR1, HCDR2, and a HCDR3 as set forth for PMAB66 in Table 13. In some embodiments, the variable heavy chain has a Fab HCDR1, HCDR2, and a HCDR3 as set forth for PMAB67 in Table 13. In some embodiments, the variable heavy chain has a Fab HCDR1, HCDR2, and a HCDR3 as set forth for PMAB68 in Table 13.


In some embodiments, the variable light chain has a Fab LCDR1, LCDR2, and a LCDR3 as set forth for PMAB61 in Table 13. In some embodiments, the variable light chain has a Fab LCDR1, LCDR2, and a LCDR3 as set forth for PMAB62 in Table 13. In some embodiments, the variable light chain has a Fab LCDR1, LCDR2, and a LCDR3 as set forth for PMAB63 in Table 13. In some embodiments, the variable light chain has a Fab LCDR1, LCDR2, and a LCDR3 as set forth for PMAB64 in Table 13. In some embodiments, the variable light chain has a Fab LCDR1, LCDR2, and a LCDR3 as set forth for PMAB65 in Table 13. In some embodiments, the variable light chain has a Fab LCDR1, LCDR2, and a LCDR3 as set forth for PMAB67 in Table 13. In some embodiments, the variable light chain has a Fab LCDR1, LCDR2, and a LCDR3 as set forth for PMAB66 in Table 13. In some embodiments, the variable light chain has a Fab LCDR1, LCDR2, and a LCDR3 as set forth for PMAB68 in Table 13.


In some embodiments, the variable heavy chain has a scFv HCDR1, HCDR2, and a HCDR3 as set forth for PMAB61 in Table 14. In some embodiments, the variable heavy chain has a scFv HCDR1, HCDR2, and a HCDR3 as set forth for PMAB62 in Table 14. In some embodiments, the variable heavy chain has a scFv HCDR1, HCDR2, and a HCDR3 as set forth for PMAB63 in Table 14. In some embodiments, the variable heavy chain has a scFv HCDR1, HCDR2, and a HCDR3 as set forth for PMAB64 in Table 14. In some embodiments, the variable heavy chain has a scFv HCDR1, HCDR2, and a HCDR3 as set forth for PMAB65 in Table 14. In some embodiments, the variable heavy chain has a scFv HCDR1, HCDR2, and a HCDR3 as set forth for PMAB66 in Table 14. In some embodiments, the variable heavy chain has a scFv HCDR1, HCDR2, and a HCDR3 as set forth for PMAB67 in Table 14. In some embodiments, the variable heavy chain has a scFv HCDR1, HCDR2, and a HCDR3 as set forth for PMAB68 in Table 14.


In some embodiments, the variable light chain has a scFv LCDR1, LCDR2, and a LCDR3 as set forth for PMAB61 in Table 14. In some embodiments, the variable light chain has a scFv LCDR1, LCDR2, and a LCDR3 as set forth for PMAB62 in Table 14. In some embodiments, the variable light chain has a scFv LCDR1, LCDR2, and a LCDR3 as set forth for PMAB63 in Table 14. In some embodiments, the variable light chain has a scFv LCDR1, LCDR2, and a LCDR3 as set forth for PMAB64 in Table 14. In some embodiments, the variable light chain has a scFv LCDR1, LCDR2, and a LCDR3 as set forth for PMAB65 in Table 14. In some embodiments, the variable light chain has a scFv LCDR1, LCDR2, and a LCDR3 as set forth for PMAB66 in Table 14. In some embodiments, the variable light chain has a scFv LCDR1, LCDR2, and a LCDR3 as set forth for PMAB67 in Table 14. In some embodiments, the variable light chain has a scFv LCDR1, LCDR2, and a LCDR3 as set forth for PMAB68 in Table 14.


In some embodiments, the CDRS are swapped for one another. For example, the Fab HCDR1 of clone PMAB61 can be substituted for the Fab HCDR1 of clone PMAB62, or vice versa. This CDR swapping can be done for any of the Fab HCDRs of the clones provided herein (e.g., HCDR1 for HCDR1; HCDR2 for HCDR2; or HCDR3 for HCDR3) or the Fab LCDRs (e.g., LCDR1 for LCDR1; LCDR2 for LCDR2; or LCDR3 for LCDR3). Furthermore, the CDR swapping can be done for any of the scFv HCDRs of the clones provided herein (e.g., HCDR1 for HCDR1; HCDR2 for HCDR2; or HCDR3 for HCDR3) or the scFv LCDRs (e.g., LCDR1 for LCDR1; LCDR2 for LCDR2; or LCDR3 for LCDR3). Therefore, in some embodiments, the antibody comprises a Fab HCDR1 as set forth in any of clones of Table 13, a HCDR2 as set forth in any of clones of Table 13, a HCDR3 as set forth in any of clones of Table 13, a LCDR1 as set forth in any of clones of Table 13, a LCDR2 as set forth in any of clones of Table 13, a LCDR3 as set forth in any of clones of Table 13, or a variant of any of the foregoing. In some embodiments, the antibody comprises a scFv HCDR1 as set forth in any of clones of Table 14, a HCDR2 as set forth in any of clones of Table 14, a HCDR3 as set forth in any of clones of Table 14, a LCDR1 as set forth in any of clones of Table 14, a LCDR2 as set forth in any of clones of Table 14, a LCDR3 as set forth in any of clones of Table 14, or a variant of any of the foregoing.


In some embodiments, an antibody, or antigen binding fragment thereof, comprises a heavy chain variable region comprising a variable heavy CDR1 (HCDR1) having at least one amino acid substitution relative to SEQ ID NO: 1709, or 1719; a variable heavy CDR2 (HCDR2) having at least one amino acid substitution relative to SEQ ID NO: 1712, or 1744; and variable heavy CDR3 (HCDR3) having at least one amino acid substitution relative to SEQ ID NO: 1715, or 1724; and a light chain variable region comprises a variable light CDR1 (LCDR1) having at least one amino acid substitution relative to SEQ ID NO: 1716, or 1726; a variable light CDR2 (LCDR2) having at least one amino acid substitution relative to SEQ ID NO: 1717, or 1728; and a variable light CDR3 (LCDR3) having at least one amino acid substitution relative to SEQ ID NO: 1718, or 1729.


In some embodiments, the heavy chain variable region comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1719, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1744, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1724.


In some embodiments, the heavy chain variable region comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1709, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1712, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1715.


In some embodiments, the light chain variable region comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1726, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1728, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1729.


In some embodiments, the light chain variable region comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1716, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1717, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1718.


In some embodiments, the antibody, or antigen binding fragment thereof, comprises the heavy chain variable region comprises a variable heavy CDR1 (HCDR1) having an amino acid sequence of SEQ ID NO: 1719; a variable heavy CDR2 (HCDR2) having an amino acid sequence of SEQ ID NO: 1744; and variable heavy CDR3 (HCDR3) having an amino acid sequence of SEQ ID NO: 1724; and the light chain variable region comprises a variable light CDR1 (LCDR1) having an amino acid sequence of SEQ ID NO: 1726; a variable light CDR2 (LCDR2) having an amino acid sequence of SEQ ID NO: 1728; and a variable light CDR3 (LCDR3) having an amino acid sequence of SEQ ID NO: 1729.


In some embodiments, the antibody, or antigen binding fragment thereof, comprises the heavy chain variable region comprises a variable heavy CDR1 (HCDR1) having at least one amino acid substitution relative to SEQ ID NO: 1731, 1721, or 1499; a variable heavy CDR2 (HCDR2) having at least one amino acid substitution relative to SEQ ID NO: 1732, 1733, 1506; and variable heavy CDR3 (HCDR3) having at least one amino acid substitution relative to SEQ ID NO: 1734, 1735, 1739, 1740, 1507, 1531, or 1532; and the light chain variable region comprises a variable light CDR1 (LCDR1) having at least one amino acid substitution relative to SEQ ID NO: 1502, 1736, or 1737; a variable light CDR2 (LCDR2) having at least one amino acid substitution relative to SEQ ID NO: 1497, 1717, or a peptide comprising the sequence of Ala-Ala-Ser; and a variable light CDR3 (LCDR3) having at least one amino acid substitution relative to SEQ ID NO: 1498, or 1738.


In some embodiments, the antibody, or antigen binding fragment thereof, comprises the heavy chain variable region comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1731, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1732, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1734; and the light chain variable region comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1736, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1717, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1738.


In some embodiments, the antibody, or antigen binding fragment thereof, comprises the heavy chain variable region comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1499, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1506, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1507; and the light chain variable region comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1502, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1497, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1498.


In some embodiments, the VH comprises a sequence as set forth in Table 12. In some embodiments, the VK comprises a sequence as set forth in Table 12. In some embodiments, the Ab comprises a VH and a VK as set forth for the clones in Table 12. In some embodiments, the VH and VK are linked by a linker. In some embodiments, the linker is a peptide linker as provided for herein. In some embodiments, the peptide linker is the linker as provided for in Table 12.


In some embodiments, an antibody, or antigen binding fragment thereof, comprises a heavy chain variable region and a light chain variable region, such as those provided herein. In some embodiments, the heavy chain variable region comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 1476, or 1478, and the light chain variable region comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 1359, or 1479.


In some embodiments, the heavy chain variable region comprises an amino acid sequence of SEQ ID NOs: 1476, or 1478, and the light chain variable region comprises an amino acid of SEQ ID NO: 1359, or 1479.


In some embodiments, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1476. In some embodiments, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1478.


In some embodiments, the light chain variable region comprises the amino acid sequence of SEQ ID NO: 1359. In some embodiments, the light chain variable region comprises the amino acid sequence of SEQ ID NO: 1479.


In some embodiments, the antibody, or antigen binding fragment thereof, comprises a light chain variable region comprising an amino acid sequence having at least 90% identity to an amino acid sequence selected from SEQ ID NOs: 1359, 1680, 1681, 1682, 1683, 1684, 1479, 1449, 1687, 1688, 1689, 1690, 1691, 1692, 1693, 1694, 1695, 1696, 1697, 1698, 1699, 1700, 1701, 1702, 1703, 1704, 1705, or 1706; and a heavy chain variable region comprising an amino acid sequence having at least 90% identity to an amino acid sequence selected from SEQ ID NOs: 1476, 1679, 1685, 1584, 1478, 1707, or 1708.


In some embodiments, the antibody, or antigen binding fragment thereof, comprises the heavy chain variable region comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 1445, 591, 1443, 1480, 1545, or 1542; and the light chain variable region comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 1367, 592, or 1543.


In some embodiments, the antibody, or antigen binding fragment thereof, comprises the heavy chain variable region comprises an amino acid sequence of SEQ ID NOs: 1445, 591, 1443, 1480, 1545, or 1542; and the light chain variable region comprises an amino acid of SEQ ID NO: 1367, 592, or 1543.


In some embodiments, a PD-1 agonist comprising four polypeptide chains, is provided. In some embodiments, the PD-1 agonist comprising four polypeptide chains comprises:

    • Chain 1: N terminus (nt)-VH1-CH1-CH2-CH3-Linker A-scFv[VL2-Linker B-VH2]-C terminus (ct);
    • Chain 2: nt-VH1-CH1-CH2-CH3-Linker A-scFv[VL2-Linker B-VH2]-ct;
    • Chain 3: nt-VL1-CK-ct; and
    • Chain 4: nt-VL1-CK-ct;
    • wherein:
      • VH1 comprises the sequence of SEQ ID NO: 1476;
      • CH1-CH2-CH3 comprises the sequence of SEQ ID NO: 44;
      • Linker A comprises the sequence of SEQ ID NO: 30;
      • VL2 comprises the sequence of SEQ ID NO: 1445;
      • Linker B comprises the sequence of SEQ ID NO: 22;
      • VH2 comprises the sequence of SEQ ID NO: 1367;
      • VL1 comprises the sequence of SEQ ID NO: 1359; and
      • CK comprises the sequence of SEQ ID NO: 45.


In some embodiments, an antibody comprises a light chain and a heavy chain. In some embodiments, the light chain comprises a sequence of:











(SEQ ID NO: 1751)



DIVMTQSPDSLAVSLGERATINCKSSQSVLYSPNNKNYLAWYQQK






PGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVA






VYYCQQYYTTPPTFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGT






ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS






LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC.






In some embodiments, the heavy chain comprises a sequence of:











(SEQ ID NO: 1752)



EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGL






EWVSGITISGGSTYY ADSVKGRFTISRDNSKNTLYLQMNSLRAE






DTAVYYCARGRGGSGWLDYWGQGTTVTVSSASTKGPSVFPLAPSS






KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS






GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK






THTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVS






HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD






WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE






MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG






SFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGG






GGGSGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFTFSS






YWMHWVRQAPGKGLEWVSYISGSGGYTNYADSVKGRFTISRDNSK






NTLYLQMNSLRAEDTAVYYCARDRPYYYDMDVWGKGTTVTVSSGG






GGSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQ






SISSSLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFT






LTISSLQPEDFATYYCQQYKSYPVTFGQGTKVEIK.






In some embodiments, an antibody, or antigen binding fragment thereof, comprises a light chain comprising an amino acid sequence having at least 90% identity to an amino acid sequence of SEQ ID NO: 1751; and a heavy chain comprising an amino acid sequence having at least 90% identity to an amino acid sequence selected of SEQ ID NO: 1752.


In some embodiments, an antibody, or antigen binding fragment thereof, comprises a light chain comprising an amino acid sequence of SEQ ID NO: 1751; and a heavy chain comprising an amino acid sequence of SEQ ID NO: 1752.


Polypeptides Derived from Reference, e.g., Human Polypeptides


In some embodiments, a component of a therapeutic molecule is derived from or based on a reference molecule, e.g., in the case of a therapeutic molecule for use in humans, from a naturally occurring human polypeptide. E.g., In some embodiments, all or a part of a CD39 molecule, a CD73 molecule, a cell surface molecule binder, a donor specific targeting moiety, an effector ligand binding molecule, an ICIM binding/modulating moiety, an IIC binding/modulating moiety, an inhibitory immune checkpoint molecule ligand molecule, an inhibitory molecule counter ligand molecule, a SM binding/modulating moiety, a specific targeting moiety, a target ligand binding molecule, or a tissue specific targeting moiety, can be based on or derived from a naturally occurring human polypeptide. E.g., a PD-L1 molecule can be based on or derived from a human PD-L1 sequence.


In some embodiments, a therapeutic compound component, e.g., a PD-L1 molecule:

    • a) comprises all or a portion of, e.g., an active portion of, a naturally occurring form of the human polypeptide;
    • b) comprises all or a portion of, e.g., an active portion of, a human polypeptide having a sequence appearing in a database, e.g., GenBank database, on Jan. 11, 2017, a naturally occurring form of the human polypeptide that is not associated with a disease state;
    • c) comprises a human polypeptide having a sequence that differs by no more than 1, 2, 3, 4, 5, 10, 20, or 30 amino acid residues from a sequence of a) or b);
    • d) comprises a human polypeptide having a sequence that differs at no more than by 1, 2, 3, 4, 5 10, 20, or 30% its amino acids residues from a sequence of a) or b);
    • e) comprises a human polypeptide having a sequence that does not differ substantially from a sequence of a) or b); or
    • f) comprises a human polypeptide having a sequence of c), d), or e) that does not differ substantially in a biological activity, e.g., ability to enhance or inhibit an immune response, from a human polypeptide having the sequence of a) or b).


In some embodiments, therapeutic compounds can comprise a plurality of effector binding/modulating moieties. For example, a therapeutic compound can comprise two or more of the following selected from:

    • (a) an ICIM binding/modulating moiety; (b) an IIC binding/modulating moiety; (c) an SM binding/modulating moiety, or (d) an ICSM binding/modulating moiety. In some embodiments, for example, a therapeutic compound can comprise a plurality, e.g., two, ICIM binding/modulating moieties (wherein they are the same or different); by way of example, two that activate or agonize PD-1; a plurality, e.g., two, IIC binding/modulating moieties; (wherein they are the same or different); a plurality, e.g., two, SM binding/modulating moieties (wherein they are the same or different), or a plurality, e.g., tow, ICSM binding/modulating moieties (wherein they are the same or different). In some embodiments, the therapeutic compound can comprise an ICIM binding/modulating moiety and an IIC binding/modulating moiety; an ICIM binding/modulating moiety and an SM binding/modulating moiety; an IIC binding/modulating moiety and an SM binding/modulating moiety, an ICIM binding/modulating moiety and an ICSM binding/modulating moiety; an IIC binding/modulating moiety and an ICSM binding/modulating moiety; or an ICSM binding/modulating moiety and an SM binding/modulating moiety. In some embodiments, the therapeutic compound comprises a plurality of targeting moieties. In some embodiments, the targeting moieties can be the same or different.


Pharmaceutical Compositions and Kits

In another aspect, the present embodiments provide compositions, e.g., pharmaceutically acceptable compositions, which include a therapeutic compound described herein, formulated together with a pharmaceutically acceptable carrier. As used herein, “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, isotonic and absorption delaying agents, and the like that are physiologically compatible.


The carrier can be suitable for intravenous, intramuscular, subcutaneous, parenteral, rectal, local, ophthalmic, topical, spinal or epidermal administration (e.g. by injection or infusion). As used herein, the term “carrier” means a diluent, adjuvant, or excipient with which a compound is administered. In some embodiments, pharmaceutical carriers can also be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The pharmaceutical carriers can also be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary, stabilizing, thickening, lubricating and coloring agents can be used. The carriers can be used in pharmaceutical compositions comprising the therapeutic compounds provided for herein.


The compositions and compounds of the embodiments provided for herein may be in a variety of forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, liposomes and suppositories. The preferred form depends on the intended mode of administration and therapeutic application. Typical compositions are in the form of injectable or infusible solutions. In some embodiments, the mode of administration is parenteral (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular). In some embodiments, the therapeutic molecule is administered by intravenous infusion or injection. In another embodiment, the therapeutic molecule is administered by intramuscular or subcutaneous injection. In another embodiment, the therapeutic molecule is administered locally, e.g., by injection, or topical application, to a target site.


The phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion.


Therapeutic compositions typically should be sterile and stable under the conditions of manufacture and storage. The composition can be formulated as a solution, microemulsion, dispersion, liposome, or other ordered structure suitable to high therapeutic molecule concentration. Sterile injectable solutions can be prepared by incorporating the active compound (i.e., therapeutic molecule) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The proper fluidity of a solution can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prolonged absorption of injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin.


As will be appreciated by the skilled artisan, the route and/or mode of administration will vary depending upon the desired results. In certain embodiments, the active compound may be prepared with a carrier that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are patented or generally known to those skilled in the art. See, e.g., Sustained and Controlled Release Drug Delivery Systems, J. R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.


In certain embodiments, a therapeutic compound can be orally administered, for example, with an inert diluent or an assimilable edible carrier. The compound (and other ingredients, if desired) may also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the subject's diet. For oral therapeutic administration, the compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. To administer a compound by other than parenteral administration, it may be necessary to coat the compound with, or co-administer the compound with, a material to prevent its inactivation. Therapeutic compositions can also be administered with medical devices known in the art.


Dosage regimens are adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.


An exemplary, non-limiting range for a therapeutically or prophylactically effective amount of a therapeutic compound is 0.1-30 mg/kg, more preferably 1-25 mg/kg. Dosages and therapeutic regimens of the therapeutic compound can be determined by a skilled artisan. In certain embodiments, the therapeutic compound is administered by injection (e.g., subcutaneously or intravenously) at a dose of about 1 to 40 mg/kg, e.g., 1 to 30 mg/kg, e.g., about 5 to 25 mg/kg, about 10 to 20 mg/kg, about 1 to 5 mg/kg, 1 to 10 mg/kg, 5 to 15 mg/kg, 10 to 20 mg/kg, 15 to 25 mg/kg, or about 3 mg/kg. The dosing schedule can vary from e.g., once a week to once every 2, 3, or 4 weeks. In one embodiment, the therapeutic compound is administered at a dose from about 10 to 20 mg/kg every other week. The therapeutic compound can be administered by intravenous infusion at a rate of more than 20 mg/min, e.g., 20-40 mg/min, and typically greater than or equal to 40 mg/min to reach a dose of about 35 to 440 mg/m2, typically about 70 to 310 mg/m2, and more typically, about 110 to 130 mg/m2. In embodiments, the infusion rate of about 110 to 130 mg/m2 achieves a level of about 3 mg/kg. In other embodiments, the therapeutic compound can be administered by intravenous infusion at a rate of less than 10 mg/min, e.g., less than or equal to 5 mg/min to reach a dose of about 1 to 100 mg/m2, e.g., about 5 to 50 mg/m2, about 7 to 25 mg/m2, or, about 10 mg/m2. In some embodiments, the therapeutic compound is infused over a period of about 30 min. It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.


The pharmaceutical compositions may include a “therapeutically effective amount” or a “prophylactically effective amount” of a therapeutic molecule. A “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result. A therapeutically effective amount of a therapeutic molecule may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the therapeutic compound to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of a therapeutic molecule t is outweighed by the therapeutically beneficial effects. A “therapeutically effective dosage” preferably inhibits a measurable parameter, e.g., immune attack at least about 20%, more preferably by at least about 40%, even more preferably by at least about 60%, and still more preferably by at least about 80% relative to untreated subjects. The ability of a compound to inhibit a measurable parameter, e.g., immune attack, can be evaluated in an animal model system predictive of efficacy in transplant rejection or autoimmune disorders. Alternatively, this property of a composition can be evaluated by examining the ability of the compound to inhibit, such inhibition in vitro by assays known to the skilled practitioner.


A “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.


Also within the scope of the embodiments is a kit comprising a therapeutic compound described herein. The kit can include one or more other elements including: instructions for use; other reagents, e.g., a label, a therapeutic agent, or an agent useful for chelating, or otherwise coupling, a therapeutic molecule to a label or other therapeutic agent, or a radioprotective composition; devices or other materials for preparing the therapeutic molecule for administration; pharmaceutically acceptable carriers; and devices or other materials for administration to a subject.


In some embodiments, an isolated nucleic acid is provided, wherein the nucleic acid encodes a polypeptide, an antibody, or antigen binding fragment thereof, as provided for herein. In some embodiments, an expression vector comprising the nucleic acid is provided. In some embodiment, a host cell comprising the isolated nucleic acid as provided for herein, or the vector as provided for herein is provided. In some embodiments, a method of making a polypeptide or antibody as provided for herein is provided. In some embodiments, the method comprises culturing a host cell as provided for herein to make the polypeptide or antibody as provided for herein. In some embodiments, a method of producing an antibody or antigen binding fragment thereof as provide for herein comprises (a) culturing a host cell comprising one or more nucleic acids encoding the antibody or antigen binding fragment thereof in a culture medium under conditions favorable for expression of the one or more nucleic acids and (b) optionally recovering the antibody or antigen binding fragment thereof from the culture medium.


In some embodiments, a method of making or producing a polypeptide, or an antibody, or antigen binding fragment thereof, is provided, wherein the polypeptide, or the antibody, or antigen binding fragment thereof, comprises a heavy chain variable region and a light chain variable region, wherein: the heavy chain variable region comprises a variable heavy CDR1 (HCDR1) having at least 90% identity to the amino acid sequence of SEQ ID NO: 1709, 1719, or 1731; a variable heavy CDR2 (HCDR2) having at least 90% identity to the amino acid sequence of SEQ ID NO: 1712, 1744, or 1732; and variable heavy CDR3 (HCDR3) having at least 90% identity to the amino acid sequence of SEQ ID NO: 1715, 1724, or 1734; and the light chain variable region comprises a variable light CDR1 (LCDR1) having at least 90% identity to the amino acid sequence of SEQ ID NO: 1716, 1726, or 1736; a variable light CDR2 (LCDR2) having at least 90% identity to the amino acid sequence of SEQ ID NO: 1717, 1728; and a variable light CDR3 (LCDR3) having at least 90% identity to the amino acid sequence of SEQ ID NO: 1718, 1729, or 1738. In some embodiments, a method of making or producing a polypeptide, or an antibody, or antigen binding fragment thereof, is provided, wherein the heavy chain variable region comprises an amino acid sequence of SEQ ID NOs: 1476, or 1478; and the light chain variable region comprises an amino acid of SEQ ID NO: 1359, or 1479.


In some embodiments, a method of making or producing a polypeptide, or an antibody, or antigen binding fragment thereof, is provided, wherein the polypeptide, or the antibody, or antigen binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a variable heavy CDR1 (HCDR1) having at least 90% identity to the amino acid sequence of SEQ ID NO: 1709, 1719, or 1731; a variable heavy CDR2 (HCDR2) having at least 90% identity to the amino acid sequence of SEQ ID NO: 1712, 1744, or 1732; and variable heavy CDR3 (HCDR3) having at least 90% identity to the amino acid sequence of SEQ ID NO: 1715, 1724, or 1734; and the light chain variable region comprises a variable light CDR1 (LCDR1) having at least 90% identity to the amino acid sequence of SEQ ID NO: 1716, 1726, or 1736; a variable light CDR2 (LCDR2) having at least 90% identity to the amino acid sequence of SEQ ID NO: 1717, 1728; and a variable light CDR3 (LCDR3) having at least 90% identity to the amino acid sequence of SEQ ID NO: 1718, 1729, or 1738; wherein the method comprises (a) culturing a host cell comprising one or more nucleic acids encoding the antibody or antigen binding fragment thereof in a culture medium under conditions favorable for expression of the one or more nucleic acids encoding the heavy chain variable region comprising a variable heavy CDR1 (HCDR1) having at least 90% identity to the amino acid sequence of SEQ ID NO: 1709, 1719, or 1731; a variable heavy CDR2 (HCDR2) having at least 90% identity to the amino acid sequence of SEQ ID NO: 1712, 1744, or 1732; and variable heavy CDR3 (HCDR3) having at least 90% identity to the amino acid sequence of SEQ ID NO: 1715, 1724, or 1734; and the light chain variable region comprising a variable light CDR1 (LCDR1) having at least 90% identity to the amino acid sequence of SEQ ID NO: 1716, 1726, or 1736; a variable light CDR2 (LCDR2) having at least 90% identity to the amino acid sequence of SEQ ID NO: 1717, 1728; and a variable light CDR3 (LCDR3) having at least 90% identity to the amino acid sequence of SEQ ID NO: 1718, 1729, or 1738; and (b) optionally recovering the antibody or antigen binding fragment thereof from the culture medium.


In some embodiments, a method of making or producing a polypeptide, or an antibody, or antigen binding fragment thereof, is provided, wherein the heavy chain variable region comprises an amino acid sequence of SEQ ID NOs: 1479, or 1478; and the light chain variable region comprises an amino acid of SEQ ID NO: 1359, or 1479; wherein the method comprises (a) culturing a host cell comprising one or more nucleic acids encoding the antibody or antigen binding fragment thereof in a culture medium under conditions favorable for expression of the one or more nucleic acids encoding the heavy chain variable region comprising an amino acid sequence of SEQ ID NOs: 1479, or 1478; and the light chain variable region comprising an amino acid of SEQ ID NO: 1359, or 1479; and (b) optionally recovering the antibody or antigen binding fragment thereof from the culture medium.


In some embodiments, embodiments provided herein also include, but are not limited to:


What is Embodimented is:

1. An antibody, or antigen binding fragment thereof, comprises comprising a heavy chain variable region and a light chain variable region, wherein:

    • the heavy chain variable region comprises a variable heavy CDR1 (HCDR1) having at least one amino acid of substitution relative to SEQ ID NOs NO: 1709, or 1719; a variable heavy CDR2 (HCDR2) having at least one amino acid substitution relative to SEQ ID NO: 1712, or 1744; and the variable heavy CDR3 has the (HCDR3) having at least one amino acid substitution relative to SEQ ID NO: 1715, or 1724; and
    • the light chain variable region comprises a variable light CDR1 (LCDR1) having at least one amino acid substitution relative to SEQ ID NO: 1716, or 1726; a variable light CDR2 (LCDR2) having at least one amino acid substitution relative to SEQ ID NO: 1717, or 1728; and a variable light CDR3 (LCDR3) having at least one amino acid substitution relative to SEQ ID NO: 1718, or 1729.


2. The antibody, or antigen binding fragment thereof, of embodiment 1, wherein the heavy chain variable region comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1719, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1744, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1724.


3. The antibody, or antigen binding fragment thereof, of embodiment 1, wherein the heavy chain variable region comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1709, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1712, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1715.


4. The antibody, or antigen binding fragment thereof, of any one of embodiments 1-3, wherein the light chain variable region comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1726, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1728, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1729.


5. The antibody, or antigen binding fragment thereof, of any one of embodiments 1-3, wherein the light chain variable region comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1716, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1717, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1718.


6. The antibody, or antigen binding fragment thereof, of embodiment 1, wherein the heavy chain variable region comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 1476, or 1478, and the light chain variable region comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 1359, or 1479.


7. The antibody, or antigen binding fragment thereof, of any one of embodiments 1-6, wherein the heavy chain variable region comprises an amino acid sequence of SEQ ID NOs: 1476, or 1478, and the light chain variable region comprises an amino acid of SEQ ID NO: 1359, or 1479.


8. The antibody, or antigen binding fragment thereof, of embodiment 7, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1476.


9. The antibody, or antigen binding fragment thereof, of embodiment 7, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1478.


10. The antibody, or antigen binding fragment thereof, of embodiment 7, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 1359.


11. The antibody, or antigen binding fragment thereof, of embodiment 7, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 1479.


12. An antibody, or antigen binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein:

    • the heavy chain variable region comprises a variable heavy CDR1 (HCDR1) having an amino acid sequence of SEQ ID NO: 1719; a variable heavy CDR2 (HCDR2) having an amino acid sequence of SEQ ID NO: 1744; and variable heavy CDR3 (HCDR3) having an amino acid sequence of SEQ ID NO: 1724; and
    • the light chain variable region comprises a variable light CDR1 (LCDR1) having an amino acid sequence of SEQ ID NO: 1726; a variable light CDR2 (LCDR2) having an amino acid sequence of SEQ ID NO: 1728; and a variable light CDR3 (LCDR3) having an amino acid sequence of SEQ ID NO: 1729.


13. The antibody, or antigen binding fragment thereof, of any one of embodiments 1-12, wherein the heavy chain variable region and the light chain variable region are in a Fab format.


14. The antibody, or antigen binding fragment thereof, of any one of embodiments 1-13, wherein the heavy chain variable region and the light variable chain region are linked with a peptide linker.


15. The antibody, or antigen binding fragment thereof, of embodiment 14, wherein the peptide linker is a glycine/serine linker.


16. The antibody, or antigen binding fragment thereof, of embodiment 15, wherein the peptide linker comprises a sequence of GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 22), GGGGSGGGGSGGGGS (SEQ ID NO: 30), GGGGSGGGGS (SEQ ID NO: 619), GGGGS (SEQ ID NO: 23), or GGGSEGGGSEGGGSE (SEQ ID NO: 1546), or any combination thereof.


17. An antibody, or antigen binding fragment thereof, wherein the antibody comprises:

    • a light chain variable region comprising an amino acid sequence having at least 90% identity to an amino acid sequence selected from SEQ ID NOs: 1359, 1680, 1681, 1682, 1683, 1684, 1479, 1449, 1687, 1688, 1689, 1690, 1691, 1692, 1693, 1694, 1695, 1696, 1697, 1698, 1699, 1700, 1701, 1702, 1703, 1704, 1705, or 1706; and
    • a heavy chain variable region comprising an amino acid sequence having at least 90% identity to an amino acid sequence selected from SEQ ID NOs: 1476, 1679, 1685, 1584, 1478, 1707, or 1708.


18. The antibody of embodiment 17, or antigen binding fragment thereof, wherein the antibody comprises:

    • i. a variable light chain sequence of SEQ ID NO: 1359, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • ii. a variable light chain sequence of SEQ ID NO: 1359, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • iii. a variable light chain sequence of SEQ ID NO: 1359, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • iv. a variable light chain sequence of SEQ ID NO: 1359, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • v. a variable light chain sequence of SEQ ID NO: 1359, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • vi. a variable light chain sequence of SEQ ID NO: 1359, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • vii. a variable light chain sequence of SEQ ID NO: 1680, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • viii. a variable light chain sequence of SEQ ID NO: 1680, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • ix. a variable light chain sequence of SEQ ID NO: 1680, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • x. a variable light chain sequence of SEQ ID NO: 1680, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • xi. a variable light chain sequence of SEQ ID NO: 1680, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • xii. a variable light chain sequence of SEQ ID NO: 1680, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • xiii. a variable light chain sequence of SEQ ID NO: 1681, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • xiv. a variable light chain sequence of SEQ ID NO: 1681, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • xv. a variable light chain sequence of SEQ ID NO: 1681, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • xvi. a variable light chain sequence of SEQ ID NO: 1681, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • xvii. a variable light chain sequence of SEQ ID NO: 1681, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • xviii. a variable light chain sequence of SEQ ID NO: 1681, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • xix. a variable light chain sequence of SEQ ID NO: 1682, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • xx. a variable light chain sequence of SEQ ID NO: 1682, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • xxi. a variable light chain sequence of SEQ ID NO: 1682, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • xxii. a variable light chain sequence of SEQ ID NO: 1682, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • xxiii. a variable light chain sequence of SEQ ID NO: 1682, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • xxiv. a variable light chain sequence of SEQ ID NO: 1682, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • xxv. a variable light chain sequence of SEQ ID NO: 1683, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • xxvi. a variable light chain sequence of SEQ ID NO: 1683, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • xxvii. a variable light chain sequence of SEQ ID NO: 1683, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • xxviii. a variable light chain sequence of SEQ ID NO: 1683, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • xxix. a variable light chain sequence of SEQ ID NO: 1683, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • xxx. a variable light chain sequence of SEQ ID NO: 1683, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • xxxi. a variable light chain sequence of SEQ ID NO: 1684, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • xxxii. a variable light chain sequence of SEQ ID NO: 1684, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • xxxiii. a variable light chain sequence of SEQ ID NO: 1684, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • xxxiv. a variable light chain sequence of SEQ ID NO: 1684, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • xxxv. a variable light chain sequence of SEQ ID NO: 1684, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • xxxvi. a variable light chain sequence of SEQ ID NO: 1684, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • xxxvii. a variable light chain sequence of SEQ ID NO: 1479, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • xxxviii. a variable light chain sequence of SEQ ID NO: 1479, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • xxxix. a variable light chain sequence of SEQ ID NO: 1479, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • xl. a variable light chain sequence of SEQ ID NO: 1479, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • xli. a variable light chain sequence of SEQ ID NO: 1479, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • xlii. a variable light chain sequence of SEQ ID NO: 1479, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • xliii. a variable light chain sequence of SEQ ID NO: 1449, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • xliv. a variable light chain sequence of SEQ ID NO: 1449, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • xlv. a variable light chain sequence of SEQ ID NO: 1449, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • xlvi. a variable light chain sequence of SEQ ID NO: 1449, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • xlvii. a variable light chain sequence of SEQ ID NO: 1449, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • xlviii. a variable light chain sequence of SEQ ID NO: 1449, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • xlix. a variable light chain sequence of SEQ ID NO: 1687, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • l. a variable light chain sequence of SEQ ID NO: 1687, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • li. a variable light chain sequence of SEQ ID NO: 1687, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • lii. a variable light chain sequence of SEQ ID NO: 1687, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • liii. a variable light chain sequence of SEQ ID NO: 1687, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • liv. a variable light chain sequence of SEQ ID NO: 1687, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • lv. a variable light chain sequence of SEQ ID NO: 1688, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • lvi. a variable light chain sequence of SEQ ID NO: 1688, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • lvii. a variable light chain sequence of SEQ ID NO: 1688, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • lviii. a variable light chain sequence of SEQ ID NO: 1688, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • lix. a variable light chain sequence of SEQ ID NO: 1688, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • lx. a variable light chain sequence of SEQ ID NO: 1688, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • lxi. a variable light chain sequence of SEQ ID NO: 1689, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • lxii. a variable light chain sequence of SEQ ID NO: 1689, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • lxiii. a variable light chain sequence of SEQ ID NO: 1689, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • lxiv. a variable light chain sequence of SEQ ID NO: 1689, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • lxv. a variable light chain sequence of SEQ ID NO: 1689, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • lxvi. a variable light chain sequence of SEQ ID NO: 1689, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • lxvii. a variable light chain sequence of SEQ ID NO: 1690, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • lxviii. a variable light chain sequence of SEQ ID NO: 1690, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • lxix. a variable light chain sequence of SEQ ID NO: 1690, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • lxx. a variable light chain sequence of SEQ ID NO: 1690, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • lxxi. a variable light chain sequence of SEQ ID NO: 1690, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • lxxii. a variable light chain sequence of SEQ ID NO: 1690, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • lxxiii. a variable light chain sequence of SEQ ID NO: 1691, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • lxxiv. a variable light chain sequence of SEQ ID NO: 1691, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • lxxv. a variable light chain sequence of SEQ ID NO: 1691, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • lxxvi. a variable light chain sequence of SEQ ID NO: 1691, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • lxxvii. a variable light chain sequence of SEQ ID NO: 1691, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • lxxviii. a variable light chain sequence of SEQ ID NO: 1691, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • lxxix. a variable light chain sequence of SEQ ID NO: 1692, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • lxxx. a variable light chain sequence of SEQ ID NO: 1692, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • lxxxi. a variable light chain sequence of SEQ ID NO: 1692, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • lxxxii. a variable light chain sequence of SEQ ID NO: 1692, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • lxxxiii. a variable light chain sequence of SEQ ID NO: 1692, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • lxxxiv. a variable light chain sequence of SEQ ID NO: 1692, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • lxxxv. a variable light chain sequence of SEQ ID NO: 1693, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • lxxxvi. a variable light chain sequence of SEQ ID NO: 1693, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • lxxxvii. a variable light chain sequence of SEQ ID NO: 1693, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • lxxxviii. a variable light chain sequence of SEQ ID NO: 1693, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • lxxxix. a variable light chain sequence of SEQ ID NO: 1693, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • xc. a variable light chain sequence of SEQ ID NO: 1693, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • xci. a variable light chain sequence of SEQ ID NO: 1694, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • xcii. a variable light chain sequence of SEQ ID NO: 1694, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • xciii. a variable light chain sequence of SEQ ID NO: 1694, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • xciv. a variable light chain sequence of SEQ ID NO: 1694, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • xcv. a variable light chain sequence of SEQ ID NO: 1694, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • xcvi. a VK of SEQ ID NO: 1694, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • xcvii. a variable light chain sequence of SEQ ID NO: 1695, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • xcviii. a variable light chain sequence of SEQ ID NO: 1695, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • xcix. a variable light chain sequence of SEQ ID NO: 1695, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • c. a variable light chain sequence of SEQ ID NO: 1695, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • ci. a variable light chain sequence of SEQ ID NO: 1695, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • cii. a variable light chain sequence of SEQ ID NO: 1695, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • ciii. a variable light chain sequence of SEQ ID NO: 1696, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • civ. a variable light chain sequence of SEQ ID NO: 1696, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • cv. a variable light chain sequence of SEQ ID NO: 1696, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • cvi. a variable light chain sequence of SEQ ID NO: 1696, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • cvii. a variable light chain sequence of SEQ ID NO: 1696, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • cviii. a variable light chain sequence of SEQ ID NO: 1696, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • cix. a variable light chain sequence of SEQ ID NO: 1697, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • cx. a variable light chain sequence of SEQ ID NO: 1697, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • cxi. a variable light chain sequence of SEQ ID NO: 1697, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • cxii. a variable light chain sequence of SEQ ID NO: 1697, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • cxiii. a variable light chain sequence of SEQ ID NO: 1697, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • cxiv. a variable light chain sequence of SEQ ID NO: 1697, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • cxv. a variable light chain sequence of SEQ ID NO: 1698, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • cxvi. a variable light chain sequence of SEQ ID NO: 1698, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • cxvii. a variable light chain sequence of SEQ ID NO: 1698, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • cxviii. a variable light chain sequence of SEQ ID NO: 1698, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • cxix. a variable light chain sequence of SEQ ID NO: 1698, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • cxx. a variable light chain sequence of SEQ ID NO: 1698, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • cxxi. a variable light chain sequence of SEQ ID NO: 1699, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • cxxii. a variable light chain sequence of SEQ ID NO: 1699, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • cxxiii. a variable light chain sequence of SEQ ID NO: 1699, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • cxxiv. a variable light chain sequence of SEQ ID NO: 1699, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • cxxv. a variable light chain sequence of SEQ ID NO: 1699, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • cxxvi. a variable light chain sequence of SEQ ID NO: 1699, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • cxxvii. a variable light chain sequence of SEQ ID NO: 1700, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • cxxviii. a variable light chain sequence of SEQ ID NO: 1700, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • cxxix. a variable light chain sequence of SEQ ID NO: 1700, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • cxxx. a variable light chain sequence of SEQ ID NO: 1700, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • cxxxi. a variable light chain sequence of SEQ ID NO: 1700, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • cxxxii. a variable light chain sequence of SEQ ID NO: 1700, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • cxxxiii. a variable light chain sequence of SEQ ID NO: 1701, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • cxxxiv. a variable light chain sequence of SEQ ID NO: 1701, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • cxxxv. a variable light chain sequence of SEQ ID NO: 1701, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • cxxxvi. a variable light chain sequence of SEQ ID NO: 1701, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • cxxxvii. a variable light chain sequence variable light chain sequence K of SEQ ID NO: 1701, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • cxxxviii. a variable light chain sequence of SEQ ID NO: 1701, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • cxxxix. a variable light chain sequence of SEQ ID NO: 1702, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • cxl. a variable light chain sequence of SEQ ID NO: 1702, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • cxli. a variable light chain sequence of SEQ ID NO: 1702, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • cxlii. a variable light chain sequence of SEQ ID NO: 1702, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • cxliii. a variable light chain sequence of SEQ ID NO: 1702, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • cxliv. a variable light chain sequence of SEQ ID NO: 1702, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • cxlv. a variable light chain sequence of SEQ ID NO: 1703, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • cxlvi. a variable light chain sequence of SEQ ID NO: 1703, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • cxlvii. a variable light chain sequence of SEQ ID NO: 1703, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • cxlviii. a variable light chain sequence of SEQ ID NO: 1703, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • cxlix. a variable light chain sequence of SEQ ID NO: 1703, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • cl. a variable light chain sequence of SEQ ID NO: 1703, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • cli. a variable light chain sequence of SEQ ID NO: 1704, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • clii. a variable light chain sequence of SEQ ID NO: 1704, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • cliii. a variable light chain sequence of SEQ ID NO: 1704, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • cliv. a variable light chain sequence of SEQ ID NO: 1704, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • clv. a variable light chain sequence of SEQ ID NO: 1704, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • clvi. a variable light chain sequence of SEQ ID NO: 1704, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • clvii. a variable light chain sequence of SEQ ID NO: 1705, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • clviii. a variable light chain sequence of SEQ ID NO: 1705, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • clix. a variable light chain sequence of SEQ ID NO: 1705, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • clx. a variable light chain sequence of SEQ ID NO: 1705, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • clxi. a variable light chain sequence of SEQ ID NO: 1705, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • clxii. a variable light chain sequence of SEQ ID NO: 1705, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;
    • clxiii. a variable light chain sequence of SEQ ID NO: 1706, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;
    • clxiv. a variable light chain sequence of SEQ ID NO: 1706, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;
    • clxv. a variable light chain sequence of SEQ ID NO: 1706, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;
    • clxvi. a variable light chain sequence of SEQ ID NO: 1706, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;
    • clxvii. a variable light chain sequence of SEQ ID NO: 1706, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;
    • clxviii. a variable light chain sequence of SEQ ID NO: 1706, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof.


19. The antibody, or antigen binding fragment thereof, of any one of embodiments 1-18, wherein the antibody, or antigen binding fragment thereof, binds to PD-1.


20. The antibody, or antigen binding fragment thereof, of embodiment 19, wherein the antibody, or antigen binding fragment thereof, that binds to PD-1 is a PD-1 agonist.


21. The antibody, or antigen binding fragment thereof, of any of embodiments 1-20, wherein the antibody is linked or associated with another antibody or targeting moiety.


22. The antibody, or antigen binding fragment thereof, of embodiment 21, wherein the another antibody or targeting moiety binds to MAdCAM.


23. The antibody, or antigen binding fragment thereof, of embodiment 22, wherein the antibody that binds to MAdCAM comprises:

    • the heavy chain variable region comprises a variable heavy CDR1 (HCDR1) having at least one amino acid substitution relative to SEQ ID NO: 1731, 1721, or 1499; a variable heavy CDR2 (HCDR2) having at least one amino acid substitution relative to SEQ ID NO: 1732, 1733, 1506; and variable heavy CDR3 (HCDR3) having at least one amino acid substitution relative to SEQ ID NO: 1734, 1735, 1739, 1740, 1507, 1531, or 1532; and
    • the light chain variable region comprises a variable light CDR1 (LCDR1) having at least one amino acid substitution relative to SEQ ID NO: 1502, 1736, or 1737; a variable light CDR2 (LCDR2) having at least one amino acid substitution relative to SEQ ID NO: 1497, 1717, or a peptide comprising the sequence of Ala-Ala-Ser; and a variable light CDR3 (LCDR3) having at least one amino acid substitution relative to SEQ ID NO: 1498, or 1738.


24. The antibody, or antigen binding fragment thereof, of any one of embodiments 22 or 23, wherein:

    • the heavy chain variable region comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1731, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1732, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1734; and
    • the light chain variable region comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1736, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1717, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1738.


25. The antibody, or antigen binding fragment thereof, of any one of embodiments 22 or 23, wherein:

    • the heavy chain variable region comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1499, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1506, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1507; and
    • the light chain variable region comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1502, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1497, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1498.


26. The antibody, or antigen binding fragment thereof, of any one of embodiments 22-25, wherein the heavy chain variable region comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 1445, 591, 1443, 1480, 1545, or 1542; and the light chain variable region comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 1367, 592, or 1543.


27. The antibody, or antigen binding fragment thereof, of any one of embodiments 22-26, wherein the heavy chain variable region comprises an amino acid sequence of SEQ ID NOs: 1445, 591, 1443, 1480, 1545, or 1542; and the light chain variable region comprises an amino acid of SEQ ID NO: 1367, 592, or 1543.


28. The antibody, or antigen binding fragment thereof, of embodiment 27, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1445.


29. The antibody, or antigen binding fragment thereof, of embodiment 27, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 1367.


30. The antibody, or antigen binding fragment thereof, of any one of embodiments 22-29, wherein the antibody, or antigen binding fragment thereof, binds to MAdCAM.


31. An antibody, or antigen binding fragment thereof, wherein the antibody comprises:

    • a light chain comprising an amino acid sequence having at least 90% identity to an amino acid sequence of SEQ ID NO: 1751; and
    • a heavy chain comprising an amino acid sequence having at least 90% identity to an amino acid sequence selected of SEQ ID NO: 1752.


32. An antibody, or antigen binding fragment thereof, wherein the antibody comprises:

    • a light chain comprising an amino acid sequence of SEQ ID NO: 1751; and
    • a heavy chain comprising an amino acid sequence of SEQ ID NO: 1752.


33. A PD-1 agonist comprising four polypeptide chains, wherein the four polypeptide chains comprise:

    • Chain 1: N terminus (nt)-VH1-CH1-CH2-CH3-Linker A-scFv[VL2-Linker B-VH2]-C terminus (ct);
    • Chain 2: nt-VH1-CH1-CH2-CH3-Linker A-scFv[VL2-Linker B-VH2]-ct;
    • Chain 3: nt-VL1-CK-ct; and
    • Chain 4: nt-VL1-CK-ct;
    • wherein:
    • VH1 comprises the sequence of SEQ ID NO: 1476;
    • CH1-CH2-CH3 comprises the sequence of SEQ ID NO: 44;
    • Linker A comprises the sequence of SEQ ID NO: 30;
    • VL2 comprises the sequence of SEQ ID NO: 1445;
    • Linker B comprises the sequence of SEQ ID NO: 2;
    • VH2 comprises the sequence of SEQ ID NO: 1367;
    • VL1 comprises the sequence of SEQ ID NO: 1359; and
    • CK comprises the sequence of SEQ ID NO: 45.


34. The PD-1 agonist of embodiment 31, wherein the PD-1 agonist is a homodimer.


35. A pharmaceutical composition comprising the antibody, or antigen binding fragment thereof, of any of embodiments 1-32, or the PD-1 agonist of embodiment 33 or 34, and a pharmaceutically acceptable carrier.


36. A method of treating inflammatory bowel disease, the method comprising administering an antibody, or antigen binding fragment thereof, of any of embodiments 1-32, a PD-1 agonist of any of embodiments 33-34, or a pharmaceutical composition of embodiment 35, to a subject in need thereof.


37. The method of embodiment 34, wherein the subject has Crohn's disease, or ulcerative colitis.


38. A method of treating auto-immune hepatitis, primary sclerosing cholangitis, Type 1 diabetes, graft-versus-host disease (GVHD), or an autoimmune disorder, the method comprising administering an antibody, or antigen binding fragment thereof, of any of embodiments 1-32, a PD-1 agonist of any of embodiments 33-34, or a pharmaceutical composition of embodiment 35, to a subject in need thereof.


39. An isolated nucleic acid molecule encoding the antibody, or an antigen binding fragment thereof, of any of embodiments 1-32.


40. An expression vector comprising the isolated nucleic acid of embodiment 39.


41. A host cell comprising the nucleic acid molecule of embodiment 39 or the expression vector of embodiment 40.


42. A method of producing an antibody, or antigen binding fragment thereof, of any one of embodiments 1-32 comprising:

    • (a) culturing a host cell comprising one or more nucleic acids of embodiment 41 in a culture medium under conditions favorable for expression of the one or more nucleic acids; and
    • (b) optionally recovering the antibody or antigen binding fragment thereof from the culture medium.


The following examples are illustrative, but not limiting, of the compounds, compositions and methods described herein. Other suitable modifications and adaptations known to those skilled in the art are within the scope of the following embodiments.


EXAMPLES

Non limiting examples of therapeutics, compounds, molecules, antibodies, compositions of matter, and examples may be found in PCT Application No. PCT/US2020/033707, which is hereby incorporated by reference in its entirety.


Example 1. Anti-MAdCAM Molecule Variants with Disrupted Poly Y Patch do not Show Non Specific Binding to DNA and Insulin

Non-specific DNA and Insulin binding is predictive of poor pharmacokinetics (PK). An immunosorbent plate was coated with dsDNA at a concentration of 1 μg/mL or Insulin at 5 μg/mL in PBS pH 7.4, 75 ul/well, and incubated overnight at 4° C. Wells were washed three times with PBS pH 7.4 containing 0.05% Tween-20 (wash buffer), and then blocked with 200 ul/well 1% BSA in PBS pH 7.4 (block buffer) for two hours at room temperature. After three washes with wash buffer, test antibodies (TAs) and controls Lenzilumab and (humanized monoclonal antibody that binds to target colony stimulating factor 2/granulocyte-macrophage colony stimulating factor) and Elotuzumab (a humanized IgG1 monoclonal antibody that binds to SLAMF7 on NK cells) were diluted to a concentration of 100 nM in PBS containing 1% BSA and 0.05% Tween-20 (assay buffer). The diluted material was added to the DNA/insulin coated plate at 75 ul/well for 1 hour at room temperature. After three washes with wash buffer, donkey anti-human FcY HRP conjugated polyclonal antibody, diluted to 1:5000 in assay buffer, was added to the plate at 75 ul/well for 1 hr at room temperature. After three washes with wash buffer followed by three washes with wash buffer (with no tween-20), the assay was developed with 3,3′,5,5′-Tetramethylbenzidine (TMB), and stopped with TN HCL. OD 450 nm was measured. The experiment included appropriate controls for non-specific binding of test articles to the plate/block in the absence of DNA or insulin. PRNT1 showed dsDNA polyreactivity score of 45.64, and Insulin polyreactivity score of 6.21; MIAB128 showed dsDNA polyreactivity score of 33.01, and Insulin polyreactivity score of 2.62; MIAB129 showed dsDNA polyreactivity score of 3.51, and Insulin polyreactivity score of 2.43; MIAB130 showed dsDNA polyreactivity score of 29.66, and Insulin polyreactivity score of 3.26; MIAB131 showed dsDNA polyreactivity score of 13.49, and Insulin polyreactivity score of 8.00; MIAB133 showed dsDNA polyreactivity score of 44.80, and Insulin polyreactivity score of 13.16; MIAB134 showed dsDNA polyreactivity score of 45.96, and Insulin polyreactivity score of 25.53; MIAB136 showed dsDNA polyreactivity score of 51.85, and Insulin polyreactivity score of 75.37; MIAB137 showed dsDNA polyreactivity score of 43.44, and Insulin polyreactivity score of 67.33; MIAB139 showed dsDNA polyreactivity score of 1.09, and Insulin polyreactivity score of 2.08; MIAB141 showed dsDNA polyreactivity score of 33.26, and Insulin polyreactivity score of 4.18; MIAB144 showed dsDNA polyreactivity score of 47.18, and Insulin polyreactivity score of 5.07; Elotuzumab control showed dsDNA polyreactivity score of 1, and Insulin polyreactivity score of 1; and Lenzilumab control showed dsDNA polyreactivity score of 52.42, and Insulin polyreactivity score of 1.52. No non-specific binding to DNA and insulin was seen with MIAB129, MIAB139, and MIAB141. MIAB129, MIAB139, and MIAB141 were not polyreactive.


Example 2. Anti-MAdCAM Molecule Variants with the A34N Substitution in LCDR1 do not Show Non Specific Binding to DNA and Insulin

Non-specific DNA and Insulin binding is predictive of poor pharmacokinetics (PK). An immunosorbent plate was coated with dsDNA at a concentration of 1 μg/mL or Insulin at 5 μg/mL in PBS pH 7.4, 75 ul/well, and incubated overnight at 4° C. Wells were washed three times with PBS pH 7.4 containing 0.05% Tween-20 (wash buffer), and then blocked with 200 ul/well 1% BSA in PBS pH 7.4 (block buffer) for two hours at room temperature. After three washes with wash buffer, TAs and controls Lenzilumab and Elotuzumab were diluted to a concentration of 100 nM in PBS containing 1% BSA and 0.05% Tween-20 (assay buffer). The diluted material was added to the DNA/insulin coated plate at 75 ul/well for 1 hour at room temperature. After three washes with wash buffer, donkey anti-human FcY HRP conjugated polyclonal antibody, diluted to 1:5000 in assay buffer, was added to the plate at 75 ul/well for 1 hr at room temperature. After three washes with wash buffer and three washes with wash buffer (with no tween-20), the assay was developed with TMB, and stopped with 1N HCL. OD 450 nm was measured. The experiment included appropriate controls for non-specific binding of test articles to the plate/block in the absence of DNA or insulin. MIAB145 showed dsDNA polyreactivity score of 43.11, and Insulin polyreactivity score of 4.58; MIAB146 showed dsDNA polyreactivity score of 24.57, and Insulin polyreactivity score of 2.61; MIAB147 showed dsDNA polyreactivity score of 8.36, and Insulin polyreactivity score of 3.81; MIAB148 showed dsDNA polyreactivity score of 3.53, and Insulin polyreactivity score of 3.63; MIAB149 showed dsDNA polyreactivity score of 27.86, and Insulin polyreactivity score of 3.53; MIAB150 showed dsDNA polyreactivity score of 9.66, and Insulin polyreactivity score of 3.74; MIAB151 showed dsDNA polyreactivity score of 2.89, and Insulin polyreactivity score of 3.63; MIAB152 showed dsDNA polyreactivity score of 7.01, and Insulin polyreactivity score of 2.83; MIAB153 showed dsDNA polyreactivity score of 1.52, and Insulin polyreactivity score of 2.46; MIAB154 showed dsDNA polyreactivity score of 8.25, and Insulin polyreactivity score of 61.91; MIAB155 showed dsDNA polyreactivity score of 1.62, and Insulin polyreactivity score of 1.99; MIAB156 showed dsDNA polyreactivity score of 4.70, and Insulin polyreactivity score of 45.25; MIAB157 showed dsDNA polyreactivity score of 6.63, and Insulin polyreactivity score of 3.99; MIAB158 showed dsDNA polyreactivity score of 1.67, and Insulin polyreactivity score of 2.67; PRNT1 showed dsDNA polyreactivity score of 38.82, and Insulin polyreactivity score of 5.02; MIAB141 showed dsDNA polyreactivity score of 1.77, and Insulin polyreactivity score of 3.60; Elotuzumab control showed dsDNA polyreactivity score of 0.95, and Insulin polyreactivity score of 1.01; and Lenzilumab control showed dsDNA polyreactivity score of 38.04, and Insulin polyreactivity score of 7.87. No non-specific binding to DNA and insulin was seen with MIAB148, MIAB151, MIAB153, MIAB155, MIAB158 and MIAB141. MIAB148, MIAB151, MIAB153, MIAB155, MIAB158 and MIAB141 were not polyreactive.


Example 3. Anti-MAdCAM Molecule Variants with the A34N Substitution in LCDR1 Bind Human MAdCAM

Anti-human Fc biosensors were equilibrated in assay buffer (1% BSA in 1×PBS with 0.05% Tween-20) for 10 minutes before the experiment was set-up. Test articles were diluted to 5 μg/mL in assay buffer and 200 μL pipetted to 96 well plate. Human MAdCAM was titrated down, two-fold dilutions (starting at 600 nM as the highest concentration, 7-point dilution). The experiment was run using data acquisition software version 10.0 for OCTET96 RED. Test articles were captured using anti-human Fc biosensors for 180 s. Biosensors loaded with test articles were then equilibrated in assay buffer for 120 s. Association was performed in wells with huMAdCAM for 180 seconds. Dissociation was performed in wells with assay buffer for 180 s. Kinetic parameters (kon and kdis) and dissociation constant (KD) were calculated from a 1:1 global fit model using the data analysis software of the Octet96 RED software version 10. MIAB148 showed Kd (M) of 2.69E-06, Kon (1/ms) of 1.17E+05, and Kdis (1/s) of 3.14E-01; MIAB151 showed Kd of 2.96E-06, Kon of 9.87E+04, and Kdis of 2.92E-01; MIAB153 showed Kd of 8.36E-06, Kon of 6.48E+04, and Kdis of 5.43E-01; and PRNT1 showed Kd of 1.84E-08, Kon of 5.83E+05, and Kdis of 1.07E-02. MIAB148, MIAB151, and MIAB153 bound human MAdCAM with lower affinity than the parent PRNT1 molecule.


Example 4. MAdCAM Molecule Variants with Y105I or Y105W and A34N Mutations in the VH do not Show Non Specific Binding to DNA and Insulin

Non-specific DNA and Insulin binding is predictive of poor pharmacokinetics (PK). An immunosorbent plate was coated with dsDNA at a concentration of 1 μg/mL or Insulin at 5 μg/mL in PBS pH 7.4, 75 ul/well, and incubated overnight at 4° C. Wells were washed three times with PBS pH 7.4 containing 0.05% Tween-20 (wash buffer), and then blocked with 200 μl/well 1% BSA in PBS pH 7.4 (block buffer) for two hours at room temperature. After three washes with wash buffer, TAs and controls Lenzilumab and Elotuzumab were diluted to a concentration of 100 nM in PBS containing 1% BSA and 0.05% Tween-20 (assay buffer). The diluted material was added to the DNA/insulin coated plate at 75 μl/well for 1 hour at room temperature. After three washes with wash buffer, donkey anti-human FcY HRP conjugated polyclonal antibody, diluted to 1:5000 in assay buffer, was added to the plate at 75 μl/well for 1 hr at room temperature. After three washes with wash buffer followed by three washes with wash buffer (with no tween-20), the assay was developed with TMB, and stopped with 1N HCL. OD 450 nm was measured. The experiment included appropriate controls for non-specific binding of test articles to the plate/block in the absence of DNA or insulin. MIAB159 showed dsDNA polyreactivity score of 9.58, and Insulin polyreactivity score of 4.66; MIAB160 showed dsDNA polyreactivity score of 42.95, and Insulin polyreactivity score of 17.80; MIAB161 showed dsDNA polyreactivity score of 25.87, and Insulin polyreactivity score of 5.00; MIAB162 showed dsDNA polyreactivity score of 21.75, and Insulin polyreactivity score of 5.31; MIAB163 showed dsDNA polyreactivity score of 28.56, and Insulin polyreactivity score of 18.53; MIAB164 showed dsDNA polyreactivity score of 25.46, and Insulin polyreactivity score of 7.07; MIAB165 showed dsDNA polyreactivity score of 19.42, and Insulin polyreactivity score of 9.53; MIAB166 showed dsDNA polyreactivity score of 37.98, and Insulin polyreactivity score of 7.89; MIAB167 showed dsDNA polyreactivity score of 26.28, and Insulin polyreactivity score of 29.56; MIAB168 showed dsDNA polyreactivity score of 7.75, and Insulin polyreactivity score of 8.35; MIAB169 showed dsDNA polyreactivity score of 3.34, and Insulin polyreactivity score of 5.59; MIAB170 showed dsDNA polyreactivity score of 2.05, and Insulin polyreactivity score of 4.73; MIAB172 showed dsDNA polyreactivity score of 26.63, and Insulin polyreactivity score of 3.79; MIAB173 showed dsDNA polyreactivity score of 29.82, and Insulin polyreactivity score of 7.10; PRNT1 showed dsDNA polyreactivity score of 34.37, and Insulin polyreactivity score of 6.91; Elotuzumab control showed dsDNA polyreactivity score of 1.05, and Insulin polyreactivity score of 1.25; and Lenzilumab control showed dsDNA polyreactivity score of 44.96, and Insulin polyreactivity score of 21.31. No non-specific binding to DNA and insulin was seen with MIAB169 and MIAB170. MIAB169 and MIAB170 were not polyreactive.


Example 5. Anti-MAdCAM Molecule Variants with the Y105I Substitution Bind Human MAdCAM

Anti-human Fc biosensors were equilibrated in assay buffer (1% BSA in 1×PBS with 0.05% Tween-20) for 10 minutes before the experiment was set-up. Test articles were diluted to 5 μg/mL in assay buffer and 200 μL pipetted to 96 well plate. Human MAdCAM was titrated down, two-fold dilutions (starting at 600 nM as the highest concentration, 7-point dilution). Experiment was run using data acquisition software version 10.0 for OCTET96 RED. Test articles were captured using anti-human Fc biosensors for 180 s. Biosensors loaded with test articles were then equilibrated in assay buffer for 120 s. Association was performed in wells with huMAdCAM for 180 seconds. Dissociation was performed in wells with assay buffer for 180 s. Kinetic parameters (kon and kdis) and dissociation constant (KD) were calculated from a 1:1 global fit model using the data analysis software of the Octet96 RED software version 10. PRNT1 showed Kd (nM) of 26.6, Kon (1/ms) of 4.16E+05, and Kdis (1/s) of 1.11E-02; MIAB169 showed Kd of 266, Kon of 2.78E+05, and Kdis of 7.38E-02; and MIAB170 showed no binding at 1 μM human MAdCAM tested. MIAB169 bound to human MAdCAM at 10 fold lower affinity than parent PRNT1.


Example 6. MAdCAM Molecule Variants with the Y105I Substitution Bind Human and Cyno MAdCAM

Anti-human Fc biosensors were equilibrated in assay buffer (1% BSA in 1×PBS with 0.05% Tween-20) for 10 minutes before the experiment was set-up. Test articles were diluted to 5 μg/mL in assay buffer and 200 μL pipetted to 96 well plate. Human MAdCAM was titrated down, two-fold dilutions (starting at 600 nM as the highest concentration, 7-point dilution). Experiment was run using data acquisition software version 10.0 for OCTET96 RED. Test articles were captured using anti-human Fc biosensors for 180 s. Biosensors loaded with test articles were then equilibrated in assay buffer for 120 s. Association was performed in wells with huMAdCAM for 180 seconds. Dissociation was performed in wells with assay buffer for 180 s. Kinetic parameters (kon and kdis) and dissociation constant (KD) were calculated from a 1:1 global fit model using the data analysis software of the Octet96 RED software version 10. PRNT1 showed Kd (nM) of 24 in human, Kd of 13 in cyno, and biphasic Kd in mouse; MIAB169 showed Kd of 340 in human, Kd of 153 in cyno, and biphasic Kd in mouse. MIAB169 showed lower affinity to human and cyno MAdCAM than parent PRNT1.


Example 7. MAdCAM Molecule Variants with the Y105I Mutation do not Show Non Specific Binding to DNA and Insulin Irrespective of Expression Host

An immunosorbent plate was coated with dsDNA at a concentration of 1 μg/mL or Insulin at 5 μg/mL in PBS pH 7.4, 75 μl/well, and incubated overnight at 4° C. Wells were washed three times with PBS pH 7.4 containing 0.05% Tween-20 (wash buffer), and then blocked with 200 μl/well 1% BSA in PBS pH 7.4 (block buffer) for two hours at room temperature. After three washes with wash buffer, TAs and controls Lenzilumab and Elotuzumab were diluted to 100 nM in PBS containing 1% BSA and 0.05% Tween-20 (assay buffer). The diluted material was added to the DNA/insulin coated plate at 75 μl/well for 1 hour at room temperature. After three washes with wash buffer, donkey anti-human FcY HRP conjugated polyclonal antibody, diluted to 1:5000 in assay buffer, was added to the plate at 75 μl/well for 1 hr at room temperature. After three washes with wash buffer followed by three washes with wash buffer (with no tween-20), the assay was developed with TMB, and stopped with 1N HCL. OD 450 nm was measured. The experiment included appropriate controls for non-specific binding of test articles to the plate/block in the absence of DNA or insulin. MIAB169-CHO showed dsDNA polyreactivity score of 1.65, and Insulin polyreactivity score of 3.38; MIAB169-HEK showed dsDNA polyreactivity score of 3.36, and Insulin polyreactivity score of 6.37; Elotuzumab control showed dsDNA polyreactivity score of 1.16, and Insulin polyreactivity score of 3.43; and Lenzilumab control showed dsDNA polyreactivity score of 49.51, and Insulin polyreactivity score of 69.23. No non-specific binding to DNA and insulin was seen with MIAB169 expressed in CHO or HEK cells.


Example 8. MAdCAM Germlined Mutants Bind Human MAdCAM

Anti-human Fc biosensors were equilibrated in assay buffer (1% BSA in 1×PBS with 0.05% Tween-20) for 10 minutes before the experiment was set-up. Test articles were diluted to 5 μg/mL in assay buffer and 200 μL pipetted to 96 well plate. Human MAdCAM was titrated down, two-fold dilutions (starting at 600 nM as the highest concentration, 7-point dilution). Experiment was run using data acquisition software version 10.0 for OCTET96 RED. Test articles were captured using anti-human Fc biosensors for 180 s. Biosensors loaded with test articles were then equilibrated in assay buffer for 120 s. Association was performed in wells with huMAdCAM for 180 seconds. Dissociation was performed in wells with assay buffer for 180 s. Kinetic parameters (kon and kdis) and dissociation constant (KD) were calculated from a 1:1 global fit model using the data analysis software of the Octet96 RED software version 10. PRNT1 showed Kd (nM) of 14, Kon (1/ms) of 6.83E+05, and Kdis (1/s) of 9.55E-03; MIAB137 (HCDR2 germlined) showed Kd (nM) of 203, Kon (1/ms) of 4.04E+05, and Kdis (1/s) of 8.2E-02; MIAB136 (HCDR1 germlined), MIAB141 (LCDR1 germlined), and MIAB141 (LCDR3 germlined) showed no binding to 150 nM human MAdCAM. MIAB137 showed a reduced binding affinity to human MAdCAM compared to parental molecule, PRNT1.


In a separate experiment PRNT1 showed Kd (nM) of 26.5, Kon (1/ms) of 4.29E+05, and Kdis (1/s) of 1.14E-02; MIAB145-001 (VK: V29I) showed Kd (nM) of 22.2, Kon (1/ms) of 4.05E+05, and Kdis (1/s) of 8.97E-03; MIAB146-001 (VK: R31S) showed Kd (nM) of 43.8, Kon (1/ms) of 4.49E+05, and Kdis (1/s) of 1.97E-02; MIAB149-001 (VK: V29I) showed Kd (nM) of 68.8, Kon (1/ms) of 3.76E+05, and Kdis (1/s) of 2.59E-02; and MIAB147-001 (VK: S32Y) showed no binding to 200 nM human MAdCAM. MIAB146 and MIAB149 have reduced binding affinity to human MAdCAM compared to parental molecule, PRNT1.


In another experiment PRNT1 showed Kd (nM) of 21.2, Kon (1/ms) of 3.85E+05, and Kdis (1/s) of 8.16E-03; MIAB133-001 (VH: D31S) showed Kd (nM) of 20.00, Kon (1/ms) of 5.64E+05, and Kdis (1/s) of 1.13E-02; MIAB174-001 (VH: HCDR1: F32Y) showed Kd (nM) of 21.8, Kon (1/ms) of 4.45E+05, and Kdis (1/s) of 9.69E-03; MIAB175-001 (VH: HCDR1: D31S, F32Y) showed Kd (nM) of 22.6, Kon (1/ms) of 4.71E+05, and Kdis (1/s) of 1.06E-02; MIAB177-001 (VH: HCDR2: I48V, Y50A, D54S, S55G, Y57S, N59Y) showed Kd (nM) of 218, Kon (1/ms) of 3.91E+05, and Kdis (1/s) of 8.51E-02; and MIAB178-001 (VH: HCDR1: D31S, F32Y; HCDR2: Y50A, D54S, Y57S, N59Y) showed Kd (nM) of 519, Kon (1/ms) of 3.72E+05, and Kdis (1/s) of 2.20E-01. MIAB177 and MIAB178 have reduced affinity to MAdCAM compared to parental molecule, PRNT1.


In another experiment PRNT1 showed Kd (nM) of 14.8, Kon (1/ms) of 3.96E+05, and Kdis (1/s) of 5.86E-03; MIAB182-001 (HCDR1: D31S, F32Y; HCDR2: I48V, Y50A, D54S, S55G, Y57S, N59Y; VK: V29I) showed Kd (nM) of 119, Kon (1/ms) of 2.26E+05, and Kdis (1/s) of 2.67E-02; MIAB183-001 (HCDR1: D31S, F32Y; HCDR2: I48V, Y50A, D54S, S55G, Y57S, N59Y; VK: R31S) showed Kd (nM) of 362, Kon (1/ms) of 1.66E+05, and Kdis (1/s) of 5.99E-02; MIAB184-001 (HCDR1: D31S, F32T; HCDR2: I48V, Y50A, D54S, S55G, Y57S, N59Y; VK: V29I, R31S) showed Kd (nM) of 563, Kon (1/ms) of 1.45E+05, and Kdis (1/s) of 8.18E-02. Germling heavy chain with V29I reduced MAdCAM affinity by 10-fold, germling heavy chain with R31S reduced MAdCAM affinity by 20-fold, and germling heavy chain and light chain reduced MAdCAM affinity by 40-fold.


Example 9. MIAB197 is Stable for 1 Month at 4 C and 37 C

MIAB197 in acetate buffer was concentrated to 5 mg/mL using spin columns. Samples were collected at various concentrations and analyzed by size exclusion chromatography on an Agilent BioAdvance SEC 300 A column. MIAB197 at 5 mg/mL was incubated at 4 and 37 C for up to 28 days to analyze molecule stability over time. Samples were collected at various time points and analyzed by size exclusion chromatography on an Agilent BioAdvance SEC 300 A column. No concentration dependent aggregation was observed with MIAB197 when concentrated up to 5 mg/mL in optimized acetate buffer as seen by analytical SEC. MIAB197 at concentration of 5 mg/mL remained stable with no loss of main peak or appearance of high or low molecular weight species at 4 C and 37 C for 1 month.


Example 10. MIAB197 has Favorable Thermal Stability

The anti-PD-1-MAdCAM antibodies were analyzed by the Nano DSC system (TA Instrument) to determine melting temperature (Tm). A temperature ramp of 1° C./min was performed with monitoring from 25° C. to 100° C. Thermograms of the blank buffer were subtracted from each antibody prior to analysis and the Tm values were calculated after deconvolution using the Nano DSC software. PRNT1 showed Tm (C) peak 1 of 64.5, peak 2 of 81.7, and peak 3 of 83.8; MIAB197 showed Tm peak 1 of 69.8, peak 2 of 81.7, and peak 3 of 84. MIAB197 has favorable thermal stability.


Example 11. MIAB197 has Desirable Characteristics for Development

To characterize the identity and purity of the anti-PD-1-MAdCAM antibodies, the anti-PD-1-MAdCAM antibodies were prepared in reducing labeling buffer before being analyzed on the LabChip GXII system (PerkinElmer). rCE SDS revealed PRNT1 to comprise 26.5% light chain and 71.6% heavy chain; and MIAB197 to comprise 28.47% light chain and 71.53% heavy chain. MIAB197 has good characteristics for development.


Example 12. MIAB197 has Isoelectric Point Compatible with Manufacturing

The anti-PD-1-MAdCAM antibodies were was diluted in a matrix of methyl cellulose, 4 M urea, 3-10 pharmalytes (4%), 5 mM Arginine, and pI markers (indicated below). The mixture was submitted to an iCE3 IEF Analyzer (ProteinSimple) and pre-focused at 1,500 V followed by focusing at 3,000 V. The isoelectric points of each peak were calculated from the bracketing pI markers. Capillary isoelectric focusing (cIEF) showed isoelectric peaks of 7.72 with peak area (%) of 0.60, 7.82 with peak area of 1.94, 7.96 with peak area of 5.98, 8.11 with peak area of 10.52, 8.24 with peak area of 32.43, 8.33 with peak area of 22.95, 8.39 with peak areak of 12.56, 8.44 with peak area of 5.21, and 8.54 with peak area of 7.81 for PRNT1; and isoelectric peaks of 8.55 with peak area (%) of 3.63, 8.60 with peak area of 8.66, 8.69 with peak area of 18.38, 8.72 with peak area of 28.79, and 8.76 with peak area of 40.54 for MIAB197. The data demonstrate that the isoelectric peaks for MIAB197 were all above pH 8.5, with ˜70% at pI of 8.7 which is favorable for manufacturability


Example 13. MIAB204 does not Show Non Specific Binding to DNA and Insulin

Non-specific DNA and Insulin binding is predictive of poor pharmacokinetics (PK). An immunosorbent plate was coated with dsDNA at a concentration of 1 μg/mL or Insulin at 5 μg/mL in PBS pH 7.4, 75 μl/well, and incubated overnight at 4° C. Wells were washed three times with PBS pH 7.4 containing 0.05% Tween-20 (wash buffer), and then blocked with 200 μl/well 1% BSA in PBS pH 7.4 (block buffer) for two hours at room temperature. After three washes with wash buffer, TAs and controls Lenzilumab and Elotuzumab were diluted to 100 nM in PBS containing 1% BSA and 0.05% Tween-20 (assay buffer). The diluted material was added to the DNA/insulin coated plate at 75 μl/well for 1 hour at room temperature. After three washes with wash buffer, donkey anti-human FcY HRP conjugated polyclonal antibody, diluted to 1:5000 in assay buffer, was added to the plate at 75 μl/well for 1 hr at room temperature. After three washes with wash buffer followed by three washes with wash buffer (with no tween-20), the assay was developed with TMB, and stopped with 1N HCL. OD 450 nm was measured. The experiment included appropriate controls for non-specific binding of test articles to the plate/block in the absence of DNA or insulin. MIAB204 showed dsDNA polyreactivity score of 1.66, and Insulin polyreactivity score of 8.43; Elotuzumab control showed dsDNA polyreactivity score of 1.16, and Insulin polyreactivity score of 3.43; and Lenzilumab control showed dsDNA polyreactivity score of 49.51, and Insulin polyreactivity score of 69.23. MIAB204 is not polyreactive.


Example 14. MIAB204 has Favorable Thermal Stability

The anti-PD-1-MAdCAM antibodies were submitted to the Nano DSC system (TA Instrument) for analysis. A temperature ramp of 1° C./min was performed with monitoring from 25° C. to 100° C. Thermograms of the blank buffer were subtracted from each antibody prior to analysis and the Tm values were calculated after deconvolution using the Nano DSC software. PRNT1 showed Tm (C) peak 1 of 64.5, peak 2 of 81.7, and peak 3 of 83.8; MIAB204 showed Tm peak 1 of 65.4, peak 2 of 69.5, and peak 3 of 84.4. MIAB204 has favorable thermal stability.


Example 15. MIAB204 has Desirable Characteristics for Development

To characterize the identity and purity of the anti-PD-1-MAdCAM antibodies, the anti-PD-1-MAdCAM antibodies were prepared in reducing labeling buffer before being submitted to the LabChip GXII system (PerkinElmer). rCE SDS revealed PRNT1 to comprise 26.5% light chain and 71.6% heavy chain; and MIAB204 to comprise one peak comprising 80.64% and second peak comprising 19.36% of the sample. MIAB204 showed different O-glycan occupancies. MIAB204 showed sufficient purity and composition identity for development.


Example 16. MIAB204 has Isoelectric Point Compatible with Manufacturing

The sample was diluted in a matrix of methyl cellulose, 4 M urea, 3-10 pharmalytes (4%), 5 mM Arginine, and pI markers (indicated below). The mixture was submitted to an iCE3 IEF Analyzer (ProteinSimple) and pre-focused at 1,500 V followed by focusing at 3,000 V. The isoelectric points of each peak were calculated from the bracketing pI markers. Capillary isoelectric focusing (cIEF) showed isoelectric peaks of 7.72 with peak area (%) of 0.60, 7.82 with peak area of 1.94, 7.96 with peak area of 5.98, 8.11 with peak area of 10.52, 8.24 with peak area of 32.43, 8.33 with peak area of 22.95, 8.39 with peak area of 12.56, 8.44 with peak area of 5.21, and 8.54 with peak area of 7.81 for PRNT1; and isoelectric peaks of 7.59 with peak area (%) of 2.92, 7.84 with peak area of 5.94, 8.00 with peak area of 14.88, 8.19 with peak area of 18.64, 8.29 with peak area of 5.80, 8.33 with peak area of 10.73, 8.38 with peak area of 22.13, 8.43 with peak area of 14.04, and 8.48 with peak area of 4.92 for MIAB204. Isoelectric peaks for MIAB204 show heterogeneity with most peaks having the pI greater than 8. MIAB204 is considered good for manufacturing.


Example 17. V69A and Q74P Substitutions in the IL-2 Mutein are Beneficial in Improving Solubility of the Molecule

The pTT5 vectors containing the full length IgG1 heavy with C-terminally fused human IL-2 mutant and light chain encoding MIAB211 (control IgG1 mAb) were co-transfected at equimolar ratios into HEK cells. After 5-7 days, cell culture supernatants expressing MIAB211 (control IgG1 mAb) were harvested, and clarified by centrifugation and filtration through a 0.22 um filtration device. MIAB211, was captured on Mab Select column. The column was washed with PBS pH 7.4 and the captured protein was eluted using 0.1M glycine pH 2.5, with neutralization using a tenth volume of 1M Tris pH 8.0. The protein was buffer exchanged into PBS pH 7.4, and analyzed by size exclusion chromatography on an Agilent BioAdvance SEC 300 A column. MIAB211 (control IgG1 mAb) was aggregated with only 67% monodispersed after ProA purification as shown by size exclusion chromatography. Additional polishing procedures like cation exchange improved the monodispersity to 86% which is not suitable for assays. V69A and Q74P are beneficial in improving solubility of molecule.


Example 18. Germline Single Mutants Bind to Human PD-1

Anti-human IgG Fc (AHC) biosensors were equilibrated in assay buffer for 20 minutes. Test article was diluted to 10 μg/mL in assay buffer (ix PBS, 1% BSA, 0.05% Tween20). A seven-point serial dilution of human PD-1 was prepared in assay buffer, starting at 1000 nM down to 15.625 nM. Test article was loaded on tips for 180 s followed by a 240 s association phase with MAdCAM and 240 s dissociation phase in assay buffer. PMAB134 bound to human PD-1 with the Kd (nM) of 6; Kon of 1.2e5, and Koff of 6.7E-4; PMAB135 bound to human PD-1 with the Kd (nM) of 3; Kon of 1.1E5, and Koff of 3.3E-4; PMAB136 bound to human PD-1 with the Kd (nM) of 36; Kon of 8.3E4, and Koff of 2.9E-3; PMAB137 did not bind to human PD-1; PMAB138 bound to human PD-1 with the Kd (nM) of 53; Kon of 1.3E5, and Koff of 6.9E-3; PMAB139 bound to human PD-1 with the Kd (nM) of 50; Kon of 1.3E5, and Koff of 6.3E-3; PMAB140 bound to human PD-1 with the Kd (nM) of 22; Kon of 9.9E4, and Koff of 2.2E-3; PMAB141 did not bind to human PD-1; PMAB142 bound to human PD-1 with the Kd (nM) of 33; Kon of 6.4E4, and Koff of 2.1E-3; PMAB143 bound to human PD-1 with the Kd (nM) of 17; Kon of 9.3E4, and Koff of 1.6E-3; PMAB144 did not bind to human PD-1; PMAB145 did not bind to human PD-1. Germlined PD-1 agonists comprising single mutations bound to human PD-1.


Example 19. Germline Mutants Bind to Human PD-1

Anti-human IgG Fc (AHC) biosensors were equilibrated in assay buffer for 20 minutes. Test article was diluted to 10 μg/mL in assay buffer (1×PBS, 1% BSA, 0.05% Tween20). A seven-point serial dilution of human PD-1 was prepared in assay buffer, starting at 1000 nM down to 15.625 nM. Test article was loaded on tips for 180 s followed by a 180-240 s association phase with PD-1 and 240 s dissociation phase in assay buffer. PMAB134 bound to human PD-1 with the Kd(M) of 1.16E-08; Kon of 6.97E+04, and Kdis of 8.07E-04; PMAB1A did not bind to human PD-1; PMAB189 did not bind to human PD-1; PMAB175 bound to human PD-1 with the Kd(M) of 7.71E-08, Kon of 3.77E+04, and Kdis of 2.91E-03; PMAB176 bound to human PD-1 with the Kd(M) of 8.94E-07; Kon of 6.18E+04, and Kdis of 5.53E-02; PMAB177 bound to human PD-1 with the Kd(M) of 8.09E-07; Kon of 8.16E+04, and Kdis of 6.60E-02; PMAB178 bound to human PD-1 with the Kd(M) of 1.30E-06; Kon of 4.74E+04, and Kdis of 6.15E-02; PMAB179 did not bind to human PD-1; PMAB182 did not bind to human PD-1; PMAB183 bound to human PD-1 with the Kd(M) of 1.13E-05; Kon of 2.97E+04, and Kdis of 3.34E-01; PMAB184 did not bind to human PD-1. Germlined PD-1 agonists comprising mutations bound to human PD-1. Germlined PD-1 agonists comprising mutations in the CDR2 did not bind human PD-1.


Example 20. Germline and Hydrophobic Patch Mutants Bind to Human PD-1

Anti-human IgG Fc (AHC) biosensors were equilibrated in assay buffer for 20 minutes. Test article was diluted to 10 μg/mL in assay buffer (ix PBS, 1% BSA, 0.05% Tween20). A seven-point serial dilution of human PD-1 was prepared in assay buffer, starting at 1000 nM down to 15.625 nM. Test article was loaded on tips for 180 s followed by a 180-240 s association phase with PD-1 and 240 s dissociation phase in assay buffer. PMAB134 bound to human PD-1 with the Kd (nM) of 1.11E-08, Kon of 5.86E+04, and Koff of 6.51E-04; PMAB194 bound to human PD-1 with the Kd (nM) of 5.77E-07, Kon of 2.17E+04, and Koff of 1.25E-02; PMAB195 bound to human PD-1 with the Kd (nM) of 6.51E-07, Kon of 3.49E+04, and Koff of 2.27E-02; PMAB198 bound to human PD-1 with the Kd (nM) of 1.04E-07, Kon of 3.46E+04, and Koff of 3.59E-03; PMAB199 bound to human PD-1 with the Kd (nM) of 9.86E-08, Kon of 3.40E+04, and Koff of 3.36E-03. Accordingly, PD-1 agonists comprising germline and hydrophobic patch mutations bind to human PD-1.


Example 21. PD-1 Agonists Comprising Germline Single Mutations Bind to Human PD-1

Anti-human IgG Fc (AHC) biosensors were equilibrated in assay buffer for 20 minutes. Test article was diluted to 10 μg/mL in assay buffer (ix PBS, 1% BSA, 0.05% Tween20). A seven-point serial dilution of human PD-1 was prepared in assay buffer, starting at 1000 nM down to 15.625 nM. Test article was loaded on tips for 180 s followed by a 240 s association phase with MAdCAM and 240 s dissociation phase in assay buffer. PMAB119 bound to human PD-1 with the Kd (nM) of 96.9, Kon of 1.50E+05, and Koff of 1.45E-02; PMAB108 bound to human PD-1 with the Kd (nM) of 55.3, Kon of 1.16E+05, and Koff of 6.40E-03; PMAB109 bound to human PD-1 with the Kd (nM) of 85.9, Kon of 4.31E+04, and Koff of 3.70E-03; PMAB110 showed inconclusive binding kinetics; PMAB111 bound to human PD-1 with the Kd (nM) of 67.6, Kon of 1.06E+05, and Koff of 7.18E-03; PMAB112 bound to human PD-1 with the Kd (nM) of 76.2, Kon of 9.45E+04, and Koff of 7.20E-03; PMAB113 bound to human PD-1 with the Kd (nM) of 91.7, Kon of 1.74E+05, and Koff of 1.59E-02; PMAB114 bound to human PD-1 with the Kd (nM) of 113, Kon of 1.03E+05, and Koff of 1.16E-02; PMAB115 bound to human PD-1 with the Kd (nM) of 229, Kon of 4.22E+04, and Koff of 9.66E-03; PMAB116, PMAB117, and PMAB118 showed inconclusive binding kinetics. PD-1 agonists comprising germline single mutations bind to human PD-1.


Example 22. PD-1 Agonists Comprising Mutations in Variable Domains Bind to Human PD-1

Plates were coated with 2 μg/mL huPD-1 in 1×PBS at 4° C. overnight. Plates were blocked with 1×PBS with 1% BSA. Antibodies were tested in duplicate for binding with a 3-fold, dilution series from 50 nM to 0.07 nM. Signal is background subtracted for coated wells with 2° antibody only. PMAB244, PMAB245, PMAB246, and PMAB247 comprised mutations in the variable heavy domain and showed binding to human PD-1. PMAB247 comprised double mutations in the variable heavy domain and showed reduced binding to human PD-1. PMAB244, PMAB249, PMAB250, PMAB251, PMAB252, PMAB253, PMAB254, PMAB258, PMAB256, PMAB259, PMAB255, PMAB257, PMAB248, PMAB260, PMAB264, PMAB265, PMAB266, PMAB267, PMAB268, PMAB269, PMAB270, PMAB271, PMAB272, PMAB273, PMAB261, PMAB262, and PMAB263 comprised mutations in the variably light chain and showed binding to human PD-1. PD-1 agonists comprising mutations in the variably heavy or light chain bind human PD-1.


Example 23. PD-1 Agonists Comprising Germline Mutations Bind to Human PD-1

Plates were coated with 2 μg/mL huPD-1 in 1×PBS at 4° C. overnight. Plates were blocked with 1×PBS with 1% BSA. Antibodies were tested in duplicate for binding with a 3-fold, dilution series from 300 nM to 0.4 nM. Signal is background subtracted for coated wells with 2° antibody only. PMAB244 bound to human PD-1 with the IC50 (nM) of 258.1; PND00915 bound to human PD-1 with the IC50 (nM) of 18.94; PMAB233 bound to human PD-1 with the IC50 (nM) of 85.87; PMAB234 bound to human PD-1 with the IC50 (nM) of 28.08; PMAB235 bound to human PD-1 with the IC50 (nM) of 23.18; PND00919 bound to human PD-1 with the IC50 (nM) of 23.2; PMAB237 bound to human PD-1 with the IC50 (nM) of 15.87; PMAB238 bound to human PD-1 with the IC50 (nM) of 36.37; PMAB239 bound to human PD-1 with the IC50 (nM) of 44.72; PMAB240 bound to human PD-1 with the IC50 (nM) of 39.04; PMAB241 bound to human PD-1 with the IC50 (nM) of 46.44; PMAB242 bound to human PD-1 with the IC50 (nM) of 30.57; PMAB243 bound to human PD-1 with the IC50 (nM) of 40.74. PD-1 agonists comprising germline mutations bind to human PD-1.


Example 24. PMAB274, PMAB275, PMAB276, PMAB277, and PMAB278 Bind to Human PD-1

Anti-human IgG Fc (AHC) biosensors were equilibrated in assay buffer for 20 minutes. Test article was diluted to 10 μg/mL in assay buffer (ix PBS, 1% BSA, 0.05% Tween20). A seven-point serial dilution of human PD-1 was prepared in assay buffer, starting at 1000 nM down to 15.625 nM. Test article was loaded on tips for 180 s followed by a 120 s association phase with PD-1 and 180 s dissociation phase in assay buffer. PMAB274 bound human PD-1 with the Kd (nM) of 1.79E-06, Kon of 2.04E+04, and Koff of 3.65E-02; PMAB275 bound human PD-1 with the Kd (nM) of 8.49E-07, Kon of 9.78E+04, and Koff of 8.30E-02; PMAB276 bound human PD-1 with the Kd (nM) of 9.85E-07, Kon of 3.81E+04, and Koff of 3.75E-02; PMAB277 bound human PD-1 with the Kd (nM) of 8.96E-07, Kon of 4.48E+04, and Koff of 4.01E-02; PMAB278 bound human PD-1 with the Kd (nM) of 8.92E-07, Kon of 2.29E+04, and Koff of 2.05E-02.


Example 25. PD-1 Agonists Bind to Human PD-1

Anti-human IgG Fc (AHC) biosensors were equilibrated in assay buffer for 20 minutes. Test article was diluted to 10 μg/mL in assay buffer (ix PBS, 1% BSA, 0.05% Tween20). A seven-point serial dilution of human PD-1 was prepared in assay buffer, starting at 1000 nM down to 15.625 nM. Test article was loaded on tips for 180 s followed by a 240 s association phase with PD-1 and 240 s dissociation phase in assay buffer. PMAB217 bound to human PD-1 with the Kd (nM) of 4.24E-07, Kon of 3.31E+05, and Koff of 1.40E-01; PMAB201 bound to human PD-1 with the Kd (nM) of 3.41E-07, Kon of 2.58E+05, and Koff of 8.78E-02; PMAB202 bound to human PD-1 with the Kd (nM) of 7.55E-07, Kon of 1.79E+05, and Koff of 1.35E-01; PMAB204 bound to human PD-1 with the Kd (nM) of 1.71E-06, Kon of 9.99E+04, and Koff of 1.71E-01; PMAB205 bound to human PD-1 with the Kd (nM) of 7.95E-07, Kon of 1.91E+05, and Koff of 1.52E-01; PMAB207 bound to human PD-1 with the Kd (nM) of 4.45E-07, Kon of 1.97E+05, and Koff of 8.76E-02; PMAB208 bound to human PD-1 with the Kd (nM) of 5.53E-07, Kon of 2.71E+05, and Koff of 1.50E-01; PMAB209 bound to human PD-1 with the Kd (nM) of 6.87E-07, Kon of 2.08E+05, and Koff of 1.43E-01; PMAB210 bound to human PD-1 with the Kd (nM) of 3.13E-06, Kon of 7.57E+04, and Koff of 2.37E-01; PMAB211 bound to human PD-1 with the Kd (nM) of 1.30E-06, Kon of 1.54E+05, and Koff of 2.00E-01; PMAB212 bound to human PD-1 with the Kd (nM) of 1.09E-06, Kon of 1.43E+05, and Koff of 1.56E-01; PMAB213 bound to human PD-1 with the Kd (nM) of 1.43E-06, Kon of 1.24E+05, and Koff of 1.78E-01; PMAB214 bound to human PD-1 with the Kd (nM) of 8.05E-06, Kon of 3.26E+04, and Koff of 2.63E-01. Accordingly, PD-1 agonists comprising germline single mutations bind human PD-1.


Example 26. PMAB65 Shows Expected Molecular Weight and Diameter in CE-SDS, SEC-MALS, and DLS, Respectively

PMAB65 was subjected to CE-SDS, SEC-MALS, and DLS in order to assess its molecular weight and diameter. The sample was prepared in nonreducing or reducing labeling buffer before being submitted to the LabChip GXII system (PerkinElmer). PMAB65 in nonreducing buffer showed peak 1 of 188.02 kDa and area of 0.99%, and peak 2 of 213.9 kDa and area of 99.01%. PMAB65 in reducing buffer showed peak 1 of 28.8 kDa and area of 24.33%, and peak 2 of 93.13 kDa and area of 75.67%.


Next, in SEC-MALS analysis 20 μL of PMAB65 was injected onto Zenix SEC-300 column and eluted for 10 minutes at 0.35 mL/min. Predicted size of PMAB65 was 199.6 kDa, and the data showed molecular weight of 204.5 kDa±7.24%, and glycan molecular weight of 20.9 kDa±78.7%.


Using DLS PMAB65 showed molecule diameter of 15 nm which was as expected of a IgG-HC-scFv antibody. Accordingly, PMAB65 shows expected monodispersed molecular weight and diameter.


Example 27. PMAB65 has Low Polyreactive Binding to Nonspecific Antigens

Plates were coated with polyreactivity antigen (ssDNA=1 μg/ml; dsDNA=1 μg/ml; KLH=5 μg/ml; insulin=5 μg/ml; LPS=10 μg/ml; cardiolipin=50 μg/ml) in 1×PBS at 4° C. overnight. Plates were blocked with 1×PBS with 1% BSA. PMAB65, PMAB1B (negative control), and PMAB1C (positive control) antibodies were tested in triplicate for binding at 100 nM. Antibody binding was detected by Anti-Kappa-HRP antibody, signal is background subtracted for coated wells with 2° antibody only. PMAB65 showed low polyreactivity against all tested antigens as compared to control antibodies. Accordingly, PMAB65 has low polyreactivity.


Example 28. PMAB65 has as Predicted Empirical and Theoretical Mass

PMAB65 sample was denatured and/or reduced by guanidine and DTT and then deglycosylated by PNGase F (MEDNA Bio M3104). The sample was analyzed by Waters ACQUITY UPLC coupled to Xevo G2-XS QTOF mass spectrometer using an ACQUITY UPLC Protein BEH SEC column. Glycosylated conditions assume glycosylation weight of G0F (1445 Da). Nonreduced condition assumes disulfide-bond weight of −2 Da per disulfide (20 disulfide-bonds). PMAB65 in non-reduced glycosylated form had expected molecular weight of 202420 Da and empirical molecular weight of 202418 Da. PMAB65 in non-reduced deglycosylated form had expected molecular weight of 199536 Da and empirical molecular weight of 199530 Da. PMAB65 in reduced glycosylated form had expected molecular weight of 76975 Da (G0F) and 24258 Da; and empirical molecular weight of 76976 Da and 24248 Da. PMAB65 in reduced deglycosylated form had expected molecular weight of 75530 Da and 24258 Da, and empirical molecular weight of 75530 Da and 24248 Da. Empirically determined masses for PMAB65 align with the expected mass for each condition.


Example 29. PMAB65 Exhibits Minimal Chemical Modifications Under Stress

In order to create deamidation stress conditions, PMAB65 was buffer exchanged into 20 mM Tris, 10 mM EDTA, pH 8.5 or control buffer and incubated for 1 week at 37° C. before snap freezing and storage at −80° C. until preparation for mass spectrometry analysis. To create oxidation stress conditions, PMAB65 was adjusted to 1 mM 2,2′-azobis(2-amidinopropane) dihydrochloride from a 100 mM stock or an equal volume of water for control condition and incubated at 37° C. for 24 hours. After incubation, samples were buffer exchanged into control buffer, snap frozen, and stored at −80° C. until preparation for mass spectrometry analysis. Samples were treated with DTT and IAM, followed by trypsin/Lys-C digestion. The digested sample was then analyzed by Waters ACQUITY UPLC coupled to Xevo G2-XS QTOF mass spectrometer using a Protein BEH C18 column. Data showed minimal modifications in the variable domains CDR3 of the scFv moiety. PMAB65 shows favorable properties for manufacturing.


Example 30. PMAB65 Binds to Human and Cynomolgus PD-1 and Human, Cynomolgus, and Mouse MAdCAM

Anti-human IgG Fc (AHC) biosensors were equilibrated in assay buffer for 20 minutes. Test article was diluted to 10 μg/mL in assay buffer (lx PBS, 1% BSA, 0.05% Tween20). A seven-point serial dilution of human and cynomolgus PD-1 or human, cynomolgus and mouse MAdCAM was prepared in assay buffer, starting at 1000 nM down to 15.625 nM. For PD-1 binding, test article was loaded on tips for 180 s followed by a 180 s association phase with PD-1 and 240 s dissociation phase in assay buffer. For MAdCAM binding, test article was loaded on tips for 180 s followed by a 120 s association phase with MAdCAM and 180 s dissociation phase in assay buffer. Fab moiety of the PMAB65 comprising PD-1 bound to human PD-1 with the Kd of 32.6 nM; cyno PD-1 with the Kd of 30.3 nM; and did not bind mouse PD-1. scFv moiety of the PMAB65 comprising MAdCAM bound to human MAdCAM with the Kd of 75.5 nM; cyno MAdCAM with the Kd of 24.3 nM; and mouse MAdCAM with the Kd of 269 nM. Accordingly, PMAB65 binds human, cyno, and mouse PD-1 and MAdCAM.


Example 31. PMAB65 Shows Specific Binding to MAdCAM and PD-1 on Human Protein Array (Retrogenix)

Over 6000 expression vectors, encoding both ZsGreen1 and full-length human plasma membrane proteins or a cell-surface tethered human secreted protein, were arrayed in duplicate across 16 microarray slides. Human HEK293 cells were used for reverse transfection/expression. The test antibodies were added to each slide after cell fixation. Detection of binding was performed by using the same fluorescent secondary antibody as used in the Pre-screen. Fluorescent images were analyzed and quantitated (for transfection) using ImageQuant software. A protein ‘hit’ is defined as a duplicate spot showing a raised signal compared to background levels. This is achieved by visual inspection using the images gridded on the ImageQuant software. Hits were classified as ‘strong, medium, weak or very weak’, depending on the intensity of the duplicate spots. PMAB65 was found to specifically interact with its two primary targets only −PDCD1 (medium/strong) and MADCAM1 (strong) only. No other significant interactions were detected. These results demonstrate that the bi-specific molecule is able to bind to its respective targets, with no unwanted off-target binding.


Example 32. PMAB65 Shows Good Storage Stability

Test article was concentrated to ˜30 mg/mL and incubated at 4° C. and 37° C. for up to 28 days. Approximately 15 μg of test article was injected onto AdvanceBio SEC-300A column and eluted for 10 minutes at 0.35 mL/min. PMAB65 was formulated in: a) NaOAc pH 5; b) NaOAc pH 6; and c) NaPO4 pH 7. Stability was calculated as % POI and showed 97.9% in a), 97.5% in b), and 96.6 in c) on day 0; 96.9% in a), 93.8% in b), and 95.9 in c) on day 3; 96.4% in a), 94.2% in b), and 95.8 in c) on day 7; 95.9% in a), 94.2% in b), and 95.5% in c) on day 14; 95.7% in a), 94.1% in b), and 95.5 in c) on day 21; and 95.7% in a), 94.2% in b), and 95.5% in c) on day 28. PMAB65 was stable at 4° C. up to 28 days at approximately 22-25 mg/ml in sodium acetate or phosphate buffers, and showed minimal aggregation. Slight degradation over time was evident in the accelerated storage conditions at 37° C.


Example 33. PMAB65 Shows Good Thermal Stability

The sample was submitted to the Nano DSC system (TA Instrument) for analysis. A temperature ramp of 1° C./min was performed with monitoring from 25° C. to 100° C. The Tm values were calculated after deconvolution using the Nano DSC software. PMAB65 showed Tm1 of 61.6° C.; Tm2 of 67.1° C.; Tm3 of 81.6° C.; and Tm4 of 82.9° C.


Next, test article intrinsic fluorescence was measured from 25-95° C. with a 1° C./min increase. Tm was calculated from local maxima of the 1st order differential equation and Tagg were measured by absorbance at 266 and 473 nm. PMAB65 showed Tm1 of 61.86° C. and Tm4 of 82.38° C.; and Tagg266 and Tagg473 of approximately 80° C. PMAB65 shows good thermal stability and low aggregation risk.


Example 34. PMAB65 and Other PD-1 Bispecific Molecules Show No Immunogenic Epitopes in Silico

Immunogenicity of PMAB65 and other PD-1 bispecific molecules was assessed in silico according to standard methods, and showed no immunogenic epitopes in Fab or scFv CDRs.


Example 35. PMAB65 has Low Viscosity and Shows Little Concentration-Dependent Increase in Viscosity

Test article concentrated to 24 mg/mL was used to generate a 6-point, 2-fold serial dilution to 0.75 mg/mL. Test article combined with 100 nm nanospheres was measured for dynamic light scattering to determine change in viscosity. PMAB65 showed little concentration dependent increase in viscosity.


Example 36. PMAB65 has Improved Concentration Dependent Aggregation Properties

PMAB134, PMAB197, and PMAB65 molecules were affinity purified and buffer exchanged into phosphate buffer, pH 7.0 containing 8.5% sucrose and 100 mM NaCl. Each antibody was then concentrated using a centrifugal concentrator with samples taken at the indicated concentrations for analysis by analytical SEC. PMAB65 showed improved concentration dependent aggregation.


Example 37. PMAB65 and PMAB197 have Decreased Polyreactivity

Plates were coated with 1% Baculovirus particle (BVP) or HEK293 cell lysate (HCL) in carbonate buffer pH 9.5, 4° C. overnight. Plates were blocked with 1×PBS with 2% BSA. PMAB134, PMAB197, and PMAB65 were tested in triplicate for binding to BVP or HCL at 150, 50, 16.7 and 5.6 μg/mL. Signal was normalized to background signal (coated wells with secondary antibody only). PMAB197 and PMAB65 showed reduced polyreactive binding to BVP or HCL at 50 μg/ml or 16.7 μg/ml. Accordingly, PMAB197 and PMAB65 have decreased polyreactivity.


Example 38. PMAB65 and PMAB197 Have Decreased Isoelectric Point

PMAB134, PMAB197, and PMAB65 were each diluted in a matrix of methyl cellulose, 4 M urea, 3-10 pharmalytes (4%), 5 mM Arginine, and pI markers (indicated below). The mixture was submitted to an iCE3 IEF Analyzer (ProteinSimple) and pre-focused at 1,500 V followed by focusing at 3,000 V. The isoelectric points of each peak were calculated from the bracketing pI markers. icIEF analysis showed charge variant species ranging from approximately 8.0-9.0 compatible with platform manufacturing processes. PMAB197 and PMAB65 have decreased isoelectric point as compared to the parental molecule, PMAB134.


Example 39. PMAB134, PMAB65, PMAB129, and PMAB61 do not have PD-1 Antagonist Activity

In separate experiments, PD-1 reporter Jurkat cells were incubated with Pembrolizumab, PMAB134, or PMAB65; or Pembrolizumab, PMAB129, or PMAB61 at concentrations ranging from 0.001 to 100 nM for 1 hour. PD-L1 expressing cells were then added and SHP-2 recruitment was assessed after 2 hours. PMAB134, PMAB65, PMAB129, and PMAB61 showed no antagonist activity. Accordingly, PMAB134, PMAB65, PMAB129, and PMAB61 do not have antagonist activity.


Example 40. PD-1 Molecules have Agonist Activity

In separate experiments, plates were coated with anti-human IgG, blocked, and PMAB1D, CC-90006, or PMAB65; or PMAB1D, CC-90006, or PMAB61 were added at concentrations ranging from 0.001 to 100 nM for 1 hour. Plates were washed and PD-1 reporter Jurkat cells were added. SHP-2 recruitment was assessed after 2 hours. Ig-tethered PMAB1D did not show agonist activity; Ig-tethered CC-90006 showed agonist activity with EC50 (nM) of 2.942; and Ig-tethered PMAB65 showed agonist activity with EC50 (nM) of 3.044. In another experiment, Ig-tethered PMAB1D did not show agonist activity; Ig-tethered CC-90006 showed agonist activity with EC50 (nM) of 2.588; and Ig-tethered PMAB61 showed agonist activity with EC50 (nM) of 4.446.


MAdCAM-expressing CHO cells were allowed to adhere and form a monolayer. PMAB1D, PMAB1E, PMAB65, or PMAB61 were added at concentrations ranging from 0.001 to 100 nM and allowed to bind for 1 h at 37 C. All wells were washed, and PD-1 reporter Jurkat cells were added. Jurkat cells were incubated with test article loaded CHO cells for 2 h at 37 C. PMAB1D showed no agonist activity; PMAB1E showed agonist activity with EC50 (nM) of less than 100; PMAB65 showed agonist activity with EC50 (nM) of 0.7802; and PMAB61 showed agonist activity with EC50 (nM) of 3.023. Ig-tethered or MAdCAM bound optimized PD-1 have agonist activity.


Example 41. PD-1 Molecules have No Detectable Soluble Agonist Activity

PD-1 reporter Jurkat cells were incubated with PMAB1D, Positive Control, PMAB65, or PMAB61 at concentrations ranging from 0.001 to 100 nM. SHP-2 recruitment was assessed after 24 hours. PMAB1D, PMAB65, and PMAB61 showed no soluble agonist activity.


Example 42. PMAB65 Prolongs Survival in xGVHD

Xenogeneic graft versus host disease was induced by the transfer of human PBMC into immunodeficient mice. Beginning 10 days after cell transfer, mice were treated subcutaneously every 3 weeks with PMAB65 or vehicle. Data were representative of 2 studies including 5 donors. Mice treated with PMAB65 showed improved survival of 64 days (median) as compared to control (41 days, median). PMAB65 improves survival in xGVHD.


Example 43. PMAB65 is Detectable in Gut Tissue

Balb/c mice were subcutaneously dosed with 1 mg/kg of PMAB65. Serum samples were collected at within 800 hours after dosing and analyzed for presence of PMAB65. Colons were collected at days 0, 5, 7, 15, 21, and 28, snap frozen, and analyzed for the presence of PMAB65. PMAB65 was detected in serum and colons of mice treated with PMAB65 at all time points. PMAB65 is detectable in gut tissue through 4 weeks following administration in mice.


Example 44. PMAB65 Increases Expression of Treg Activation Markers

Eight-week-old human PD-1 knock-in mice were dosed subcutaneously in the dorsal scruff with vehicle, PMAB1F, PMAB1G, or PMAB65. After 7 days mice were euthanized, spleens dissected and splenocytes stained with antibodies against surface and intracellular markers to immunophenotype T cell subsets and measure expression of the activation markers LAG3 and CTLA4. Data showed increase in the frequency and number of splenic Treg co-expressing LAG3 and CTLA4. PMAB1F, PMAB1G, and PMAB65 increase the frequency and cell number of splenic Treg co-expressing LAG3 and CTLA4.


Example 45. Optimized PD-1 Molecules Increase Expression of Treg Activation Markers

Eight-week-old human PD-1 knock-in mice were dosed subcutaneously in the dorsal scruff with vehicle, PMAB1F, PMAB65, PMAB68, or PMAB68. After 7 days mice were euthanized, spleens dissected and splenocytes stained with antibodies against surface and intracellular markers to immunophenotype T cell subsets and measure expression of the activation markers LAG3 and CTLA4. Data showed increase in the frequency and number of splenic Treg co-expressing LAG3 and CTLA4. Optimized PD-1 molecules increase the frequency and cell number of splenic Treg co-expressing LAG3 and CTLA4.


The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety. While various embodiments have been disclosed with reference to specific aspects, it is apparent that other aspects and variations of these embodiments may be devised by others skilled in the art without departing from the true spirit and scope of the embodiments. The appended claims are intended to be construed to include all such aspects and equivalent variations.

Claims
  • 1. An antibody, or antigen binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein: the heavy chain variable region comprises a heavy chain variable region CDR1 (HCDR1) having the amino acid sequence of SEQ ID NO: 1709, or 1719; a heavy chain variable region CDR2 (HCDR2) having the amino acid sequence of SEQ ID NO: 1712, or 1744; and heavy chain variable region CDR3 (HCDR3) having the amino acid sequence of SEQ ID NO: 1715, or 1724; andthe light chain variable region comprises a light chain variable region CDR1 (LCDR1) having the amino acid sequence of SEQ ID NO: 1716, or 1726; a light chain variable region CDR2 (LCDR2) having the amino acid sequence of SEQ ID NO: 1717, or 1728; and a light chain variable region CDR3 (LCDR3) having the amino acid sequence of SEQ ID NO: 1718, or 1729.
  • 2. The antibody, or antigen binding fragment thereof, of claim 1, wherein: the heavy chain variable region comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1719, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1744, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1724;the heavy chain variable region comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1709, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1712, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1715;the light chain variable region comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1726, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1728, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1729; orthe light chain variable region comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1726, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1728, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1729.
  • 3-6. (canceled)
  • 7. The antibody, or antigen binding fragment thereof, of claim 1, wherein the heavy chain variable region comprises an amino acid sequence of SEQ ID NOs: 1476, or 1478, and the light chain variable region comprises an amino acid of SEQ ID NO: 1359, or 1479.
  • 8-11. (canceled)
  • 12. An antibody, or antigen binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein: the heavy chain variable region comprises a heavy chain variable region CDR1 (HCDR1) having an amino acid sequence of SEQ ID NO: 1719; a heavy chain variable region CDR2 (HCDR2) having an amino acid sequence of SEQ ID NO: 1744; and heavy chain variable region CDR3 (HCDR3) having an amino acid sequence of SEQ ID NO: 1724; andthe light chain variable region comprises a light chain variable region CDR1 (LCDR1) having an amino acid sequence of SEQ ID NO: 1726; a light chain variable region CDR2 (LCDR2) having an amino acid sequence of SEQ ID NO: 1728; and a light chain variable region CDR3 (LCDR3) having an amino acid sequence of SEQ ID NO: 1729.
  • 13. The antibody, or antigen binding fragment thereof, of claim 1, wherein the heavy chain variable region and the light chain variable region are in a Fab format.
  • 14. The antibody, or antigen binding fragment thereof, of claim 1, wherein the heavy chain variable region and the light variable chain region are linked with a peptide linker, optionally wherein the peptide linker is a glycine/serine linker.
  • 15. (canceled)
  • 16. The antibody, or antigen binding fragment thereof of claim 14, wherein the peptide linker comprises a sequence of GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 22), GGGGSGGGGSGGGGS (SEQ ID NO: 30), GGGGSGGGGS (SEQ ID NO: 619), GGGGS (SEQ ID NO: 23), or GGGSEGGGSEGGGSE (SEQ ID NO: 1546), or any combination thereof.
  • 17. An antibody, or antigen binding fragment thereof, wherein the antibody comprises: a light chain variable region comprising an amino acid sequence having at least 90% identity to an amino acid sequence selected from SEQ ID NOs: 1359, 1680, 1681, 1682, 1683, 1684, 1479, 1449, 1687, 1688, 1689, 1690, 1691, 1692, 1693, 1694, 1695, 1696, 1697, 1698, 1699, 1700, 1701, 1702, 1703, 1704, 1705, or 1706; anda heavy chain variable region comprising an amino acid sequence having at least 90% identity to an amino acid sequence selected from SEQ ID NOs: 1476, 1679, 1685, 1584, 1478, 1707, or 1708.
  • 18. The antibody of claim 17, or antigen binding fragment thereof, wherein the antibody comprises: i. a variable light chain sequence of SEQ ID NO: 1359, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof,ii. a variable light chain sequence of SEQ ID NO: 1359, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof,iii. a variable light chain sequence of SEQ ID NO: 1359, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;iv. a variable light chain sequence of SEQ ID NO: 1359, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;v. a variable light chain sequence of SEQ ID NO: 1359, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;vi. a variable light chain sequence of SEQ ID NO: 1359, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;vii. a variable light chain sequence of SEQ ID NO: 1680, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;viii. a variable light chain sequence of SEQ ID NO: 1680, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;ix. a variable light chain sequence of SEQ ID NO: 1680, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;x. a variable light chain sequence of SEQ ID NO: 1680, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;xi. a variable light chain sequence of SEQ ID NO: 1680, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;xii. a variable light chain sequence of SEQ ID NO: 1680, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;xiii. a variable light chain sequence of SEQ ID NO: 1681, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;xiv. a variable light chain sequence of SEQ ID NO: 1681, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;xv. a variable light chain sequence of SEQ ID NO: 1681, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;xvi. a variable light chain sequence of SEQ ID NO: 1681, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;xvii. a variable light chain sequence of SEQ ID NO: 1681, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;xviii. a variable light chain sequence of SEQ ID NO: 1681, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;xix. a variable light chain sequence of SEQ ID NO: 1682, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;xx. a variable light chain sequence of SEQ ID NO: 1682, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;xxi. a variable light chain sequence of SEQ ID NO: 1682, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;xxii. a variable light chain sequence of SEQ ID NO: 1682, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;xxiii. a variable light chain sequence of SEQ ID NO: 1682, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;xxiv. a variable light chain sequence of SEQ ID NO: 1682, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;xxv. a variable light chain sequence of SEQ ID NO: 1683, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;xxvi. a variable light chain sequence of SEQ ID NO: 1683, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;xxvii. a variable light chain sequence of SEQ ID NO: 1683, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;xxviii. a variable light chain sequence of SEQ ID NO: 1683, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;xxix. a variable light chain sequence of SEQ ID NO: 1683, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;xxx. a variable light chain sequence of SEQ ID NO: 1683, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;xxxi. a variable light chain sequence of SEQ ID NO: 1684, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;xxxii. a variable light chain sequence of SEQ ID NO: 1684, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;xxxiii. a variable light chain sequence of SEQ ID NO: 1684, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;xxxiv. a variable light chain sequence of SEQ ID NO: 1684, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;xxxv. a variable light chain sequence of SEQ ID NO: 1684, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;xxxvi. a variable light chain sequence of SEQ ID NO: 1684, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;xxxvii. a variable light chain sequence of SEQ ID NO: 1479, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;xxxviii. a variable light chain sequence of SEQ ID NO: 1479, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;xxxix. a variable light chain sequence of SEQ ID NO: 1479, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;xl. a variable light chain sequence of SEQ ID NO: 1479, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;xli. a variable light chain sequence of SEQ ID NO: 1479, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;xlii. a variable light chain sequence of SEQ ID NO: 1479, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;xliii. a variable light chain sequence of SEQ ID NO: 1449, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;xliv. a variable light chain sequence of SEQ ID NO: 1449, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;xlv. a variable light chain sequence of SEQ ID NO: 1449, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;xlvi. a variable light chain sequence of SEQ ID NO: 1449, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;xlvii. a variable light chain sequence of SEQ ID NO: 1449, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;xlviii. a variable light chain sequence of SEQ ID NO: 1449, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;xlix. a variable light chain sequence of SEQ ID NO: 1687, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;l. a variable light chain sequence of SEQ ID NO: 1687, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;li. a variable light chain sequence of SEQ ID NO: 1687, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;lii. a variable light chain sequence of SEQ ID NO: 1687, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;liii. a variable light chain sequence of SEQ ID NO: 1687, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;liv. a variable light chain sequence of SEQ ID NO: 1687, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;lv. a variable light chain sequence of SEQ ID NO: 1688, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;lvi. a variable light chain sequence of SEQ ID NO: 1688, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;lvii. a variable light chain sequence of SEQ ID NO: 1688, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;lviii. a variable light chain sequence of SEQ ID NO: 1688, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;lix. a variable light chain sequence of SEQ ID NO: 1688, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;lx. a variable light chain sequence of SEQ ID NO: 1688, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;lxi. a variable light chain sequence of SEQ ID NO: 1689, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;lxii. a variable light chain sequence of SEQ ID NO: 1689, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;lxiii. a variable light chain sequence of SEQ ID NO: 1689, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;lxiv. a variable light chain sequence of SEQ ID NO: 1689, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;lxv. a variable light chain sequence of SEQ ID NO: 1689, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;lxvi. a variable light chain sequence of SEQ ID NO: 1689, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;lxvii. a variable light chain sequence of SEQ ID NO: 1690, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;lxviii. a variable light chain sequence of SEQ ID NO: 1690, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;lxix. a variable light chain sequence of SEQ ID NO: 1690, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;lxx. a variable light chain sequence of SEQ ID NO: 1690, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;lxxi. a variable light chain sequence of SEQ ID NO: 1690, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;lxxii. a variable light chain sequence of SEQ ID NO: 1690, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;lxxiii. a variable light chain sequence of SEQ ID NO: 1691, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;lxxiv. a variable light chain sequence of SEQ ID NO: 1691, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;lxxv. a variable light chain sequence of SEQ ID NO: 1691, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;lxxvi. a variable light chain sequence of SEQ ID NO: 1691, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;lxxvii. a variable light chain sequence of SEQ ID NO: 1691, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;lxxviii. a variable light chain sequence of SEQ ID NO: 1691, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;lxxix. a variable light chain sequence of SEQ ID NO: 1692, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;lxxx. a variable light chain sequence of SEQ ID NO: 1692, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;lxxxi. a variable light chain sequence of SEQ ID NO: 1692, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;lxxxii. a variable light chain sequence of SEQ ID NO: 1692, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;lxxxiii. a variable light chain sequence of SEQ ID NO: 1692, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;lxxxiv. a variable light chain sequence of SEQ ID NO: 1692, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;lxxxv. a variable light chain sequence of SEQ ID NO: 1693, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;lxxxvi. a variable light chain sequence of SEQ ID NO: 1693, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;lxxxvii. a variable light chain sequence of SEQ ID NO: 1693, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;lxxxviii. a variable light chain sequence of SEQ ID NO: 1693, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;lxxxix. a variable light chain sequence of SEQ ID NO: 1693, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;xc. a variable light chain sequence of SEQ ID NO: 1693, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;xci. a variable light chain sequence of SEQ ID NO: 1694, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;xcii. a variable light chain sequence of SEQ ID NO: 1694, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;xciii. a variable light chain sequence of SEQ ID NO: 1694, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;xciv. a variable light chain sequence of SEQ ID NO: 1694, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;xcv. a variable light chain sequence of SEQ ID NO: 1694, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;xcvi. a variable light chain sequence of SEQ ID NO: 1694, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;xcvii. a variable light chain sequence of SEQ ID NO: 1695, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;xcviii. a variable light chain sequence of SEQ ID NO: 1695, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;xcix. a variable light chain sequence of SEQ ID NO: 1695, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;c. a variable light chain sequence of SEQ ID NO: 1695, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;ci. a variable light chain sequence of SEQ ID NO: 1695, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;cii. a variable light chain sequence of SEQ ID NO: 1695, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;ciii. a variable light chain sequence of SEQ ID NO: 1696, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;civ. a variable light chain sequence of SEQ ID NO: 1696, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;cv. a variable light chain sequence of SEQ ID NO: 1696, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;cvi. a variable light chain sequence of SEQ ID NO: 1696, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;cvii. a variable light chain sequence of SEQ ID NO: 1696, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;cviii. a variable light chain sequence of SEQ ID NO: 1696, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;cix. a variable light chain sequence of SEQ ID NO: 1697, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;cx. a variable light chain sequence of SEQ ID NO: 1697, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;cxi. a variable light chain sequence of SEQ ID NO: 1697, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;cxii. a variable light chain sequence of SEQ ID NO: 1697, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;cxiii. a variable light chain sequence of SEQ ID NO: 1697, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;cxiv. a variable light chain sequence of SEQ ID NO: 1697, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;cxv. a variable light chain sequence of SEQ ID NO: 1698, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;cxvi. a variable light chain sequence of SEQ ID NO: 1698, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;cxvii. a variable light chain sequence of SEQ ID NO: 1698, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;cxviii. a variable light chain sequence of SEQ ID NO: 1698, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;cxix. a variable light chain sequence of SEQ ID NO: 1698, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;cxx. a variable light chain sequence of SEQ ID NO: 1698, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;cxxi. a variable light chain sequence of SEQ ID NO: 1699, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;cxxii. a variable light chain sequence of SEQ ID NO: 1699, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;cxxiii. a variable light chain sequence of SEQ ID NO: 1699, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;cxxiv. a variable light chain sequence of SEQ ID NO: 1699, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;cxxv. a variable light chain sequence of SEQ ID NO: 1699, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;cxxvi. a variable light chain sequence of SEQ ID NO: 1699, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;cxxvii. a variable light chain sequence of SEQ ID NO: 1700, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;cxxviii. a variable light chain sequence of SEQ ID NO: 1700, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;cxxix. a variable light chain sequence of SEQ ID NO: 1700, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;cxxx. a variable light chain sequence of SEQ ID NO: 1700, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;cxxxi. a variable light chain sequence of SEQ ID NO: 1700, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;cxxxii. a variable light chain sequence of SEQ ID NO: 1700, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;cxxxiii. a variable light chain sequence of SEQ ID NO: 1701, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;cxxxiv. a variable light chain sequence of SEQ ID NO: 1701, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;cxxxv. a variable light chain sequence of SEQ ID NO: 1701, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;cxxxvi. a variable light chain sequence of SEQ ID NO: 1701, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;cxxxvii. a variable light chain sequence of SEQ ID NO: 1701, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;cxxxviii. a variable light chain sequence of SEQ ID NO: 1701, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;cxxxix. a variable light chain sequence of SEQ ID NO: 1702, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;cxl. a variable light chain sequence of SEQ ID NO: 1702, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;cxli. a variable light chain sequence of SEQ ID NO: 1702, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;cxlii. a variable light chain sequence of SEQ ID NO: 1702, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;cxliii. a variable light chain sequence of SEQ ID NO: 1702, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;cxliv. a variable light chain sequence of SEQ ID NO: 1702, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;cxlv. a variable light chain sequence of SEQ ID NO: 1703, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;cxlvi. a variable light chain sequence of SEQ ID NO: 1703, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;cxlvii. a variable light chain sequence of SEQ ID NO: 1703, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;cxlviii. a variable light chain sequence of SEQ ID NO: 1703, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;cxlix. a variable light chain sequence of SEQ ID NO: 1703, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;cl. a variable light chain sequence of SEQ ID NO: 1703, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;cli. a variable light chain sequence of SEQ ID NO: 1704, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;clii. a variable light chain sequence of SEQ ID NO: 1704, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;cliii. a variable light chain sequence of SEQ ID NO: 1704, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;cliv. a variable light chain sequence of SEQ ID NO: 1704, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;clv. a variable light chain sequence of SEQ ID NO: 1704, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;clvi. a variable light chain sequence of SEQ ID NO: 1704, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;clvii. a variable light chain sequence of SEQ ID NO: 1705, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;clviii. a variable light chain sequence of SEQ ID NO: 1705, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;clix. a variable light chain sequence of SEQ ID NO: 1705, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;clx. a variable light chain sequence of SEQ ID NO: 1705, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;clxi. a variable light chain sequence of SEQ ID NO: 1705, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;clxii. a variable light chain sequence of SEQ ID NO: 1705, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof;clxiii. a variable light chain sequence of SEQ ID NO: 1706, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1476, or a variant thereof;clxiv. a variable light chain sequence of SEQ ID NO: 1706, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1679, or a variant thereof;clxv. a variable light chain sequence of SEQ ID NO: 1706, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1685, or a variant thereof;clxvi. a variable light chain sequence of SEQ ID NO: 1706, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1584, or a variant thereof;clxvii. a variable light chain sequence of SEQ ID NO: 1706, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1478, or a variant thereof;clxviii. a variable light chain sequence of SEQ ID NO: 1706, or a variant thereof, and a variable heavy chain sequence of SEQ ID NO: 1707, or a variant thereof.
  • 19. The antibody, or antigen binding fragment thereof, of claim 1, wherein the antibody, or antigen binding fragment thereof binds to PD-1, optionally wherein the antibody, or antigen binding fragment thereof that binds to PD-1 is a PD-1 agonist.
  • 20. (canceled)
  • 21. The antibody, or antigen binding fragment thereof of claim 1, wherein the antibody is linked or associated with another antibody or targeting moiety, optionally wherein the another antibody or targeting moiety binds to MAdCAM.
  • 22. (canceled)
  • 23. The antibody, or antigen binding fragment thereof of claim 21, wherein the antibody that binds to MAdCAM comprises: the heavy chain variable region comprises a heavy chain variable region CDR1 (HCDR1) having the amino acid sequence of SEQ ID NO: 1731, 1721, or 1499; a heavy chain variable region CDR2 (HCDR2) having the amino acid sequence of SEQ ID NO: 1732, 1733, 1506; and a heavy chain variable region CDR3 (HCDR3) having the amino acid sequence of SEQ ID NO: 1734, 1735, 1739, 1740, 1507, 1531, or 1532; andthe light chain variable region comprises a light chain variable region CDR1 (LCDR1) having the amino acid sequence of SEQ ID NO: 1502, 1736, or 1737; a light chain variable region CDR2 (LCDR2) having the amino acid sequence of SEQ ID NO: 1497, or 1717; and a light chain variable region CDR3 (LCDR3) having the amino acid sequence of SEQ ID NO: 1498, or 1738.
  • 24. The antibody, or antigen binding fragment thereof, of claim 23, wherein: (i) the heavy chain variable region comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1731, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1732, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1734; and the light chain variable region comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1736, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1717, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1738 or(ii) the heavy chain variable region comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1499, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 1506, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 1507, and the light chain variable region comprises a LCDR1 comprising the amino acid sequence of SEQ ID NO: 1502, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 1497, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 1498.
  • 25. (canceled)
  • 26. The antibody, or antigen binding fragment thereof, of claim 21, wherein the heavy chain variable region comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 1445, 591, 1443, 1480, 1545, or 1542; and the light chain variable region comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 1367, 592, or 1543.
  • 27. (canceled)
  • 28. The antibody, or antigen binding fragment thereof of claim 26, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1445 and/or the light chain variable region comprises the amino acid sequence of SEQ ID NO: 1367.
  • 29-30. (canceled)
  • 31. An antibody, or antigen binding fragment thereof, wherein the antibody comprises: a light chain comprising an amino acid sequence having at least 90% identity to an amino acid sequence of SEQ ID NO: 1751; anda heavy chain comprising an amino acid sequence having at least 90% identity to an amino acid sequence selected of SEQ ID NO: 1752.
  • 32. (canceled)
  • 33. A PD-1 agonist comprising four polypeptide chains, wherein the four polypeptide chains comprise: Chain 1: N terminus (nt)-VH1-CH1-CH2-CH3-Linker A-scFv[VL2-Linker B-VH2]-C terminus (ct);Chain 2: nt-VH1-CH1-CH2-CH3-Linker A-scFv[VL2-Linker B-VH2]-ct;Chain 3: nt-VL1-CK-ct; andChain 4: nt-VL1-CK-ct;wherein: VH1 comprises the sequence of SEQ ID NO: 1476;CH1-CH2-CH3 comprises the sequence of SEQ ID NO: 44;Linker A comprises the sequence of SEQ ID NO: 30;VL2 comprises the sequence of SEQ ID NO: 1445;Linker B comprises the sequence of SEQ ID NO: 22;VH2 comprises the sequence of SEQ ID NO: 1367;VL1 comprises the sequence of SEQ ID NO: 1359; andCK comprises the sequence of SEQ ID NO: 45.
  • 34. The PD-1 agonist of claim 31, wherein the PD-1 agonist is a homodimer.
  • 35. A pharmaceutical composition comprising the antibody, or antigen binding fragment thereof, of claim 1, and a pharmaceutically acceptable carrier.
  • 36. A method of treating inflammatory bowel disease, the method comprising administering an antibody, or antigen binding fragment thereof of claim 1 to a subject in need thereof.
  • 37. (canceled)
  • 38. A method of treating auto-immune hepatitis, primary sclerosing cholangitis, Type 1 diabetes, graft-versus-host disease (GVHD), or an autoimmune disorder, the method comprising administering an antibody, or antigen binding fragment thereof of claim 1 to a subject in need thereof.
  • 39. An isolated nucleic acid molecule encoding the antibody, or an antigen binding fragment thereof of claim 1.
  • 40. An expression vector comprising the isolated nucleic acid of claim 39.
  • 41. A host cell comprising the nucleic acid molecule of claim 39.
  • 42. A method of producing an antibody, or antigen binding fragment thereof, of claim 1 comprising: (a) culturing a host cell comprising one or more nucleic acids in a culture medium under conditions favorable for expression of the one or more nucleic acids; and(b) optionally recovering the antibody or antigen binding fragment thereof from the culture medium.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application No. 63/152,701, filed on Feb. 23, 2021, which is hereby incorporated by reference in its entirety.

PCT Information
Filing Document Filing Date Country Kind
PCT/US2022/070791 2/23/2022 WO
Provisional Applications (1)
Number Date Country
63152701 Feb 2021 US